

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAPplus and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS EXPRESS	FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008		
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 07:18:20 ON 21 MAY 2008

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 07:18:28 ON 21 MAY 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 MAY 2008 HIGHEST RN 1021642-73-8

DICTIONARY FILE UPDATES: 20 MAY 2008 HIGHEST RN 1021642-73-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10509919c.str

G2:C,H,O

G3:C,H,O,S,N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:CLASS
12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 22:CLASS
24:CLASS 25:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,O,N,OH

G2 C,H,O

G3 C,H,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 07:18:48 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 3596 TO ITERATE

100.0% PROCESSED 3596 ITERATIONS

886 ANSWERS

SEARCH TIME: 00.00.01

L2 886 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

178.57

FILE 'CAPLUS' ENTERED AT 07:18:58 ON 21 MAY 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 May 2008 VOL 148 ISS 21
FILE LAST UPDATED: 20 May 2008 (20080520/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s 12 full
L3 126 L2

=> d ibib abs hitstr tot

L3 ANSWER 1 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:155083 CAPLUS

DOCUMENT NUMBER: 148:415052

TITLE: Electronic transport properties of
1-(p-R-phenacyl)-4-[[1'-ethylcarboxylate)-(3'-p-R'-phenacyl)]-7'-indoliziny]pyridinium bromides in thin films

AUTHOR(S): Leontie, L.; Danac, R.; Druta, I.; Rusu, G. I.

CORPORATE SOURCE: Faculty of Physics, "Al.I. Cuza" University, Iasi, RO-700506, Rom.

SOURCE: Thin Solid Films (2008), 516(7), 1599-1603

CODEN: THSFAP; ISSN: 0040-6090

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The temperature dependences of elec. conductivity, σ , and Seebeck coefficient, S, for

some new pyridium monoquaternary salts derivs., 1-(p-R-phenacyl)-4-[[1'-ethylcarboxylate)-(3'-p-R'-phenacyl)]-7'-indoliziny]pyridinium bromides were studied. The film samples (d = 0.08-0.28 μm) were deposited onto glass by an immersion technique (DMF was used as a solvent). The studied compds. behave as typical p-type polycryst. semiconductors. The activation energy of elec. conduction ranged between 0.65 and 1.72 eV, while the ratio of charge carrier mobilities laid in the range (0.60-0.83). The model based on band gap representation is suitable in explaining the electronic transport in present compds. in the higher

temperature

range (385-500 K).


IT 1015691-76-5 1015691-78-7 1015691-79-8

RL: PRP (Properties)

(elec. conductivity and Seebeck coefficient of pyridium monoquaternary salts and derivs.)



RN 1015691-76-5 CAPLUS

CN Pyridinium, 4-[1-(ethoxycarbonyl)-3-(4-methoxybenzoyl)-7-indoliziny]-1-(2-oxo-2-phenylethyl)-, bromide (1:1) (CA INDEX NAME)




RN 1015691-78-7 CAPLUS

CN Pyridinium, 4-[1-(ethoxycarbonyl)-3-(4-nitrobenzoyl)-7-indoliziny]-1-[2-(4-methylphenyl)-2-oxoethyl]-, bromide (1:1) (CA INDEX NAME)



RN 1015691-79-8 CAPLUS
 CN Pyridinium, 1-[2-(4-chlorophenyl)-2-oxoethyl]-4-[1-(ethoxycarbonyl)-3-(4-methylbenzoyl)-7-indoliziny]-, bromide (1:1) (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2008:127846 CAPLUS

DOCUMENT NUMBER: 148:198671

TITLE: Use of 1,2,3-substituted indolizine derivatives,
inhibitors of basic fibroblast growth factors, for the
preparation of a medicament intended for the treatment
of degenerative joint diseases

INVENTOR(S): Bono, Francoise; Rudolphi, Karl

PATENT ASSIGNEE(S): Sanofi-Aventis, Fr.

SOURCE: PCT Int. Appl., 17pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008012690	A2	20080131	WO 2007-IB3150	20070720
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1891955	A1	20080227	EP 2006-291194	20060724
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			

PRIORITY APPLN. INFO.: EP 2006-291194 A 20060724

OTHER SOURCE(S): MARPAT 148:198671

AB The present invention concerns the use of 1,2,3-substituted indolizine derivs. and in particular the 2-amino-5-[(1-methoxy-2-methylindolizin-3-yl)carbonyl]benzoic acid, and their pharmaceutically acceptable salts and solvates for the preparation of a medicament intended for the treatment of degenerative joint diseases, such as osteoarthritis, spondyloses, cartilage loss following joint trauma or a relatively long period of joint immobilization following meniscus or patella injuries or ligament ruptures, and chronic diseases of the locomotory apparatus such as inflammatory, immunol. or metabolism-associated acute and chronic arthritides, arthropathies, myalgias and disturbances of bone metabolism. Thus, sodium 2-amino-5-[(1-methoxy-2-methylindolizin-3-yl)carbonyl]benzoic acid monohydrate was blended with the standard food at concns. of 300 ppm (0.3 g/kg food) and administered to osteoarthritic mice. The tested compound was well tolerated and significantly reduced the degree of histopathol. joint damage by 32%.


IT 1003568-56-6

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(use of 1,2,3-substituted indolizine derivs., inhibitors of basic fibroblast growth factors, for preparation of a medicament intended for treatment of degenerative joint diseases)

RN 1003568-56-6 CAPLUS


CN Benzoic acid, 2-amino-5-[(1-methoxy-2-methyl-3-indoliziny)carbonyl]-, sodium salt, hydrate (1:1:1) (CA INDEX NAME)



● Na

● H₂O

IT 848463-13-8
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (use of 1,2,3-substituted indolizine derivs., inhibitors of basic
 fibroblast growth factors, for preparation of a medicament intended for
 treatment of degenerative joint diseases)
 RN 848463-13-8 CAPLUS
 CN Benzoic acid, 2-amino-5-[(1-methoxy-2-methyl-3-indolizinyl)carbonyl]- (CA
 INDEX NAME)



L3 ANSWER 3 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1368512 CAPLUS

DOCUMENT NUMBER: 148:168546

TITLE: A novel approach to 3-acylated indolizine structures via iodine-mediated hydrative cyclization

AUTHOR(S): Kim, Ikyon; Kim, Sun Gi; Kim, Ji Young; Lee, Ge Hyeong

CORPORATE SOURCE: Center for Medicinal Chemistry, Korea Research Institute of Chemical Technology, Daejeon, 305-600, S. Korea

SOURCE: Tetrahedron Letters (2007), 48(51), 8976-8981

CODEN: TELEAY; ISSN: 0040-4039

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 148:168546

AB A new route to 3-ethoxycarbonylindolizine structures via iodine-mediated hydrative cyclization of pyridin-2-yl ethoxycarbonylalkynes is reported. Reaction mechanism is proposed for this novel transformation, which involves a 5-exo-dig iodocyclization, deprotonation, incorporation of another iodo group, deprotonation, and subsequent replacement of the diiodo group by H₂O. Various 3-ethoxycarbonylindolizine derivs. were obtained using this mild procedure in good yields.

IT 40624-43-9P 107846-98-0P 502762-20-1P


883818-60-8P 1003050-04-1P 1003050-08-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of ethoxycarbonylindolizines via iodine-mediated hydrative cyclization of pyridin-2-yl ethoxycarbonylalkynes generated from Et pyridinylacetate and propargylic bromides)


RN 40624-43-9 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-, ethyl ester (CA INDEX NAME)




RN 107846-98-0 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-2-methyl-, ethyl ester (CA INDEX NAME)




RN 502762-20-1 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-(4-methylbenzoyl)-, ethyl ester (CA INDEX NAME)




RN 883818-60-8 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-(3-methoxybenzoyl)-, ethyl ester (CA INDEX NAME)




RN 1003050-04-1 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-(4-methoxybenzoyl)-, ethyl ester (CA INDEX NAME)



RN 1003050-08-5 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-2-ethyl-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT:

43

THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:809823 CAPLUS

DOCUMENT NUMBER: 147:322808

TITLE: Application of DMF-methyl sulfate adduct in the regioselective synthesis of 3-acylated indolizines

AUTHOR(S): Przewloka, Teresa; Chen, Shoujun; Xia, Zhiqiang; Li, Hao; Zhang, Shijie; Chimmanamada, Dinesh; Kostik, Elena; James, David; Koya, Keizo; Sun, Lijun

CORPORATE SOURCE: Synta Pharmaceuticals Corp., Lexington, MA, 02421, USA

SOURCE: Tetrahedron Letters (2007), 48(33), 5739-5742

CODEN: TELEAY; ISSN: 0040-4039

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 147:322808

AB A number of 3-acylated indolizines were synthesized in good to excellent yields by a newly established reaction between picolinium salts and the Me sulfate salt of MeOCH:N+Me₂, the adduct formed from DMF-Me₂SO₄ as the key reagent. The low cost, short reaction time, mild reaction condition, and easy purification of the products make this an attractive new method for the synthesis of indolizine compds. A variety of functional groups (nitro, cyano, ester, methoxy, and halogens) were well tolerated under the reaction conditions.


IT 675139-24-9P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of acylated indolizines by regioselective cyclocondensation of picolinium salts with DMF-Me sulfate adduct)

RN 675139-24-9 CAPLUS

CN Benzonitrile, 4-[(1-methyl-3-indoliziny)carbonyl]- (CA INDEX NAME)



REFERENCE COUNT:

26

THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:789680 CAPLUS

DOCUMENT NUMBER: 147:189173

TITLE: Preparation of FGF receptor agonist dimeric compounds,
particularly bisindolizines, bisimidazo[1,5-
a]pyridines and their derivatives

INVENTOR(S): Bono, Francoise; Guillo, Nathalie; Maffrand,
Jean-Pierre; Fons, Pierre; Olsen, Jacob-Alsboek;
Anne-Archard, Gilles

PATENT ASSIGNEE(S): Sanofi-Aventis, Fr.

SOURCE: PCT Int. Appl., 154pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2007080325	A1	20070719	WO 2007-FR51	20070112
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
FR 2896247	A1	20070720	FR 2006-317	20060113
FR 2896247	B1	20080229		
PRIORITY APPLN. INFO.:			FR 2006-317	A 20060113
OTHER SOURCE(S):	MARPAT	147:189173		

GI



AB Title compds. M1-L-M2 (I) [M1, M2 = independently a monomer unit M; L = linker containing 1-25 members and selected from alk(en/yn)ylene, (CH₂CH₂O)_nCH₂CH₂; (CH₂)_mNR₁'CO-alkylene-CONR₁''(CH₂)_q, etc.; n = 1-7; m, q = independently 0-8; m, m' and n are chosen so that the number of members in the linker is not > 25; R₁', R₁'' = independently H, C1-5 alkyl; or R₁' and R₁'' optionally can form a ring; X = N, CR₂*; A = CO, SO₂; * = bonding site between L and M1 on one side and M2 on the other side; that bonding site of each monomer unit M1 or M2 is located on one of the substituents R, R₁, R₂; R = H, halo, alkyl, OH, CO₂H and derivs., NH₂ and derivs., etc.; R₁ = H, CN, halo, CONH₂ and derivs., (un)substituted aryl, etc.; R₂ = cyclo/alkyl, or Ph optionally substituted; R₃, R₄ = independently H, OH, NH₂, NO₂, CONHOH, NHOH, NHCOPh, etc.; or R₃CCR₄ = Ph to which is attached a 6-membered ring containing a N and another heteroatom such as O] were prepared

as selective fibroblast growth factor (FGF) antagonists and angiogenesis inhibitors. Thus, bisindolizine II disodium salt was prepared, in 50% yield, by dimerization of Me 2-amino-5-[(8-hydroxy-1-methoxy-2-methylindolizin-3-yl)carbonyl]benzoate with 1,20-diiodo-3,6,9,12,15,18-hexaoxaicosane (m.p. = 199°). I displayed a specific activity towards FGFR1β and FGF-R4α in the range of 1x10⁻⁶ M to 3x10⁻⁵ M. I exhibited a specific activity in the range of 10⁻¹² M to 10⁻⁶ M in an angiogenesis test in vitro. I were active at doses of 1 to 50 mg/kg/day in a postischemic revascularization model. Thus, I are useful for treatment of diseases that require an activation of FGFs receptors, especially cardiac ischemia.

IT 944445-84-5P 944446-90-6P 944446-91-7P
944446-93-9P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of bisindolizines, bisimidazo[1,5-a]pyridines and their derivs. as FGF receptor agonists for therapeutic use)


RN 944445-84-5 CAPLUS

CN Benzoic acid, 3,3'-[(1,4-dioxo-1,4-butanediyl)bis[imino-2,1-ethanediyl]oxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 944446-90-6 CAPLUS
 CN Benzoic acid, 3,3'-[carbonylbis[imino-2,1-ethanediylloxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-(CA INDEX NAME)]


PAGE 1-A



Me


HO₂C

PAGE 1-B



RN 944446-91-7 CAPLUS
 CN Benzoic acid, 3,3'-[1,2-ethanediylbis[imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-3-carboxyphenyl]
 (CA INDEX NAME)


PAGE 1-A





Me

HO₂C

PAGE 1-B



RN 944446-93-9 CAPLUS
 CN Benzoic acid, 3,3'-[1,2-ethanediylbis[imino(2-oxo-2,1-ethanediyl)oxy-4,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-(CA INDEX NAME)]



IT	944443-86-1P	944443-87-2P	944443-88-3P
	944443-89-4P	944443-90-7P	944443-91-8P
	944443-92-9P	944443-96-3P	944443-97-4P
	944443-98-5P	944443-99-6P	944444-00-2P
	944444-01-3P	944444-06-8P	944444-07-9P
	944444-08-0P	944444-09-1P	944444-10-4P
	944444-11-5P	944444-12-6P	944444-13-7P
	944444-14-8P	944444-15-9P	944444-16-0P
	944444-17-1P	944444-18-2P	944444-19-3P
	944444-20-6P	944444-21-7P	944444-22-8P
	944444-23-9P	944444-24-0P	944444-25-1P
	944444-26-2P	944444-27-3P	944444-28-4P
	944444-29-5P	944444-30-8P	944444-31-9P
	944444-32-0P	944444-36-4P	944444-41-1P
	944444-42-2P	944444-43-3P	944444-44-4P

944444-45-5P 944444-46-6P 944444-47-7P
 944444-48-8P 944444-49-9P 944444-50-2P
 944444-51-3P 944444-52-4P 944444-53-5P
 944444-54-6P 944444-55-7P 944444-56-8P
 944444-57-9P 944444-58-0P 944444-59-1P
 944444-61-5P 944444-63-7P 944444-65-9P
 944444-66-0P 944444-67-1P 944444-69-3P
 944444-71-7P 944444-73-9P 944444-75-1P
 944444-77-3P 944444-79-5P 944444-81-9P
 944444-83-1P 944444-85-3P 944444-87-5P
 944444-89-7P 944444-91-1P 944444-93-3P
 944444-95-5P 944444-97-7P 944444-99-9P
 944445-01-6P 944445-03-8P 944445-05-0P
 944445-07-2P 944445-09-4P 944445-11-8P
 944445-13-0P 944445-15-2P 944445-17-4P
 944445-19-6P 944445-20-9P 944445-30-1P
 944445-32-3P 944445-34-5P 944445-35-6P
 944445-37-8P 944445-38-9P 944445-39-0P
 944445-40-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of bisindolizines, bisimidazo[1,5-a]pyridines
 and their derivs. as FGF receptor agonists for therapeutic use)

RN 944443-86-1 CAPLUS

CN Benzoic acid, 3,3'-[3,6,9,12,15,18-hexaoxaecosane-1,20-diylbis[oxy(1-
 methoxy-2-methyl-8,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt
 (1:2) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




PAGE 3-A






● 2 Na


RN 944443-87-2 CAPLUS
 CN Benzoic acid, 3,3'-[3,6,9,12,15-pentaoxaheptadecane-1,17-diylbis[oxy(1-methoxy-2-methyl-8,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)



PAGE 2-A




PAGE 3-A




● 2 Na


RN 944443-88-3 CAPLUS
 CN Benzoic acid, 3,3'-[3,6,9,12-tetraoxatetradecane-1,14-diylbis[oxy(1-methoxy-2-methyl-8,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A






●2 Na


RN 944443-89-4 CAPLUS
 CN Benzoic acid, 3,3'-[oxybis[2,1-ethanedioxy-2,1-ethanedioxy(1-methoxy-2-methyl-8,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)



PAGE 2-A




PAGE 3-A




● 2 Na


RN 944443-90-7 CAPLUS
 CN Benzoic acid, 3,3'-[1,2-ethanediylbis[oxy-2,1-ethanediyl]oxy(1-methoxy-2-methyl-8,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A








● 2 Na

RN 944443-91-8 CAPLUS
 CN Benzoic acid, 3,3'-[oxybis[2,1-ethanediyl]oxy(1-methoxy-2-methyl-8,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)






RN 944443-92-9 CAPLUS
 CN Benzoic acid, 3,3'-[1,11-undecanediylbis[imino(2-oxo-2,1-ethanediyl)oxy(1-methoxy-2-methyl-8,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)




RN 944443-96-3 CAPLUS
 CN Benzoic acid, 3,3'-[3,6,9,12,15,18-hexaoxaeicosane-1,20-diylbis[oxy(1-methoxy-2-methyl-6,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)

PAGE 1-A




● 2 Na


PAGE 1-B




PAGE 1-C



RN 944443-97-4 CAPLUS
 CN Benzoic acid, 3,3'-[3,6,9,12,15-pentaoxaheptadecane-1,17-diylbis[oxy(1-methoxy-2-methyl-6,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)




●2 Na



RN 944443-98-5 CAPLUS


CN Benzoic acid, 3,3'-[3,6,9,12-tetraoxatetradecane-1,14-diylbis[oxy(1-methoxy-2-methyl-6,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)

PAGE 1-A



● 2 Na


PAGE 1-B



RN 944443-99-6 CAPLUS


CN Benzoic acid, 3,3'-[oxybis[2,1-ethanediylloxy-2,1-ethanediylloxy(1-methoxy-2-methyl-6,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)

PAGE 1-A



● 2 Na


PAGE 1-B



RN 944444-00-2 CAPLUS


CN Benzoic acid, 3,3'-[1,2-ethanediylbis[oxy-2,1-ethanediyl]oxy(1-methoxy-2-methyl-6,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)

PAGE 1-A




● 2 Na

PAGE 1-B




RN 944444-01-3 CAPLUS
CN Benzoic acid, 3,3'-[oxybis[2,1-ethanediylloxy(1-methoxy-2-methyl-6,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)

PAGE 1-A



● 2 Na


PAGE 1-B



RN 944444-06-8 CAPLUS


CN Benzoic acid, 3,3'-[3,6,9,12,15,18-hexaoxaeicosane-1,20-diylbis[oxy(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)

PAGE 1-A



●2 Na


PAGE 1-B



RN 944444-07-9 CAPLUS


CN Benzoic acid, 3,3'-[3,6,9,12,15-pentaoxaheptadecane-1,17-diylbis[oxy(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)

PAGE 1-A



● 2 Na


PAGE 1-B



RN 944444-08-0 CAPLUS


CN Benzoic acid, 3,3'-[3,6,9,12-tetraoxatetradecane-1,14-diylbis[oxy(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)

PAGE 1-A



● 2 Na


PAGE 1-B



RN 944444-09-1 CAPLUS


CN Benzoic acid, 3,3'-[oxybis[2,1-ethanediylloxy-2,1-ethanediylloxy(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)

PAGE 1-A




●2 Na

PAGE 1-B




RN 944444-10-4 CAPLUS

CN Benzoic acid, 3,3'-[1,2-ethanediylbis[oxy-2,1-ethanediyl]oxy(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)



●2 Na


RN 944444-11-5 CAPLUS
 CN Benzoic acid, 3,3'-[oxybis[2,1-ethanediylloxy(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)




● 2 Na

RN 944444-12-6 CAPLUS
 CN Benzoic acid, 3,3'-[1,2-ethanediylbis[oxy-2,1-ethanediylloxy-3,1-phenylenemethyleneoxy(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)

PAGE 1-A





● 2 Na



RN 944444-13-7 CAPLUS


CN Benzoic acid, 3,3'-[1,2-ethanediylbis[oxy-2,1-ethanediyl]oxy-4,1-phenylenemethyleneoxy(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)






RN 944444-14-8 CAPLUS

CN Benzoic acid, 3,3'-[1,8-octanediylbis[oxy-4,1-phenylenemethyleneoxy(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)



● 2 Na




RN 944444-15-9 CAPLUS

CN Benzoic acid, 3,3'-[1,2-ethanediylbis[imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylenemethyleneoxy(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-,

PAGE 1-A




PAGE 1-B



RN 944444-16-0 CAPLUS

CN Benzoic acid, 2-amino-5-[[[2-[[2-[[2-[[3-(4-amino-3-carboxybenzoyl)-2-methyl-1-indolizinyloxy]acetyl]amino]ethyl]amino]-2-oxoethoxy]-2-methyl-3-indolizinyloxy]carbonyl]-, sodium salt (1:2) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 Na


RN 944444-17-1 CAPLUS
 CN Benzoic acid, 3,3'-[1,3-propanediylbis[imino(2-oxo-2,1-ethanediyl)oxy(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)

PAGE 1-A




● 2 Na


RN 944444-18-2 CAPLUS
 CN Benzoic acid, 3,3'-[3,6,9,12-tetraoxatetradecane-1,14-diylbis[imino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)



● 2 Na




RN 944444-19-3 CAPLUS
 CN Benzoic acid, 3,3'-[1,8-octanediylbis[oxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)




●2 Na

RN 944444-20-6 CAPLUS
 CN Benzoic acid, 3,3'-[3,6,9,12,15-pentaoxaheptadecane-1,17-diylbis[oxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)


PAGE 1-A




●2 Na




RN 944444-21-7 CAPLUS
 CN Benzoic acid, 3,3'-[3,6,9,12-tetraoxatetradecane-1,14-diylbis[oxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)






RN 944444-22-8 CAPLUS


CN Benzoic acid, 3,3'-[oxybis[2,1-ethanediyloxy-2,1-ethanediyloxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)






RN 944444-23-9 CAPLUS


CN Benzoic acid, 3,3'-[1,2-ethanediylbis[oxy-2,1-ethanediyl]oxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)





RN 944444-24-0 CAPLUS


CN Benzoic acid, 3,3'-[oxybis[2,1-ethanediylloxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)




● 2 Na

RN 944444-25-1 CAPLUS

CN Benzoic acid, 3,3'-[1,4-piperazinediylbis[2,1-ethanediylloxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)




● 2 Na




RN 944444-26-2 CAPLUS

CN Benzoic acid, 3,3'-[(5-methoxy-1,3-phenylene)bis[oxy-2,1-ethanediyloxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)




● 2 Na




RN 944444-27-3 CAPLUS

CN Benzoic acid, 3,3'-[(1,4-dioxo-1,4-butanediyl)bis[imino-2,1-ethanediylloxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)




●2 Na




RN 944444-28-4 CAPLUS
 CN Benzoic acid, 3,3'-[carbonylbis[imino-2,1-ethanedioxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)

PAGE 1-A



● 2 Na


PAGE 1-B



RN 944444-29-5 CAPLUS


CN Benzoic acid, 3,3'-[1,2-ethanediylbis[imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)

PAGE 1-A




●2 Na

PAGE 1-B




RN 944444-30-8 CAPLUS
 CN Benzoic acid, 3,3'-[1,3-propanediylbis[imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)

PAGE 1-A




● 2 Na

PAGE 1-B




RN 944444-31-9 CAPLUS
 CN Benzoic acid, 3,3'-[1,4-butanediylbis[imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)

PAGE 1-A




● 2 Na

PAGE 1-B




RN 944444-32-0 CAPLUS
 CN Benzoic acid, 3,3'-[1,4-piperazinediylbis[(2-oxo-2,1-ethanediyl)oxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)

PAGE 1-A




●2 Na

PAGE 1-B




RN 944444-36-4 CAPLUS
 CN Benzoic acid, 3,3'-[1,2-ethanediylbis[oxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)




● 2 Na

RN 944444-41-1 CAPLUS
 CN Benzamide, 4,4'-[1,2-ethanediylbis[imino(2-oxo-2,1-ethanediyl)oxy]]bis[N-
 [3-(4-amino-3-methoxybenzoyl)-2-methyl-1-indolizinyloxy]-, hydrochloride
 (1:2) (CA INDEX NAME)


PAGE 1-A






RN 944444-42-2 CAPLUS


CN Benzamide, 3,3'-[[2-(dimethylamino)-1,3-propanediyl]bis[imino(2-oxo-2,1-ethanediyl)oxy]]bis[N-[3-(4-amino-3-methoxybenzoyl)-2-methyl-1-indoliziny]]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl





RN 944444-43-3 CAPLUS
 CN Benzamide, 3,3'-[[2-[(dimethylamino)methyl]-1,3-propanediyl]bis[imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, hydrochloride (1:3) (CA INDEX NAME)






RN 944444-44-4 CAPLUS
 CN Benzamide, 3,3'-[(2-hydroxy-1,3-propanediyl)bis[imino(2-oxo-2,1-ethanediyl)oxy]]bis[N-[3-(4-amino-3-methoxybenzoyl)-2-methyl-1-indoliziny]]-, hydrochloride (1:2) (CA INDEX NAME)






RN 944444-45-5 CAPLUS
 CN Benzamide, 3,3'-[1,2-ethanediylbis[(methylimino)-2,1-ethanediylloxy]]bis[N-
 [3-(4-amino-3-methoxybenzoyl)-2-methyl-1-indoliziny]]-, hydrochloride
 (1:2) (CA INDEX NAME)




MeO

● 2 HCl




RN 944444-46-6 CAPLUS

CN Benzamide, 3,3'-[1,2-ethanediylbis[[(phenylmethyl)imino]-2,1-ethanediylloxy]]bis[N-[3-(4-amino-3-methoxybenzoyl)-2-methyl-1-indolizinyloxy]-, hydrochloride (1:2) (CA INDEX NAME)





Me

MeO





RN 944444-47-7 CAPLUS
 CN Benzamide, 4,4'-[1,2-ethanediylbis[(methylimino)-2,1-ethanediylloxy]]bis[N-
 [3-(4-amino-3-methoxybenzoyl)-2-methyl-1-indoliziny]]-, hydrochloride
 (1:2) (CA INDEX NAME)






RN 944444-48-8 CAPLUS
 CN Benzamide, 3,3'-[(3,4-dioxo-1-cyclobutene-1,2-diyl)bis(imino-2,1-ethanedioxy)]bis[N-[3-(4-amino-3-methoxybenzoyl)-2-methyl-1-indoliziny]]-, hydrochloride (1:2) (CA INDEX NAME)






● 2 HCl


RN 944444-49-9 CAPLUS
 CN Ethanediame, N1,N2-bis[2-[3-[[[3-(4-amino-3-methoxybenzoyl)-2-methyl-1-indoliziny]amino]carbonyl]phenoxy]ethyl]- (CA INDEX NAME)






RN 944444-50-2 CAPLUS

CN Benzoic acid, 3,3'-[1,2-ethanediylbis[imino(2-oxo-2,1-ethanediyl)oxy-4,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)





Me

HO₂C





RN 944444-51-3 CAPLUS
 CN Benzoic acid, 3,3'-[1,2-ethanediylbis[(methylimino)(2-oxo-2,1-ethanediyl)oxy-4,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)







RN 944444-52-4 CAPLUS
 CN Benzoic acid, 3,3'-[oxybis[2,1-ethanediylloxy-2,1-ethanediylloxy-4,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)






RN 944444-53-5 CAPLUS
 CN Benzoic acid, 3,3'-[1,2-ethanediylbis[oxy-2,1-ethanediyl]oxy-4,1-phenylene]bis[6-amino-2-methyl-1,3-indolizinediyl]carboxylate sodium salt (1:2) (CA INDEX NAME)






RN 944444-54-6 CAPLUS
 CN Benzoic acid, 3,3'-[oxybis[2,1-ethanedioxy-4,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)



RN 944444-55-7 CAPLUS
 CN Benzoic acid, 3,3'-[1,3-propanediylbis[oxy-4,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 Na

RN 944444-56-8 CAPLUS
 CN Benzoic acid, 3,3'-[1,2-ethanediylbis[oxy-4,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 Na

RN 944444-57-9 CAPLUS

CN Benzoic acid, 3,3'-[1,2-ethanediylbis[imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis-, sodium salt (1:2) (CA INDEX NAME)

PAGE 1-A




Me

HO₂C


● 2 Na

PAGE 1-B




RN 944444-58-0 CAPLUS


CN Benzoic acid, 3,3'-[1,3-phenylenebis[sulfonylimino-2,1-ethanediyl]oxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)




● 2 Na



RN 944444-59-1 CAPLUS
 CN Benzoic acid, 3,3'-[(1,3-dioxo-1,3-propanediyl)bis[imino-2,1-ethanedioxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)



● 2 Na




RN 944444-61-5 CAPLUS
 CN L-Lysine, 3,3'-[1,4-phenylenebis(carbonylimino-2,1-ethanedioxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl)]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)


CM 1

CRN 944444-60-4
 CMF C60 H50 N8 O12

PAGE 1-A



PAGE 1-B




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 944444-63-7 CAPLUS


CN L-Lysine, 3,3'-[3,5-pyridinediylbis(carbonylimino-2,1-ethanediylloxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl)]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)

CM 1


CRN 944444-62-6


CMF C59 H49 N9 O12

PAGE 1-A



PAGE 2-A






CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 944444-65-9 CAPLUS


CN L-Lysine, 3,3'-[1,2-ethanediylbis[(methylimino)(2-oxo-2,1-ethanediyl)oxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)

CM 1

CRN 944444-64-8

CMF C56 H50 N8 O12






CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 944444-66-0 CAPLUS


CN Benzoic acid, 3,3'-[(1R,2R)-1,2-cyclopropanediylbis[imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



RN 944444-67-1 CAPLUS

CN Benzoic acid, 3,3'-[(1R,2S)-1,2-cyclopropanediylbis[imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, sodium salt (1:2), rel- (CA INDEX NAME)

Relative stereochemistry.



RN 944444-69-3 CAPLUS


CN L-Lysine, 3,3'-[methylenebis[imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)

CM 1


CRN 944444-68-2

CMF C53 H44 N8 O12

PAGE 1-A



PAGE 1-B




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 944444-71-7 CAPLUS


CN L-Lysine, 3,3'-[1,2-ethanediylbis[(methylimino)-2,1-ethanediyl]oxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)

CM 1

CRN 944444-70-6


CMF C56 H54 N8 O10

PAGE 1-A



HO₂C

PAGE 1-B




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 944444-73-9 CAPLUS
 CN L-Lysine, 3,3'-[1,2-ethanediylbis[(methylimino)(1,4-dioxo-4,1-butanediyl)imino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)


CM 1

CRN 944444-72-8
 CMF C46 H46 N8 O10

PAGE 1-A




PAGE 1-B



CM 2


CRN 56-87-1
 CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 944444-75-1 CAPLUS
 CN L-Lysine, 3,3'-[(5,14-dimethyl-1,4,15,18-tetraoxo-8,11-dioxa-5,14-diazaoctadecane-1,18-diyl)bis[imino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)
 CM 1
 CRN 944444-74-0
 CMF C50 H54 N8 O12

PAGE 1-A




PAGE 1-B



CM 2

CRN 56-87-1
CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 944444-77-3 CAPLUS
CN L-Lysine, 3,3'-[oxybis[2,1-ethanediyl(methylimino)(1,4-dioxo-4,1-butanediyl)imino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)


CM 1

CRN 944444-76-2
CMF C48 H50 N8 O11

PAGE 1-A



PAGE 1-B




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 944444-79-5 CAPLUS

CN L-Lysine, 3,3'-[(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis[(1,4-dioxo-4,1-butanediyl)imino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)

CM 1

CRN 944444-78-4

CMF C47 H46 N8 O10




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 944444-81-9 CAPLUS

CN L-Lysine, 3,3'-[1,8-octanediylbis[(methylimino)(1,4-dioxo-4,1-


butanediyl)imino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)

CM 1


CRN 944444-80-8

CMF C52 H58 N8 O10

PAGE 1-A



PAGE 1-B




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 944444-83-1 CAPLUS

CN L-Lysine, 3,3'-[1,3-propanediylbis[(methylimino)(1,4-dioxo-4,1-butanediyl)imino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)


CM 1

CRN 944444-82-0
CMF C47 H48 N8 O10

PAGE 1-A




PAGE 1-B



CM 2

CRN 56-87-1
CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 944444-85-3 CAPLUS
CN L-Lysine, 3,3'-[(6,15-dimethyl-1,5,16,20-tetraoxo-9,12-dioxa-6,15-diazaeicosane-1,20-diyl)bis[imino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)


CM 1

CRN 944444-84-2
CMF C52 H58 N8 O12

PAGE 1-A



PAGE 1-B




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 944444-87-5 CAPLUS

CN L-Lysine, 3,3'-[1,8-octanediylbis[(methylimino)(1,5-dioxo-5,1-pentanedyl)imino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)

CM 1


CRN 944444-86-4
 CMF C54 H62 N8 O10



CM 2

CRN 56-87-1
 CMF C6 H14 N2 O2


Absolute stereochemistry.



RN 944444-89-7 CAPLUS
 CN L-Lysine, 3,3'-[1,6-hexanediylbis[(methylimino)(1,5-dioxo-5,1-pentanediy1)imino(2-methyl-1,3-indolizinediy1)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)

CM 1

CRN 944444-88-6
 CMF C52 H58 N8 O10




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.





RN 944444-91-1 CAPLUS

CN L-Lysine, 3,3'-[oxybis[2,1-ethanediyl(methylimino)(1,5-dioxo-5,1-pentanediy)imino(2-methyl-1,3-indolizinediy)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)

CM 1

CRN 944444-90-0

CMF C50 H54 N8 O11




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 944444-93-3 CAPLUS

CN L-Lysine, 3,3'-[1,2-ethanediylbis[(methylimino)(1,5-dioxo-5,1-pentanedyl)imino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)

CM 1


CRN 944444-92-2
 CMF C48 H50 N8 O10



CM 2

CRN 56-87-1
 CMF C6 H14 N2 O2


Absolute stereochemistry.



RN 944444-95-5 CAPLUS
 CN L-Lysine, 3,3'-[(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis[(1,5-dioxo-5,1-pentanediy)imino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)

CM 1

CRN 944444-94-4
 CMF C49 H50 N8 O10




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 944444-97-7 CAPLUS


CN L-Lysine, 3,3'-[(6,15-dimethyl-1,5,16,20-tetraoxo-3,9,12,18-tetraoxa-6,15-diazaeicosane-1,20-diyl)bis[imino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)

CM 1


CRN 944444-96-6

CMF C50 H54 N8 O14

PAGE 1-A



PAGE 1-B




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 944444-99-9 CAPLUS

CN L-Lysine, 3,3'-[(6,15-dimethyl-1,5,16,20-tetraoxo-3,18-dioxa-6,15-diazaeicosane-1,20-diyl)bis[imino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)


CM 1

CRN 944444-98-8
 CMF C52 H58 N8 O12

PAGE 1-A




PAGE 1-B



CM 2

CRN 56-87-1
 CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 944445-01-6 CAPLUS
 CN L-Lysine, 3,3'-[(6,13-dimethyl-1,5,14,18-tetraoxo-3,16-dioxa-6,13-


diazaoctadecane-1,18-diyl)bis[imino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)

CM 1


CRN 944445-00-5

CMF C50 H54 N8 O12

PAGE 1-A



PAGE 1-B




CM 2

CRN 56-87-1


CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 944445-03-8 CAPLUS
 CN L-Lysine, 3,3'-[(6,10-dimethyl-1,5,11,15-tetraoxo-3,13-dioxo-6,10-diazapentadecane-1,15-diyl)bis[imino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)
 CM 1
 CRN 944445-02-7
 CMF C47 H48 N8 O12

PAGE 1-A




PAGE 1-B



CM 2

CRN 56-87-1
CMF C6 H14 N2 O2


Absolute stereochemistry.



RN 944445-05-0 CAPLUS
CN L-Lysine, 3,3'-[1,4-piperazinediylbis[(1,5-dioxo-5,1-pentanediy1)imino(2-methyl-1,3-indolizinediy1)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)

CM 1


CRN 944445-04-9
CMF C48 H48 N8 O10



CM 2

CRN 56-87-1
CMF C6 H14 N2 O2


Absolute stereochemistry.



RN 944445-07-2 CAPLUS
CN L-Lysine, 3,3'-[1,4-piperazinediylbis[(2-oxo-2,1-ethanediy1)oxy(1-oxo-2,1-ethanediy1)imino(2-methyl-1,3-indolizinediy1)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)

CM 1


CRN 944445-06-1
CMF C46 H44 N8 O12



CM 2

CRN 56-87-1
CMF C6 H14 N2 O2


Absolute stereochemistry.



RN 944445-09-4 CAPLUS
CN L-Lysine, 3,3'-[1,3-propanediylbis[(methylimino)(1,6-dioxo-6,1-hexanediyl)imino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)

CM 1

CRN 944445-08-3
CMF C51 H56 N8 O10




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 944445-11-8 CAPLUS


CN L-Lysine, 3,3'-[1,6-hexanediylbis[(methylimino)(1,4-dioxo-4,1-butanediyl)imino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)

CM 1


CRN 944445-10-7

CMF C50 H54 N8 O10

PAGE 1-A



PAGE 1-B




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 944445-13-0 CAPLUS


CN L-Lysine, 3,3'-[(6,12-dimethyl-1,5,13,17-tetraoxo-3,9,15-trioxa-6,12-diazaheptadecane-1,17-diyl)bis[imino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)

CM 1


CRN 944445-12-9

CMF C48 H50 N8 O13

PAGE 1-A



PAGE 1-B




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 944445-15-2 CAPLUS

CN L-Lysine, 3,3'-[1,2-ethanediylbis[(methylimino)(1,6-dioxo-6,1-hexanediyl)imino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)

CM 1


CRN 944445-14-1
 CMF C50 H54 N8 O10



CM 2

CRN 56-87-1
 CMF C6 H14 N2 O2


Absolute stereochemistry.



RN 944445-17-4 CAPLUS
 CN L-Lysine, 3,3'-[1,3-propanediylbis[(methylimino)(1,5-dioxo-5,1-pentenediyl)imino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)

CM 1

CRN 944445-16-3
 CMF C49 H52 N8 O10




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 944445-19-6 CAPLUS


CN L-Lysine, 3,3'-[(6,9-dimethyl-1,5,10,14-tetraoxo-3,12-dioxa-6,9-diazatetradecane-1,14-diyl)bis[imino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)

CM 1


CRN 944445-18-5

CMF C46 H46 N8 O12

PAGE 1-A



PAGE 1-B




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2


Absolute stereochemistry.



RN 944445-20-9 CAPLUS


CN Benzoic acid, 2-amino-5-[[[1-[[3-[2-[[2-[[2-[3-[[[3-(4-amino-3-carboxybenzoyl)-2-methyl-1-indoliziny]amino]carbonyl]phenoxy]acetyl]amino]acetyl]amino]ethoxy]benzoyl]amino]-2-methyl-3-indoliziny]carbonyl]-, sodium salt (1:2) (CA INDEX NAME)

PAGE 1-A



● 2 Na

PAGE 1-B




RN 944445-30-1 CAPLUS
 CN L-Lysine, 3,3'-[(4,8,13,17-tetraoxo-6,15-dioxa-3,9,12,18-tetraazaeicosane-1,20-diyl)bis[oxy(1-methoxy-2-methyl-6,3-indolizinediyl)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)


CM 1

CRN 944445-29-8
 CMF C50 H54 N8 O16


PAGE 1-A



PAGE 1-B



PAGE 1-C




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 944445-32-3 CAPLUS

CN L-Lysine, 3,3'-[(4,8,16,20-tetraoxo-6,12,18-trioxa-3,9,15,21-tetraazatricosane-1,23-diyl)bis[oxy(1-methoxy-2-methyl-6,3-indolizinediyl)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)


CM 1

CRN 944445-31-2
CMF C52 H58 N8 O17


PAGE 1-A



PAGE 1-B




PAGE 1-C



CM 2

CRN 56-87-1
CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 944445-34-5 CAPLUS
CN L-Lysine, 3,3'-[(4,8,19,23-tetraoxo-6,12,15,21-tetraoxa-3,9,18,24-tetraazahexacosane-1,26-diyl)bis[oxy(1-methoxy-2-methyl-6,3-indolizinediyl)carbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)

CM 1


CRN 944445-33-4

CMF C54 H62 N8 O18


PAGE 1-A



PAGE 1-B



PAGE 1-C




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 944445-35-6 CAPLUS

CN Benzoic acid, 2-amino-5-[[[1-[[3-[2-[[2-[[2-[3-[[[3-(4-amino-3-carboxybenzoyl)imidazo[1,5-a]pyridin-1-yl]amino]carbonyl]phenoxy]acetyl]am


ino]ethyl]amino]-2-oxoethoxy]benzoyl]amino]-2-methyl-3-indoliziny]carbonyl]-, sodium salt (1:2) (CA INDEX NAME)

PAGE 1-A



● 2 Na

PAGE 1-B




RN 944445-37-8 CAPLUS
 CN L-Lysine, 3,3'-[1,2-ethanediylbis[imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylenecarbonyl]]bis[6-aminobenzoate] (2:1) (CA INDEX NAME)

CM 1

CRN 944446-91-7
 CMF C54 H46 N8 O12


PAGE 1-A



Me

HO₂C

PAGE 1-B




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2


Absolute stereochemistry.




RN 944445-38-9 CAPLUS

CN Benzoic acid, 2-amino-5-[[1-[[20-[[3-(4-amino-3-carboxybenzoyl)-1-methoxy-2-methyl-8-indolizinyloxy]-3,6,9,12,15,18-hexaoxaeicos-1-yl]oxy]-2-methyl-3-indolizinyloxy]carbonyl]-, sodium salt (1:2) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



PAGE 3-A




PAGE 4-A




● 2 Na

RN 944445-39-0 CAPLUS
 CN Benzoic acid, 2-amino-5-[[6-[[20-[[3-(4-amino-3-carboxybenzoyl)-1-methoxy-2-methyl-8-indolizinyloxy]-3,6,9,12,15,18-hexaoxaeicos-1-yl]oxy]-1-methoxy-2-methyl-3-indolizinyloxy]carbonyl]-, sodium salt (1:2) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




PAGE 2-A


● 2 Na



RN 944445-40-3 CAPLUS
 CN Benzoic acid, 2-amino-5-[[1-[[20-[4-[3-(4-amino-3-carboxybenzoyl)-1-methoxy-2-indoliziny]]phenoxy]-3,6,9,12,15,18-hexaoxaicos-1-yl]oxy]-2-methyl-3-indoliziny]]carbonyl]-, sodium salt (1:2) (CA INDEX NAME)



●2 Na



IT 944445-44-7P, Methyl 5-[[8-[(Benzyl)oxy]-1-methoxy-2-methylindolizin-3-yl]carbonyl]-2-[(trifluoroacetyl)amino]benzoate
 944445-45-8P, Methyl 2-Amino-5-[[8-[(benzyl)oxy]-1-methoxy-2-methylindolizin-3-yl]carbonyl]benzoate 944445-46-9P, Methyl
 2-Amino-5-[(8-hydroxy-1-methoxy-2-methylindolizin-3-yl)carbonyl]benzoate
 944445-47-0P 944445-48-1P, Methyl 2-Amino-5-[[8-(2-tert-butoxy-2-oxoethoxy)-1-methoxy-2-methylindolizin-3-yl]carbonyl]benzoate
 944445-49-2P, [[3-[4-Amino-3-(methoxycarbonyl)benzoyl]-1-methoxy-2-methylindolizin-8-yl]oxy]acetic acid 944445-50-5P


944445-58-3P, 2-Amino-5-[[6-[(benzyl)oxy]-1-methoxy-2-methylindolizin-3-yl]carbonyl]benzoic acid 944445-59-4P, Methyl 2-Amino-5-[[6-[(benzyl)oxy]-1-methoxy-2-methylindolizin-3-yl]carbonyl]benzoate 944445-60-7P, Methyl 2-Amino-5-[(6-hydroxy-1-methoxy-2-methylindolizin-3-yl)carbonyl]benzoate 944445-61-8P 944445-65-2P 944445-66-3P, Methyl 2-Amino-5-[[1-[[3-(2-tert-butoxy-2-oxoethoxy)phenyl]methyl]oxy]-2-methylindolizin-3-yl]carbonyl]benzoate 944445-67-4P, [3-[[[3-[4-Amino-3-(methoxycarbonyl)benzoyl]-2-methylindolizin-1-yl]oxy]methyl]phenoxy]acetic acid 944445-68-5P 944445-71-0P 944445-72-1P, Methyl 5-[[1-[[3-(Acetyloxy)benzoyl]amino]-2-methylindolizin-3-yl]carbonyl]-2-aminobenzoate 944445-74-3P, Methyl 2-Amino-5-[[1-[(3-hydroxybenzoyl)amino]-2-methylindolizin-3-yl]carbonyl]benzoate 944445-75-4P 944445-79-8P, Benzyl 5-[[1-[[3-[2-[(tert-Butoxycarbonyl)amino]ethoxy]benzoyl]amino]-2-methylindolizin-3-yl]carbonyl]-2-[(trifluoroacetyl)amino]benzoate 944445-81-2P, Benzyl 5-[[1-[[3-(2-Aminoethoxy)benzoyl]amino]-2-methylindolizin-3-yl]carbonyl]-2-[(trifluoroacetyl)amino]benzoate 944445-82-3P 944445-83-4P 944445-85-6P 944445-88-9P, Benzyl 5-[[1-[[3-(2-tert-Butoxy-2-oxoethoxy)benzoyl]amino]-2-methylindolizin-3-yl]carbonyl]-2-[(trifluoroacetyl)amino]benzoate 944445-89-0P, [3-[[[3-[3-[(Benzyloxy)carbonyl]-4-[(trifluoroacetyl)amino]benzoyl]-2-methylindolizin-1-yl]amino]carbonyl]phenoxy]acetic acid 944445-90-3P 944445-93-6P, Methyl 2-amino-5-[[1-[[3-(2-hydroxyethoxy)benzoyl]amino]-2-methylindolizin-3-yl]carbonyl]benzoate 944445-94-7P, Methyl 2-Amino-5-[[2-methyl-1-[[3-[2-[(methylsulfonyl)oxy]ethoxy]benzoyl]amino]indolizin-3-yl]carbonyl]benzoate 944445-95-8P 944446-04-2P 944446-06-4P 944446-12-2P 944446-13-3P 944446-22-4P, 3-[2-[[2-[[[3-[[[3-[3-[(Benzyloxy)carbonyl]-4-[(trifluoroacetyl)amino]benzoyl]-2-methylindolizin-1-yl]amino]carbonyl]phenoxy]acetyl]amino]ethyl]amino]-2-oxoethoxy]benzoic acid 944446-23-5P 944446-24-6P 944446-26-8P 944446-27-9P 944446-29-1P 944446-89-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of bisindolizines, bisimidazo[1,5-a]pyridines and their derivs. as GGF receptor agonists for therapeutic use)


RN 944445-44-7 CAPLUS

CN Benzoic acid, 5-[[1-methoxy-2-methyl-8-(phenylmethoxy)-3-indoliziny]carbonyl]-2-[(2,2,2-trifluoroacetyl)amino]-, methyl ester (CA INDEX NAME)




RN 944445-45-8 CAPLUS

CN Benzoic acid, 2-amino-5-[[1-methoxy-2-methyl-8-(phenylmethoxy)-3-indoliziny]carbonyl]-, methyl ester (CA INDEX NAME)



RN 944445-46-9 CAPLUS


CN Benzoic acid, 2-amino-5-[(8-hydroxy-1-methoxy-2-methyl-3-indoliziny)carbonyl]-, methyl ester (CA INDEX NAME)




RN 944445-47-0 CAPLUS

CN Benzoic acid, 3,3'-[3,6,9,12,15,18-hexaoxaicosane-1,20-diylbis[oxy(1-methoxy-2-methyl-8,3-indolizinediyl)carbonyl]]bis[6-amino-, 1,1'-dimethyl ester (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



PAGE 3-A




PAGE 4-A



RN 944445-48-1 CAPLUS


CN Benzoic acid, 2-amino-5-[[8-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-1-methoxy-2-methyl-3-indolizinyloxy]carbonyl]-, methyl ester (CA INDEX NAME)



RN 944445-49-2 CAPLUS


CN Benzoic acid, 2-amino-5-[[8-(carboxymethoxy)-1-methoxy-2-methyl-3-

indoliziny]carbonyl]-, 1-methyl ester (CA INDEX NAME)




RN 944445-50-5 CAPLUS

CN Benzoic acid, 3,3'-[1,11-undecanediylbis[imino(2-oxo-2,1-ethanediyl)oxy(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, 1,1'-dimethyl ester (CA INDEX NAME)




RN 944445-58-3 CAPLUS

CN Benzoic acid, 2-amino-5-[[1-methoxy-2-methyl-6-(phenylmethoxy)-3-indoliziny]carbonyl]- (CA INDEX NAME)




RN 944445-59-4 CAPLUS

CN Benzoic acid, 2-amino-5-[[1-methoxy-2-methyl-6-(phenylmethoxy)-3-indoliziny]carbonyl]-, methyl ester (CA INDEX NAME)



RN 944445-60-7 CAPLUS


CN Benzoic acid, 2-amino-5-[(6-hydroxy-1-methoxy-2-methyl-3-indoliziny)carbonyl]-, methyl ester (CA INDEX NAME)




RN 944445-61-8 CAPLUS

CN Benzoic acid, 3,3'-[3,6,9,12,15,18-hexaoxaicosane-1,20-diylbis[oxy(1-methoxy-2-methyl-6,3-indolizinediyl)carbonyl]]bis[6-amino-, 1,1'-dimethyl ester (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




PAGE 1-C




RN 944445-65-2 CAPLUS
 CN Benzoic acid, 3,3'-[3,6,9,12,15-pentaoxaheptadecane-1,17-diylbis[oxy(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, 1,1'-dimethyl ester (CA INDEX NAME)


PAGE 1-A



CN Benzoic acid, 2-amino-5-[[1-[[3-[2-(1,1-dimethylethoxy)-2-oxoethoxy]phenyl]methoxy]-2-methyl-3-indolizinyl]carbonyl]-, methyl ester
(CA INDEX NAME)





CN Benzoic acid, 2-amino-5-[[1-[[3-(carboxymethoxy)phenyl]methoxy]-2-methyl-3-indoliziny]carbonyl]-, 1-methyl ester (CA INDEX NAME)





RN 944445-68-5 CAPLUS
 CN Benzoic acid, 3,3'-[1,2-ethanediylbis[imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylenemethyleneoxy(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, 1,1'-dimethyl ester (CA INDEX NAME)

PAGE 1-A






RN 944445-71-0 CAPLUS
 CN Benzoic acid, 3,3'-[3,6,9,12-tetraoxatetradecane-1,14-diylbis[imino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, 1,1'-dimethyl ester (CA INDEX NAME)




RN 944445-72-1 CAPLUS
 CN Benzoic acid, 5-[[1-[[3-(acetyloxy)benzoyl]amino]-2-methyl-3-indoliziny]carbonyl]-2-amino-, methyl ester (CA INDEX NAME)




RN 944445-74-3 CAPLUS

CN Benzoic acid, 2-amino-5-[[1-[(3-hydroxybenzoyl)amino]-2-methyl-3-indoliziny]carbonyl]-, methyl ester (CA INDEX NAME)




RN 944445-75-4 CAPLUS

CN Benzoic acid, 3,3'-[1,8-octanediylbis[oxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, 1,1'-dimethyl ester (CA INDEX NAME)




RN 944445-79-8 CAPLUS

CN Benzoic acid, 5-[[[1-[[3-[2-[[[1,1-dimethylethoxy)carbonyl]amino]ethoxy]benzoyl]amino]-2-methyl-3-indolizinyloxy]carbonyl]-2-[(2,2,2-trifluoroacetyl)amino]-, phenylmethyl ester (CA INDEX NAME)




RN 944445-81-2 CAPLUS

CN Benzoic acid, 5-[[[1-[[3-(2-aminoethoxy)benzoyl]amino]-2-methyl-3-indolizinyloxy]carbonyl]-2-[(2,2,2-trifluoroacetyl)amino]-, phenylmethyl ester (CA INDEX NAME)




RN 944445-82-3 CAPLUS
 CN Benzoic acid, 3,3'-[(1,4-dioxo-1,4-butanediyl)bis[imino-2,1-ethanediyl]oxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-[(2,2,2-trifluoroacetyl)amino]-, 1,1'-bis(phenylmethyl) ester (CA INDEX NAME)

PAGE 1-A





Ph—



RN 944445-83-4 CAPLUS


CN Benzoic acid, 3,3'-[(1,4-dioxo-1,4-butanediyl)bis[imino-2,1-ethanediyl]oxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)






RN 944445-85-6 CAPLUS


CN Benzoic acid, 3,3'-[carbonylbis[imino-2,1-ethanedioxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-[(2,2,2-trifluoroacetyl)amino]-, 1,1'-bis(phenylmethyl) ester (CA INDEX NAME)






RN 944445-88-9 CAPLUS


CN Benzoic acid, 5-[[[1-[[3-[2-(1,1-dimethylethoxy)-2-oxoethoxy]benzoyl]amino]-2-methyl-3-indoliziny]carbonyl]-2-[(2,2,2-trifluoroacetyl)amino]-, phenylmethyl ester (CA INDEX NAME)



RN 944445-89-0 CAPLUS


CN Benzoic acid, 5-[[1-[[3-(carboxymethoxy)benzoyl]amino]-2-methyl-3-indoliziny]carbonyl]-2-[(2,2,2-trifluoroacetyl)amino]-, 1-(phenylmethyl) ester (CA INDEX NAME)

CC1=C(C(=O)N2C=CC=CC=C2C(=O)N(C1)C(=O)c3ccc(cc3)C(=O)OCC4=CC=CC=C4)C(=O)c5ccc(cc5)C(=O)NCCNCC(=O)NCC(=O)Oc6ccc(cc6)C(=O)OCC7=CC=CC=C7C(=O)N(C)C(=O)c8ccc(cc8)C(=O)OCC9=CC=CC=C9C(=O)N(C)C(=O)c10ccc(cc10)C(=O)OCC11=CC=CC=C11C(=O)N(C)C(=O)c12ccc(cc12)C(=O)OCC13=CC=CC=C13C(=O)N(C)C(=O)c14ccc(cc14)C(=O)OCC15=CC=CC=C15C(=O)N(C)C(=O)c16ccc(cc16)C(=O)OCC17=CC=CC=C17C(=O)N(C)C(=O)c18ccc(cc18)C(=O)OCC19=CC=CC=C19C(=O)N(C)C(=O)c20ccc(cc20)C(=O)OCC21=CC=CC=C21C(=O)N(C)C(=O)c22ccc(cc22)C(=O)OCC23=CC=CC=C23C(=O)N(C)C(=O)c24ccc(cc24)C(=O)OCC25=CC=CC=C25C(=O)N(C)C(=O)c26ccc(cc26)C(=O)OCC27=CC=CC=C27C(=O)N(C)C(=O)c28ccc(cc28)C(=O)OCC29=CC=CC=C29C(=O)N(C)C(=O)c30ccc(cc30)C(=O)OCC31=CC=CC=C31C(=O)N(C)C(=O)c32ccc(cc32)C(=O)OCC33=CC=CC=C33C(=O)N(C)C(=O)c34ccc(cc34)C(=O)OCC35=CC=CC=C35C(=O)N(C)C(=O)c36ccc(cc36)C(=O)OCC37=CC=CC=C37C(=O)N(C)C(=O)c38ccc(cc38)C(=O)OCC39=CC=CC=C39C(=O)N(C)C(=O)c40ccc(cc40)C(=O)OCC41=CC=CC=C41C(=O)N(C)C(=O)c42ccc(cc42)C(=O)OCC43=CC=CC=C43C(=O)N(C)C(=O)c44ccc(cc44)C(=O)OCC45=CC=CC=C45C(=O)N(C)C(=O)c46ccc(cc46)C(=O)OCC47=CC=CC=C47C(=O)N(C)C(=O)c48ccc(cc48)C(=O)OCC49=CC=CC=C49C(=O)N(C)C(=O)c50ccc(cc50)C(=O)OCC51=CC=CC=C51C(=O)N(C)C(=O)c52ccc(cc52)C(=O)OCC53=CC=CC=C53C(=O)N(C)C(=O)c54ccc(cc54)C(=O)OCC55=CC=CC=C55C(=O)N(C)C(=O)c56ccc(cc56)C(=O)OCC57=CC=CC=C57C(=O)N(C)C(=O)c58ccc(cc58)C(=O)OCC59=CC=CC=C59C(=O)N(C)C(=O)c60ccc(cc60)C(=O)OCC61=CC=CC=C61C(=O)N(C)C(=O)c62ccc(cc62)C(=O)OCC63=CC=CC=C63C(=O)N(C)C(=O)c64ccc(cc64)C(=O)OCC65=CC=CC=C65C(=O)N(C)C(=O)c66ccc(cc66)C(=O)OCC67=CC=CC=C67C(=O)N(C)C(=O)c68ccc(cc68)C(=O)OCC69=CC=CC=C69C(=O)N(C)C(=O)c70ccc(cc70)C(=O)OCC71=CC=CC=C71C(=O)N(C)C(=O)c72ccc(cc72)C(=O)OCC73=CC=CC=C73C(=O)N(C)C(=O)c74ccc(cc74)C(=O)OCC75=CC=CC=C75C(=O)N(C)C(=O)c76ccc(cc76)C(=O)OCC77=CC=CC=C77C(=O)N(C)C(=O)c78ccc(cc78)C(=O)OCC79=CC=CC=C79C(=O)N(C)C(=O)c80ccc(cc80)C(=O)OCC81=CC=CC=C81C(=O)N(C)C(=O)c82ccc(cc82)C(=O)OCC83=CC=CC=C83C(=O)N(C)C(=O)c84ccc(cc84)C(=O)OCC85=CC=CC=C85C(=O)N(C)C(=O)c86ccc(cc86)C(=O)OCC87=CC=CC=C87C(=O)N(C)C(=O)c88ccc(cc88)C(=O)OCC89=CC=CC=C89C(=O)N(C)C(=O)c90ccc(cc90)C(=O)OCC91=CC=CC=C91C(=O)N(C)C(=O)c92ccc(cc92)C(=O)OCC93=CC=CC=C93C(=O)N(C)C(=O)c94ccc(cc94)C(=O)OCC95=CC=CC=C95C(=O)N(C)C(=O)c96ccc(cc96)C(=O)OCC97=CC=CC=C97C(=O)N(C)C(=O)c98ccc(cc98)C(=O)OCC99=CC=CC=C99C(=O)N(C)C(=O)c100ccc(cc100)C(=O)OCC101=CC=CC=C101C(=O)N(C)C(=O)c102ccc(cc102)C(=O)OCC103=CC=CC=C103C(=O)N(C)C(=O)c104ccc(cc104)C(=O)OCC105=CC=CC=C105C(=O)N(C)C(=O)c106ccc(cc106)C(=O)OCC107=CC=CC=C107C(=O)N(C)C(=O)c108ccc(cc108)C(=O)OCC109=CC=CC=C109C(=O)N(C)C(=O)c110ccc(cc110)C(=O)OCC111=CC=CC=C111C(=O)N(C)C(=O)c112ccc(cc112)C(=O)OCC113=CC=CC=C113C(=O)N(C)C(=O)c114ccc(cc114)C(=O)OCC115=CC=CC=C115C(=O)N(C)C(=O)c116ccc(cc116)C(=O)OCC117=CC=CC=C117C(=O)N(C)C(=O)c118ccc(cc118)C(=O)OCC119=CC=CC=C119C(=O)N(C)C(=O)c120ccc(cc120)C(=O)OCC121=CC=CC=C121C(=O)N(C)C(=O)c122ccc(cc122)C(=O)OCC123=CC=CC=C123C(=O)N(C)C(=O)c124ccc(cc124)C(=O)OCC125=CC=CC=C125C(=O)N(C)C(=O)c126ccc(cc126)C(=O)OCC127=CC=CC=C127C(=O)N(C)C(=O)c128ccc(cc128)C(=O)OCC129=CC=CC=C129C(=O)N(C)C(=O)c130ccc(cc130)C(=O)OCC131=CC=CC=C131C(=O)N(C)C(=O)c132ccc(cc132)C(=O)OCC133=CC=CC=C133C(=O)N(C)C(=O)c134ccc(cc134)C(=O)OCC135=CC=CC=C135C(=O)N(C)C(=O)c136ccc(cc136)C(=O)OCC137=CC=CC=C137C(=O)N(C)C(=O)c138ccc(cc138)C(=O)OCC139=CC=CC=C139C(=O)N(C)C(=O)c140ccc(cc140)C(=O)OCC141=CC=CC=C141C(=O)N(C)C(=O)c142ccc(cc142)C(=O)OCC143=CC=CC=C143C(=O)N(C)C(=O)c144ccc(cc144)C(=O)OCC145=CC=CC=C145C(=O)N(C)C(=O)c146ccc(cc146)C(=O)OCC147=CC=CC=C147C(=O)N(C)C(=O)c148ccc(cc148)C(=O)OCC149=CC=CC=C149C(=O)N(C)C(=O)c150ccc(cc150)C(=O)OCC151=CC=CC=C151C(=O)N(C)C(=O)c152ccc(cc152)C(=O)OCC153=CC=CC=C153C(=O)N(C)C(=O)c154ccc(cc154)C(=O)OCC155=CC=CC=C155C(=O)N(C)C(=O)c156ccc(cc156)C(=O)OCC157=CC=CC=C157C(=O)N(C)C(=O)c158ccc(cc158)C(=O)OCC159=CC=CC=C159C(=O)N(C)C(=O)c160ccc(cc160)C(=O)OCC161=CC=CC=C161C(=O)N(C)C(=O)c162ccc(cc162)C(=O)OCC163=CC=CC=C163C(=O)N(C)C(=O)c164ccc(cc164)C(=O)OCC165=CC=CC=C165C(=O)N(C)C(=O)c166ccc(cc166)C(=O)OCC167=CC=CC=C167C(=O)N(C)C(=O)c168ccc(cc168)C(=O)OCC169=CC=CC=C169C(=O)N(C)C(=O)c170ccc(cc170)C(=O)OCC171=CC=CC=C171C(=O)N(C)C(=O)c172ccc(cc172)C(=O)OCC173=CC=CC=C173C(=O)N(C)C(=O)c174ccc(cc174)C(=O)OCC175=CC=CC=C175C(=O)N(C)C(=O)c176ccc(cc176)C(=O)OCC177=CC=CC=C177C(=O)N(C)C(=O)c178ccc(cc178)C(=O)OCC179=CC=CC=C179C(=O)N(C)C(=O)c180ccc(cc180)C(=O)OCC181=CC=CC=C181C(=O)N(C)C(=O)c182ccc(cc182)C(=O)OCC183=CC=CC=C183C(=O)N(C)C(=O)c184ccc(cc184)C(=O)OCC185=CC=CC=C185C(=O)N(C)C(=O)c186ccc(cc186)C(=O)OCC187=CC=CC=C187C(=O)N(C)C(=O)c188ccc(cc188)C(=O)OCC189=CC=CC=C189C(=O)N(C)C(=O)c190ccc(cc190)C(=O)OCC191=CC=CC=C191C(=O)N(C)C(=O)c192ccc(cc192)C(=O)OCC193=CC=CC=C193C(=O)N(C)C(=O)c194ccc(cc194)C(=O)OCC195=CC=CC=C195C(=O)N(C)C(=O)c196ccc(cc196)C(=O)OCC197=CC=CC=C197C(=O)N(C)C(=O)c198ccc(cc198)C(=O)OCC199=CC=CC=C199C(=O)N(C)C(=O)c200ccc(cc200)C(=O)OCC201=CC=CC=C201C(=O)N(C)C(=O)c202ccc(cc202)C(=O)OCC203=CC=CC=C203C(=O)N(C)C(=O)c204ccc(cc204)C(=O)OCC205=CC=CC=C205C(=O)N(C)C(=O)c206ccc(cc206)C(=O)OCC207=CC=CC=C207C(=O)N(C)C(=O)c208ccc(cc208)C(=O)OCC209=CC=CC=C209C(=O)N(C)C(=O)c210ccc(cc210)C(=O)OCC211=CC=CC=C211C(=O)N(C)C(=O)c212ccc(cc212)C(=O)OCC213=CC=CC=C213C(=O)N(C)C(=O)c214ccc(cc214)C(=O)OCC215=CC=CC=C215C(=O)N(C)C(=O)c216ccc(cc216




RN 944445-93-6 CAPLUS

CN Benzoic acid, 2-amino-5-[[1-[[3-(2-hydroxyethoxy)benzoyl]amino]-2-methyl-3-indoliziny]carbonyl]-, methyl ester (CA INDEX NAME)




RN 944445-94-7 CAPLUS

CN Benzoic acid, 2-amino-5-[[2-methyl-1-[[3-[2-[(methylsulfonyl)oxy]ethoxy]benzoyl]amino]-3-indoliziny]carbonyl]-, methyl ester (CA INDEX NAME)



RN 944445-95-8 CAPLUS


CN Benzoic acid, 3,3'-[1,2-ethanediylbis[oxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, 1,1'-dimethyl ester (CA INDEX NAME)



RN 944446-04-2 CAPLUS

CN Benzamide, 4,4'-[1,2-ethanediylbis[imino(2-oxo-2,1-ethanediyl)oxy]]bis[N-[3-(4-amino-3-methoxybenzoyl)-2-methyl-1-indoliziny]]- (CA INDEX NAME)


PAGE 1-A



Me


MeO

PAGE 1-B




RN 944446-06-4 CAPLUS
 CN Benzoic acid, 3,3'-[1,2-ethanediylbis[imino(2-oxo-2,1-ethanediyl)oxy-4,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-[(2,2,2-trifluoroacetyl)amino]-, 1,1'-bis(phenylmethyl) ester (CA INDEX NAME)


PAGE 1-A



PAGE 1-B





RN 944446-12-2 CAPLUS
 CN Benzoic acid, 5-[[1-[[3-[2-[(2-aminoacetyl)amino]ethoxy]benzoyl]amino]-2-methyl-3-indolizinyloxy]carbonyl]-2-[(2,2,2-trifluoroacetyl)amino]-, phenylmethyl ester (CA INDEX NAME)



RN 944446-13-3 CAPLUS
 CN Benzoic acid, 3,3'-[1-oxo-1,2-ethanediylbis[imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylenecarbonylimino(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-[(2,2,2-trifluoroacetyl)amino]-, 1,1'-bis(phenylmethyl) ester (CA INDEX NAME)


PAGE 1-A






RN 944446-22-4 CAPLUS


CN Benzoic acid, 5-[[[1-[[3-[2-[[2-[[2-(3-carboxyphenoxy)acetyl]amino]ethyl]amino]-2-oxoethoxy]benzoyl]amino]-2-methyl-3-indoliziny]carbonyl]-2-[(2,2,2-trifluoroacetyl)amino]-, 1-(phenylmethyl) ester (CA INDEX NAME)






RN 944446-23-5 CAPLUS


CN Benzoic acid, 5-[[[1-[[3-[2-[[2-[[2-[3-[[[3-[4-amino-3-(methoxycarbonyl)benzoyl]imidazo[1,5-a]pyridin-1-yl]amino]carbonyl]phenoxy]acetyl]amino]ethyl]amino]-2-oxoethoxy]benzoyl]amino]-2-methyl-3-indolizinyllcarbonyl]-2-[(2,2,2-trifluoroacetyl)amino]-, 1,1'-bis(phenylmethyl) ester (CA INDEX NAME)





RN 944446-24-6 CAPLUS


CN Benzoic acid, 2-amino-5-[[[1-[[3-[2-[[2-[[2-[3-[[[3-(4-amino-3-carboxybenzoyl)imidazo[1,5-a]pyridin-1-yl]amino]carbonyl]phenoxy]acetyl]amino]ethyl]amino]-2-oxoethoxy]benzoyl]amino]-2-methyl-3-indoliziny]carbonyl]- (CA INDEX NAME)



Me

HO₂C


PAGE 1-B




RN 944446-26-8 CAPLUS

CN Benzoic acid, 2-amino-5-[[8-[(20-iodo-3,6,9,12,15,18-hexaoxaecos-1-yl)oxy]-1-methoxy-2-methyl-3-indoliziny]carbonyl]-, methyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 944446-27-9 CAPLUS

CN Benzoic acid, 3,3'-[3,6,9,12,15,18-hexaoxaecosane-1,20-diylbis[oxy(2-methyl-1,3-indolizinediyl)carbonyl]]bis[6-amino-, 1,1'-dimethyl ester (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



PAGE 3-A




PAGE 4-A




RN 944446-29-1 CAPLUS
 CN Benzoic acid, 2-amino-5-[[1-[[20-[4-[3-[4-amino-3-(methoxycarbonyl)benzoyl]-1-methoxy-2-indoliziny]phenoxy]-3,6,9,12,15,18-hexaoxaicos-1-yl]oxy]-2-methyl-3-indoliziny]carbonyl]-, methyl ester
 (CA INDEX NAME)



PAGE 1-A



PAGE 1-B




RN 944446-89-3 CAPLUS
 CN 5,8,11,14-Tetraoxa-2,17-diazaoctadecanedioic acid, 2,17-bis[3-[4-amino-3-(methoxycarbonyl)benzoyl]-2-methyl-1-indoliziny]-, 1,18-bis(1,1-dimethylethyl) ester (CA INDEX NAME)




IT 944445-64-1, Methyl 2-amino-5-[(1-hydroxy-2-methylindolizin-3-yl)carbonyl]benzoate 944445-69-6, [[3-[4-Amino-3-(methoxycarbonyl)benzoyl]-2-methylindolizin-1-yl]oxy]acetic acid 944445-70-9, Methyl 2-amino-5-[[1-[(tert-butoxycarbonyl)amino]-2-methylindolizin-3-yl]carbonyl]benzoate 944445-73-2, Methyl 2-amino-5-[(1-amino-2-methylindolizin-3-yl)carbonyl]benzoate 944446-05-3, (4-Amino-3-methoxyphenyl)(1-amino-2-methylindolizin-3-yl)methanone 944446-07-5, Benzyl 5-[(1-amino-2-methylindolizin-3-yl)carbonyl]-2-[(trifluoroacetyl)amino]benzoate 944446-08-6, Methyl 3-[(1-amino-2-methylindolizin-3-yl)carbonyl]benzoate 944446-09-7, 2-Amino-5-[(1-amino-2-methylindolizin-3-yl)carbonyl]benzoic acid 944446-10-0 944446-21-3, Methyl 2-amino-5-[[6-(2-aminoethoxy)-1-methoxy-2-methylindolizin-3-yl]carbonyl]benzoate
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of bisindolizines, bisimidazo[1,5-a]pyridines and their derivs.
 as FGF receptor agonists for therapeutic use)
 RN 944445-64-1 CAPLUS

CN Benzoic acid, 2-amino-5-[(1-hydroxy-2-methyl-3-indoliziny)carbonyl]-, methyl ester (CA INDEX NAME)




RN 944445-69-6 CAPLUS

CN Benzoic acid, 2-amino-5-[[1-(carboxymethoxy)-2-methyl-3-indoliziny]carbonyl]-, 1-methyl ester (CA INDEX NAME)




RN 944445-70-9 CAPLUS

CN Benzoic acid, 2-amino-5-[[1-[[1-(1,1-dimethylethoxy)carbonyl]amino]-2-methyl-3-indoliziny]carbonyl]-, methyl ester (CA INDEX NAME)




RN 944445-73-2 CAPLUS


CN Benzoic acid, 2-amino-5-[(1-amino-2-methyl-3-indoliziny)carbonyl]-, methyl ester (CA INDEX NAME)




RN 944446-05-3 CAPLUS
 CN Methanone, (4-amino-3-methoxyphenyl)(1-amino-2-methyl-3-indoliziny)- (CA INDEX NAME)




RN 944446-07-5 CAPLUS
 CN Benzoic acid, 5-[(1-amino-2-methyl-3-indoliziny)carbonyl]-2-[(2,2,2-trifluoroacetyl)amino]-, phenylmethyl ester (CA INDEX NAME)



RN 944446-08-6 CAPLUS
 CN Benzoic acid, 3-[(1-amino-2-methyl-3-indoliziny)carbonyl]-, methyl ester (CA INDEX NAME)




RN 944446-09-7 CAPLUS
 CN Benzoic acid, 2-amino-5-[(1-amino-2-methyl-3-indoliziny)carbonyl]- (CA INDEX NAME)



RN 944446-10-0 CAPLUS
 CN Benzoic acid, 2-amino-5-[(1-amino-2-methyl-3-indoliziny)carbonyl]-, sulfate (1:1) (CA INDEX NAME)


CM 1

CRN 944446-09-7
 CMF C17 H15 N3 O3




CM 2

CRN 7664-93-9
 CMF H2 O4 S



RN 944446-21-3 CAPLUS
 CN Benzoic acid, 2-amino-5-[[6-(2-aminoethoxy)-1-methoxy-2-methyl-3-indoliziny]carbonyl]-, methyl ester (CA INDEX NAME)




REFERENCE COUNT:

4


THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2007:403332 CAPLUS
 DOCUMENT NUMBER: 147:502536
 TITLE: Anabasine as a precursor for the synthesis of potential agonists of neuronal acetylcholine receptors
 AUTHOR(S): Shults, E. E.; Musina, L. A.; Adekenov, S. M.; Tolstikov, G. A.
 CORPORATE SOURCE: Vorozhtsov Institute of Organic Chemistry, Siberian Division, Russian Academy of Sciences, Novosibirsk, 630090, Russia
 SOURCE: Doklady Chemistry (2007), 413(1), 59-63
 CODEN: DKCHAY; ISSN: 0012-5008
 PUBLISHER: Pleiades Publishing, Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB Ring fused anabasine derivs., such as I and II (R = Me, R1 = CPh, R2 = H, R3 = CO₂Et; R = Me, Ph, R1 = CPh, R2 = R3 = CO₂Me; R = Ph, R1 = CN, R2 = H, R3 = COC₆H₄-4-OMe), were prepared via cycloaddn. reactions of the corresponding anabasine derived pyridinium salts III (R = Me, Ph, R4 = H; R = Ph, R4 = OMe) with HC.tplbond.CC₂OEt, MeO₂CC.tplbond.CC₂OEt, or H₂C:CHCN. E.g., pyridinium salt III (R = Me, R4 = H) was reacted with HC.tplbond.CC₂OEt using Et₃N in CH₂Cl₂ at rt for 9 h to give isomeric cycloadducts I and II (R = Me, R1 = CO₂Et, R2 = H, R3 = CPh) with 75% overall yield and a 1:1 isomer ratio.
 IT 954502-10-4P 954502-11-5P 954502-12-6P
 954502-13-7P 954502-15-9P 954502-16-0P
 954502-18-2P 954502-19-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (asym. synthesis of anabasine derivs. as potential agonists of neuronal acetylcholine receptors)
 RN 954502-10-4 CAPLUS
 CN 1-Indolizinecarboxylic acid, 6-[(2S)-1-acetyl-2-piperidinyl]-3-benzoyl-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 954502-11-5 CAPLUS

CN 1-Indolizinecarboxylic acid, 8-[(2S)-1-acetyl-2-piperidinyl]-3-benzoyl-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 954502-12-6 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 6-[(2S)-1-acetyl-2-piperidinyl]-3-benzoyl-, 1,2-dimethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 954502-13-7 CAPLUS


CN 1,2-Indolizinedicarboxylic acid, 8-[(2S)-1-acetyl-2-piperidinyl]-3-benzoyl-, 1,2-dimethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 954502-15-9 CAPLUS
 CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-6-[(2S)-1-benzoyl-2-piperidinyl]-, 1,2-dimethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 954502-16-0 CAPLUS
 CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-8-[(2S)-1-benzoyl-2-piperidinyl]-, 1,2-dimethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 954502-18-2 CAPLUS
 CN 1-Indolizinecarbonitrile, 6-[(2S)-1-benzoyl-2-piperidinyl]-3-(4-methoxybenzoyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954502-19-3 CAPLUS

CN 1-Indolizinecarbonitrile, 8-[(2S)-1-benzoyl-2-piperidinyl]-3-(4-methoxybenzoyl)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:359287 CAPLUS

DOCUMENT NUMBER: 147:465024

TITLE: In vitro antimicrobial activity of new nitrogen heterocycles derivatives from 4,4'-bipyridine

AUTHOR(S): Furdui, Bianca; Bahrim, Gabriela; Dinica, Rodica; Druta, Ioan; Demeunynck, Martine

CORPORATE SOURCE: University "Dunarea de Jos" Faculty of Sciences, Galati, Rom.

SOURCE: Roumanian Biotechnological Letters (2007), 12(1), 3073-3078

CODEN: RBLEFU; ISSN: 1224-5984

PUBLISHER: Ars Docendi

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The antimicrobial activity of some new diquatery salts and pyridinium-indolizines derived from 4,4'-bipyridine was investigated. Some of these compds. inhibit the growth of microorganisms (bacteria and fungus) in function of structure and doses.

IT 913605-86-4P


RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);

BIOL (Biological study); PREP (Preparation)

(in vitro antimicrobial activity of new nitrogen heterocycles derivatives from 4,4'-bipyridine)

RN 913605-86-4 CAPLUS

CN Pyridinium, 4-[1-(ethoxycarbonyl)-3-(4-methoxybenzoyl)-7-indolizinyll]-1-methyl- (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:267521 CAPLUS

DOCUMENT NUMBER: 148:66767

TITLE: On the mechanism of electrical conduction in some new quaternary salts of bipyridine and indolizine pyridine in thin films

AUTHOR(S): Leontie, L.; Druta, I.; Furdui, B.; Rusu, G. I.

CORPORATE SOURCE: Faculty of Physics, "Al.I. Cuza" University, Iasi, 700506, Rom.

SOURCE: Progress in Organic Coatings (2007), 58(4), 303-311
CODEN: POGCAT; ISSN: 0300-9440

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The temperature dependences of dc elec. conductivity, σ , and Seebeck coefficient, S,


for six recently synthesized quaternary salts of bipyridine and indolizine pyridine (GAL compds.) in thin films, have been investigated. The thin-film samples ($d = 0.06\text{--}0.60\ \mu\text{m}$) were deposited by spin-coating using DMF solns., onto glass. XRD was used for structure investigations, while AFM technique, corroborated to optical microscopy, was used for the examination of surface morphol. of samples. The present compds. behave as typical n-type polycryst. semiconductors. The activation energy of elec. conduction, ΔE , ranged between 1.61 and 1.73 eV, while the ratio of charge carrier mobilities, b , laid in the range 1.08-1.14. By studying optical absorption, direct band gaps ranging between 3.78 and 4.00 eV have been found. Some correlations between semiconducting parameters and mol. structure of the compds. were established. The model based on band gap representation can be conveniently used for the explanation of electronic transport in investigated compds. The investigated compds. are also suitable for applications in thermistor manufacture

IT 913530-39-9P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(mechanism of elec. conduction in thin films of quaternary salts of bipyridine and indolizine pyridine)

RN 913530-39-9 CAPLUS

CN Pyridinium, 4-[1-(ethoxycarbonyl)-3-(4-nitrobenzoyl)-7-indolizinyll]-1-methyl-, iodide (1:1) (CA INDEX NAME)



● I⁻

REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1283281 CAPLUS

DOCUMENT NUMBER: 147:406640

TITLE: Synthesis and evaluation of some 3-benzoylindolizine-1-carboxamides as possible anti-inflammatory and analgesic agents

AUTHOR(S): Som, Sukhen; Das, Amit Kumar

CORPORATE SOURCE: Dep. Pharmaceutical Chem., Krupanidhi Coll. Pharmacy, Bangalore, 560 034, India

SOURCE: Oriental Journal of Chemistry (2006), 22(2), 415-420

CODEN: OJCHEG; ISSN: 0970-020X

PUBLISHER: Oriental Scientific Publishing Co.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 147:406640

AB A series of 3-benzoylindolizine-1-carboxamide derivs. were synthesized by condensation of 3-benzoylindolizine-1-methylcarboxylate with various amino acids and amines and evaluated their anti-inflammatory and analgesic activity. Their structures were confirmed by their anal. and spectral data. Out of all compds., 2a, 2c, 2d, 3a, 3d, 3f, 3g and 3h have shown significant analgesic effect and 2a, 2b, 2c, 2d, 3b, 3d, 3f and 3g have shown significant anti-inflammatory activity.

IT 950860-74-9P 950860-76-1P 950860-78-3P

950860-79-4P 950860-80-7P 950860-81-8P

950860-82-9P 950860-83-0P 950860-84-1P

950860-85-2P 950860-86-3P 950860-87-4P

950860-88-5P 950860-89-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and antiinflammatory and analgesic activities of benzoylindolizine-carboxamides by condensation of benzoylindolizine-methylcarboxylate with amino acids and amines)

RN 950860-74-9 CAPLUS

CN L-Phenylalanine, N-[(3-benzoyl-1-indoliziny)carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 950860-76-1 CAPLUS


CN L-Valine, N-[(3-benzoyl-1-indoliziny)carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 950860-78-3 CAPLUS
 CN L-Leucine, N-[(3-benzoyl-1-indoliziny)carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 950860-79-4 CAPLUS
 CN L-Isoleucine, N-[(3-benzoyl-1-indoliziny)carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 950860-80-7 CAPLUS
 CN L-Lysine, N2-[(3-benzoyl-1-indoliziny)carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 950860-81-8 CAPLUS
 CN L-Alanine, N-[(3-benzoyl-1-indoliziny)carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 950860-82-9 CAPLUS
 CN 1-Indolizinecarboxamide, 3-benzoyl-N-phenyl- (CA INDEX NAME)




RN 950860-83-0 CAPLUS
 CN 1-Indolizinecarboxamide, 3-benzoyl-N,N-diethyl- (CA INDEX NAME)




RN 950860-84-1 CAPLUS
CN 1-Indolizinecarboxamide, 3-benzoyl-N-(1-methylethyl)- (CA INDEX NAME)




RN 950860-85-2 CAPLUS
CN 1-Indolizinecarboxamide, 3-benzoyl-N-propyl- (CA INDEX NAME)



RN 950860-86-3 CAPLUS
CN 1-Indolizinecarboxamide, 3-benzoyl-N-cyclohexyl- (CA INDEX NAME)




RN 950860-87-4 CAPLUS
CN 1-Indolizinecarboxamide, 3-benzoyl-N,N-diphenyl- (CA INDEX NAME)




RN 950860-88-5 CAPLUS

CN 1-Indolizinecarboxamide, 3-benzoyl-N,N-dimethyl- (CA INDEX NAME)



RN 950860-89-6 CAPLUS

CN 1-Indolizinecarboxamide, 3-benzoyl-N-(4-nitrophenyl)- (CA INDEX NAME)




IT 17281-79-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and antiinflammatory and analgesic activities of benzoylindolizine-carboxamides by condensation of benzoylindolizine-methylcarboxylate with amino acids and amines)

RN 17281-79-7 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-, methyl ester (CA INDEX NAME)



REFERENCE COUNT:

12

THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1135210 CAPLUS

DOCUMENT NUMBER: 146:45461

TITLE: Reaction of hexachloroacetone with activated acetylenes in the presence of N-heterocycles. Synthesis of trichloromethylated bridgehead N-heterocycles

AUTHOR(S): Yavari, Issa; Sabbaghan, Maryam; Hossaini, Zinatossadat

CORPORATE SOURCE: Chemistry Department, Tarbiat Modarres University, Tehran, Iran

SOURCE: Synlett (2006), (15), 2501-2503

CODEN: SYNLES; ISSN: 0936-5214

PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 146:45461

AB Pyridine reacts smoothly with hexachloroacetone (HCA) in the presence of dialkyl acetylenedicarboxylates or dibenzoylacetylene to produce indolizines. Under similar conditions, isoquinoline led to oxazino[2,3-a]isoquinolines and/or pyrrolo[2,1-a]isoquinolines. 3,3-Bis(trichloromethyl)-3H,4aH-[1,3]oxazino[2,3-a]quinoline-1,2-dicarboxylate or 1-methyl-7-(2,2,2-trichloroacetyl)-1H-pyrrolo[1,2-a]imidazole-5,6-dicarboxylate was obtained from the reaction of quinoline or N-methylimidazole with acetylenedicarboxylate in the presence of HCA.


IT 916486-34-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of bicyclic nitrogen hetarenes by reaction of perchloroacetone with activated acetylenes in presence of heterocycles)

RN 916486-34-5 CAPLUS

CN Ethanone, 2,2,2-trichloro-1-(2,3-dibenzoyl-1-indoliziny)- (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:920113 CAPLUS

DOCUMENT NUMBER: 145:454920

TITLE: Improved synthesis of cationic pyridinium-substituted indolizines

AUTHOR(S): Furdui, Bianca; Dinica, Rodica; Druta, Ioan I.; Demeunynck, Martine

CORPORATE SOURCE: LEDSS UMR5616 & ICMG-FR2607, Universite Joseph Fourier, Grenoble, 38041, Fr.

SOURCE: Synthesis (2006), (16), 2640-2642

CODEN: SYNTBF; ISSN: 0039-7881

PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 145:454920

AB This paper describes the optimization of the synthesis of pyridinium-substituted indolizines. Different conditions, solution and solid-phase synthesis were used for the key step of [3 + 2] cycloaddn. The best yields and shortest reaction time were obtained by microwave-assisted solid-phase synthesis.


IT 913530-37-7P 913530-38-8P 913530-39-9P

RL: SPN (Synthetic preparation); PREP (Preparation)

(improved preparation of cationic pyridinium-substituted indolizines starting from methyl-pyridyl-pyridinium iodide and iodides via solution and solid-phase synthesis and key step of [3 + 2] cycloaddn. under microwave irradiation)

RN 913530-37-7 CAPLUS


CN Pyridinium, 4-[3-benzoyl-1-(ethoxycarbonyl)-7-indolizinyll]-1-methyl-, iodide (1:1) (CA INDEX NAME)




● I⁻

RN 913530-38-8 CAPLUS

CN Pyridinium, 4-[1-(ethoxycarbonyl)-3-(4-methoxybenzoyl)-7-indolizinyll]-1-methyl-, iodide (1:1) (CA INDEX NAME)



RN 913530-39-9 CAPLUS
 CN Pyridinium, 4-[1-(ethoxycarbonyl)-3-(4-nitrobenzoyl)-7-indolizinyll]-1-methyl-, iodide (1:1) (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:710810 CAPLUS
DOCUMENT NUMBER: 145:159773
TITLE: Benzimidazole derivative transcription
factor-modulating compounds for use as antiinfective
agents
INVENTOR(S): Alekshun, Michael N.; Amoo, Victor; Kim, Oak K.;
Verma, Atul K.
PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 405 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2006076009	A2	20060720	WO 2005-US14345	20050425
WO 2006076009	A3	20071227		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2005324492	A1	20060720	AU 2005-324492	20050425
CA 2562763	A1	20060720	CA 2005-2562763	20050425
US 20060160799	A1	20060720	US 2005-115024	20050425
EP 1742637	A2	20070117	EP 2005-856651	20050425
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			
JP 2008504233	T	20080214	JP 2007-509742	20050425
PRIORITY APPLN. INFO.:			US 2004-565047P	P 20040423
			US 2004-569032P	P 20040507
			US 2004-623251P	P 20041028
			WO 2005-US14345	W 20050425

OTHER SOURCE(S): MARPAT 145:159773

AB The invention provides substituted benzimidazole compds. useful as antiinfectives that decrease resistance, virulence, or growth of microbes. Also provided are methods for making and using the substituted benzimidazole compds., as well as pharmaceutical preps. for e.g. reducing antibiotic resistance and inhibiting biofilms.


IT 71348-79-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(benzimidazole derivative transcription factor-modulating compds. for use as antiinfective agents)

RN 71348-79-3 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-5,8-dimethyl-7-phenyl-, dimethyl ester (9CI) (CA INDEX NAME)



L3 ANSWER 13 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:583018 CAPLUS

DOCUMENT NUMBER: 145:210856

TITLE: Synthesis of a library of 1,2,3,7-tetrasubstituted indolizines using poly(ethylene glycol) as soluble support

AUTHOR(S): Yue, Guizhou; Chen, Zuxing; Yang, Guichun

CORPORATE SOURCE: School of Life Science, Sichuan Agriculture

University, Ya'an, Sichuan, 625014, Peop. Rep. China

SOURCE: Journal of Heterocyclic Chemistry (2006), 43(3), 781-786

CODEN: JHTCAD; ISSN: 0022-152X

PUBLISHER: HeteroCorporation

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A library of 1,2,3,7-tetrasubstituted indolizines was synthesized using poly(ethylene glycol) (PEG) as soluble polymer support. PEG-bound pyridinium salts reacted with alkenes or alkynes in the presence of Et₃N via 1,3-dipolar cycloaddn. to give PEG-bound indolizine derivs., which were cleaved by 1% KCN/MeOH to afford 1,2,3,7-tetrasubstituted indolizines in good to excellent yields.


IT 904811-35-4DP, PEG-supported 904812-99-3DP, PEG-supported

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn, of indolizine by dipolar cycloaddn. of pyridinium salts with alkenes or alkynes using poly(ethylene glycol) as soluble support)


RN 904811-35-4 CAPLUS

CN 7-Indolizinecarboxylic acid, 3-benzoyl-1-cyano- (CA INDEX NAME)



RN 904812-99-3 CAPLUS

CN 1,2,7-Indolizinetricarboxylic acid, 3-benzoyl-, 1,2-dimethyl ester (CA INDEX NAME)




IT 27415-65-2P 154224-64-3P


RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn, of indolizine by dipolar cycloaddn. of pyridinium salts with alkenes or alkynes using poly(ethylene glycol) as soluble support)

RN 27415-65-2 CAPLUS
CN 1,2,7-Indolizinetricarboxylic acid, 3-benzoyl-, trimethyl ester (8CI, 9CI)
(CA INDEX NAME)



RN 154224-64-3 CAPLUS
CN 7-Indolizinecarboxylic acid, 3-benzoyl-1-cyano-, methyl ester (CA INDEX
NAME)



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 14 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:430765 CAPLUS

DOCUMENT NUMBER: 145:124452

TITLE: Preparation of indolizine-1-carboxylic acid derivatives from pyridine ylide and electron deficient olefin

INVENTOR(S): Wang, Bingxiang; Xu, Zhuxiong; Yuan, Sheng; Dai, Yijun; Shen, Jian

PATENT ASSIGNEE(S): Nanjing Normal University, Peop. Rep. China

SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 10 pp.
CODEN: CNXXEV

DOCUMENT TYPE: Patent

LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
CN 1763039	A	20060426	CN 2005-10094358	20050915
PRIORITY APPLN. INFO.:			CN 2005-10094358	20050915

AB Indolizine-1-carboxylic acid derivs. are prepared by carrying out 1,3-dipole cycloaddn. of pyridine Ylide and electron deficient olefin (e.g. acrylate, acrylonitrile, or acrylamide) in solvent (e.g. benzene, toluene, dimethylbenzene, etc.) in the presence of oxidant (air, oxygen, or Cr (VI) compound, etc.) to obtain an indolizine derivative followed by hydrolysis.


IT 25627-87-6P

RL: IMF (Industrial manufacture); PREP (Preparation)

(Preparation of indolizine-1-carboxylic acid derivs. from pyridine ylide and electron deficient olefin)

RN 25627-87-6 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl- (CA INDEX NAME)



L3 ANSWER 15 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:103074 CAPLUS

DOCUMENT NUMBER: 145:281435

TITLE: Dimethyl 7-(N,N-dimethylamino)-3-(2-methoxybenzoyl)indolizine-1,2-dicarboxylate

AUTHOR(S): Hema, R.; Parthasarathi, V.; Ravikumar, K.; Sarkunam, K.; Nallu, M.

CORPORATE SOURCE: Department of Physics, Bharathidasan University, Tiruchirappalli, 620 024, India

SOURCE: Acta Crystallographica, Section E: Structure Reports Online (2006), E62(2), o706-o707
CODEN: ACSEBH; ISSN: 1600-5368
URL: <http://journals.iucr.org/e/issues/2006/02/00/1h6577/index.html>

PUBLISHER: Blackwell Publishing Ltd.

DOCUMENT TYPE: Journal; (online computer file)

LANGUAGE: English


AB In the title mol., C₂₂H₂₂N₂O₆, the planes of the two methoxycarbonyl groups are oriented at angles of 5.19(14) and 80.21(9)° with respect to that of the indolizine ring. In the crystal structure, the mols. are linked by weak intermol. C-H...O interactions to form centrosym. ring motifs. Crystallog. data are given.

IT 850131-20-3P, Dimethyl 7-(N,N-dimethylamino)-3-(2-methoxybenzoyl)indolizine-1,2-dicarboxylate

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(crystal structure of)

RN 850131-20-3 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 7-(dimethylamino)-3-(2-methoxybenzoyl)-, 1,2-dimethyl ester (CA INDEX NAME)




REFERENCE COUNT:

10

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 16 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1241435 CAPLUS
DOCUMENT NUMBER: 144:171228
TITLE: 3-Substituted indolizine-1-carbonitrile derivatives as
phosphatase inhibitors
AUTHOR(S): Weide, Timo; Arve, Lars; Prinz, Heino; Waldmann,
Herbert; Kessler, Horst
CORPORATE SOURCE: Department Chemie, Lehrstuhl II fuer Organische
Chemie, Technische Universitaet Muenchen, Garching,
D-85747, Germany
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006),
16(1), 59-63
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:171228
GI




AB In the course of studies directed toward the discovery of novel scaffolds
for medicinal application, we synthesized a series of 3-substituted
indolizine-1-carbonitrile derivs. Some of them, e.g., I, displayed
activity against MPtpA/MPtpB phosphatases which are involved in infectious
diseases. We report here the solid-phase synthesis and antiphosphatase
activity of a series of indolizines.
IT 873198-12-0P 873198-15-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)
(preparation of indolizinecarbonitrile amino acid derivs. as phosphatase
inhibitors)
RN 873198-12-0 CAPLUS
CN Benzenepropanoic acid, β -[[[(2S)-2-[(3-benzoyl-1-cyano-6-
indolizinyloxy]-4-methyl-1-oxopentyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 873198-15-3 CAPLUS

CN Benzenepropanoic acid, β -[[2-[4-[(3-benzoyl-1-cyano-5-indolizinyloxy)methoxy]phenyl]-4-methyl-1-oxopentyl]amino]- (CA INDEX NAME)




REFERENCE COUNT:

36

THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005:1154430 CAPLUS
 DOCUMENT NUMBER: 143:416211
 TITLE: 1-Glyoxylamide indolizines for treating lung and ovarian cancer
 INVENTOR(S): Li, Hao; Koya, Keizo; Sun, Lijun
 PATENT ASSIGNEE(S): Syntha Pharmaceuticals, Corp., USA
 SOURCE: PCT Int. Appl., 53 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005099824	A1	20051027	WO 2005-US9519	20050322
WO 2005099824	A8	20060413		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20050272766	A1	20051208	US 2005-88253	20050323
PRIORITY APPLN. INFO.:			US 2004-557467P	P 20040330
OTHER SOURCE(S):	MARPAT 143:416211			
GI				



AB A method of treating a subject having lung cancer or ovarian cancer is disclosed, comprising administering to the subject an effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt, solvate, or polymorph thereof: Ring A is substituted or unsubstituted and optionally fused to an aryl group. Z¹ and Z² are independently O, S, N-OR¹² or NR¹²; R¹ and R² are independently -H, an aliphatic group, a substituted aliphatic group, an unsubstituted non-aromatic heterocyclic group, a substituted non-aromatic heterocyclic group, an aryl group or a substituted aryl group, provided that R¹ and R² are not both -H. Alternatively, -NR¹R², taken together, is a substituted or unsubstituted non-aromatic nitrogen-containing heterocyclic group or a substituted or unsubstituted nitrogen-containing heteroaryl group. R³ is a substituted or unsubstituted aryl group or a substituted or unsubstituted aliphatic group. X is a covalent bond, -C(R⁴R⁵)-, -N(R⁴)-, -O-, -S-, -S(O)-, -S(O)₂-, -C(=O)-, -C(=O)-N(R⁴)-, or -N(R⁴)-C(=O)-. R⁴ and R⁵ are

independently -H or a substituted or unsubstituted aliphatic group. R12 is -H or a substituted or unsubstituted alkyl group.


IT 501948-27-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(1-glyoxylamide indolizines for treating lung and ovarian cancer)

RN 501948-27-2 CAPLUS

CN 1-Indolizineacetamide, 3-(4-cyanobenzoyl)-N-(3-methyl-5-isothiazolyl)- α -oxo- (CA INDEX NAME)



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 18 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1030602 CAPLUS

DOCUMENT NUMBER: 145:62482

TITLE: Solvent effects on the fluorescence properties of indolizines

AUTHOR(S): Shen, Zhuying; Chen, Wei; Shen, Yongmiao; Du, Jiangyan; Wang, Bingxiang; Shen, Jian; Hu, Hongwen

CORPORATE SOURCE: School of Chemistry and Environmental Science, Nanjing Normal University; Jiangsu Research Center of Biomedical Functional Materials Engineering, Nanjing, Jiangsu Province, 210097, Peop. Rep. China

SOURCE: Nanjing Shida Xuebao, Ziran Kexueban (2005), 28(1), 58-61

CODEN: NSXZEN; ISSN: 1001-4616

PUBLISHER: Nanjing Shida Xuebao Bianjibu

DOCUMENT TYPE: Journal

LANGUAGE: Chinese

AB A series of indolizines were synthesized with pyridinium and alkene through cyclization reaction. Their photophys. properties in ethanol, dichloromethane, toluene and cyclohexane were analyzed by their UV-visible (UV-Vis) absorption and fluorescence spectra. The relationships between their microcosmic structures and corresponding optical properties were investigated. The results showed that the effects of solvent polarity on Stoke's shift, fluorescence intensity and fluorescence quantum field were more evident than that on UV-Vis absorption spectra. The fluorescence properties of indolizines were mainly determined by their chemical structures. However, the effects of external factors such as solvent, temperature and pressure should be taken into consideration, too.


IT 154224-60-9

RL: FMU (Formation, unclassified); PRP (Properties); FORM (Formation, nonpreparative)

(solvent effects on fluorescence properties of indolizines)

RN 154224-60-9 CAPLUS

CN 1-Indolizinecarbonitrile, 3-benzoyl-5-methyl- (CA INDEX NAME)



L3 ANSWER 19 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:842568 CAPLUS

DOCUMENT NUMBER: 143:386877

TITLE: A novel coupling 1,3-dipolar cycloaddition sequence as a three-component approach to highly fluorescent indolizines

AUTHOR(S): Retaru, Alexandru V.; Druta, Ioan D.; Oeser, Thomas; Mueller, Thomas J. J.

CORPORATE SOURCE: Organisch-Chemisches Institut der Ruprecht-Karls-Universitaet Heidelberg, Heidelberg, D-69120, Germany

SOURCE: Helvetica Chimica Acta (2005), 88(7), 1798-1812

CODEN: HCACAV; ISSN: 0018-019X

PUBLISHER: Verlag Helvetica Chimica Acta

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:386877



AB Indolizine derivs. and biindolizine derivs. can be synthesized in moderate yields in a consecutive one-pot three-component process by a coupling/1,3-dipolar cycloaddn. sequence of a (hetero)arene carbonyl chloride, a terminal alkyne, and a suitable 1-(2-oxoethyl)pyridinium bromide. After the Sonogashira coupling, a [2+3] cycloaddn. of the in situ formed pyridinium ylide, an allyl-type 1,3-dipole, furnishes a cycloadduct that is instantaneously oxidatively aromatized to give the highly fluorescent indolizine derivs. that were unambiguously characterized by the X-ray-structure anal. of one compound Addnl., fluorescence studies with pyridinyl-substituted representatives reveal not only that indolizine derivs. and biindolizine derivs. are highly interesting fluorescence dyes but that their fluorescence color can also be reversibly switched upon altering the pH of the medium.

IT 866621-40-1P 866621-41-2P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (preparation of indolizine derivs. and study of their fluorescence properties)

RN 866621-40-1 CAPLUS



CN Methanone, [2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1-(4-methoxybenzoyl)-7-(4-pyridinyl)-3-indoliziny] (4-methoxyphenyl)- (CA INDEX NAME)



RN 866621-41-2 CAPLUS

CN Methanone, [1-benzoyl-2-[4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]butyl]-7-

(4-pyridinyl)-3-indolizinyll (4-methoxyphenyl)- (CA INDEX NAME)



REFERENCE COUNT:

48

THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 20 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:731272 CAPLUS

DOCUMENT NUMBER: 143:206426

TITLE: Use of 1,2,3-substituted indolizine derivatives as FGF inhibitors for the preparation of drugs for the treatment of diseases connected with pathological choroidal angiogenesis

INVENTOR(S): Badorc, Alain; Bono, Francoise; Bordes, Marie Francoise; Foidart, Jean Michel; Guillo, Nathalie; Noel, Agnes; Rakic, Jean Marie

PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.

SOURCE: Fr. Demande, 25 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
FR 2865934	A1	20050812	FR 2004-1094	20040205
FR 2865934	B1	20060505		
AU 2005216671	A1	20050909	AU 2005-216671	20050204
CA 2553895	A1	20050909	CA 2005-2553895	20050204
WO 2005082457	A2	20050909	WO 2005-FR253	20050204
WO 2005082457	A3	20051110		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1713543	A2	20061025	EP 2005-717556	20050204
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU			
CN 1917922	A	20070221	CN 2005-80004150	20050204
BR 2005007509	A	20070626	BR 2005-7509	20050204
JP 2007520534	T	20070726	JP 2006-551884	20050204
IN 2006KN02105	A	20070518	IN 2006-KN2105	20060726
MX 2006PA08864	A	20061030	MX 2006-PA8864	20060804
KR 2007034986	A	20070329	KR 2006-717920	20060904
PRIORITY APPLN. INFO.:			FR 2004-1094	A 20040205
			WO 2005-FR253	W 20050204

OTHER SOURCE(S): MARPAT 143:206426

GI



AB The invention discloses the use of 1,2,3-substituted indolizine derivs. I (R1 = OH, C1-5 alkoxy, carboxy, etc.; R2 = H, C1-5 alkyl, C3-6 cycloalkyl, etc.; A =CO, SO, SO2; R3, R4 = H, C1-5 alkoxy, amino, carboxy, etc.), or a pharmaceutically acceptable salt thereof, for the preparation of a medicament useful for the treatment of diseases related to pathol. choroidal angiogenesis.


IT 610765-84-9 610766-65-9 610766-66-0
610767-08-3 724700-78-1 727650-85-3
736133-23-6 741669-12-5 778573-49-2
848318-25-2 848463-13-8 862156-48-7
862156-49-8 862156-50-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(indolizine derivative FGF inhibitors for treatment of diseases connected with pathol. choroidal angiogenesis)


RN 610765-84-9 CAPLUS

CN Benzoic acid, 4-[(1-methoxy-2-methyl-3-indolizinyl)carbonyl]-, methyl ester (CA INDEX NAME)




RN 610766-65-9 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-(4-amino-3-methoxybenzoyl)-2-methyl- (CA INDEX NAME)




RN 610766-66-0 CAPLUS


CN Acetic acid, 2-[[3-(4-amino-3-methoxybenzoyl)-2-methyl-1-indolizinyl]oxy]- (CA INDEX NAME)




RN 610767-08-3 CAPLUS
 CN Methanone, (4-amino-3-methoxyphenyl) (1-methoxy-2-methyl-3-indolizinyloxy)-
 (CA INDEX NAME)



RN 724700-78-1 CAPLUS
 CN Methanone, (4-amino-3-methoxyphenyl) [1-[(4-chlorophenyl)methoxy]-2-methyl-3-indolizinyloxy]- (CA INDEX NAME)




RN 727650-85-3 CAPLUS
 CN Methanone, (4-amino-3-methoxyphenyl) [1-[(3-methoxyphenyl)methoxy]-2-methyl-3-indolizinyloxy]- (CA INDEX NAME)




RN 736133-23-6 CAPLUS

CN Benzoic acid, 4-[(1-methoxy-2-methyl-3-indolizinyloxy)methyl]- (CA INDEX NAME)




RN 741669-12-5 CAPLUS

CN Benzoic acid, 4-[[[3-(4-amino-3-methoxybenzoyl)-2-methyl-1-indolizinyloxy]methyl]- (CA INDEX NAME)




RN 778573-49-2 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-(4-carboxybenzoyl)-2-methyl- (CA INDEX NAME)



RN 848318-25-2 CAPLUS


CN Benzoic acid, 2-amino-5-[(1-methoxy-2-methyl-3-indoliziny)carbonyl]-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 848463-13-8 CAPLUS

CN Benzoic acid, 2-amino-5-[(1-methoxy-2-methyl-3-indoliziny)carbonyl]- (CA INDEX NAME)




RN 862156-48-7 CAPLUS

CN Benzoic acid, 2-amino-5-[[1-[(3-methoxybenzoyl)amino]-2-methyl-3-indoliziny]carbonyl]- (CA INDEX NAME)




RN 862156-49-8 CAPLUS

CN Benzoic acid, 2-amino-5-[[2-methyl-1-[(3,4,5-trimethoxybenzoyl)amino]-3-indoliziny]carbonyl]- (CA INDEX NAME)



RN 862156-50-1 CAPLUS

CN Benzoic acid, 2-amino-5-[[1-[[[(3-methoxyphenyl)sulfonyl]amino]-2-methyl-3-indoliziny]carbonyl]- (CA INDEX NAME)



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 21 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:555119 CAPLUS

DOCUMENT NUMBER: 143:241008

TITLE: Structural investigations of pyridin-4-yl indolizine modified β -cyclodextrin derivatives as

fluorescent chemosensors for organic guest molecules
AUTHOR(S): Delattre, Francois; Woisel, Patrice; Bria, Marc; Surpateanu, Gheorghe

CORPORATE SOURCE: Laboratoire de Synthèse Organique et Environnement, Université du Littoral Côte d'Opal, Dunkerque, F-59140, Fr.

SOURCE: Carbohydrate Research (2005), 340(10), 1706-1713
CODEN: CRBRAT; ISSN: 0008-6215

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB To study the substituent effects on their conformations and spectroscopic properties, pyridin-4-ylindolizine modified β -cyclodextrin derivs. were studied by 2-dimensional NMR (ROESY spectra) in D₂O, CD, and fluorescence spectroscopy. The linked indolizin- β -cyclodextrin compds. exhibited two types of conformations, as a function of the substituent, in which fluorescent moieties formed either an intramol. complex or were not included in the hydrophobic cavity of the macrocycle. Under addition of organic guest species in a phosphate buffer at neutral pH,

the

variation of emission fluorescence intensity showed that these compds. are of significance for detection of volatile organic mols. and adamantane derivs. and might be used as mol. chemosensor.

IT 676255-72-4 676255-73-5 676255-75-7

RL: ARU (Analytical role, unclassified); DEV (Device component use); PRP (Properties); ANST (Analytical study); USES (Uses)


(structural investigations of pyridin-4-yl indolizine modified β -cyclodextrin derivs. as fluorescent chemosensors for organic guest mols.)

RN 676255-72-4 CAPLUS


CN β -Cyclodextrin, 6A-[[[3-benzoyl-7-(4-pyridinyl)-1-indolizinyl]carbonyl]amino]-6A-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 676255-73-5 CAPLUS



CN β -Cyclodextrin, 6A-deoxy-6A-[[[3-(4-methylbenzoyl)-7-(4-pyridinyl)-1-indoliziny]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A



RN 676255-75-7 CAPLUS

CN β -Cyclodextrin, 6A-deoxy-6A-[[[3-(4-methoxybenzoyl)-7-(4-pyridinyl)-1-indolizinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

26

THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 22 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:497502 CAPLUS

DOCUMENT NUMBER: 143:53440

TITLE: Substituted benzoimidazole compounds as transcription factor-modulating compounds useful as anti-infectives

INVENTOR(S): Levy, Stuart B.; Alekshun, Michael N.; Podlogar, Brent L.; Ohemeng, Kwasi; Verma, Atul K.; Warchol, Tadeusz; Bhatia, Beena; Bowser, Todd; Grier, Mark

PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 463 pp., Cont.-in-part of U.S. Ser. No. 139,591.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050124678	A1	20050609	US 2003-700661	20031103
CA 2445515	A1	20021104	CA 2002-2445515	20020506
AU 2002367953	A1	20040106	AU 2002-367953	20020506
EP 1524974	A2	20050427	EP 2002-807554	20020506
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005519998	T	20050707	JP 2004-515557	20020506
US 20030229065	A1	20031211	US 2002-139591	20020814
US 20040106553	A1	20040603	US 2003-602562	20030624
PRIORITY APPLN. INFO.:				US 2001-288660P P 20010504
				US 2002-139591 A2 20020814
				US 2002-423319P P 20021101
				US 2002-425916P P 20021113
				WO 2002-US14255 W 20020506
				US 2002-391345P P 20020624
				US 2002-421218P P 20021025
				US 2002-429142P P 20021126
				US 2003-458935P P 20030331

OTHER SOURCE(S): MARPAT 143:53440

AB Substituted benzoimidazole compds. useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. Methods of making and using substituted benzoimidazole compds., as well as pharmaceutical preps. thereof, in, e.g., reducing antibiotic resistance and inhibiting biofilms. The present invention identifies microbial transcription factors, especially transcription factors of the AraC-XylS family,

as virulence factors in microbes and shows that inhibition of these factors reduces the virulence of microbial cells. Because these transcription factors control virulence, rather than essential cellular processes, the development of resistance is much less likely.


IT 71348-79-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(substituted benzoimidazole compds. as transcription factor-modulating compds. useful as anti-infectives)

RN 71348-79-3 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-5,8-dimethyl-7-phenyl-, dimethyl ester (9CI) (CA INDEX NAME)



L3 ANSWER 23 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:348086 CAPLUS

DOCUMENT NUMBER: 143:44021

TITLE: 1-(4-nitrophenoxy-carbonyl)-7-pyridin-4-yl indolizine:
A new versatile fluorescent building block.
Application to the synthesis of a series of
fluorescent β -cyclodextrins

AUTHOR(S): Delattre, Francois; Woisel, Patrice; Surpateanu,
Gheorghe; Cazier, Francine; Blach, Philippe

CORPORATE SOURCE: Laboratoire de Synthèse Organique et Environnement,
Université du Littoral Côte d'Opale, Dunkerque, 59140,
Fr.

SOURCE: Tetrahedron (2005), 61(16), 3939-3945

CODEN: TETRAB; ISSN: 0040-4020

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:44021

AB The synthesis of a series of new fluorescent building blocks incorporating
a pyridinoindolizine unit and two potentially reactive sites is described.
The reaction of fluorescent building blocks these with the
mono-6-amino-6-deoxy- β -cyclodextrin provides the corresponding
fluorescent water soluble hosts in good yield. The sensor properties of the
hosts in the presence of 1-adamantanol is described.

IT 853268-97-0 853268-98-1 853268-99-2

RL: PRP (Properties)

(fluorescence emission spectra of 1-(4-nitrophenoxy-carbonyl)-7-pyridin-
4-yl indol β -cyclodextrins with 1-adamantanol inclusion complexes)

RN 853268-97-0 CAPLUS

CN β -Cyclodextrin, 6A-[[[3-benzoyl-7-(4-pyridinyl)-1-
indolizinyl]carbonyl]amino]-6A-deoxy-, compd. with
tricyclo[3.3.1.1^{3,7}]decan-1-ol (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 676255-72-4


CMF C63 H83 N3 O36

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 768-95-6
CMF C10 H16 O




RN 853268-98-1 CAPLUS
 CN β -Cyclodextrin, 6A-deoxy-6A-[[[3-(4-methylbenzoyl)-7-(4-pyridinyl)-1-indolizinyl]carbonyl]amino]-, compd. with tricyclo[3.3.1.3⁷]decan-1-ol (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 676255-73-5
 CMF C64 H85 N3 O36

Absolute stereochemistry.

PAGE 1-A






CM 2

CRN 768-95-6

CMF C10 H16 O



RN 853268-99-2 CAPLUS

CN β -Cyclodextrin, 6A-deoxy-6A-[[[3-(4-methoxybenzoyl)-7-(4-pyridinyl)-1-indolizinyl]carbonyl]amino]-, compd. with tricyclo[3.3.1.3⁰,7]decan-1-ol (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 676255-75-7



CMF C64 H85 N3 O37

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




CM 2


CRN 768-95-6
CMF C10 H16 O




IT 853268-93-6P 853268-94-7P 853268-95-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of 1-(4-nitrophenoxy carbonyl)-7-pyridin-4-yl indolizine for use
 as a fluorescent synthon toward the synthesis of fluorescent
 β -cyclodextrins)
 RN 853268-93-6 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-benzoyl-7-(4-pyridinyl)-, 4-nitrophenyl
 ester (CA INDEX NAME)



RN 853268-94-7 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-(4-methylbenzoyl)-7-(4-pyridinyl)-,
 4-nitrophenyl ester (CA INDEX NAME)




RN 853268-95-8 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-(4-methoxybenzoyl)-7-(4-pyridinyl)-,
 4-nitrophenyl ester (CA INDEX NAME)




IT 676255-72-4P 676255-73-5P 676255-75-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of 1-(4-nitrophenoxycarbonyl)-7-pyridin-4-yl indolizine for use
 as a fluorescent synthon toward the synthesis of fluorescent
 β -cyclodextrins)
 RN 676255-72-4 CAPLUS
 CN β -Cyclodextrin, 6A-[[[3-benzoyl-7-(4-pyridinyl)-1-
 indolizinyl]carbonyl]amino]-6A-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 676255-73-5 CAPLUS

CN β -Cyclodextrin, 6A-deoxy-6A-[[[3-(4-methylbenzoyl)-7-(4-pyridinyl)-1-indoliziny]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 676255-75-7 CAPLUS

CN β -Cyclodextrin, 6A-deoxy-6A-[[[3-(4-methoxybenzoyl)-7-(4-pyridinyl)-1-indolizinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT:

63

THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 24 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:258661 CAPLUS

DOCUMENT NUMBER: 142:316694

TITLE: Preparation of 1,2,3-substituted indolizines as selective b-FGF antagonists and angiogenesis inhibitors for treatment of cancer and cardiovascular diseases

INVENTOR(S): Badorc, Alain; Bono, Francoise; Bordes, Marie Francoise; Guillo, Nathalie; Herbert, Jean Marc

PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.

SOURCE: Fr. Demande, 70 pp.

CODEN: FRXXBL



DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
FR 2859997	A1	20050325	FR 2003-10957	20030918
FR 2859997	B1	20060203		
WO 2005028476	A1	20050331	WO 2004-FR2347	20040916
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1664047	A1	20060607	EP 2004-787388	20040916
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007505867	T	20070315	JP 2006-526664	20040916
US 20060199962	A1	20060907	US 2006-378972	20060317
PRIORITY APPLN. INFO.:			FR 2003-10957	A 20030918
			WO 2004-FR2347	W 20040916
OTHER SOURCE(S):	MARPAT	142:316694		
GI				



- AB Title compds. I [wherein R = H, halo, Me, OH and derivs., CO₂H, etc.; R₁ = alkoxy, CO₂H and derivs., (un)substituted Ph; R₂ = cyclo/alkyl, (un)substituted Ph; R₃, R₄ = independently OH and derivs., NH₂, CO₂H, alkoxy, carbonyl, NO₂, etc.; and their pharmaceutically acceptable salts] were prepared as selective basic fibroblast growth factor (b-FGF) antagonists and angiogenesis inhibitors. For example, II (m.p. = 125°) was prepared by Chichibabin cyclization of Me 2-[5-(benzyloxy)pyridin-2-yl]acetate with chloroacetone followed by benzoylation with 3-methoxy-4-nitrobenzoyl chloride in DCE at room temperature for 60 h. I inhibited the growth of b-FGF-expressing tumor cell lines (HUVEC) with a specific activity in the range of 10⁻⁹ M to 10⁻⁵ M. I exhibited a specific activity in the range of 10⁻¹¹ M to 10⁻⁷ M in an angiogenesis test in vitro. I are active by oral administration of doses of 0.1 to 100 mg/kg. Thus, I are useful for treatment of cancer, certain cardiovascular diseases, diabetic retinopathy, chronic inflammations, hypo- and achondroplasia.
- IT 848317-36-2P, Methyl 8-hydroxy-3-(3-methoxy-4-nitrobenzoyl)-2-methylindolizine-1-carboxylate 848317-37-3P 848317-40-8P 848317-49-7P, Benzyl 7-[N-(tert-butoxycarbonyl)amino]-3-(3-methoxy-4-nitrobenzoyl)-2-methylindolizine-1-carboxylate 848317-51-1P, Benzyl 7-amino-3-(3-methoxy-4-nitrobenzoyl)-2-methylindolizine-1-carboxylate 848317-52-2P, Benzyl 7-(acetylamino)-3-(3-methoxy-4-nitrobenzoyl)-2-methylindolizine-1-carboxylate 848317-54-4P, Benzyl 7-[N-(tert-butoxycarbonyl)-N-methylamino]-3-(3-methoxy-4-nitrobenzoyl)-2-methylindolizine-1-carboxylate 848317-55-5P, Benzyl 3-(3-methoxy-4-nitrobenzoyl)-2-methyl-7-(methylamino)indolizine-1-carboxylate 848317-63-5P 848317-66-8P, Methyl 3-(4-amino-3-methoxybenzoyl)-6-hydroxy-2-methylindolizine-1-carboxylate 848317-72-6P, Methyl 3-(4-amino-3-methoxybenzoyl)-6-methoxy-2-methylindolizine-1-carboxylate 848317-74-8P, Methyl 3-(4-amino-3-methoxybenzoyl)-6-(2-ethoxy-2-oxoethoxy)-2-methylindolizine-1-carboxylate 848318-00-3P 848318-02-5P
- RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (b-FGF inhibitor; preparation of indolizines as selective b-FGF inhibitors)


RN 848317-36-2 CAPLUS

CN 1-Indolizinecarboxylic acid, 8-hydroxy-3-(3-methoxy-4-nitrobenzoyl)-2-methyl-, methyl ester (CA INDEX NAME)




RN 848317-37-3 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-(3-methoxy-4-nitrobenzoyl)-2-methyl-6-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 848317-40-8 CAPLUS

CN Benzoic acid, 5-[[[1-methoxy-2-methyl-6-[(methylamino)carbonyl]-3-indoliziny]carbonyl]-2-[(2,2,2-trifluoroacetyl)amino]-, methyl ester (CA INDEX NAME)




RN 848317-49-7 CAPLUS


CN 1-Indolizinecarboxylic acid, 7-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(3-methoxy-4-nitrobenzoyl)-2-methyl-, phenylmethyl ester (CA INDEX NAME)




RN 848317-51-1 CAPLUS
 CN 1-Indolizinecarboxylic acid, 7-amino-3-(3-methoxy-4-nitrobenzoyl)-2-methyl-, phenylmethyl ester (CA INDEX NAME)



RN 848317-52-2 CAPLUS
 CN 1-Indolizinecarboxylic acid, 7-(acetylamino)-3-(3-methoxy-4-nitrobenzoyl)-2-methyl-, phenylmethyl ester (CA INDEX NAME)




RN 848317-54-4 CAPLUS
 CN 1-Indolizinecarboxylic acid, 7-[[[(1,1-dimethylethoxy)carbonyl]methylamino]-3-(3-methoxy-4-nitrobenzoyl)-2-methyl-, phenylmethyl ester (CA INDEX NAME)




RN 848317-55-5 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-(3-methoxy-4-nitrobenzoyl)-2-methyl-7-(methylamino)-, phenylmethyl ester (CA INDEX NAME)




RN 848317-63-5 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-(4-amino-3-methoxybenzoyl)-8-(2-ethoxy-2-oxoethoxy)-2-methyl-, methyl ester (CA INDEX NAME)




RN 848317-66-8 CAPLUS


CN 1-Indolizinecarboxylic acid, 3-(4-amino-3-methoxybenzoyl)-6-hydroxy-2-methyl-, methyl ester (CA INDEX NAME)




RN 848317-72-6 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-(4-amino-3-methoxybenzoyl)-6-methoxy-2-methyl-, methyl ester (CA INDEX NAME)




RN 848317-74-8 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-(4-amino-3-methoxybenzoyl)-6-(2-ethoxy-2-oxoethoxy)-2-methyl-, methyl ester (CA INDEX NAME)



RN 848318-00-3 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-(3-methoxy-4-nitrobenzoyl)-2-methyl-6-(phenylmethoxy)- (CA INDEX NAME)



RN 848318-02-5 CAPLUS
 CN 1-Indolizinecarboxylic acid, 8-[2-(dimethylamino)ethoxy]-3-(3-methoxy-4-nitrobenzoyl)-2-methyl- (CA INDEX NAME)



IT 848317-35-1P, Methyl 8-(benzyloxy)-3-(3-methoxy-4-nitrobenzoyl)-2-methylindolizine-1-carboxylate 848317-38-4P 848317-39-5P
 848317-41-9P 848317-42-0P 848317-43-1P
 848317-44-2P, Methyl 8-methoxy-3-(3-methoxy-4-nitrobenzoyl)-2-methylindolizine-1-carboxylate 848317-45-3P 848317-46-4P
 848317-50-0P, Benzyl 7-[N-(ethoxycarbonyl)amino]-3-(3-methoxy-4-nitrobenzoyl)-2-methylindolizine-1-carboxylate 848317-53-3P,
 Benzyl 3-(3-methoxy-4-nitrobenzoyl)-2-methyl-7-[(methylsulfonyl)amino]indolizine-1-carboxylate 848317-56-6P,
 Benzyl 7-(dimethylamino)-3-(3-methoxy-4-nitrobenzoyl)-2-methylindolizine-1-carboxylate 848317-59-9P 848317-60-2P
 848317-61-3P 848317-62-4P 848317-64-6P, Methyl 3-(4-amino-3-methoxybenzoyl)-6-(benzyloxy)-2-methylindolizine-1-carboxylate hydrochloride 848317-68-0P, 3-(4-Amino-3-methoxybenzoyl)-6-hydroxy-2-methylindolizine-1-carboxylic acid sodium salt 848317-70-4P, 3-(4-Amino-3-methoxybenzoyl)-8-[2-(dimethylamino)ethoxy]-2-methylindolizine-1-carboxylic acid lithium salt 848317-76-0P, 7-(Acetyl-amino)-3-(4-amino-3-methoxybenzoyl)-2-methylindolizine-1-carboxylic acid 848317-77-1P
 848317-79-3P 848317-80-6P 848317-82-8P
 848317-84-0P 848317-86-2P, 2-[[3-(4-Amino-3-methoxybenzoyl)-1-(methoxycarbonyl)-2-methylindolizin-6-yl]oxy]acetic acid sodium salt 848317-88-4P, 3-(4-Amino-3-methoxybenzoyl)-6-(benzyloxy)-2-methylindolizine-1-carboxylic acid sodium salt 848317-90-8P 848317-92-0P 848317-94-2P,
 3-(4-Amino-3-methoxybenzoyl)-6-(carbomethoxy)-2-methylindolizine-1-carboxylic acid sodium salt 848317-96-4P, 3-(4-Amino-3-methoxybenzoyl)-8-(carbomethoxy)-2-methylindolizine-1-carboxylic acid disodium salt 848317-98-6P, 3-(4-Amino-3-methoxybenzoyl)-6-(methoxy)-2-methylindolizine-1-carboxylic acid sodium salt 848318-04-7P, 2-Amino-5-[[1-methoxy-2-methyl-6-[(methylamino)carbonyl]indolizin-3-yl]carbonyl]benzoic acid sodium salt 848318-05-8P 848318-06-9P 848318-07-0P,
 2-Amino-5-[(1-methoxy-2-methylindolizin-3-yl)carbonyl]benzamide


848318-08-1P, 2-Amino-N-hydroxy-5-[(1-methoxy-2-methylindolizin-3-yl)carbonyl]benzamide 848318-26-3P, 3-(4-Amino-3-methoxybenzoyl)-6-methoxy-2-methylindolizine-1-carboxylic acid 848318-27-4P, 3-(4-Amino-3-methoxybenzoyl)-1-methoxy-N-methyl-2-methylindolizine-6-carboxamide 848318-28-5P, 2-Amino-5-[[1-methoxy-2-methyl-6-[(methylamino)carbonyl]indolizin-3-yl]carbonyl]benzoic acid 848318-29-6P, 2-Amino-5-[(1,6-dimethoxy-2-methylindolizin-3-yl)carbonyl]benzoic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(b-FGF inhibitor; preparation of indolizines as selective b-FGF inhibitors)


RN 848317-35-1 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-(3-methoxy-4-nitrobenzoyl)-2-methyl-8-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 848317-38-4 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-(3-methoxy-4-nitrobenzoyl)-2,7-dimethyl-, methyl ester (CA INDEX NAME)




RN 848317-39-5 CAPLUS


CN 6-Indolizinecarboxamide, 1-methoxy-3-(3-methoxy-4-nitrobenzoyl)-N,2-dimethyl- (CA INDEX NAME)




RN 848317-41-9 CAPLUS
 CN 6-Indolizinecarboxamide, 1-methoxy-3-(3-methoxy-4-nitrobenzoyl)-N,N,2-trimethyl- (CA INDEX NAME)



RN 848317-42-0 CAPLUS
 CN Benzoic acid, 5-[[6-[(dimethylamino)carbonyl]-1-methoxy-2-methyl-3-indoliziny]carbonyl]-2-[(2,2,2-trifluoroacetyl)amino]-, methyl ester (CA INDEX NAME)




RN 848317-43-1 CAPLUS
 CN Benzoic acid, 5-[(1,6-dimethoxy-2-methyl-3-indoliziny]carbonyl]-2-[(2,2,2-trifluoroacetyl)amino]-, methyl ester (CA INDEX NAME)




RN 848317-44-2 CAPLUS

CN 1-Indolizinecarboxylic acid, 8-methoxy-3-(3-methoxy-4-nitrobenzoyl)-2-methyl-, methyl ester (CA INDEX NAME)




RN 848317-45-3 CAPLUS

CN 1-Indolizinecarboxylic acid, 8-(2-ethoxy-2-oxoethoxy)-3-(3-methoxy-4-nitrobenzoyl)-2-methyl-, methyl ester (CA INDEX NAME)




RN 848317-46-4 CAPLUS

CN 1-Indolizinecarboxylic acid, 8-[2-(dimethylamino)ethoxy]-3-(3-methoxy-4-nitrobenzoyl)-2-methyl-, methyl ester (CA INDEX NAME)




RN 848317-50-0 CAPLUS

CN 1-Indolizinecarboxylic acid, 7-[(ethoxycarbonyl)amino]-3-(3-methoxy-4-nitrobenzoyl)-2-methyl-, phenylmethyl ester (CA INDEX NAME)




RN 848317-53-3 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-(3-methoxy-4-nitrobenzoyl)-2-methyl-7-[(methylsulfonyl)amino]-, phenylmethyl ester (CA INDEX NAME)




RN 848317-56-6 CAPLUS

CN 1-Indolizinecarboxylic acid, 7-(dimethylamino)-3-(3-methoxy-4-nitrobenzoyl)-2-methyl-, phenylmethyl ester (CA INDEX NAME)




RN 848317-59-9 CAPLUS
 CN 6-Indolizinecarboxamide, 3-(4-amino-3-methoxybenzoyl)-1-methoxy-N,2-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 848317-60-2 CAPLUS
 CN 6-Indolizinecarboxamide, 3-(4-amino-3-methoxybenzoyl)-1-methoxy-N,N,2-trimethyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 848317-61-3 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-(4-amino-3-methoxybenzoyl)-2,7-dimethyl-, methyl ester (CA INDEX NAME)




RN 848317-62-4 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-(4-amino-3-methoxybenzoyl)-8-methoxy-2-methyl-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 848317-64-6 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-(4-amino-3-methoxybenzoyl)-2-methyl-6-(phenylmethoxy)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 848317-68-0 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-(4-amino-3-methoxybenzoyl)-6-hydroxy-2-methyl-, sodium salt (1:?) (CA INDEX NAME)




● x Na

RN 848317-70-4 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-(4-amino-3-methoxybenzoyl)-8-[2-(dimethylamino)ethoxy]-2-methyl-, lithium salt (1:1) (CA INDEX NAME)




● Li


RN 848317-76-0 CAPLUS
 CN 1-Indolizinecarboxylic acid, 7-(acetylamino)-3-(4-amino-3-methoxybenzoyl)-2-methyl- (CA INDEX NAME)




RN 848317-77-1 CAPLUS
 CN 1-Indolizinecarboxylic acid, 7-amino-3-(4-amino-3-methoxybenzoyl)-2-methyl- (CA INDEX NAME)




RN 848317-79-3 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-(4-amino-3-methoxybenzoyl)-7-
 [(ethoxycarbonyl)amino]-2-methyl- (CA INDEX NAME)




RN 848317-80-6 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-(4-amino-3-methoxybenzoyl)-2-methyl-7-
 [(methylsulfonyl)amino]- (CA INDEX NAME)




RN 848317-82-8 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-(4-amino-3-methoxybenzoyl)-2-methyl-7-
 (methylamino)- (CA INDEX NAME)



RN 848317-84-0 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-(4-amino-3-methoxybenzoyl)-7-(dimethylamino)-2-methyl- (CA INDEX NAME)




RN 848317-86-2 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-(4-amino-3-methoxybenzoyl)-6-(carboxymethoxy)-2-methyl-, 1-methyl ester, monosodium salt (9CI) (CA INDEX NAME)




● Na

RN 848317-88-4 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-(4-amino-3-methoxybenzoyl)-2-methyl-6-(phenylmethoxy)-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 848317-90-8 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-(4-amino-3-methoxybenzoyl)-2,7-dimethyl- (CA INDEX NAME)




RN 848317-92-0 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-(4-amino-3-methoxybenzoyl)-8-methoxy-2-methyl- (CA INDEX NAME)



RN 848317-94-2 CAPLUS


CN 1,6-Indolizinedicarboxylic acid, 3-(4-amino-3-methoxybenzoyl)-2-methyl-, 6-methyl ester, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 848317-96-4 CAPLUS


CN 1,8-Indolizinedicarboxylic acid, 3-(4-amino-3-methoxybenzoyl)-2-methyl-, 8-methyl ester, sodium salt (1:2) (CA INDEX NAME)



● 2 Na

RN 848317-98-6 CAPLUS


CN 1-Indolizinecarboxylic acid, 3-(4-amino-3-methoxybenzoyl)-6-methoxy-2-methyl-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 848318-04-7 CAPLUS


CN Benzoic acid, 2-amino-5-[[1-methoxy-2-methyl-6-[(methylamino)carbonyl]-3-indoliziny]carbonyl]-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 848318-05-8 CAPLUS

CN Benzoic acid, 2-amino-5-[[6-[(dimethylamino)carbonyl]-1-methoxy-2-methyl-3-indoliziny]carbonyl]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 848318-06-9 CAPLUS
 CN Benzoic acid, 2-amino-5-[(1,6-dimethoxy-2-methyl-3-indoliziny)carbonyl]-, sodium salt (1:1) (CA INDEX NAME)




● Na


RN 848318-07-0 CAPLUS
 CN Benzamide, 2-amino-5-[(1-methoxy-2-methyl-3-indoliziny)carbonyl]- (CA INDEX NAME)




RN 848318-08-1 CAPLUS
 CN Benzamide, 2-amino-N-hydroxy-5-[(1-methoxy-2-methyl-3-indoliziny)carbonyl]- (CA INDEX NAME)




RN 848318-26-3 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-(4-amino-3-methoxybenzoyl)-6-methoxy-2-methyl- (CA INDEX NAME)




RN 848318-27-4 CAPLUS
 CN 6-Indolizinecarboxamide, 3-(4-amino-3-methoxybenzoyl)-1-methoxy-N,2-dimethyl- (CA INDEX NAME)



RN 848318-28-5 CAPLUS
 CN Benzoic acid, 2-amino-5-[[1-methoxy-2-methyl-6-[(methylamino)carbonyl]-3-indoliziny]carbonyl]- (CA INDEX NAME)




RN 848318-29-6 CAPLUS
 CN Benzoic acid, 2-amino-5-[(1,6-dimethoxy-2-methyl-3-indoliziny)carbonyl]-
 (CA INDEX NAME)




IT 848318-23-0, Methyl [3-(4-amino-3-methoxybenzoyl)-6-(2-ethoxy-2-oxoethoxy)-2-methylindolizin-1-yloxy]acetate 848318-24-1, Methyl 3-(4-amino-3-methoxybenzoyl)-6-(benzyloxy)-2-methylindolizine-1-carboxylate 848318-25-2, Sodium 2-amino-5-[(1-methoxy-2-methylindolizin-3-yl)carbonyl]benzoate
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of indolizines as selective b-FGF inhibitors)


RN 848318-23-0 CAPLUS
 CN Acetic acid, 2-[[3-(4-amino-3-methoxybenzoyl)-6-(2-ethoxy-2-oxoethoxy)-2-methyl-1-indolizinyloxy]-, methyl ester (CA INDEX NAME)



RN 848318-24-1 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-(4-amino-3-methoxybenzoyl)-2-methyl-6-(phenylmethoxy)-, methyl ester (CA INDEX NAME)



RN 848318-25-2 CAPLUS
 CN Benzoic acid, 2-amino-5-[(1-methoxy-2-methyl-3-indoliziny)carbonyl]-, sodium salt (1:1) (CA INDEX NAME)



● Na

REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005:208275 CAPLUS
 DOCUMENT NUMBER: 143:247921
 TITLE: Adamantanol inclusion in fluorescent β -cyclodextrin derivatives. Theoretical study by molecular mechanics and quantum semi-empirical methods
 AUTHOR(S): Delattre, Francois; Woisel, Patrice; Cazier, Francine; Decock, Patrick; Surpateanu, Gheorghe
 CORPORATE SOURCE: Laboratoire de Synthèse Organique et Environnement, Dunkerque, 59140, Fr.
 SOURCE: Internet Electronic Journal of Molecular Design (2005), 4(1), 1-8
 CODEN: IEJMAT; ISSN: 1538-6414
 URL: ftp://biochempress.com/iejmd_2005_4_0001.pdf
 PUBLISHER: BioChem Press
 DOCUMENT TYPE: Journal; (online computer file)
 LANGUAGE: English

AB The more stable conformers of fluorescent β -CDs 1a-e have been established by MM3, AM1 and PM3 procedure methods. The inclusion of 1-adamantanol into the toroidal cavity of β -CD fragments of fluorescent β -CDs 1b-e was studied by the AM1 method and indicates that the internal closed complex 1 as more probable. The calculated results are in good agreement with the exptl. data obtained by fluorescence spectroscopy.

IT 863499-22-3

RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); PRP (Properties); RCT (Reactant); PROC (Process); RACT (Reactant or reagent)


(host; adamantanol inclusion in fluorescent β -cyclodextrin derivs. studied by mol. mechanics and semi-empirical methods)


RN 863499-22-3 CAPLUS

CN β -Cyclodextrin, 6A-[[[(3-benzoyl-7-phenyl-1-indoliziny]carbonyl]amino]-6A-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A






IT 863499-23-4 863499-24-5
 RL: PRP (Properties)
 (host; adamantanol inclusion in fluorescent β -cyclodextrin derivs.
 studied by mol. mechanics and semi-empirical methods)
 RN 863499-23-4 CAPLUS
 CN β -Cyclodextrin, 6A-deoxy-6A-[[[3-(4-methylbenzoyl)-7-phenyl-1-indoliziny]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 863499-24-5 CAPLUS
 CN β -Cyclodextrin, 6A-deoxy-6A-[[[3-(4-methoxybenzoyl)-7-phenyl-1-indoliziny]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





IT 863499-26-7
 RL: FMU (Formation, unclassified); PRP (Properties); FORM (Formation, nonpreparative)
 (inclusion complex; adamantanol inclusion in fluorescent β -cyclodextrin derivs. studied by mol. mechanics and semi-empirical methods)

RN 863499-26-7 CAPLUS

CN β -Cyclodextrin, 6A-[[[3-benzoyl-7-phenyl-1-indoliziny]carbonyl]amino]-6A-deoxy-, compd. with tricyclo[3.3.1.1^{3,7}]decan-1-ol (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 863499-22-3



CMF C64 H84 N2 O36

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2


CRN 768-95-6
CMF C10 H16 O




IT 863499-27-8 863499-28-9
 RL: PRP (Properties)
 (inclusion complex; adamantanol inclusion in fluorescent
 β -cyclodextrin derivs. studied by mol. mechanics and
 semi-empirical methods)
 RN 863499-27-8 CAPLUS
 CN β -Cyclodextrin, 6A-deoxy-6A-[[[3-(4-methylbenzoyl)-7-phenyl-1-
 indoliziny]carbonyl]amino]-, compd. with tricyclo[3.3.1.1^{3,7}]decan-1-ol
 (1:1) (9CI) (CA INDEX NAME)
 CM 1
 CRN 863499-23-4
 CMF C65 H86 N2 O36

Absolute stereochemistry.

PAGE 1-A






CM 2

CRN 768-95-6

CMF C10 H16 O



RN 863499-28-9 CAPLUS

CN β -Cyclodextrin, 6A-deoxy-6A-[[[3-(4-methoxybenzoyl)-7-phenyl-1-indoliziny]carbonyl]amino]-, compd. with tricyclo[3.3.1.1.3,7]decan-1-ol (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 863499-24-5



CMF C65 H86 N2 O37

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 768-95-6
CMF C10 H16 O




REFERENCE COUNT:


16

THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 26 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:167268 CAPLUS
 DOCUMENT NUMBER: 142:392243
 TITLE: Synthesis of some new indolizines
 AUTHOR(S): Sarkunam, K.; Nallu, M.
 CORPORATE SOURCE: Department of Chemistry, Bharathidasan University,
 Tiruchirappalli, 620 024, India
 SOURCE: Journal of Heterocyclic Chemistry (2005), 42(1), 5-11
 CODEN: JHTCAD; ISSN: 0022-152X
 PUBLISHER: HeteroCorporation
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 142:392243
 GI




I




II


AB The reaction between 4-dimethylaminopyridine and 2-bromoacetophenone(s) readily gives 1-[2-(4-substituted phenyl)-2-oxoethyl]-4-(dimethylamino)pyridinium bromides (I, R = H, 4-Me, 4-Cl, 2-MeO, 2,4-Cl₂, etc.). Action of aqueous NaOH on eight of these pyridinium bromides generates the corresponding pyridinium ylides, isolated as colored stable crystalline solids. Addition of the pyridinium ylides to di-Me acetylenedicarboxylate gives di-Me 3-(substituted benzoyl)-7-(dimethylamino)indolizine-1,2-dicarboxylates (II, same R) in 46-62% yields.
 IT 711603-81-5P 713542-02-0P 850131-18-9P
 850131-20-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of 3-(substituted benzoyl)-7-(dimethylamino)indolizine-1,2-dicarboxylates by dipolar cycloaddn. of pyridinium ylides and di-Me acetylenedicarboxylate)
 RN 711603-81-5 CAPLUS
 CN 1,2-Indolizinedicarboxylic acid, 7-(dimethylamino)-3-(4-methylbenzoyl)-, 1,2-dimethyl ester (CA INDEX NAME)




RN 713542-02-0 CAPLUS
 CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-7-(dimethylamino)-,
 1,2-dimethyl ester (CA INDEX NAME)



RN 850131-18-9 CAPLUS
 CN 1,2-Indolizinedicarboxylic acid, 7-(dimethylamino)-3-(4-methoxybenzoyl)-,
 1,2-dimethyl ester (CA INDEX NAME)



RN 850131-20-3 CAPLUS
 CN 1,2-Indolizinedicarboxylic acid, 7-(dimethylamino)-3-(2-methoxybenzoyl)-,
 1,2-dimethyl ester (CA INDEX NAME)



REFERENCE COUNT:

29

THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 27 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:79118 CAPLUS

DOCUMENT NUMBER: 142:316668

TITLE: Synthesis of new non-symmetrical substituted
7,7'-bisindolizines by the direct reaction of
4,4'-bipyridinium-ylides with dimethyl
acetylenedicarboxylate

AUTHOR(S): Rotaru, Alexandru V.; Danac, Ramona P.; Druta, Ioan D.

CORPORATE SOURCE: Department of Organic Chemistry, Faculty of Chemistry,
"Al. I. Cuza" University, Iasi, 700506, Rom.

SOURCE: Journal of Heterocyclic Chemistry (2004), 41(6),
893-897

CODEN: JHTCAD; ISSN: 0022-152X


PUBLISHER: HeteroCorporation

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:316668

GI



I

AB The authors report here on the synthesis of some novel non-sym.
substituted bisindolizines I (R = H, 4-Me, 4-MeO, 3-MeO, 4-Br, 4-Cl) by [3
+ 2] dipolar cycloaddn. reaction. New compds. were prepared by the direct
reaction of isolated non-sym. substituted 4,4'-bipyridinium bisylides with
di-Me acetylenedicarboxylate (DMAD). The obtained compds. can be used as
precursors of fluorescent markers in fluorometric anal.

IT 848005-69-6P 848005-70-9P 848005-71-0P


848005-72-1P 848005-73-2P 848005-74-3P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of non-sym. substituted 7,7'-bisindolizines by direct reaction
of di-Me acetylenedicarboxylate with 4,4'-bipyridinium-ylides obtained
from phenacylbromide and 4,4'-pyridine)


RN 848005-69-6 CAPLUS

CN [7,7'-Biindolizine]-1,1',2,2'-tetracarboxylic acid, 3-benzoyl-3'-(4-
nitrobenzoyl)-, 1,1',2,2'-tetramethyl ester (CA INDEX NAME)




RN 848005-70-9 CAPLUS

CN [7,7'-Biindolizine]-1,1',2,2'-tetracarboxylic acid, 3-(4-methylbenzoyl)-3'-(4-nitrobenzoyl)-, 1,1',2,2'-tetramethyl ester (CA INDEX NAME)




RN 848005-71-0 CAPLUS

CN [7,7'-Biindolizine]-1,1',2,2'-tetracarboxylic acid, 3-(4-methoxybenzoyl)-3'-(4-nitrobenzoyl)-, 1,1',2,2'-tetramethyl ester (CA INDEX NAME)




RN 848005-72-1 CAPLUS

CN [7,7'-Biindolizine]-1,1',2,2'-tetracarboxylic acid, 3-(3-methoxybenzoyl)-3'-(4-nitrobenzoyl)-, 1,1',2,2'-tetramethyl ester (CA INDEX NAME)




RN 848005-73-2 CAPLUS

CN [7,7'-Biindolizine]-1,1',2,2'-tetracarboxylic acid, 3-(4-bromobenzoyl)-3'-(4-nitrobenzoyl)-, 1,1',2,2'-tetramethyl ester (CA INDEX NAME)



RN 848005-74-3 CAPLUS

CN [7,7'-Biindolizine]-1,1',2,2'-tetracarboxylic acid, 3-(4-chlorobenzoyl)-3'-(4-nitrobenzoyl)-, 1,1',2,2'-tetramethyl ester (CA INDEX NAME)



REFERENCE COUNT:

15

THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 28 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:757276 CAPLUS

DOCUMENT NUMBER: 142:261356

TITLE: Synthesis and fluorescence properties of indolizines substituted with cyano groups

AUTHOR(S): Wang, Bing-Xiang; Shen, Yong-Miao; Shen, Jian; Li, Chun; Hu, Hong-Wen

CORPORATE SOURCE: College of Chemistry and Environment Science, Nanjing Normal University, Nanjing, 210097, Peop. Rep. China

SOURCE: Huaxue Xuebao (2004), 62(17), 1649-1652

CODEN: HHHPA4; ISSN: 0567-7351

PUBLISHER: Kexue Chubanshe

DOCUMENT TYPE: Journal

LANGUAGE: Chinese

OTHER SOURCE(S): CASREACT 142:261356

AB A series of indolizines were synthesized. The fluorescence spectra and fluorescence quantum yields of the title compds. were examined. It was found that the quantum yields increased if the cyano group was introduced into the indolizines, while the presence of carbonyl groups as substituents of indolizines resulted in fluorescence quenching.


IT 154224-60-9

RL: PRP (Properties)

(synthesis and fluorescence properties of indolizines substituted with cyano groups)

RN 154224-60-9 CAPLUS

CN 1-Indolizinecarbonitrile, 3-benzoyl-5-methyl- (CA INDEX NAME)



L3 ANSWER 29 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:731897 CAPLUS
DOCUMENT NUMBER: 142:197802
TITLE: Synthesis of 4-methylpyrrolo[2,1,5-cd]indolizines
AUTHOR(S): Li, Bin; Pan, Guo-Jun; He, Ting; Hu, Hong-Wen
CORPORATE SOURCE: Department of Chemistry, Nanjing University, Nanjing, 210093, Peop. Rep. China
SOURCE: Gaodeng Xuexiao Huaxue Xuebao (2004), 25(8), 1461-1464
CODEN: KTHPDM; ISSN: 0251-0790
PUBLISHER: Gaodeng Jiaoyu Chubanshe
DOCUMENT TYPE: Journal
LANGUAGE: Chinese
OTHER SOURCE(S): CASREACT 142:197802

AB Pyrrolo[2,1,5-cd]indolizine is the most interesting member of bicyclo[3,2,2]azine. Its derivs. have received considerable attention in the field of synthetic organic chemical due to their novel structure and properties, increasing biol. interest and because their partially saturated frameworks occur in natural products. Over recent years the [8+2] cycloaddn. of indolizine with an electron-deficient acetylene has been frequently employed for this purpose. In this paper we reported the synthesis of 5-methylpyrrolo[2,1,5-cd]indolizines starting from α -Et pyridine, which was converted at first to 3-acyl-5-Et indolizines by 1,3-dipolar cycloaddn. of the corresponding pyridinium ylide with electron-deficient olefines and then the indolizines were transformed to pyrrolo[2,1,5-cd]indolizines by intramol. condensation between the 3-acyl and the 5-Et groups.


IT 839698-07-6P 839698-09-8P 839698-11-2P

839698-13-4P 839698-14-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of methylpyrroloindolizines)


RN 839698-07-6 CAPLUS

CN 1-Indolizinecarbonitrile, 3-benzoyl-5-ethyl- (CA INDEX NAME)




RN 839698-09-8 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-5-ethyl-, methyl ester (CA INDEX NAME)




RN 839698-11-2 CAPLUS

CN Methanone, (1-benzoyl-5-ethyl-3-indoliziny)phenyl- (CA INDEX NAME)




RN 839698-13-4 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-5-ethyl-, 1,2-dimethyl ester
(CA INDEX NAME)



RN 839698-14-5 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-5-ethyl-, 1,2-diethyl ester
(CA INDEX NAME)



L3 ANSWER 30 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:534300 CAPLUS

DOCUMENT NUMBER: 141:65094

TITLE: Substituted 1-benzoyl-3-cyano-pyrrolo[1,2-a]quinolines and analogs as activators of caspases and inducers of apoptosis

INVENTOR(S): Cai, Sui Xiong; Drewe, John A.; Jiang, Sungchun; Kasibhatla, Shailaja; Kuemmerle, Jared Daniel; Sirisoma, Nilantha Sudath; Zhang, Han-Zhong

PATENT ASSIGNEE(S): Cytovia, Inc., USA

SOURCE: PCT Int. Appl., 106 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004055163	A2	20040701	WO 2003-US39550	20031212
WO 2004055163	A3	20040826		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003300883	A1	20040709	AU 2003-300883	20031212
US 20050014759	A1	20050120	US 2003-733229	20031212
US 7135480	B2	20061114		
EP 1578424	A2	20050928	EP 2003-813401	20031212
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRIORITY APPLN. INFO.:			US 2002-432608P	P 20021212
			WO 2003-US39550	W 20031212

OTHER SOURCE(S): MARPAT 141:65094

AB The invention discloses substituted 1-benzoyl-3-cyanopyrrolo[1,2-a]quinolines and analogs thereof. Compds. of the invention are activators of caspases and inducers of apoptosis. Therefore, the compds. of the invention can be used to induce cell death in a variety of clin. conditions in which uncontrolled growth and spread of abnormal cells occurs. Compound prepn is described.


IT 25627-81-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(benzoylcyanopyrroloquinolines and analogs as activators of caspases and inducers of apoptosis)

RN 25627-81-0 CAPLUS

CN 1-Indolizinecarbonitrile, 3-benzoyl- (CA INDEX NAME)




L3 ANSWER 31 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:445402 CAPLUS
 DOCUMENT NUMBER: 141:174037
 TITLE: Synthesis of monofluorinated indolizines and their derivatives by the 1,3-dipolar reaction of N-ylides with fluorinated vinyl tosylates
 AUTHOR(S): Fang, Xiang; Wu, Yong-Ming; Deng, Juan; Wang, Shao-Wu
 CORPORATE SOURCE: Key Laboratory of Organofluorine Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, 200032, Peop. Rep. China
 SOURCE: Tetrahedron (2004), 60(25), 5487-5493
 CODEN: TETRAB; ISSN: 0040-4020
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 141:174037
 GI



AB Monofluorinated indolizines, benzo[d]indolizines and 4H-pyrrolo[1,2-a]benzimidazoles were synthesized in moderate yields by 1,3-dipolar cycloaddn. reaction between fluorinated vinyl tosylates and N-ylides of pyridinium, isoquinolinium and benzimidazolium, generated in situ from their halide salts. When the same N-ylides were allowed to react with 2,3,3-trifluoro-1-propenyl tosylate, the unexpected product formylated indolizines and their derivs., e.g., I, were obtained. A reaction mechanism is also proposed.

IT 733054-21-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of indolizines via [3 + 2]-dipolar cycloaddn. of fluorovinyl tosylates with pyridinium halides)

RN 733054-21-2 CAPLUS
 CN 1-Indolizinecarboxaldehyde, 3-benzoyl-8-bromo- (CA INDEX NAME)



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 32 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:350189 CAPLUS

DOCUMENT NUMBER: 142:45034

TITLE: Synthesis and optical properties of indolizines carrying ester groups

AUTHOR(S): Shen, Yongmiao; Gu, Xiaotian; Feng, Yuying; Shen, Zhuying; Yuan, Liangzheng; Li, Chun; Hu, Hongwen; Wang, Bingxiang

CORPORATE SOURCE: School of Chemistry and Environmental Science, Nanjing Normal University, Nanjing, 210097, Peop. Rep. China

SOURCE: Nanjing Shida Xuebao, Ziran Kexueban (2003), 26(4), 65-68

CODEN: NSXZEN; ISSN: 1001-4616

PUBLISHER: Nanjing Shida Xuebao Bianjibu

DOCUMENT TYPE: Journal

LANGUAGE: Chinese

AB A series of indolizines were synthesized. The fluorescence spectrum and fluorescence quantum yields of the compds. were examined The indolizines (3b, 3d, 3e) have high fluorescence quantum yields.


IT 133619-68-8P

RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)

(preparation and optical properties of indolizines carrying ester groups)

RN 133619-68-8 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-5-methyl-, methyl ester (CA INDEX NAME)



L3 ANSWER 33 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:265443 CAPLUS

DOCUMENT NUMBER: 141:79729

TITLE: Dimethyl 7-(N,N-dimethylamino)-3-(4-methylbenzoyl)indolizine-1,2-dicarboxylate

AUTHOR(S): Hema, R.; Parthasarathi, V.; Ravikumar, K.; Sarkunam, K.; Nallu, M.

CORPORATE SOURCE: Department of Physics, Bharathidasan University, Tiruchirappalli, 620 024, India

SOURCE: Acta Crystallographica, Section E: Structure Reports Online (2004), E60(4), o537-o538
CODEN: ACSEBH; ISSN: 1600-5368

PUBLISHER: International Union of Crystallography

DOCUMENT TYPE: Journal; (online computer file)

LANGUAGE: English


AB In the title compound, C₂₂H₂₂N₂O₅, there are two mols. in the asym. unit. Crystallog. data are given. In each of them, the carboxylate groups are oriented perpendicular to each other and one of the carboxylate groups is almost coplanar with the indolizine moiety. In the solid state, weak intermol. C-H...O contacts are observed

IT 711603-81-5P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and crystal structure of)

RN 711603-81-5 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 7-(dimethylamino)-3-(4-methylbenzoyl)-, 1,2-dimethyl ester (CA INDEX NAME)




REFERENCE COUNT:

10

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 34 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:265419 CAPLUS
 DOCUMENT NUMBER: 141:96949
 TITLE: Dimethyl 3-benzoyl-7-(N,N-dimethylamino)indolizine-1,2-dicarboxylate
 AUTHOR(S): Hema, R.; Parthasarathi, V.; Ravikumar, K.; Sarkunam, K.; Nallu, M.
 CORPORATE SOURCE: Department of Physics, Bharathidasan University, Tiruchirappalli, 620 024, India
 SOURCE: Acta Crystallographica, Section E: Structure Reports Online (2004), E60(4), o479-o480
 CODEN: ACSEBH; ISSN: 1600-5368
 PUBLISHER: International Union of Crystallography
 DOCUMENT TYPE: Journal; (online computer file)
 LANGUAGE: English
 AB Crystals of the title compound are monoclinic, space group P21/c, with a 8.6333(9), b 27.515(3), c 7.9705(9) Å, β 99.781(2)°; Z = 4, dc = 1.354; R = 0.045, Rw(F2) = 0.134 for 4265 reflections. The mol. packing is influenced by weak intermol. C-H...O and C-H... π interactions. The carboxylate groups are oriented perpendicular to each other and one of them is almost coplanar with the indolizine moiety.
 IT 713542-02-0P, Dimethyl 3-benzoyl-7-(N,N-dimethylamino)indolizine-1,2-dicarboxylate
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (preparation and crystal structure of)
 RN 713542-02-0 CAPLUS
 CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-7-(dimethylamino)-, 1,2-dimethyl ester (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 35 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:252511 CAPLUS

DOCUMENT NUMBER: 140:287263

TITLE: Synthesis of 3-acylindolizines via cyclization of 2-methyl-1-phenacylpyridinium halides with sterically hindered reagents, and their use as intermediates in the preparation of 1-glyoxylamide indolizines

INVENTOR(S): Sun, Lijun; Koya, Keizo; Xia, Zhi-qiang; Przewloka, Teresa; Zhang, Shijie; Ono, Mitsunori

PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA

SOURCE: PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2004024727	A2	20040325	WO 2003-US28252	20030910
WO 2004024727	A3	20040603		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2496764	A1	20040325	CA 2003-2496764	20030910
AU 2003267071	A1	20040430	AU 2003-267071	20030910
EP 1537105	A2	20050608	EP 2003-749545	20030910
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1681813	A	20051012	CN 2003-821740	20030910
JP 2006504692	T	20060209	JP 2004-536391	20030910
US 20040152897	A1	20040805	US 2003-660358	20030911
NO 2005001009	A	20050404	NO 2005-1009	20050224
MX 2005PA02745	A	20050603	MX 2005-PA2745	20050311
PRIORITY APPLN. INFO.:			US 2002-410679P	P 20020913
			WO 2003-US28252	W 20030910

OTHER SOURCE(S): MARPAT 140:287263

GI



AB The invention is related to a method for preparing 3-acylindolizines I by reacting a substrate II with either the cyclization reagent $R_3C(OR_2)2N(R_4)_2$ or, a reagent prepared by reaction of $R_3C(:O)N(R_4)_2$ with an alkylating agent [A = (un)substituted aryl; X = covalent bond, or C(:O), S(:O), SO₂, NH and derivs., (un)substituted methylene; R₀ = H, halo, CN, CO₂H and derivs., C(:O)H and derivs., CONH₂ and derivs., SO₂H and derivs., SO₂NH₂ and derivs., (un)substituted aliphatic, aryl, non-aromatic heterocyclyl; R₁ = H, CN, OH and derivs., SH and derivs., NH₂ and derivs., (un)substituted aliphatic, aryl, non-aromatic heterocyclyl; R₂ = independently (un)substituted aliphatic, aryl, or both R₂ = linking group; R₃ = H, (un)substituted aryl; or an electron-withdrawing, or electron-donating group provided that if R₃ = H, at least one R₂ = secondary or tertiary alkyl, (un)substituted aryl; R₄ = independently H, (un)substituted aliphatic, aryl; or R₄NR₄ = (un)substituted heterocyclyl]. The advantages include high yields in the 3-acylindolizine, absence of 2-acylindolizine byproduct, and an environmental-friendly process. The invention is also directed to the use of I in the preparation of pharmacol. active 1-glyoxylamide indolizines III by further acylation of I with oxalyl chloride or a synthetic equivalent, and reaction with amines [B = (un)substituted ring or fused to an aryl group; R₅, R₆ = independently H, (un)substituted aliphatic, non-aromatic heterocyclyl, aryl, provided that R₅ or R₆ are not both H, or NR₅R₆ = (un)substituted non-aromatic heterocyclyl, aryl; R₁, R₂, X defined as above]. For example, 4-[(Indolizin-3-yl)carbonyl]benzonitrile was prepared by cyclization of IV•Br⁻ with N,N-dimethylformamide di-tert-butylacetal in DMF.


IT 675139-41-0DP, derivs.

RL: PNU (Preparation, unclassified); PREP (Preparation)


(1-glyoxylamide indolizine; synthesis of indolizines via cyclization of 2-methyl-1-phenacylpyridinium halides with amidoacetals)

RN 675139-41-0 CAPLUS

CN 1-Indolizineacetamide, 3-benzoyl- α -oxo- (CA INDEX NAME)



IT 675139-24-9P, 4-[(1-Methylindolizin-3-yl)carbonyl]benzonitrile
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP
 (Preparation)
 (indolizine product; synthesis of indolizines via cyclization of
 2-methyl-1-phenacylpyridinium halides with amidoacetals)
 RN 675139-24-9 CAPLUS
 CN Benzonitrile, 4-[(1-methyl-3-indoliziny)carbonyl]- (CA INDEX NAME)



L3 ANSWER 36 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:164572 CAPLUS

DOCUMENT NUMBER: 140:374815

TITLE: Reaction Modes and Mechanism in Indolizine
Photooxygenation Reactions

AUTHOR(S): Li, Yun; Hu, Hua-You; Ye, Jian-Ping; Fun, Hoong-Kun;
Hu, Hong-Wen; Xu, Jian-Hua

CORPORATE SOURCE: Department of Chemistry, Nanjing University, Nanjing,
210093, Peop. Rep. China

SOURCE: Journal of Organic Chemistry (2004), 69(7), 2332-2339
CODEN: JOCEAH; ISSN: 0022-3263

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 140:374815

AB Photooxygenations of 1,2-, 1,3-, and 2,3-di- and 1,2,3-trisubstituted indolizines under different reaction conditions in methanol and acetonitrile have been investigated to establish the general reaction pattern and mechanism in indolizine photooxygenation in view of the influence of the ring substituents and substitution pattern. Photooxygenations of 1-acyl-2-phenylindolizines and 1,3-dibenzoyl-2-phenylindolizine are self-sensitized, while those of 1-(p-nitrobenzoyl)-2-phenylindolizine and 2-phenyl-3-(p-chlorobenzoyl)indolizine need to be sensitized by rose bengal (RB) or methylene blue (MB). These reactions proceed via a singlet oxygen mechanism yet follow different pathways in methanol and in acetonitrile, with peroxidic zwitterion (in methanol) and dioxetane across the indolizine C2-C3 bond (in acetonitrile) as the intervening intermediates. Methanol trapping of the peroxidic zwitterion results in C3-N bond cleavage and pyrrole ring opening to give the corresponding (E)- and (Z)-3-(2-pyridinyl)-3-benzoylpropenoic acid Me esters and 4-(2-pyridinyl)-3-phenyl-5-aryl-5-hydroxyfuran-2-one as products in methanol, while O-O bond homolysis of the dioxetane furnishes 3-(2-pyridinyl)-3-benzoyl-2-phenyloxirane-2-carboxaldehyde and 1-(6-methyl-2-pyridinyl)-2-phenylethanedione as products in acetonitrile. 3-Benzoyl-1-indolizinecarboxylic acid Me ester is unreactive toward singlet oxygen; however, it could be photooxygenated under electron transfer conditions with 9,10-dicyanoanthracene (DCA) as a sensitizer. This reaction takes place by the combination of the indolizine cation radical with the superoxide anion radical (or mol. oxygen) to give the pyridine ring oxidized Me 3-benzoyl-5-methoxy-8-hydroxy-1-indolizinecarboxylate, di-Me 2-(2-pyridinyl)fumarate, and di-Me 2-(2-pyridinyl)maleate as products.


IT 496034-76-5P

RL: SPN (Synthetic preparation); PREP (Preparation)


(0..reaction modes and mechanism in indolizine photooxygenation reactions)

RN 496034-76-5 CAPLUS


CN 1-Indolizinecarboxylic acid, 3-benzoyl-8-hydroxy-5-methoxy-, methyl ester
(CA INDEX NAME)



IT 683774-96-1
 RL: CPS (Chemical process); FMU (Formation, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); RCT (Reactant); FORM (Formation, nonpreparative); PROC (Process); RACT (Reactant or reagent) (radical cation intermediate; reaction modes and mechanism in indolizine photooxygenation reactions)
 RN 683774-96-1 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-benzoyl-, methyl ester, radical ion(1+) (9CI) (CA INDEX NAME)



IT 17281-79-7
 RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); RCT (Reactant); PROC (Process); RACT (Reactant or reagent) (reaction modes and mechanism in indolizine photooxygenation reactions)
 RN 17281-79-7 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-benzoyl-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 67 THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2004:75169 CAPLUS
 DOCUMENT NUMBER: 140:287610
 TITLE: 1,3-Dipolar cycloaddition reaction of bipyridinium ylides with the propynamido- β -cyclodextrin. A regiospecific synthesis of a new class of fluorescent β -cyclodextrins
 AUTHOR(S): Delattre, Francois; Woisel, Patrice; Surpateanu, Gheorghe; Bria, Marc; Cazier, Francine; Decock, Patrick
 CORPORATE SOURCE: Laboratoire de Synthèse Organique et Environnement, Dunkerque, 59140, Fr.
 SOURCE: Tetrahedron (2004), 60(7), 1557-1562
 CODEN: TETRAB; ISSN: 0040-4020
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 140:287610

AB The 1,3-dipolar cycloaddn. reaction of bipyridinium ylides with the electron deficient propynamido- β -cyclodextrin was studied. This reaction resulted in the regiospecific formation of a new class of fluorescent β -cyclodextrins. The new fluorophore systems were characterized spectroscopically by their absorption and emission maxima and their quantum yields.

IT 676255-72-4P 676255-73-5P 676255-75-7P
 676255-76-8P


RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (regioselective preparation of fluorescent β -cyclodextrins via dipolar cycloaddn. reaction of bipyridinium ylides with propynamido- β -CD)


RN 676255-72-4 CAPLUS

CN β -Cyclodextrin, 6A-[[[3-benzoyl-7-(4-pyridinyl)-1-indoliziny]carbonyl]amino]-6A-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A






RN 676255-73-5 CAPLUS
 CN β -Cyclodextrin, 6A-deoxy-6A-[[[3-(4-methylbenzoyl)-7-(4-pyridinyl)-1-indoliziny]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 676255-75-7 CAPLUS

CN β -Cyclodextrin, 6A-deoxy-6A-[[[3-(4-methoxybenzoyl)-7-(4-pyridinyl)-1-indolizinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 676255-76-8 CAPLUS

CN β -Cyclodextrin, 6A-deoxy-6A-[[[3-(4-nitrobenzoyl)-7-(4-pyridinyl)-1-indoliziny]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT:

62

THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 38 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:20322 CAPLUS
DOCUMENT NUMBER: 140:87658
TITLE: Peptidomimetic modulators of cell adhesion
INVENTOR(S): Gour, Barbara J.; Blaschuk, Orest W.; Ali, Anmar; Ni, Feng; Chen, Zhigang; Michaud, Stephanie Denise; Wang, Shaomeng; Hu, Zengjian
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 280 pp., Cont.-in-part of U.S. Ser. No. 6,982.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 15
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040006011	A1	20040108	US 2003-425557	20030428
US 6031072	A	20000229	US 1997-893534	19970711
US 6326352	B1	20011204	US 2000-507102	20000217
US 20020168761	A1	20021114	US 2001-769145	20010124
US 20020151475	A1	20021017	US 2001-6982	20011204
US 6914044	B2	20050705		

PRIORITY APPLN. INFO.:

US 1996-21612P	P	19960712
US 1997-893534	A1	19970711
US 2000-491078	B2	20000124
US 2000-507102	A1	20000217
US 2001-769145	B2	20010124
US 2001-6982	A2	20011204

OTHER SOURCE(S): MARPAT 140:87658


AB Peptidomimetics of cyclic peptides, and compns. comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.

IT 256432-37-8, Ethanone, 1-[3-benzoyl-7-[(4-nitrophenyl)methyl]-1-indoliziny]-
indoliziny]-
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)

(peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

RN 256432-37-8 CAPLUS

CN Ethanone, 1-[3-benzoyl-7-[(4-nitrophenyl)methyl]-1-indoliziny]- (CA INDEX NAME)



L3 ANSWER 39 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:971725 CAPLUS
DOCUMENT NUMBER: 140:35893
TITLE: Transcription factor modulating compounds and methods of use thereof
INVENTOR(S): Levy, Stuart B.; Alekshun, Michael N.; Podlogar, Brent L.; Ohemeng, Kwasi; Verma, Atul K.; Warchol, Tadeusz; Bhatia, Beena
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 301 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030229065	A1	20031211	US 2002-139591	20020814
CA 2445515	A1	20021104	CA 2002-2445515	20020506
WO 2004001058	A2	20031231	WO 2002-US14255	20020506
WO 2004001058	A3	20050303		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002367953	A1	20040106	AU 2002-367953	20020506
EP 1524974	A2	20050427	EP 2002-807554	20020506
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2005519998	T	20050707	JP 2004-515557	20020506
US 20050124678	A1	20050609	US 2003-700661	20031103
PRIORITY APPLN. INFO.:			US 2001-288660P	P 20010504
			WO 2002-US14255	W 20020506
			US 2002-139591	A2 20020814
			US 2002-423319P	P 20021101
			US 2002-425916P	P 20021113

OTHER SOURCE(S): MARPAT 140:35893

AB Methods for identifying compound useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. In one embodiment, the method comprises contacting a microbial cell comprising: (1) a selectable marker under the control of a transcription factor responsive element and (2) a transcription factor, with a compound under conditions which allow interaction of the compound with the microbial cell; and measuring the ability of the compound to affect the growth or survival of the microbial cell as an indication of whether the test compound modulates the activity of a transcription factor.

IT 71348-79-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(transcription factor modulating compds. as anti-infectives agents that decrease resistance and virulence and growth identified by determining


marker

under control of responsive element)

RN 71348-79-3 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-5,8-dimethyl-7-phenyl-,

dimethyl ester (9CI) (CA INDEX NAME)



L3 ANSWER 40 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:887680 CAPLUS
DOCUMENT NUMBER: 139:364844
TITLE: Preparation of indolizines as sPLA2 inhibitors
INVENTOR(S): Dillard, Robert D.; Hagishita, Sanji; Ohtani, Mitsuaki
PATENT ASSIGNEE(S): Eli Lilly and Company, USA; Shiongi and Company, Ltd.
SOURCE: U.S., 62 pp., Cont.-in-part of U.S. Ser. No. 278,445.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6645976	B1	20031111	US 1997-765566	19970428
WO 9603383	A1	19960208	WO 1995-US9381	19950720
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 1994-278445	A2 19940721
			WO 1995-US9381	W 19950720
OTHER SOURCE(S):			MARPAT 139:364844	
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I, II, III [wherein X = O or S; R11 = independently H, alkyl, or halo; R12 = H, halo, (cyclo)alkyl, cycloalkenyl, alkoxy, alkylthio, or a non-interfering substituent having 1-3 atoms other than H; R13 = (un)substituted alkyl, alkenyl, alkynyl, (hetero)cyclyl optionally connected by a linking group; R15 and R16 = independently H, non-interfering substituent, or (un)substituted (hetero)cyclyl; R17 and R18 = independently H, non-interfering substituent, or acidic linker; with the proviso that at least one of R17 and R18 must be an acidic linker; or pharmaceutically acceptable salt, ester, or amide prodrug derivs. thereof], and their 3-acetamide, 3-acetic acid hydrazide, and 3-glyoxylamide analogs were prepared as inhibitors of human secreted phospholipase A2 (sPLA2) mediated release of fatty acids. For example, conversion of 2-methyl-5-methoxypyridine to the anion in THF using lithium diisopropylamide and subsequent reaction with benzonitrile produced 5-methoxy-2-phenacylpyridine (57.0%). Cyclization of the pyridine derivative with 1-bromo-2-butanone using NaHCO₃ in acetone gave the 1-benzoylindolizine (90.7%), which was reduced by LAH to give 1-benzyl-2-ethyl-6-methoxyindolizine (94.5%). Acylation (98.5%) with Et oxalyl chloride in benzene, followed by saponification with LiOH in H₂O and amidation using NH₄OH, provided 2-(1-benzyl-2-ethyl-6-methoxyindolizin-3-yl)glyoxylamide. Demethylation by BBr₃ in CH₂Cl₂, coupling with Et 4-bromobutyrate (56.2%) in the presence of NaH in DMF, and hydrolysis with LiOH gave the title indolizine IV (49.9%). Eighty-eight compds. of the invention inhibited recombinant human sPLA2 in a chromogenic assay with IC₅₀ values ranging from 0.006 μ M to 1.1 μ M, in contrast to IC₅₀ values >50 μ M for comparative examples. Administration of 10/mg/kg of the representative compound, 2-[8-(carbomethoxymethoxy)-2-ethyl-3-(2-phenylbenzyl)indolizin-1-yl]glyoxylamide, improved the survival rate of

male Wistar rats with sPLA2-induced pancreatitis from 33.3% (vehicle) to 91.7%. Thus, invention compds. and their pharmaceutical formulations are useful for the treatment of conditions such as septic shock, adult respiratory distress syndrome, pancreatitis, trauma, bronchial asthma, allergic rhinitis, and rheumatoid arthritis.


- IT 177558-52-0P, Ethyl 2-[8-benzyloxy-2-ethyl-3-(o-phenylbenzoyl)indolizin-1-yl]acetate 177558-53-1P, 2-[8-Benzyloxy-2-ethyl-3-(o-phenylbenzoyl)indolizin-1-yl]acetamide 177558-54-2P, 2-[8-Benzyloxy-3-(m-chlorobenzoyl)-2-ethylindolizin-1-yl]acetamide 177558-55-3P, 2-[3-(m-Chlorobenzoyl)-2-ethyl-8-(2-oxobutyloxy)indolizin-1-yl]acetamide 177558-66-6P, Ethyl 3-benzoyl-8-benzyloxy-2-ethylindolizine-1-carboxylate 177558-67-7P, Ethyl 8-benzyloxy-2-ethyl-3-(o-phenylbenzoyl)indolizine-1-carboxylate 177558-68-8P, Ethyl 8-benzyloxy-3-(m-chlorobenzoyl)-2-ethylindolizine-1-carboxylate 177558-69-9P, Ethyl 8-benzyloxy-2-ethyl-3-(m-trifluoromethylbenzoyl)indolizine-1-carboxylate 177558-70-2P, Ethyl 8-benzyloxy-2-ethyl-3-(1-naphthoyl)indolizine-1-carboxylate 622835-97-6P, 2-[8-Benzyloxy-2-ethyl-3-(o-phenylbenzoyl)indolizin-1-yl]ethanol
- RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
- (intermediate; preparation of indolizines as inhibitors of sPLA2 mediated release of fatty acids)
- RN 177558-52-0 CAPLUS
- CN 1-Indolizineacetic acid, 3-([1,1'-biphenyl]-2-ylcarbonyl)-2-ethyl-8-(phenylmethoxy)-, ethyl ester (CA INDEX NAME)




- RN 177558-53-1 CAPLUS
- CN 1-Indolizineacetamide, 3-([1,1'-biphenyl]-2-ylcarbonyl)-2-ethyl-8-(phenylmethoxy)- (CA INDEX NAME)




- RN 177558-54-2 CAPLUS
- CN 1-Indolizineacetamide, 3-(3-chlorobenzoyl)-2-ethyl-8-(phenylmethoxy)- (CA INDEX NAME)




RN 177558-55-3 CAPLUS
 CN 1-Indolizineacetamide, 3-(3-chlorobenzoyl)-2-ethyl-8-(2-oxobutoxy)- (CA INDEX NAME)



RN 177558-66-6 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-benzoyl-2-ethyl-8-(phenylmethoxy)-, ethyl ester (CA INDEX NAME)




RN 177558-67-7 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-([1,1'-biphenyl]-2-ylcarbonyl)-2-ethyl-8-(phenylmethoxy)-, ethyl ester (CA INDEX NAME)




RN 177558-68-8 CAPLUS


CN 1-Indolizinecarboxylic acid, 3-(3-chlorobenzoyl)-2-ethyl-8-(phenylmethoxy)-
, ethyl ester (CA INDEX NAME)




RN 177558-69-9 CAPLUS
CN 1-Indolizinecarboxylic acid, 2-ethyl-8-(phenylmethoxy)-3-[3-(trifluoromethyl)benzoyl]-, ethyl ester (CA INDEX NAME)



RN 177558-70-2 CAPLUS
CN 1-Indolizinecarboxylic acid, 2-ethyl-3-(1-naphthalenylcarbonyl)-8-(phenylmethoxy)-, ethyl ester (CA INDEX NAME)



RN 622835-97-6 CAPLUS
CN Methanone, [1,1'-biphenyl]-2-yl[2-ethyl-1-(2-hydroxyethyl)-8-(phenylmethoxy)-3-indoliziny]- (CA INDEX NAME)



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 41 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:798417 CAPLUS

DOCUMENT NUMBER: 139:307679

TITLE: Preparation of 1,2,3-substituted indolizines as selective b-FGF antagonists and angiogenesis inhibitors for treatment of cancer and cardiovascular diseases

INVENTOR(S): Badorc, Alain; Guillo, Nathalie; Bono, Francoise; Herbert, Jean Marc

PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.

SOURCE: Fr. Demande, 71 pp.

CODEN: FRXXBL



DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
FR 2838123	A1	20031010	FR 2002-4220	20020404
FR 2838123	B1	20050610		
CA 2476056	A1	20031016	CA 2003-2476056	20030402
WO 2003084956	A1	20031016	WO 2003-FR1030	20030402
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003240984	A1	20031020	AU 2003-240984	20030402
EP 1495023	A1	20050112	EP 2003-730302	20030402
EP 1495023	B1	20050907		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003009026	A	20050209	BR 2003-9026	20030402
CN 1649867	A	20050803	CN 2003-807736	20030402
AT 304013	T	20050915	AT 2003-730302	20030402
JP 2005532286	T	20051027	JP 2003-582153	20030402
ES 2247540	T3	20060301	ES 2003-730302	20030402
NZ 534786	A	20060630	NZ 2003-534786	20030402
IN 2004KN01212	A	20060303	IN 2004-KN1212	20040819
NO 2004004156	A	20050103	NO 2004-4156	20040930
MX 2004PA09639	A	20050713	MX 2004-PA9639	20041001
US 20050203126	A1	20050915	US 2004-509919	20041004
PRIORITY APPLN. INFO.:			FR 2002-4220	A 20020404
			WO 2003-FR1030	W 20030402
OTHER SOURCE(S):	MARPAT 139:307679			
GI				




AB Title compds. I [wherein R1 = OH, carboxy, alkoxy, alkoxy, amino and derivs., (un)substituted alkoxy, aminoalkylcarbonyl, etc.; R2 = alkyl, cycloalkyl, (un)substituted Ph; A = CO, SO or SO₂; R3, R4 = identical or different selected from H, alkoxy, amino and derivs., carboxy, alkoxy, amino, NO₂, hydroxyamino, (un)substituted alkylsulfonylamino, aminoalkoxy, etc.; or R3 and R4 = 5 or 6-membered heterocycle; with the proviso that when R3 = alkoxy, and R4 = (un)substituted aminoalkoxy or OH, R1 cannot be alkoxy; and their pharmaceutical acceptable salts] were prepared as selective basic fibroblast growth factor (b-FGF) antagonists and angiogenesis inhibitors. For example, II was prepared by Chichibabin cyclization of 2-(methoxymethyl)pyridine with chloroacetone, followed by benzoylation of the 1-methoxy-2-methylindolizine intermediate with 3-methoxy-4-nitrobenzoyl chloride in DCE at room temperature for 4 h. I inhibited the growth of b-FGF-expressing tumor cell lines (HUVEC) with a specific activity in the range of 10⁻⁹ M to 10⁻⁵ M. I exhibited a specific activity in the range of 10⁻¹¹ M to 10⁻⁷ M in an angiogenesis test in vitro. I are active by oral administration of doses of 0.1 to 100 mg/kg. Thus, I are useful for treatment of cancer, certain cardiovascular diseases, diabetic retinopathy, chronic inflammations, hypo- and achondroplasia.

II 610765-77-0P, (1-Methoxy-2-methyl-indolizin-3-yl)(3-methoxy-4-nitrophenyl)methanone 610765-79-2P, (1-Benzyloxy-2-methyl-indolizin-3-yl)(3-methoxy-4-nitrophenyl)methanone 610765-84-9P, (1-Methoxy-2-methyl-indolizin-3-yl)(4-methoxycarbonylphenyl)methanone 610765-89-4P, (1-Ethoxycarbonyl-2-methyl-indolizin-3-yl)(3-methoxy-4-nitrophenyl)methanone 610765-95-2P, (1-Amino-2-methyl-indolizin-3-yl)(3-methoxy-4-nitrophenyl)methanone 610765-97-4P, (3-Methoxy-4-nitrophenyl)[2-methyl-1-(methylamino)-indolizin-3-yl]methanone 610765-99-6P, (1-Hydroxy-2-methyl-indolizin-3-yl)(3-methoxy-4-nitrophenyl)methanone 610766-01-3P, [1-(2-Chloro-benzyloxy)-2-methyl-indolizin-3-yl](3-methoxy-4-nitrophenyl)methanone 610766-11-5P, [1-(2-Acetyloxyethoxy)-2-methyl-indolizin-3-yl](3-methoxy-4-nitrophenyl)methanone 610766-16-0P, Methyl 4-[(1-hydroxy-2-methyl-indolizin-3-yl)carbonyl]benzoate 610766-19-3P, 3-(3-Methoxy-4-nitrobenzoyl)-2-methyl-1-carboxyindolizine 610766-24-0P, (4-Amino-3-methoxyphenyl)(1-methoxy-2-methyl-indolizin-3-yl)methanone hydrochloride 610766-27-3P, (4-Amino-3-methoxyphenyl)(1-ethoxycarbonyl-2-methyl-


indolizin-3-yl)methanone hydrochloride 610766-65-9P,
 3-(4-Amino-3-methoxybenzoyl)-2-methyl-1-indolizine carboxylic acid
 610766-77-3P, Ethyl 2-[2-methoxy-4-[(1-methoxy-2-methyl-indolizin-
 3-yl)carbonyl]anilino]acetate 610766-81-9P, 3-(Dibutylamino)-N-
 [2-methoxy-4-[(1-methoxy-2-methyl-indolizin-3-
 yl)carbonyl]phenyl]propanamide hydrochloride 610766-85-3P, Ethyl
 2-[3-(dibutylamino)propanoyl]-2-methoxy-4-[(1-methoxy-2-methyl-indolizin-
 3-yl)carbonyl]anilino]acetate hydrochloride 610766-89-7P,
 N-[2-Methoxy-4-[(1-methoxy-2-methyl-indolizin-3-yl)carbonyl]phenyl]-2-
 (dibutylamino)-1-ethanesulfonamide hydrochloride 610766-92-2P,
 3-[3-Methoxy-4-[(methylsulfonyl)amino]benzoyl]-2-methyl-1-
 (ethoxycarbonyl)indolizine 610767-04-9P, (4-Amino-3-
 methoxyphenyl)[1-[(2-chlorobenzyl)oxy]-2-methyl-indolizin-3-yl]methanone
 610767-08-3P, (4-Amino-3-methoxyphenyl)(1-methoxy-2-methyl-
 indolizin-3-yl)methanone 610767-11-8P, 2-[[[2-
 (Dibutylamino)ethyl]sulfonyl]-2-methoxy-4-[(1-methoxy-2-methyl-indolizin-3-
 yl)carbonyl]anilino]acetic acid 610767-12-9P,
 N-[2-Methoxy-4-[(1-methoxy-2-methyl-indolizin-3-yl)carbonyl]phenyl]-2-
 (dibutylamino)-1-ethanesulfonamide 610767-13-0P,
 3-[3-Methoxy-4-[(methylsulfonyl)amino]benzoyl]-2-methyl-1-
 carboxyindolizine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (b-FGF inhibitor; preparation of indolizines as selective b-FGF inhibitors)
 RN 610765-77-0 CAPLUS
 CN Methanone, (1-methoxy-2-methyl-3-indoliziny1)(3-methoxy-4-nitrophenyl)-
 (CA INDEX NAME)




RN 610765-79-2 CAPLUS
 CN Methanone, (3-methoxy-4-nitrophenyl)[2-methyl-1-(phenylmethoxy)-3-
 indoliziny1]- (CA INDEX NAME)




RN 610765-84-9 CAPLUS
 CN Benzoic acid, 4-[(1-methoxy-2-methyl-3-indoliziny1)carbonyl]-, methyl
 ester (CA INDEX NAME)




RN 610765-89-4 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-(3-methoxy-4-nitrobenzoyl)-2-methyl-, ethyl ester (CA INDEX NAME)



RN 610765-95-2 CAPLUS
 CN Methanone, (1-amino-2-methyl-3-indoliziny) (3-methoxy-4-nitrophenyl)- (CA INDEX NAME)




RN 610765-97-4 CAPLUS
 CN Methanone, (3-methoxy-4-nitrophenyl) [2-methyl-1-(methylamino)-3-indoliziny]- (CA INDEX NAME)




RN 610765-99-6 CAPLUS

CN Methanone, (1-hydroxy-2-methyl-3-indoliziny1) (3-methoxy-4-nitrophenyl)-
(CA INDEX NAME)




RN 610766-01-3 CAPLUS

CN Methanone, [1-[(2-chlorophenyl)methoxy]-2-methyl-3-indoliziny1] (3-methoxy-4-nitrophenyl)- (CA INDEX NAME)




RN 610766-11-5 CAPLUS

CN Methanone, [1-[2-(acetyloxy)ethoxy]-2-methyl-3-indoliziny1] (3-methoxy-4-nitrophenyl)- (CA INDEX NAME)




RN 610766-16-0 CAPLUS


CN Benzoic acid, 4-[(1-hydroxy-2-methyl-3-indoliziny1)carbonyl]-, methyl ester (CA INDEX NAME)



RN 610766-19-3 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-(3-methoxy-4-nitrobenzoyl)-2-methyl- (CA INDEX NAME)




RN 610766-24-0 CAPLUS
 CN Methanone, (4-amino-3-methoxyphenyl)(1-methoxy-2-methyl-3-indoliziny)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 610766-27-3 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-(4-amino-3-methoxybenzoyl)-2-methyl-, ethyl ester, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 610766-65-9 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-(4-amino-3-methoxybenzoyl)-2-methyl- (CA INDEX NAME)




RN 610766-77-3 CAPLUS

CN Glycine, N-[2-methoxy-4-[(1-methoxy-2-methyl-3-indoliziny]carbonyl]phenyl]-, ethyl ester (CA INDEX NAME)




RN 610766-81-9 CAPLUS

CN Propanamide, 3-(dibutylamino)-N-[2-methoxy-4-[(1-methoxy-2-methyl-3-indoliziny]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 610766-85-3 CAPLUS
 CN Glycine, N,N-dibutyl- β -alanyl-N-[2-methoxy-4-[(1-methoxy-2-methyl-3-indolizinyl)carbonyl]phenyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 610766-89-7 CAPLUS
 CN Ethanesulfonamide, 2-(dibutylamino)-N-[2-methoxy-4-[(1-methoxy-2-methyl-3-indolizinyl)carbonyl]phenyl]-, hydrochloride (1:?) (CA INDEX NAME)



●_x HCl


RN 610766-92-2 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-[3-methoxy-4-[(methylsulfonyl)amino]benzoyl]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 610767-04-9 CAPLUS

CN Methanone, (4-amino-3-methoxyphenyl) [1-[(2-chlorophenyl)methoxy]-2-methyl-3-indoliziny]- (CA INDEX NAME)




RN 610767-08-3 CAPLUS

CN Methanone, (4-amino-3-methoxyphenyl) (1-methoxy-2-methyl-3-indoliziny)- (CA INDEX NAME)




RN 610767-11-8 CAPLUS

CN Glycine, N-[[2-(dibutylamino)ethyl]sulfonyl]-N-[2-methoxy-4-[(1-methoxy-2-methyl-3-indoliziny)carbonyl]phenyl]- (CA INDEX NAME)




RN 610767-12-9 CAPLUS

CN Ethanesulfonamide, 2-(dibutylamino)-N-[2-methoxy-4-[(1-methoxy-2-methyl-3-indoliziny]carbonyl]phenyl]- (CA INDEX NAME)



RN 610767-13-0 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-[3-methoxy-4-[(methylsulfonyl)amino]benzoyl]-2-methyl- (CA INDEX NAME)



IT 610323-42-7P, (4-Amino-3-methoxyphenyl)-(1-t-butoxycarbonylamino-2-methyl-indolizin-3-yl)methanone 610765-80-5P, (1-Benzyloxy-2-methyl-indolizin-3-yl)(4-methoxycarbonylphenyl)methanone 610765-83-8P, (1-Methoxy-2-methyl-indolizin-3-yl)(4-nitrophenyl)methanone 610765-85-0P, (1-Methoxy-2-methyl-indolizin-3-yl)(3-methoxycarbonylphenyl)methanone 610765-86-1P, (1-Methoxy-2-methyl-indolizin-3-yl)(3-nitro-4-methoxycarbonylphenyl)methanone 610765-87-2P, (1-Methoxy-2-methyl-indolizin-3-yl)(3-methoxy-4-methoxycarbonylphenyl)methanone 610765-88-3P, (1-Methoxy-2-methyl-indolizin-3-yl)(4-methoxycarbonylmethylphenyl)methanone 610765-90-7P, (1-Ethoxycarbonyl-2-methyl-indolizin-3-yl)(3-methoxy-4-methoxycarbonylphenyl)methanone 610765-92-9P, (1-Ethoxycarbonyl-2-methyl-indolizin-3-yl)(4-methoxycarbonylphenyl)methanone 610765-93-0P, [1-[(Methyl)(benzyl)amino]-2-methyl-indolizin-3-yl](3-methoxy-4-nitrophenyl)methanone 610765-94-1P, (1-t-Butoxycarbonylamino-2-methyl-indolizin-3-yl)(3-methoxy-4-


nitrophenyl)methanone 610765-96-3P, N-[3-(3-Methoxy-4-nitrobenzoyl)-2-methyl-indolizin-1-yl]methanesulfonamide 610765-98-5P, [1-(Dimethylamino)-2-methyl-indolizin-3-yl](3-methoxy-4-nitrophenyl)methanone 610766-02-4P, [1-(3-Chloro-benzyloxy)-2-methyl-indolizin-3-yl](3-methoxy-4-nitrophenyl)methanone 610766-03-5P, [1-(4-Chloro-benzyloxy)-2-methyl-indolizin-3-yl](3-methoxy-4-nitrophenyl)methanone 610766-04-6P, [1-(2-Methoxy-benzyloxy)-2-methyl-indolizin-3-yl](3-methoxy-4-nitrophenyl)methanone 610766-05-7P, [1-(3-Methoxy-benzyloxy)-2-methyl-indolizin-3-yl](3-methoxy-4-nitrophenyl)methanone 610766-06-8P, [1-(4-Methoxy-benzyloxy)-2-methyl-indolizin-3-yl](3-methoxy-4-nitrophenyl)methanone 610766-07-9P, [1-(3-Methoxycarbonyl-benzyloxy)-2-methyl-indolizin-3-yl](3-methoxy-4-nitrophenyl)methanone 610766-08-0P, [1-(Ethoxycarbonylmethyloxy)-2-methyl-indolizin-3-yl](3-methoxy-4-nitrophenyl)methanone 610766-09-1P, [1-(Aminocarbonylmethyloxy)-2-methyl-indolizin-3-yl](3-methoxy-4-nitrophenyl)methanone 610766-10-4P, [1-(2-Dimethylaminoethoxy)-2-methyl-indolizin-3-yl](3-methoxy-4-nitrophenyl)methanone 610766-12-6P, [1-(2-Hydroxyethoxy)-2-methyl-indolizin-3-yl](3-methoxy-4-nitrophenyl)methanone 610766-13-7P, [1-(Cyanomethyloxy)-2-methyl-indolizin-3-yl](3-methoxy-4-nitrophenyl)methanone 610766-14-8P, (1-i-Propoxy-2-methyl-indolizin-3-yl)(3-methoxy-4-nitrophenyl)methanone 610766-15-9P, [1-(Cyclopropylmethoxy)-2-methyl-indolizin-3-yl](3-methoxy-4-nitrophenyl)methanone 610766-17-1P, Methyl 4-[[1-(2-ethoxy-2-oxoethoxy)-2-methyl-indolizin-3-yl]carbonyl]benzoate 610766-18-2P, Methyl 4-[[1-(3-methoxybenzyloxy)-2-methyl-indolizin-3-yl]carbonyl]benzoate 610766-20-6P, N-Ethyl 3-(3-methoxy-4-nitrobenzoyl)-2-methyl-1-indolizinecarboxamide 610766-21-7P, Ethyl 2-[[[3-(3-methoxy-4-nitrobenzoyl)-2-methyl-indolizin-1-yl]carbonyl]amino]acetate 610766-28-4P, (4-Amino-3-methoxyphenyl)(1-(ethoxycarbonylmethoxy)-2-methyl-indolizin-3-yl)methanone hydrochloride 610766-29-5P, (4-Amino-3-methoxyphenyl)(1-(2-aminocarbonylmethyloxy)-2-methyl-indolizin-3-yl)methanone hydrochloride 610766-30-8P, (4-Amino-3-methoxyphenyl)(1-(2-hydroxyethoxy)-2-methyl-indolizin-3-yl)methanone hydrochloride 610766-31-9P, (4-Aminophenyl)(1-methoxy-2-methyl-indolizin-3-yl)methanone hydrochloride 610766-32-0P, (3-Methoxy-4-aminophenyl)(1-ethylaminocarbonyl-2-methyl-indolizin-3-yl)methanone hydrochloride 610766-33-1P, (4-Amino-3-methoxyphenyl)[1-[(2-chlorobenzyl)oxy]-2-methyl-indolizin-3-yl]methanone hydrochloride 610766-35-3P, (4-Amino-3-methoxyphenyl)(1-[2-(dimethylamino)ethoxy]-2-methyl-indolizin-3-yl)methanone hydrochloride 610766-36-4P, (4-Amino-3-methoxyphenyl)[1-[(4-chlorobenzyl)oxy]-2-methyl-indolizin-3-yl]methanone hydrochloride 610766-37-5P, (4-Amino-3-methoxyphenyl)[1-[(3-methoxybenzyl)oxy]-2-methyl-indolizin-3-yl]methanone hydrochloride 610766-38-6P, (4-Amino-3-methoxyphenyl)[1-[(4-methoxybenzyl)oxy]-2-methyl-indolizin-3-yl]methanone hydrochloride 610766-40-0P, (4-Amino-3-methoxyphenyl)[1-[(2-methoxybenzyl)oxy]-2-methyl-indolizin-3-yl]methanone hydrochloride 610766-42-2P, (4-Amino-3-methoxyphenyl)[1-[(3-methoxycarbonylbenzyl)oxy]-2-methyl-indolizin-3-yl]methanone hydrochloride 610766-43-3P, (4-Amino-3-methoxyphenyl)[1-[(4-methoxycarbonylbenzyl)oxy]-2-methyl-indolizin-3-yl]methanone hydrochloride 610766-44-4P, (4-Amino-3-methoxyphenyl)[1-[(3-chlorobenzyl)oxy]-2-methyl-indolizin-3-yl]methanone hydrochloride 610766-45-5P, (4-Amino-3-methoxyphenyl)-[1-[(methyl)(benzyl)amino]-2-methyl-indolizin-3-yl]methanone hydrochloride 610766-46-6P, (4-Amino-3-methoxyphenyl)-[2-methyl-1-(methylamino)-indolizin-3-yl]methanone hydrochloride 610766-47-7P, (4-Amino-3-methoxyphenyl)-[2-methyl-1-(methylsulfonylamino)-indolizin-3-yl]methanone hydrochloride 610766-48-8P, [3-Amino-4-(methoxycarbonyl)phenyl](1-methoxy-2-

methyl-indolizin-3-yl)methanone 610766-51-3P,
 (4-Amino-3-methoxyphenyl)[1-(cyclopropylmethoxy)-2-methyl-indolizin-3-yl]methanone hydrochloride 610766-52-4P, (4-Amino-3-methoxyphenyl)[1-(isobutoxy)-2-methyl-indolizin-3-yl]methanone hydrochloride 610766-54-6P, (4-Amino-3-methoxyphenyl)[1-(dimethylamino)-2-methyl-indolizin-3-yl]methanone dihydrochloride 610766-56-8P, Sodium 4-[(1-methoxy-2-methyl-indolizin-3-yl)carbonyl]benzoate 610766-57-9P, Sodium 3-[(1-methoxy-2-methyl-indolizin-3-yl)carbonyl]benzoate 610766-59-1P, Sodium 2-nitro-4-[(1-methoxy-2-methyl-indolizin-3-yl)carbonyl]benzoate 610766-61-5P, Sodium 2-amino-4-[(1-methoxy-2-methyl-indolizin-3-yl)carbonyl]benzoate 610766-62-6P, Sodium 4-[[1-[(3-methoxybenzyl)oxy]-2-methyl-indolizin-3-yl]carbonyl]benzoate 610766-63-7P, Sodium 2-methoxy-4-[(1-methoxy-2-methyl-indolizin-3-yl)carbonyl]benzoate 610766-64-8P 610766-66-0P, 3-(4-Amino-3-methoxybenzoyl)-2-methyl-1-carboxymethoxyindolizine 610766-67-1P, 3-(4-Amino-3-methoxybenzoyl)-2-methyl-1-[[(carboxymethyl)amino]carbonyl]indolizine sodium salt 610766-68-2P, 3-(4-Amino-3-methoxybenzoyl)-2-methyl-1-(3-carboxybenzyloxy)indolizine sodium salt 610766-69-3P, 3-(4-Amino-3-methoxybenzoyl)-2-methyl-1-(4-carboxybenzyloxy)indolizine sodium salt 610766-71-7P, 3-(4-Carboxybenzoyl)-2-methyl-1-carboxyindolizine disodium salt 610766-72-8P, 3-(4-Carboxybenzoyl)-2-methyl-1-(carboxymethoxy)-indolizine disodium salt 610766-73-9P, 3-(3-Methoxy-4-carboxybenzoyl)-2-methyl-1-carboxyindolizine disodium salt 610766-74-0P, (1-Methoxy-2-methyl-indolizin-3-yl)[4-[[3-(dibutylamino)propyl]amino]-3-methoxyphenyl]methanone hydrochloride 610766-75-1P, (1-Methoxy-2-methyl-indolizin-3-yl)[3-methoxy-4-(methylamino)phenyl]methanone hydrochloride 610766-78-4P, 2-[2-Methoxy-4-[(1-methoxy-2-methyl-indolizin-3-yl)carbonyl]anilino]acetic acid 610766-83-1P, N-[2-Methoxy-4-[(1-methoxy-2-methyl-indolizin-3-yl)carbonyl]phenyl]acetamide 610766-84-2P, Ethyl [2-Methoxy-4-[(1-methoxy-2-methyl-indolizin-3-yl)carbonyl]phenyl]carbamate 610766-86-4P, 2-[[3-(Dibutylamino)propanoyl]-2-methoxy-4-[(1-methoxy-2-methyl-indolizin-3-yl)carbonyl]anilino]acetic acid hydrochloride 610766-91-1P, N-[2-Methoxy-4-[(1-methoxy-2-methyl-indolizin-3-yl)carbonyl]phenyl]methanesulfonamide 610766-93-3P, 3-[3-Methoxy-4-[(methylsulfonyl)amino]benzoyl]-2-methyl-1-carboxyindolizine sodium salt 610766-94-4P, 2-[[[2-(Dibutylamino)ethyl]sulfonyl]-2-methoxy-4-[(1-methoxy-2-methyl-indolizin-3-yl)carbonyl]anilino]acetic acid hydrochloride 610767-02-7DP, 3-(4-Amino-3-methoxybenzoyl)-2-methyl-1-[[(carboxymethyl)amino]carbonyl]indolizine hydrochloride, ester 610767-05-0P, 3-(4-Amino-3-methoxybenzoyl)-2-methyl-1-carboxyindolizine sodium salt 610767-06-1P, 3-(4-Amino-3-methoxybenzoyl)-2-methyl-1-carboxyindolizine hydrochloride
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(b-FGF inhibitor; preparation of indolizines as selective b-FGF inhibitors)

RN 610323-42-7 CAPLUS


CN Carbamic acid, [3-(4-amino-3-methoxybenzoyl)-2-methyl-1-indolizinyll]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 610765-80-5 CAPLUS
 CN Benzoic acid, 4-[[2-methyl-1-(phenylmethoxy)-3-indoliziny]carbonyl]-, methyl ester (CA INDEX NAME)




RN 610765-83-8 CAPLUS
 CN Methanone, (1-methoxy-2-methyl-3-indoliziny)(4-nitrophenyl)- (CA INDEX NAME)




RN 610765-85-0 CAPLUS
 CN Benzoic acid, 3-[(1-methoxy-2-methyl-3-indoliziny)carbonyl]-, methyl ester (CA INDEX NAME)




RN 610765-86-1 CAPLUS
 CN Benzoic acid, 4-[(1-methoxy-2-methyl-3-indoliziny)carbonyl]-2-nitro-, methyl ester (CA INDEX NAME)




RN 610765-87-2 CAPLUS
 CN Benzoic acid, 2-methoxy-4-[(1-methoxy-2-methyl-3-indoliziny)carbonyl]-,
 methyl ester (CA INDEX NAME)




RN 610765-88-3 CAPLUS
 CN Benzeneacetic acid, 4-[(1-methoxy-2-methyl-3-indoliziny)carbonyl]-,
 methyl ester (CA INDEX NAME)




RN 610765-90-7 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-[3-methoxy-4-(methoxycarbonyl)benzoyl]-2-
 methyl-, ethyl ester (CA INDEX NAME)




RN 610765-92-9 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-[4-(methoxycarbonyl)benzoyl]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 610765-93-0 CAPLUS
 CN Methanone, (3-methoxy-4-nitrophenyl)[2-methyl-1-[methyl(phenylmethyl)amino]-3-indoliziny]- (CA INDEX NAME)



RN 610765-94-1 CAPLUS
 CN Carbamic acid, [3-(3-methoxy-4-nitrobenzoyl)-2-methyl-1-indoliziny]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 610765-96-3 CAPLUS
 CN Methanesulfonamide, N-[3-(3-methoxy-4-nitrobenzoyl)-2-methyl-1-indoliziny]- (CA INDEX NAME)




RN 610765-98-5 CAPLUS

CN Methanone, [1-(dimethylamino)-2-methyl-3-indoliziny] (3-methoxy-4-nitrophenyl)- (CA INDEX NAME)




RN 610766-02-4 CAPLUS

CN Methanone, [1-[(3-chlorophenyl)methoxy]-2-methyl-3-indoliziny] (3-methoxy-4-nitrophenyl)- (CA INDEX NAME)




RN 610766-03-5 CAPLUS

CN Methanone, [1-[(4-chlorophenyl)methoxy]-2-methyl-3-indoliziny] (3-methoxy-4-nitrophenyl)- (CA INDEX NAME)




RN 610766-04-6 CAPLUS

CN Methanone, (3-methoxy-4-nitrophenyl) [1-[(2-methoxyphenyl)methoxy]-2-methyl-3-indoliziny]- (CA INDEX NAME)




RN 610766-05-7 CAPLUS

CN Methanone, (3-methoxy-4-nitrophenyl) [1-[(3-methoxyphenyl)methoxy]-2-methyl-3-indoliziny]- (CA INDEX NAME)




RN 610766-06-8 CAPLUS

CN Methanone, (3-methoxy-4-nitrophenyl) [1-[(4-methoxyphenyl)methoxy]-2-methyl-3-indolizinyloxy]- (CA INDEX NAME)




RN 610766-07-9 CAPLUS


CN Benzoic acid, 3-[[[3-(3-methoxy-4-nitrobenzoyl)-2-methyl-1-indolizinyloxy]methyl]-4-methoxyphenyl]-, methyl ester (CA INDEX NAME)




RN 610766-08-0 CAPLUS
 CN Acetic acid, 2-[[3-(3-methoxy-4-nitrobenzoyl)-2-methyl-1-indolizinyloxy]-
 , ethyl ester (CA INDEX NAME)




RN 610766-09-1 CAPLUS
 CN Acetamide, 2-[[3-(3-methoxy-4-nitrobenzoyl)-2-methyl-1-indolizinyloxy]-
 (CA INDEX NAME)




RN 610766-10-4 CAPLUS
 CN Methanone, [1-[2-(dimethylamino)ethoxy]-2-methyl-3-indolizinyloxy](3-methoxy-
 4-nitrophenyl)- (CA INDEX NAME)




RN 610766-12-6 CAPLUS
 CN Methanone, [1-(2-hydroxyethoxy)-2-methyl-3-indolizinyll (3-methoxy-4-nitrophenyl)- (CA INDEX NAME)




RN 610766-13-7 CAPLUS
 CN Acetonitrile, 2-[[3-(3-methoxy-4-nitrobenzoyl)-2-methyl-1-indolizinyll oxy]- (CA INDEX NAME)



RN 610766-14-8 CAPLUS
 CN Methanone, (3-methoxy-4-nitrophenyl) [2-methyl-1-(1-methylethoxy)-3-indolizinyll]- (CA INDEX NAME)




RN 610766-15-9 CAPLUS
 CN Methanone, [1-(cyclopropylmethoxy)-2-methyl-3-indolizinyll (3-methoxy-4-nitrophenyl)- (CA INDEX NAME)




RN 610766-17-1 CAPLUS

CN Benzoic acid, 4-[[1-(2-ethoxy-2-oxoethoxy)-2-methyl-3-indoliziny]carbonyl]-, methyl ester (CA INDEX NAME)




RN 610766-18-2 CAPLUS

CN Benzoic acid, 4-[[1-[(3-methoxyphenyl)methoxy]-2-methyl-3-indoliziny]carbonyl]-, methyl ester (CA INDEX NAME)




RN 610766-20-6 CAPLUS

CN 1-Indolizinecarboxamide, N-ethyl-3-(3-methoxy-4-nitrobenzoyl)-2-methyl- (CA INDEX NAME)




RN 610766-21-7 CAPLUS

CN Glycine, N-[[3-(3-methoxy-4-nitrobenzoyl)-2-methyl-1-indolizinyl]carbonyl]-, ethyl ester (CA INDEX NAME)



RN 610766-28-4 CAPLUS


CN Acetic acid, 2-[[3-(4-amino-3-methoxybenzoyl)-2-methyl-1-indolizinyl]oxy]-, ethyl ester, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

RN 610766-29-5 CAPLUS


CN Acetamide, 2-[[3-(4-amino-3-methoxybenzoyl)-2-methyl-1-indolizinyl]oxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 610766-30-8 CAPLUS


CN Methanone, (4-amino-3-methoxyphenyl)[1-(2-hydroxyethoxy)-2-methyl-3-indoliziny]-, hydrochloride (1:?) (CA INDEX NAME)



●_x HCl

RN 610766-31-9 CAPLUS


CN Methanone, (4-aminophenyl)(1-methoxy-2-methyl-3-indoliziny)-, hydrochloride (1:?) (CA INDEX NAME)



●_x HCl

RN 610766-32-0 CAPLUS


CN 1-Indolizinecarboxamide, 3-(4-amino-3-methoxybenzoyl)-N-ethyl-2-methyl-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 610766-33-1 CAPLUS


CN Methanone, (4-amino-3-methoxyphenyl)[1-[(2-chlorophenyl)methoxy]-2-methyl-3-indoliziny]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 610766-35-3 CAPLUS

CN Methanone, (4-amino-3-methoxyphenyl)[1-[2-(dimethylamino)ethoxy]-2-methyl-3-indoliziny]-, hydrochloride (1:?) (CA INDEX NAME)




●_x HCl

RN	610766-36-4	CAPLUS
CN	Methanone, (4-amino-3-methoxyphenyl)[1-[(4-chlorophenyl)methoxy]-2-methyl-3-indoliziny]-, hydrochloride (1:?) (CA INDEX NAME)	




●_x HCl

RN	610766-37-5	CAPLUS
CN	Methanone, (4-amino-3-methoxyphenyl) [1-[(3-methoxyphenyl)methoxy]-2-methyl-3-indoliziny]-, hydrochloride (1:?) (CA INDEX NAME)	




●_x HCl

RN 610766-38-6 CAPLUS
 CN Methanone, (4-amino-3-methoxyphenyl) [1-[(4-methoxyphenyl)methoxy]-2-methyl-3-indoliziny]-, hydrochloride (1:?) (CA INDEX NAME)




●_x HCl

RN 610766-40-0 CAPLUS
 CN Methanone, (4-amino-3-methoxyphenyl) [1-[(2-methoxyphenyl)methoxy]-2-methyl-3-indoliziny]-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 610766-42-2 CAPLUS
 CN Benzoic acid, 3-[[[3-(4-amino-3-methoxybenzoyl)-2-methyl-1-indolizinyloxy]methyl]-, methyl ester, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 610766-43-3 CAPLUS
 CN Benzoic acid, 4-[[[3-(4-amino-3-methoxybenzoyl)-2-methyl-1-indolizinyloxy]methyl]-, methyl ester, hydrochloride (1:?) (CA INDEX NAME)




RN 610766-44-4 CAPLUS

CN Methanone, (4-amino-3-methoxyphenyl) [1-[(3-chlorophenyl)methoxy]-2-methyl-3-indolizinyloxy]-, hydrochloride (1:?) (CA INDEX NAME)



RN 610766-45-5 CAPLUS


CN Methanone, (4-amino-3-methoxyphenyl) [2-methyl-1-[methyl(phenylmethyl)amino]-3-indolizinyloxy]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 610766-46-6 CAPLUS


CN Methanone, (4-amino-3-methoxyphenyl)[2-methyl-1-(methylamino)-3-indoliziny]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 610766-47-7 CAPLUS


CN Methanesulfonamide, N-[3-(4-amino-3-methoxybenzoyl)-2-methyl-1-indoliziny]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 610766-48-8 CAPLUS

CN Benzoic acid, 2-amino-4-[(1-methoxy-2-methyl-3-indoliziny)carbonyl]-, methyl ester (CA INDEX NAME)



RN 610766-51-3 CAPLUS


CN Methanone, (4-amino-3-methoxyphenyl)[1-(cyclopropylmethoxy)-2-methyl-3-indoliziny]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 610766-52-4 CAPLUS


CN Methanone, (4-amino-3-methoxyphenyl)[2-methyl-1-(2-methylpropoxy)-3-indoliziny]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 610766-54-6 CAPLUS

CN Methanone, (4-amino-3-methoxyphenyl)[1-(dimethylamino)-2-methyl-3-indoliziny]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 610766-56-8 CAPLUS
 CN Benzoic acid, 4-[(1-methoxy-2-methyl-3-indolizinyl)carbonyl]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 610766-57-9 CAPLUS
 CN Benzoic acid, 3-[(1-methoxy-2-methyl-3-indolizinyl)carbonyl]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 610766-59-1 CAPLUS
 CN Benzoic acid, 4-[(1-methoxy-2-methyl-3-indolizinyl)carbonyl]-2-nitro-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 610766-61-5 CAPLUS
 CN Benzoic acid, 2-amino-4-[(1-methoxy-2-methyl-3-indoliziny)carbonyl]-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 610766-62-6 CAPLUS
 CN Benzoic acid, 4-[[1-[(3-methoxyphenyl)methoxy]-2-methyl-3-indoliziny]carbonyl]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 610766-63-7 CAPLUS


CN Benzoic acid, 2-methoxy-4-[(1-methoxy-2-methyl-3-indoliziny)carbonyl]-,
sodium salt (1:1) (CA INDEX NAME)



● Na

RN 610766-64-8 CAPLUS


CN Benzeneacetic acid, 4-[(1-methoxy-2-methyl-3-indoliziny)carbonyl]-,
sodium salt (1:1) (CA INDEX NAME)



● Na


RN 610766-66-0 CAPLUS

CN Acetic acid, 2-[[3-(4-amino-3-methoxybenzoyl)-2-methyl-1-indolizinyloxy]-
(CA INDEX NAME)



RN 610766-67-1 CAPLUS


CN Glycine, N-[[3-(4-amino-3-methoxybenzoyl)-2-methyl-1-indoliziny]carbonyl]-,
monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 610766-68-2 CAPLUS


CN Benzoic acid, 3-[[[3-(4-amino-3-methoxybenzoyl)-2-methyl-1-indolizinyl]oxy]methyl]-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 610766-69-3 CAPLUS

CN Benzoic acid, 4-[[[3-(4-amino-3-methoxybenzoyl)-2-methyl-1-indolizinyl]oxy]methyl]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 610766-71-7 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-(4-carboxybenzoyl)-2-methyl-, sodium salt
 (1:2) (CA INDEX NAME)




●2 Na

RN 610766-72-8 CAPLUS
 CN Benzoic acid, 4-[[1-(carboxymethoxy)-2-methyl-3-indoliziny]carbonyl]-,
 sodium salt (1:2) (CA INDEX NAME)




●2 Na

RN 610766-73-9 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-(4-carboxy-3-methoxybenzoyl)-2-methyl-,
 sodium salt (1:2) (CA INDEX NAME)




● 2 Na

RN 610766-74-0 CAPLUS
 CN Methanone, [4-[[3-(dibutylamino)propyl]amino]-3-methoxyphenyl](1-methoxy-2-methyl-3-indoliziny)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 610766-75-1 CAPLUS
 CN Methanone, [3-methoxy-4-(methylamino)phenyl](1-methoxy-2-methyl-3-indoliziny)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 610766-78-4 CAPLUS

CN Glycine, N-[2-methoxy-4-[(1-methoxy-2-methyl-3-indoliziny)carbonyl]phenyl]- (CA INDEX NAME)




RN 610766-83-1 CAPLUS

CN Acetamide, N-[2-methoxy-4-[(1-methoxy-2-methyl-3-indoliziny)carbonyl]phenyl]- (CA INDEX NAME)




RN 610766-84-2 CAPLUS

CN Carbamic acid, [2-methoxy-4-[(1-methoxy-2-methyl-3-indoliziny)carbonyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 610766-86-4 CAPLUS


CN Glycine, N,N-dibutyl-β-alanyl-N-[2-methoxy-4-[(1-methoxy-2-methyl-3-indoliziny)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 610766-91-1 CAPLUS

CN Methanesulfonamide, N-[2-methoxy-4-[(1-methoxy-2-methyl-3-indoliziny)carbonyl]phenyl]- (CA INDEX NAME)



RN 610766-93-3 CAPLUS


CN 1-Indolizinecarboxylic acid, 3-[3-methoxy-4-[(methanesulfonyl)amino]benzoyl]-2-methyl-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 610766-94-4 CAPLUS


CN Glycine, N-[[2-(dibutylamino)ethyl]sulfonyl]-N-[2-methoxy-4-[(1-methoxy-2-methyl-3-indoliziny)carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 610767-02-7 CAPLUS


CN Glycine, N-[[3-(4-amino-3-methoxybenzoyl)-2-methyl-1-indoliziny]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 610767-05-0 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-(4-amino-3-methoxybenzoyl)-2-methyl-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 610767-06-1 CAPLUS


CN 1-Indolizinecarboxylic acid, 3-(4-amino-3-methoxybenzoyl)-2-methyl-,

hydrochloride (1:?) (CA INDEX NAME)




●x HCl


IT 610767-01-6P, tert-Butyl N-[3-(3-methoxy-4-nitrobenzoyl)-2-methylindolizin-1-yl](methyl)carbamate 610767-10-7P, Benzyl 2-[[[2-(dibutylamino)ethyl]sulfonyl]-2-methoxy-4-[(1-methoxy-2-methylindolizin-3-yl)carbonyl]anilino]acetate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of indolizines as selective b-FGF inhibitors)
 RN 610767-01-6 CAPLUS
 CN Carbamic acid, [3-(3-methoxy-4-nitrobenzoyl)-2-methyl-1-indoliziny]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 610767-10-7 CAPLUS
 CN Glycine, N-[2-(dibutylamino)ethyl]sulfonyl]-N-[2-methoxy-4-[(1-methoxy-2-methyl-3-indoliziny]carbonyl]phenyl]-, phenylmethyl ester (CA INDEX NAME)



IT 610767-07-2P, 3-[4-(Methoxycarbonyl)benzoyl]-2-methyl-1-carboxyindolizine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of indolizines as selective b-FGF inhibitors)
 RN 610767-07-2 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-[4-(methoxycarbonyl)benzoyl]-2-methyl- (CA INDEX NAME)



IT 610767-14-1, Ethyl 3-(4-amino-3-methoxybenzoyl)-2-methyl-1-indolizinecarboxylate
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of indolizines as selective b-FGF inhibitors)
 RN 610767-14-1 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-(4-amino-3-methoxybenzoyl)-2-methyl-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 42 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:659429 CAPLUS

DOCUMENT NUMBER: 139:364548

TITLE: Photophysics of some indolizines, derivatives from
bipyridyl, in various media

AUTHOR(S): Vlahovici, A.; Andrei, M.; Alupoae, R.; Drochioiu, G.;
Druta, I.

CORPORATE SOURCE: Faculty of Physics, "Al. I. Cuza" University, Iasi,
Rom.

SOURCE: Romanian Reports in Physics (2003), Volume Date 2001,
53(9-10), 687-691

CODEN: RORPED; ISSN: 1221-1451

PUBLISHER: Editura Academiei Romane

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of photoluminescent properties of some new indolizinic compds.,
recently synthesized, derivs. from bipyridyl, are analyzed. Significant
differences are observed between the monoindolizinic compds. and the
bisindolizinic ones regarding the absorption and fluorescence in the
UV-VIS spectral range. Extended conjugation in bisindolizinic compds.
dets. a strong increase in the molar absorptivity and fluorescence quantum
yield and a shift of the fluorescence spectrum towards violet.

IT 203588-19-6 203588-20-9 213988-89-7


252201-18-6 252201-19-7

RL: PRP (Properties)

(UV and fluorescence spectra of some indolizines, derivs. from
bipyridyl, in various media)


RN 203588-19-6 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-5-(2-pyridinyl)-, dimethyl
ester (9CI) (CA INDEX NAME)




RN 203588-20-9 CAPLUS


CN 1,2-Indolizinedicarboxylic acid, 3-(4-nitrobenzoyl)-5-(2-pyridinyl)-,
dimethyl ester (9CI) (CA INDEX NAME)




RN 213988-89-7 CAPLUS
 CN [7,7'-Biindolizine]-1,1'-dicarboxylic acid, 3,3'-dibenzoyl-, diethyl ester
 (9CI) (CA INDEX NAME)



RN 252201-18-6 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-benzoyl-5-(2-pyridinyl)-, ethyl ester (CA
 INDEX NAME)



RN 252201-19-7 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-(4-nitrobenzoyl)-5-(2-pyridinyl)-, ethyl
 ester (CA INDEX NAME)



REFERENCE COUNT:

9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 43 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:221687 CAPLUS

DOCUMENT NUMBER: 138:238174

TITLE: Preparation of 2-(indolizin-1-yl)-N-(isothiazol-5-yl)-
2-oxo-acetamides for treating cancer

INVENTOR(S): Koya, Keizo; Sun, Lijun; Ono, Mitsunori; Ying, Weiwen;
Li, Hao

PATENT ASSIGNEE(S): SBR Pharmaceuticals Corp., USA

SOURCE: PCT Int. Appl., 78 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022846	A1	20030320	WO 2002-US29154	20020913
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2459886	A1	20030320	CA 2002-2459886	20020913
AU 2002333626	A1	20030324	AU 2002-333626	20020913
AU 2002333626	B2	20060629		
EP 1432709	A1	20040630	EP 2002-798231	20020913
EP 1432709	B1	20050727		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012794	A	20041005	BR 2002-12794	20020913
CN 1568324	A	20050119	CN 2002-820284	20020913
JP 2005504795	T	20050217	JP 2003-526921	20020913
AT 300542	T	20050815	AT 2002-798231	20020913
PT 1432709	T	20051031	PT 2002-798231	20020913
EP 1598352	A1	20051123	EP 2005-16203	20020913
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
ES 2245747	T3	20060116	ES 2002-798231	20020913
NZ 531700	A	20061027	NZ 2002-531700	20020913
NO 2004001035	A	20040430	NO 2004-1035	20040311
MX 2004PA02323	A	20050408	MX 2004-PA2323	20040311
ZA 2004001996	A	20050531	ZA 2004-1996	20040311
IN 2004DN00664	A	20050401	IN 2004-DN664	20040316
HK 1063322	A1	20051209	HK 2004-106091	20040813
PRIORITY APPLN. INFO.:			US 2001-322020P	P 20010913
			EP 2002-798231	A3 20020913
			WO 2002-US29154	W 20020913
OTHER SOURCE(S):	MARPAT 138:238174			
GI				



I



II

AB The title 1-glyoxylylamide indolizines [I; Ring A is (un)substituted and optionally fused to an aryl group; Z1, Z2 = O, S, N(OR12), NR12; R1, R2 = H, (un)substituted aliphatic group, (un)substituted non-aromatic heterocyclic group, etc.; or NR1R2 = (un)substituted non-aromatic nitrogen-containing heterocyclic group or nitrogen-containing heteroaryl group; R3 = (un)substituted aryl or aliphatic group; X = a bond, CR4R5, NR4, O, etc.; R4, R5 = H, (un)substituted aliphatic group; R12 = H, (un)substituted alkyl], useful in treating a multi-drug resistant cancer, were prepared E.g., multi-step synthesis of II, starting from 4-cyanophenacyl bromide and pyridine, was given. The compound II demonstrated significantly high anti-cancer activity (IC50: 0.01-0.05 μ M) against seven cancer cell lines from different tissue type, and also high anti-cancer activity (0.02-0.05 μ M) against two MDR cancer cell lines.


IT 501948-27-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-(indolizin-1-yl)-N-(isothiazol-5-yl)-2-oxo-acetamides for treating cancer)

RN 501948-27-2 CAPLUS

CN 1-Indolizineacetamide, 3-(4-cyanobenzoyl)-N-(3-methyl-5-isothiazolyl)- α -oxo- (CA INDEX NAME)




IT 501948-41-0P, 1-Acetyl-3-(4-cyanobenzoyl)indolizine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2-(indolizin-1-yl)-N-(isothiazol-5-yl)-2-oxo-acetamides for treating cancer)

RN 501948-41-0 CAPLUS

CN Benzonitrile, 4-[(1-acetyl-3-indoliziny)carbonyl]- (CA INDEX NAME)



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 44 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:137811 CAPLUS

DOCUMENT NUMBER: 139:6757

TITLE: Synthesis of an annulenoannulenone,
3H-benzo[e]cycl[3.3.2]azin-3-one

AUTHOR(S): Matsuda, Yoshiro; Kohra, Shinya; Katou, Keisuke;
Uemura, Takashi; Yamashita, Kouhei

CORPORATE SOURCE: Faculty Environmental Studies, Nagasaki Univ.,
Nagasaki, 852-8521, Japan

SOURCE: Heterocycles (2003), 60(2), 405-411

CODEN: HTCYAM; ISSN: 0385-5414

PUBLISHER: Japan Institute of Heterocyclic Chemistry

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 139:6757

AB A new nitrogen-bridged annulenoannulenone, 3H-benzo[e]cycl[3.3.2]-azin-3-one was synthesized from the starting phenylpyridine via the reaction of the indolizine derivative with polyphosphoric acid (PPA) as the key step.


IT 535961-04-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 3H-benzo[e]cycl[3.3.2]azin-3-one and other annulenoannulenones)

RN 535961-04-7 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-(2-bromobenzoyl)-, methyl ester (CA INDEX NAME)



REFERENCE COUNT:

19

THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 45 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:53760 CAPLUS

DOCUMENT NUMBER: 138:255038

TITLE: A Novel Microwave-Mediated One-Pot Synthesis of Indolizines via a Three-Component Reaction

AUTHOR(S): Bora, Utpal; Saikia, Anil; Boruah, Romesh C.

CORPORATE SOURCE: Medicinal Chemistry Division, Regional Research Laboratory, Jorhat, 785006, India

SOURCE: Organic Letters (2003), 5(4), 435-438

CODEN: ORLEF7; ISSN: 1523-7060

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:255038

AB The microwave-mediated three-component reaction of acyl bromide, pyridine, and acetylene is catalyzed by basic alumina to give corresponding indolizines in excellent yields in a one-pot reaction.

IT 17281-78-6P 40624-43-9P 502762-20-1P


502762-21-2P 502762-30-3P 502762-31-4P

RL: SPN (Synthetic preparation); PREP (Preparation)

(microwave-mediated one-pot synthesis of indolizines via a three-component reaction)


RN 17281-78-6 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-, dimethyl ester (6CI, 8CI, 9CI) (CA INDEX NAME)




RN 40624-43-9 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-, ethyl ester (CA INDEX NAME)




RN 502762-20-1 CAPLUS


CN 1-Indolizinecarboxylic acid, 3-(4-methylbenzoyl)-, ethyl ester (CA INDEX NAME)




RN 502762-21-2 CAPLUS
 CN 1,2-Indolizinedicarboxylic acid, 3-(4-methylbenzoyl)-, dimethyl ester
 (9CI) (CA INDEX NAME)



RN 502762-30-3 CAPLUS
 CN 1-Indolizinecarboxylic acid, 5-methyl-3-(4-methylbenzoyl)-, ethyl ester
 (CA INDEX NAME)



RN 502762-31-4 CAPLUS
 CN 1-Indolizinecarboxylic acid, 6-methyl-3-(4-methylbenzoyl)-, ethyl ester
 (CA INDEX NAME)



REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 46 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:911885 CAPLUS

DOCUMENT NUMBER: 138:161353

TITLE: Methyl 3-benzoyl-8-hydroxy-5-methoxyindolizine-1-carboxylate

AUTHOR(S): Usman, Anwar; Li, Yun; Zhang, Yan; Fun, Hoong Kun; Xu, Jian Hua

CORPORATE SOURCE: School of Physics, X-ray Crystallography Unit, Universiti Sains Malaysia, Penang, 11800 USM, Malay.

SOURCE: Acta Crystallographica, Section E: Structure Reports

Online (2002), E58(12), o1427-o1429

CODEN: ACSEBH; ISSN: 1600-5368

URL: <http://journals.iucr.org/e/issues/2002/12/00/wn6127/index.html>

PUBLISHER: International Union of Crystallography

DOCUMENT TYPE: Journal; (online computer file)

LANGUAGE: English


AB In the title compound, C₁₈H₁₅NO₅, the methoxycarbonyl substituent, disregarding H atoms, is almost coplanar with the indolizine ring system in each of the two crystallog. independent mols. in the asym. unit. In the crystal structure, symmetry-related mols. form mol. dimers, held together by two C-H...O H bonds, and are interconnected into a three-dimensional network by another C-H...O H bond. Crystallog. data are given.

IT 496034-76-5, Methyl 3-benzoyl-8-hydroxy-5-methoxyindolizine-1-carboxylate

RL: PRP (Properties)
(crystal structure of)

RN 496034-76-5 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-8-hydroxy-5-methoxy-, methyl ester (CA INDEX NAME)




IT 51386-41-5, 1-Acetyl-3-benzoylindolizine

RL: RCT (Reactant); RACT (Reactant or reagent)
(photooxygenation of)

RN 51386-41-5 CAPLUS

CN Ethanone, 1-(3-benzoyl-1-indoliziny)- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 47 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:903424 CAPLUS

DOCUMENT NUMBER: 138:255048

TITLE: Isocyanatophosphoric acid dichloride: a novel reagent for the introduction of a cyano group into the molecules of electron-rich heterocycles and enamines

AUTHOR(S): Smaliy, Radomir V.; Chaikovskaya, Aleksandra A.; Pinchuk, Aleksandr M.; Tolmachev, Andrei A.

CORPORATE SOURCE: Institute of Organic Chemistry, National Academy of Sciences of the Ukraine, Kiev, 02094/94, Ukraine

SOURCE: Synthesis (2002), (16), 2416-2420
CODEN: SYNTBF; ISSN: 0039-7881

PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:255048


AB A new synthetic method is developed which enables a direct one-step introduction of a cyano group into electron-rich heterocyclic systems of the indole, pyrrole, and indolizine series, and also to enamines using isocyanatophosphoryl dichloride. Thus, reaction of OCNP(O)Cl₂ with N-methylpyrrole in ClCH₂CH₂Cl for 1h at 20° gave 64% 1-methyl-1H-pyrrole-2-carbonitrile.

IT 502925-11-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(isocyanatophosphoric acid dichloride as novel reagent for introduction of cyano group into electron-rich heterocycles and enamines)

RN 502925-11-3 CAPLUS

CN 1-Indolizinecarbonitrile, 2-methyl-3-(3-nitrobenzoyl)- (CA INDEX NAME)



REFERENCE COUNT:

9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 48 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:869496 CAPLUS

DOCUMENT NUMBER: 137:363033

TITLE: Peptidomimetic modulators of cell adhesion

INVENTOR(S): Gour, Barbara J.; Blaschuk, Orest W.; Ali, Anmar; Ni, Feng; Chen, Zhigang; Michaud, Stephanie D.; Wang, Shoameng; Hu, Zenjian

PATENT ASSIGNEE(S): Can.

SOURCE: U.S. Pat. Appl. Publ., 309 pp., Cont.-in-part of U.S. Ser. No. 491,078.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 15

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020168761	A1	20021114	US 2001-769145	20010124
US 20040058864	A1	20040325	US 2003-412701	20030410
US 7268115	B2	20070911		
US 20040006011	A1	20040108	US 2003-425557	20030428
US 20080081831	A1	20080403	US 2007-762015	20070612
PRIORITY APPLN. INFO.:			US 2000-491078	A2 20000124
			US 1996-21612P	P 19960712
			US 1997-893534	A1 19970711
			US 2000-507102	A1 20000217
			US 2001-769145	B1 20010124
			US 2001-6982	A2 20011204
			US 2003-412701	A1 20030410

OTHER SOURCE(S): MARPAT 137:363033


AB Peptidomimetics of cyclic peptides, and compns. comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.

IT 256432-37-8, Ethanone, 1-[3-benzoyl-7-[(4-nitrophenyl)methyl]-1-indoliziny]-
indoliziny]-
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)


(peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

RN 256432-37-8 CAPLUS


CN Ethanone, 1-[3-benzoyl-7-[(4-nitrophenyl)methyl]-1-indoliziny]- (CA INDEX NAME)




L3 ANSWER 49 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:861066 CAPLUS
 DOCUMENT NUMBER: 139:117275
 TITLE: Product class 16: indolizines
 AUTHOR(S): Shipman, M.
 CORPORATE SOURCE: School of Chemistry, University of Exeter, Exeter, EX4
 4QD, UK
 SOURCE: Science of Synthesis (2001), 10, 745-787
 CODEN: SSCYJ9
 PUBLISHER: Georg Thieme Verlag
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 AB A review describes some of the most useful methods for the synthesis of
 indolizines. The methods described are categorized as synthesis by
 ring-closure reactions; ring transformation; and substituent modification.
 IT 25627-87-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of indolizines and synthetic modification of substituents)
 RN 25627-87-6 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-benzoyl- (CA INDEX NAME)



IT 17281-78-6P 25627-81-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of indolizines via ring-closure reactions and ring
 transformations)
 RN 17281-78-6 CAPLUS
 CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-, dimethyl ester (6CI, 8CI,
 9CI) (CA INDEX NAME)



RN 25627-81-0 CAPLUS
 CN 1-Indolizinecarbonitrile, 3-benzoyl- (CA INDEX NAME)



REFERENCE COUNT:

176

THERE ARE 176 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

ACCESSION NUMBER: 2002:178568 CAPLUS
 DOCUMENT NUMBER: 136:376634
 TITLE: A study of the dimethyl 3-benzoyl-5(2'-pyridyl)-indolizine-1,2-dicarboxylate exciplexes with alcohols
 AUTHOR(S): Vlahovici, A.; Andrei, M.; Druta, I.
 CORPORATE SOURCE: Faculty of Physics, "Al. I. Cuza" University of Iasi, Iasi, R-6600, Rom.
 SOURCE: Journal of Luminescence (2002), 96(2-4), 279-285
 CODEN: JLUMA8; ISSN: 0022-2313
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The formation of fluorescent intermol. exciplexes between di-Me 3-benzoyl-5(2'-pyridyl)-indolizine-1,2-dicarboxylate (DBI) and 15 alcs. as well as with HOAc, was proved. The probability of formation of these exciplexes is less than unity, except for the HOAc, ranging between 0.14 and 0.92, depending on the nature of the alc. This is exactly the reason for a strong alteration in the fluorescence band of the DBI in different alcs., consisting in both large shifts of the maximum, from 18,920 cm⁻¹ in cyclohexanol to 16,260 cm⁻¹ in benzyl alc., and changes in its shape and half-width. The probability of exciplex formation was determined supposing that in solution with a certain alc. of the excited state of DBI, symbolized by (DBI)*, there are 2 mol species: the A species, representing the noncomplexed (DBI)* mols., and the E ones representing the mol. complex (DBI)*-alc. By approximating the fluorescence spectrum of the A species with that obtained in acetone, the spectrum of the A species was subtracted from the total fluorescence band, thus obtaining the spectrum of the E species. Every time the fluorescence spectrum of the HOAc was obtained with an error <7%. This has pointed out the fact that the E species are only generated with a probability equal to unity in HOAc only, and the position of the fluorescence band of this species in the whole spectrum depends to a slight extent on the nature of the alc. only. The results obtained by heating its solution in 4 alcs. (for which the intensity of exciplex fluorescence is much higher) confirm the hypothesis regarding the 2 mol species, and also the fact that the possibility to generate E species decreases with increasing temperature Anal. of the obtained data showed


that the (DBI)*-alc. exciplex is formed by a double H bond involving the OH group of the alc. and both N atoms of (DBI)*.

IT 203588-19-6

RL: PRP (Properties); RCT (Reactant); RACT (Reactant or reagent)
 (exciplexes with alcs.)

RN 203588-19-6 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-5-(2-pyridinyl)-, dimethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 51 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:29437 CAPLUS

DOCUMENT NUMBER: 136:340556

TITLE: Synthesis of substituted 7,7'-bis-indolizines via 1,3-dipolar cycloaddition under microwave irradiation

AUTHOR(S): Dinica, Rodica M.; Pettinari, Claudio

CORPORATE SOURCE: Chemistry Department, "Dunarea de Jos", University, Galati, 6200, Rom.

SOURCE: Heterocyclic Communications (2001), 7(4), 381-386

CODEN: HCOMEX; ISSN: 0793-0283

PUBLISHER: Freund Publishing House Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 136:340556

AB An efficient method for preparation of substituted 7,7'-bis[indolizine] derivs., based on 1,3-dipolar cycloaddn. of 4,4'-bipyridinium ylides generated in situ with activated alkynes, is proposed. The reactants thus prepared in situ from 4,4'-bipyridine and phenacyl bromides included 1,1'-bis(2-oxo-2-phenylethyl)-4,4'-bipyridinium dibromide, 1,1'-bis[2-(4-chlorophenyl)-2-oxoethyl]-4,4'-bipyridinium dibromide, 1,1'-bis[2-(4-bromophenyl)-2-oxoethyl]-4,4'-bipyridinium dibromide, 1,1'-bis[2-(4-nitrophenyl)-2-oxoethyl]-4,4'-bipyridinium dibromide, 1,1'-bis[2-(4-methoxyphenyl)-2-oxoethyl]-4,4'-bipyridinium dibromide and 1,1'-bis[2-(3-methoxyphenyl)-2-oxoethyl]-4,4'-bipyridinium dibromide. The reaction was carried out in good yields by microwave irradiation and KF/alumina under solvent-free conditions. The products comprised 3,3'-dibenzoyl-[7,7'-biindolizine]-1,1',2,2'-tetracarboxylic acid tetra-Et ester derivs. and 3,3'-dibenzoyl-[7,7'-biindolizine]-1,1'-dicarboxylic acid dialkyl ester derivs.

IT 213988-89-7P 295328-44-8P 295328-45-9P

295328-56-2P 295328-57-3P 295328-61-9P

295328-62-0P 295328-67-5P 295328-68-6P


417725-57-6P 417725-60-1P 417725-63-4P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of 7,7'-bis[indolizine] derivs. via 1,3-dipolar cycloaddn. of 1,1'-bis(2-oxo-2-phenylethyl)-4,4'-bipyridinium dibromide with alkynoic acid esters under microwave irradiation)


RN 213988-89-7 CAPLUS

CN [7,7'-Biindolizine]-1,1'-dicarboxylic acid, 3,3'-dibenzoyl-, diethyl ester (9CI) (CA INDEX NAME)




RN 295328-44-8 CAPLUS


CN [7,7'-Biindolizine]-1,1',2,2'-tetracarboxylic acid, 3,3'-dibenzoyl-, tetraethyl ester (9CI) (CA INDEX NAME)




RN 295328-45-9 CAPLUS
 CN [7,7'-Biindolizine]-1,1'-dicarboxylic acid, 3,3'-dibenzoyl-, dimethyl ester (9CI) (CA INDEX NAME)



RN 295328-56-2 CAPLUS
 CN [7,7'-Biindolizine]-1,1',2,2'-tetracarboxylic acid, 3,3'-bis(3-methoxybenzoyl)-, tetraethyl ester (9CI) (CA INDEX NAME)




RN 295328-57-3 CAPLUS
 CN [7,7'-Biindolizine]-1,1',2,2'-tetracarboxylic acid, 3,3'-bis(4-methoxybenzoyl)-, tetraethyl ester (9CI) (CA INDEX NAME)




RN 295328-61-9 CAPLUS

CN [7,7'-Biindolizine]-1,1'-dicarboxylic acid, 3,3'-bis(3-methoxybenzoyl)-, dimethyl ester (9CI) (CA INDEX NAME)




RN 295328-62-0 CAPLUS

CN [7,7'-Biindolizine]-1,1'-dicarboxylic acid, 3,3'-bis(4-methoxybenzoyl)-, dimethyl ester (9CI) (CA INDEX NAME)




RN 295328-67-5 CAPLUS

CN [7,7'-Biindolizine]-1,1'-dicarboxylic acid, 3,3'-bis(3-methoxybenzoyl)-, diethyl ester (9CI) (CA INDEX NAME)




RN 295328-68-6 CAPLUS

CN [7,7'-Biindolizine]-1,1'-dicarboxylic acid, 3,3'-bis(4-methoxybenzoyl)-, diethyl ester (9CI) (CA INDEX NAME)




RN 417725-57-6 CAPLUS

CN [7,7'-Biindolizine]-1,1',2,2'-tetracarboxylic acid, 3,3'-bis(4-nitrobenzoyl)-, tetraethyl ester (9CI) (CA INDEX NAME)




RN 417725-60-1 CAPLUS

CN [7,7'-Biindolizine]-1,1'-dicarboxylic acid, 3,3'-bis(4-nitrobenzoyl)-, dimethyl ester (9CI) (CA INDEX NAME)



RN 417725-63-4 CAPLUS

CN [7,7'-Biindolizine]-1,1'-dicarboxylic acid, 3,3'-bis(4-nitrobenzoyl)-, diethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 52 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:633822 CAPLUS

DOCUMENT NUMBER: 135:371591

TITLE: Preparation of pyrrolo[2,1,5-cd]indolizine derivatives by intramolecular condensation of 3-acyl-5-methylindolizines

AUTHOR(S): Liang, Feng; Hu, Jiaxin; Zhang, Lande; Hu, Yuefei; Hu, Hongwen

CORPORATE SOURCE: Department of Chemistry, Nanjing University, Nanjing, 210093, Peop. Rep. China

SOURCE: Journal of Heterocyclic Chemistry (2001), 38(4), 853-857

CODEN: JHTCAD; ISSN: 0022-152X

PUBLISHER: HeteroCorporation

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 135:371591

AB An efficient two step route was developed to synthesize pyrrolo[2,1,5-cd]indolizine derivs. The reaction sequence proceeds via preparation of 3-acyl-5-methylindolizines followed by an intramol. condensation. The procedures were carried out under convenient conditions and gave the products in high yields. It could be expected to be used to prepare a broad range of potentially interesting pyrrolo[2,1,5-cd]indolizine derivs.


IT 133619-68-8P 154224-60-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrrolo[2,1,5-cd]indolizine derivs. by condensation of (acyl)(methyl)indolizines)


RN 133619-68-8 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-5-methyl-, methyl ester (CA INDEX NAME)



RN 154224-60-9 CAPLUS

CN 1-Indolizinecarbonitrile, 3-benzoyl-5-methyl- (CA INDEX NAME)



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 53 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:545724 CAPLUS

DOCUMENT NUMBER: 135:147398

TITLE: Peptidomimetic modulators of cell adhesion

INVENTOR(S): Gour, Barbara J.; Blaschuk, Orest W.; Ali, Anmar; Ni, Feng; Chen, Zhigang; Michaud, Stephanie Denise; Wang, Shoameng; Hu, Zengjian

PATENT ASSIGNEE(S): Adherex Technologies, Inc., Can.

SOURCE: PCT Int. Appl., 416 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 15

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001053331	A2	20010726	WO 2001-US2508	20010124
WO 2001053331	A3	20020711		
WO 2001053331	A9	20021031		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-491078 A 20000124

OTHER SOURCE(S): MARPAT 135:147398

AB Peptidomimetics of cyclic peptides, and compns. comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic peptide that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.


IT 256432-37-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(peptidomimetic modulators of cell adhesion)

RN 256432-37-8 CAPLUS

CN Ethanone, 1-[3-benzoyl-7-[(4-nitrophenyl)methyl]-1-indoliziny]- (CA INDEX NAME)



L3 ANSWER 54 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:541395 CAPLUS

DOCUMENT NUMBER: 135:357831

TITLE: Novel synthetic routes to nitrogen-bridged tricyclic derivatives of pyrrolo[2,1,5-cd]indolizine and pyrrolo[2,1,5-de]quinolizine derived from 2-acyl-N-(acylmethyl)pyridinium halides

AUTHOR(S): Hu, Jiaxin; Jiang, Xin; He, Ting; Zhou, Jian; Hu, Yuefei; Hu, Hongwen

CORPORATE SOURCE: Department of Chemistry, Nanjing University, Nanjing, 210093, Peop. Rep. China

SOURCE: Journal of the Chemical Society, Perkin Transactions 1 (2001), (15), 1820-1825

CODEN: JCSPCE; ISSN: 1472-7781

PUBLISHER: Royal Society of Chemistry

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 135:357831

AB Novel synthetic routes to nitrogen-bridged derivs. of pyrrolo[2,1,5-cd]indolizine and pyrrolo[2,1,5-de]quinolizine were developed starting from 2-acyl-1-(acylmethyl)pyridinium halides. Thus, 2-benzoyl-N-phenacylpyridinium bromide gave 3,4-diphenylpyrrolo[2,1,5-cd]indolizines via 1,3-dipolar cycloaddn., which yielded 3,5-dibenzoylindolizines, followed by intramol. McMurry coupling. Similarly, 2-(1,3-dioxolan-2-yl)-N-phenacylpyridinium bromide gave 3-phenylpyrrolo[2,1,5-cd]indolizine together with an unexpected products, 3-phenyl-4-hydroxypyrrolo[2,1,5-cd]indolizines. However, 2-acetyl-N-phenacylpyridinium bromide or 2-benzoyl-N-acetonylpyridinium bromide underwent a tandem reaction of aldol condensation and 1,3-dipolar cycloaddn. to form 3-phenyl-5H-pyrrolo[2,1,5-de]quinolizin-5-ones or 5-phenyl-3H-pyrrolo[2,1,5-de]quinolizin-3-ones in a single step. These novel procedures are general and can be carried out under convenient conditions.

IT 135489-62-2P 213549-46-3P 213549-49-6P


372517-24-3P 372517-26-5P 372517-27-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrrolo[2,1,5-cd]indolizine and pyrrolo[2,1,5-de]quinolizine derivs. from 2-acyl-1-(acylmethyl)pyridinium halides)


RN 135489-62-2 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-5-formyl-, methyl ester (CA INDEX NAME)




RN 213549-46-3 CAPLUS


CN 1-Indolizinecarbonitrile, 3-benzoyl-5-formyl- (CA INDEX NAME)




RN 213549-49-6 CAPLUS
 CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-5-formyl-, diethyl ester (9CI)
 (CA INDEX NAME)




RN 372517-24-3 CAPLUS
 CN 1-Indolizinecarbonitrile, 3,5-dibenzoyl- (CA INDEX NAME)



RN 372517-26-5 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3,5-dibenzoyl-, methyl ester (CA INDEX NAME)



RN 372517-27-6 CAPLUS
 CN 1,2-Indolizinedicarboxylic acid, 3,5-dibenzoyl-, diethyl ester (9CI) (CA
 INDEX NAME)



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 55 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:482859 CAPLUS

DOCUMENT NUMBER: 135:282674

TITLE: 4-(Benzoylindoliziny1)butyric acids; novel
nonsteroidal inhibitors of steroid 5 α -reductase.
III

AUTHOR(S): Sawada, Kozo; Okada, Satoshi; Kuroda, Akio; Watanabe,
Shinya; Sawada, Yuki; Tanaka, Hirokazu

CORPORATE SOURCE: Exploratory Research Laboratories, Fujisawa
Pharmaceutical Co., Ltd., Tsukuba, 300-2698, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (2001), 49(7),
799-813

CODEN: CPBTAL; ISSN: 0009-2363

PUBLISHER: Pharmaceutical Society of Japan

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 135:282674

AB A novel series of indolizinebutyric acids with various benzoyl
substituents was synthesized to develop nonsteroidal inhibitors of steroid
5 α -reductase, and the structure-activity relationships in this
series were studied. The authors previously reported the
structure-activity relationships in a series of indolebutyric acids as
well as the discovery of the novel nonsteroidal 5 α -reductase
inhibitor, FK143. The authors have now made other modifications to this
compound to improve in vivo inhibitory activity. By altering the
heterocyclic nucleus and changing the benzoyl substituent the authors have
succeeded in identifying the strongly active compound, FK687,
(S)-4-[1-[4-[[1-(4-isobutylphenyl)butyl]oxy]benzoyl]indolizin-3-yl]butyric
acid, which displays strong in vitro inhibitory activity against the human
enzyme and in vivo inhibitory activity against the castrated young rat
model. This compound should be a useful agent for the treatment of benign
prostatic hyperplasia.


IT 365280-19-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (benzoylindoliziny1)butyric acids as novel nonsteroidal
inhibitors of steroid 5 α -reductase in relation to structure and
treatment of benign prostatic hyperplasia)

RN 365280-19-9 CAPLUS

CN 1-Indolizinebutanoic acid, 3-[3-[[bis[4-(2-methylpropyl)phenyl]methyl]amin
o]benzoyl]- (CA INDEX NAME)



IT 146922-53-4P 146922-61-4P 146923-35-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of (benzoylindoliziny1)butyric acids as novel nonsteroidal

inhibitors of steroid 5 α -reductase in relation to structure and treatment of benign prostatic hyperplasia)


RN 146922-53-4 CAPLUS

CN 1-Indolizinebutanoic acid, 3-(3-nitrobenzoyl)-, ethyl ester (CA INDEX NAME)




RN 146922-61-4 CAPLUS

CN 1-Indolizinebutanoic acid, 3-(3-aminobenzoyl)-, ethyl ester (CA INDEX NAME)



RN 146923-35-5 CAPLUS

CN 1-Indolizinebutanoic acid, 3-[3-[[bis[4-(2-methylpropyl)phenyl]methyl]amino]benzoyl]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT:

30

THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 56 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:251286 CAPLUS

DOCUMENT NUMBER: 135:61204

TITLE: Heterocyclic compounds with a bridge nitrogen atom.
14. Cycloaddition of acetylenedicarboxylic acid ester to 2-chloro-N-phenacylpyridinium ylide. Crystal structure of dimethyl ester of 5-chloro-3-(p-nitrobenzoyl)-indolizine-1,2-dicarboxylic acid

AUTHOR(S): Babaev, E. V.; Pasichnichenko, K. Yu.; Rybakov, V. B.; Zhukov, S. G.

CORPORATE SOURCE: M. V. Lomonosov Moscow State University, Moscow, 119899, Russia

SOURCE: Chemistry of Heterocyclic Compounds (New York, NY, United States) (Translation of Khimiya Geterotsiklicheskikh Soedinenii) (2000), 36(10), 1192-1197

CODEN: CHCCAL; ISSN: 0009-3122

PUBLISHER: Consultants Bureau

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 135:61204


AB A derivative of 5-chloroindolizine is formed in the reaction of 2-chloro-1-(p-nitrophenacyl)pyridinium ylide with acetylenedicarboxylic acid di-Me ester, the structure of which was demonstrated by X-ray diffraction anal. According to the ¹H NMR and mass spectra the indolizine obtained undergoes an unusual intramol. cyclization with the formation of benz[e]cycl[3.3.2]azine nucleus.

IT 345891-36-3P

RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(cycloaddn. of acetylenedicarboxylate to 2-chloro-N-phenacylpyridinium ylide)

RN 345891-36-3 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 5-chloro-3-(4-nitrobenzoyl)-, dimethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 57 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:101137 CAPLUS

DOCUMENT NUMBER: 134:147609

TITLE: Preparation of tricyclic indolizine compounds having sPLA2-inhibitory activities

INVENTOR(S): Ohtani, Mitsuaki; Fuji, Masahiro; Okada, Tetsuo; Adachi, Makoto; Ogawa, Tomoyuki

PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan

SOURCE: PCT Int. Appl., 81 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001009130	A1	20010208	WO 2000-JP4908	20000724
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000060232	A	20010219	AU 2000-60232	20000724
US 6673781	B1	20040106	US 2002-48348	20020201
PRIORITY APPLN. INFO.:			JP 1999-218291	A 19990802
			WO 2000-JP4908	W 20000724
OTHER SOURCE(S):		MARPAT 134:147609		
GI				




I




II


Q=




Q1=




Q2=




Q3=




Q4=



Q5=



Q6=



AB Fused pyrrolo[1,2-a]pyridine compds. of the general formula (I), prodrugs of the same, pharmaceutically acceptable salts of both, or hydrates thereof [R1 is (a) C1-20 alkyl, C2-20 alkenyl, C2-20 alkynyl, a carbocyclic group, or a heterocyclic group, (b) group (a) substituted with ≥ 1 nonobstructive substituents, or (c) (L1)-R5 [wherein L1 is a divalent linkage group consisting of 1-18 atoms selected from H, N, C, O, and S; R5 is a group selected from group (a) and (b)]; R2 is CONH2 or CONHNNH2; and either of R3 and either of R3 and R4 is -(L2)-(acid group) (wherein L2 is a group connecting with an acid group and the length of the connecting group is 1 to 5) and the other is hydrogen; A is Q - Q6 (wherein X is a single bond or CR22R23; X1 is a single bond or CR20R21; R2 is same as above; R18 -R23 is H or lower alkyl; R24 and R25 are H, C1-6 alkyl, aryl, halo, aralkyl)], which exhibit secretory phospholipase A2 (sPLA2), are prepared These compds. are useful for the treatment or prevention of inflammatory diseases, septic shock, adult respiratory distress syndrome, pancreatitis, trauma, bronchial asthma, allergic rhinitis, chronic articular rheumatism, arteriosclerosis, cerebral apoplexy, cerebral infarction, inflammatory bowel syndrome, psoriasis, heart failure, or myocardial infarction. Thus, a Pyrido[2,1-a]isoindole derivative (II) was prepared from 2-methyl-3-(benzyloxy)pyridine in 10 steps

via

intramol. Wittig condensation of [3-[1-(carbamoylcarbonyl)-3-benzyl-8-(methoxycarbonylmethoxy)-indolizin-2-yl]propyl]triphenylphosphonium bromide for cyclization to the precursor ester followed by hydrolysis. II showed IC50 of 0.008 μ M against sPLA2.


IT 324520-15-2

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of tricyclic indolizine compds. having secretory phospholipase A2 (sPLA2)-inhibitory activity as therapeutics)

RN 324520-15-2 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-8-(phenylmethoxy)-, dimethyl ester (9CI) (CA INDEX NAME)



IT 324520-16-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of tricyclic indolizine compds. having secretory phospholipase
 A2 (sPLA2)-inhibitory activity as therapeutics)
 RN 324520-16-3 CAPLUS
 CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-8-(phenylmethoxy)- (CA INDEX
 NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 58 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:521079 CAPLUS

DOCUMENT NUMBER: 133:252249

TITLE: The synthesis of substituted 7,7'-bisindolizines via 1,3-dipolar cycloaddition under microwave irradiation

AUTHOR(S): Dinica, Rodica M.; Druta, Ioan I.; Pettinari, Claudio

CORPORATE SOURCE: Chemistry Department, "Dunarea de Jos", University, Galati, 6200, Rom.

SOURCE: Synlett (2000), (7), 1013-1015

CODEN: SYNLES; ISSN: 0936-5214


PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 133:252249

GI




AB Microwave irradiation under solvent-free conditions induced 4,4'-bipyridinium ylides generated in situ, to undergo 1,3-dipolar cycloaddn. with activated alkynes, on KF/alumina, giving 7,7'-bisindolizines I (R = R1 = CO2Et; R = CO2Me, R1 = H; R = CO2Et, R1 = H; R3 = R4 = H; R3 = Cl, Br, OMe, R4 = H; R3 = H, R4 = OMe) in high yields.

IT 213988-89-7P 295328-44-8P 295328-45-9P
295328-51-7P 295328-52-8P 295328-55-1P
295328-56-2P 295328-57-3P 295328-58-4P
295328-59-5P 295328-60-8P 295328-61-9P
295328-62-0P 295328-63-1P 295328-64-2P
295328-65-3P 295328-67-5P 295328-68-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of substituted 7,7'-bisindolizines via 1,3-dipolar cycloaddn. under microwave irradiation)


RN 213988-89-7 CAPLUS

CN [7,7'-Biindolizine]-1,1'-dicarboxylic acid, 3,3'-dibenzoyl-, diethyl ester (9CI) (CA INDEX NAME)




RN 295328-44-8 CAPLUS


CN [7,7'-Biindolizine]-1,1',2,2'-tetracarboxylic acid, 3,3'-dibenzoyl-, tetraethyl ester (9CI) (CA INDEX NAME)




RN 295328-45-9 CAPLUS
 CN [7,7'-Biindolizine]-1,1'-dicarboxylic acid, 3,3'-dibenzoyl-, dimethyl ester (9CI) (CA INDEX NAME)



RN 295328-51-7 CAPLUS
 CN [7,7'-Biindolizine]-1,1',2,2'-tetracarboxylic acid, 3,3'-bis(3-chlorobenzoyl)-, tetraethyl ester (9CI) (CA INDEX NAME)




RN 295328-52-8 CAPLUS
 CN [7,7'-Biindolizine]-1,1',2,2'-tetracarboxylic acid, 3,3'-bis(3-bromobenzoyl)-, tetraethyl ester (9CI) (CA INDEX NAME)




RN 295328-55-1 CAPLUS

CN [7,7'-Biindolizine]-1,1',2,2'-tetracarboxylic acid, 3,3'-bis(3-nitrobenzoyl)-, tetraethyl ester (9CI) (CA INDEX NAME)




RN 295328-56-2 CAPLUS

CN [7,7'-Biindolizine]-1,1',2,2'-tetracarboxylic acid, 3,3'-bis(3-methoxybenzoyl)-, tetraethyl ester (9CI) (CA INDEX NAME)




RN 295328-57-3 CAPLUS

CN [7,7'-Biindolizine]-1,1',2,2'-tetracarboxylic acid, 3,3'-bis(4-methoxybenzoyl)-, tetraethyl ester (9CI) (CA INDEX NAME)




RN 295328-58-4 CAPLUS

CN [7,7'-Biindolizine]-1,1'-dicarboxylic acid, 3,3'-bis(3-chlorobenzoyl)-, dimethyl ester (9CI) (CA INDEX NAME)




RN 295328-59-5 CAPLUS

CN [7,7'-Biindolizine]-1,1'-dicarboxylic acid, 3,3'-bis(3-bromobenzoyl)-, dimethyl ester (9CI) (CA INDEX NAME)




RN 295328-60-8 CAPLUS

CN [7,7'-Biindolizine]-1,1'-dicarboxylic acid, 3,3'-bis(3-nitrobenzoyl)-,
dimethyl ester (9CI) (CA INDEX NAME)




RN 295328-61-9 CAPLUS

CN [7,7'-Biindolizine]-1,1'-dicarboxylic acid, 3,3'-bis(3-methoxybenzoyl)-,
dimethyl ester (9CI) (CA INDEX NAME)




RN 295328-62-0 CAPLUS


CN [7,7'-Biindolizine]-1,1'-dicarboxylic acid, 3,3'-bis(4-methoxybenzoyl)-,
dimethyl ester (9CI) (CA INDEX NAME)




RN 295328-63-1 CAPLUS
CN [7,7'-Biindolizine]-1,1'-dicarboxylic acid, 3,3'-bis(3-chlorobenzoyl)-,
diethyl ester (9CI) (CA INDEX NAME)



RN 295328-64-2 CAPLUS
CN [7,7'-Biindolizine]-1,1'-dicarboxylic acid, 3,3'-bis(3-bromobenzoyl)-,
diethyl ester (9CI) (CA INDEX NAME)




RN 295328-65-3 CAPLUS
CN [7,7'-Biindolizine]-1,1'-dicarboxylic acid, 3,3'-bis(3-nitrobenzoyl)-,
diethyl ester (9CI) (CA INDEX NAME)




RN 295328-67-5 CAPLUS

CN [7,7'-Biindolizine]-1,1'-dicarboxylic acid, 3,3'-bis(3-methoxybenzoyl)-, diethyl ester (9CI) (CA INDEX NAME)



RN 295328-68-6 CAPLUS

CN [7,7'-Biindolizine]-1,1'-dicarboxylic acid, 3,3'-bis(4-methoxybenzoyl)-, diethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT:

21

THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 59 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:84619 CAPLUS
DOCUMENT NUMBER: 132:117566
TITLE: Small molecule inhibitors of Bcl-2 proteins for inducing apoptosis
INVENTOR(S): Huang, Ziwei; Lui, Dongxiang; Han, Xiaobing; Zhang, Zhijia; Wang, Jialun
PATENT ASSIGNEE(S): Thomas Jefferson University, USA
SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000004901	A1	20000203	WO 1999-US12384	19990720
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2338328	A1	20000203	CA 1999-2338328	19990720
EP 1100496	A1	20010523	EP 1999-937146	19990720
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6492389	B1	20021210	US 1999-357229	19990720
PRIORITY APPLN. INFO.:			US 1998-93561P	P 19980721
			US 1999-128100P	P 19990407
			WO 1999-US12384	W 19990720

OTHER SOURCE(S): MARPAT 132:117566

AB Small mol. inhibitors of Bcl-2 function are used to induce apoptosis of cells which are subject to Bcl-2, which cells are otherwise subject to Bcl-2-mediated blockage of apoptosis. The compds. are useful for treating cancer, autoimmune disorders and viral infection. The binding to Bcl-2 protein of 716 organic compds. selected from computer screening studies were initially tested at 100 μ M concentration. A group of compds. was found to be active in the Bcl-2 ligand binding assay with a level of inhibition ranging from 35% to 98%. Four of the active compds., designated as HA01 (HA12-16), HA02, HA03, and HA04, showed a concentration-dependent competition binding. The two most potent compds., HA01 and HA02, exhibited a binding affinity (KD) of 7 μ M and 15 μ M, resp. Compound HA14-1 was tested in the same manner. A clear concentration-dependent competition binding was observed

for this compound over a concentration of 1-100 μ M. Also, the compds. HA01, HA02 and HA04 induced apoptosis in a human pre-B leukemia cell line (697 cells) using taxol as a pos. control.


IT 256432-37-8, HA 13

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(apoptosis induced by inhibitors of Bcl-2 protein for treatment of autoimmune disorders, cancer, and viral infection)

RN 256432-37-8 CAPLUS

CN Ethanone, 1-[3-benzoyl-7-[(4-nitrophenyl)methyl]-1-indoliziny]- (CA INDEX NAME)




REFERENCE COUNT:


1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 60 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1999:801102 CAPLUS
 DOCUMENT NUMBER: 132:122502
 TITLE: Preparation of 1-(trifluoroacetyl)indolizines and their derivatives via cycloaddition of pyridinium N-ylides with 4-ethoxy-1,1,1-trifluorobut-3-en-2-one
 AUTHOR(S): Zhu, Shi-zheng; Qin, Chao-yue; Wang, Yan-Li; Chu, Qian-li
 CORPORATE SOURCE: Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, 200032, Peop. Rep. China
 SOURCE: Journal of Fluorine Chemistry (1999), 99(2), 183-187
 CODEN: JFLCAR; ISSN: 0022-1139
 PUBLISHER: Elsevier Science S.A.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 132:122502
 GI



AB Under basic reaction conditions pyridinium or isoquinolinium N-ylides (C₅H₅N+CH₂Y Br⁻ or C₉H₇N+CH₂Y Br⁻; Y = CO₂Me, CO₂Et, CN, PhCO) reacted readily with 4-ethoxy-1,1,1-trifluorobut-3-en-2-one to give 1-(trifluoroacetyl)indolizines or -pyrrolo[1,2-a]isoquinolines. The mol. structure of product I was determined
 IT 256234-53-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (cycloaddn. of pyridinium or isoquinolinium N-ylides with ethoxytrifluorobutenone)
 RN 256234-53-4 CAPLUS
 CN Ethanone, 1-(3-benzoyl-1-indoliziny)-2,2,2-trifluoro- (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 61 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:688009 CAPLUS

DOCUMENT NUMBER: 132:49869

TITLE: Synthesis of indolizine derivatives by the reaction of 2-(2'-pyridyl)pyridinium ylides with ethylenic dipolarophiles

AUTHOR(S): Druta, Ioan I.; Andrei, Mioara A.; Ganj, Cristian I.; Aburel, Pompiliu S.

CORPORATE SOURCE: Organic Chemistry Department, "Al. I. Cuza" University, Iasi, 6600, Rom.

SOURCE: Tetrahedron (1999), 55(45), 13063-13070
CODEN: TETRAB; ISSN: 0040-4020

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 132:49869

AB The reaction of 2-(2'-pyridyl)pyridinium N-ylides with substituted ethylenes such as acrylonitrile and Et acrylate gave the corresponding tetrahydroindolizine derivs. in high yields. Tetrahydroindolizine derivs. were dehydrogenated by treating with tetrapyridinecobalt(II) bichromate [CoPy₄(HCrO₄)₂] to give aromatic indolizines bearing cyano, aroyl, 2'-pyridyl, and ester groups at different positions.

IT 252201-18-6P 252201-19-7P 252986-67-7P


252986-69-9P 252986-70-2P 252986-71-3P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of of indolizines derivs. by [3+2] dipolar cycloaddn. of (pyridyl)pyridinium ylides with ethylenic dipolarophiles)


RN 252201-18-6 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-5-(2-pyridinyl)-, ethyl ester (CA INDEX NAME)




RN 252201-19-7 CAPLUS


CN 1-Indolizinecarboxylic acid, 3-(4-nitrobenzoyl)-5-(2-pyridinyl)-, ethyl ester (CA INDEX NAME)




RN 252986-67-7 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-(4-methoxybenzoyl)-5-(2-pyridinyl)-, ethyl ester (CA INDEX NAME)



RN 252986-69-9 CAPLUS
 CN 1-Indolizinecarbonitrile, 3-benzoyl-5-(2-pyridinyl)- (CA INDEX NAME)




RN 252986-70-2 CAPLUS
 CN 1-Indolizinecarbonitrile, 3-(4-nitrobenzoyl)-5-(2-pyridinyl)- (CA INDEX NAME)



RN 252986-71-3 CAPLUS

CN 1-Indolizinecarbonitrile, 3-(4-methoxybenzoyl)-5-(2-pyridinyl)- (CA INDEX NAME)




REFERENCE COUNT:


20

THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 62 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1999:563227 CAPLUS
 DOCUMENT NUMBER: 131:310616
 TITLE: Novel 1,3-dipolar cycloaddition of quinoxalinium
 N-ylide to alkene promoted by MnO₂: a new approach to
 synthesis of pyrrolo[1,2-a]-quinoxalines
 AUTHOR(S): Zhou, Jian; Zhang, Lande; Hu, Yuefei; Hu, Hongwen
 CORPORATE SOURCE: Department of Chemistry, Nanjing University, Nanjing,
 210093, Peop. Rep. China
 SOURCE: Journal of Chemical Research, Synopses (1999), (9),
 552-553
 CODEN: JRPSDC; ISSN: 0308-2342
 PUBLISHER: Royal Society of Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 131:310616
 GI



AB A novel approach to synthesize pyrrolo[1,2-a]quinoxalines I [R₁ = H, CO₂Et, R₂ = cyano, CO₂Me, COMe, CO₂Et; R₁R₂ = CO(NPh)CO] was developed successfully by 1,3-dipolar cycloaddn. of a quinoxalinium N-ylide to alkenes R₁CH:CHR₂ in the presence of MnO₂ under very convenient conditions and with moderate yields (40-52%).
 IT 25627-81-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of pyrroloquinoxalines by dipolar cycloaddn. of alkenes to quinoxalinium N-ylide)
 RN 25627-81-0 CAPLUS
 CN 1-Indolizinecarbonitrile, 3-benzoyl- (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 63 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:436060 CAPLUS
DOCUMENT NUMBER: 131:235015
TITLE: Photophysics of some indolizines, derivatives from
bipyridyl, in various media
AUTHOR(S): Vlahovici, Alexandru; Druta, Ioan; Andrei, Mioara;
Cotlet, Mircea; Dinica, Rodica
CORPORATE SOURCE: Faculty of Physics, "Al. I. Cuza" University, Iasi,
6600, Rom.
SOURCE: Journal of Luminescence (1999), 82(2), 155-162
CODEN: JLUMA8; ISSN: 0022-2313
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English


AB A series of luminescent properties of some new indolizinic compds., recently synthesized derivs. from bipyridyl, are analyzed. Significant differences are observed between monoindolizinic compds. and bisindolizinic ones regarding the absorption and fluorescence in the UV-VIS spectral range. Extended conjugation in bisindolizinic compds. causes a strong increase in the molar absorptivity and fluorescence quantum yield and a shift of the fluorescence spectrum towards violet. Unlike monoindolizinic compds., the bisindolizinic ones have near planar conformations and rigid structures as they experience less changes with excitation. The transitions of the analyzed mols. are of the type $\pi \rightarrow \pi^*$ and that the mixing of the S1 and S2 states is not strong.

IT 203588-19-6

RL: PRP (Properties)
(pectroscopic properties of)

RN 203588-19-6 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-5-(2-pyridinyl)-, dimethyl ester (9CI) (CA INDEX NAME)




IT 203588-20-9 213988-89-7 252201-18-6
252201-19-7


RL: PRP (Properties)
(spectroscopic properties of)

RN 203588-20-9 CAPLUS


CN 1,2-Indolizinedicarboxylic acid, 3-(4-nitrobenzoyl)-5-(2-pyridinyl)-, dimethyl ester (9CI) (CA INDEX NAME)




RN 213988-89-7 CAPLUS
 CN [7,7'-Biindolizine]-1,1'-dicarboxylic acid, 3,3'-dibenzoyl-, diethyl ester
 (9CI) (CA INDEX NAME)



RN 252201-18-6 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-benzoyl-5-(2-pyridinyl)-, ethyl ester (CA
 INDEX NAME)



RN 252201-19-7 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-(4-nitrobenzoyl)-5-(2-pyridinyl)-, ethyl
 ester (CA INDEX NAME)



REFERENCE COUNT:

23

THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 64 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:327734 CAPLUS

DOCUMENT NUMBER: 131:73717

TITLE: C-acylation of electron-rich heterocyclic compounds with Kirsanov isocyanate

AUTHOR(S): Tolmachev, Andrei A.; Chaikovskaya, Aleksandra A.; Smaliy, Radomir V.; Kudrya, Tamara N.; Yurchenko, Aleksandr A.; Pinchuk, Aleksandr M.

CORPORATE SOURCE: Institute of Organic Chemistry, National Academy of Sciences of Ukraine, Kiev, 253660, Ukraine

SOURCE: Heteroatom Chemistry (1999), 10(4), 343-348
CODEN: HETCE8; ISSN: 1042-7163

PUBLISHER: John Wiley & Sons, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 131:73717


AB Pyrroles, indoles, indolizines, and 2-methylfuran are vigorously C-acylated with isocyanatophosphoryl dichloride. E.g., N-methylpyrrole reacts with Cl₂P(O)NCO in octane at room temperature to give a 90% yield of 1-methylpyrrole-2-carboxamidophosphoryl dichloride. The resulting heteroaryl-substituted isocyanatophosphoryl dichlorides provide a convenient access to a variety of products.

IT 228566-54-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 228566-54-9 CAPLUS

CN 1-Indolizinecarboxamide, N-(di-4-morpholinylphosphinyl)-2-methyl-3-(3-nitrobenzoyl)- (CA INDEX NAME)



REFERENCE COUNT:

12

THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 65 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:325791 CAPLUS

DOCUMENT NUMBER: 130:338017

TITLE: Method for the treatment of disorders associated with apoptosis using N-heterocyclic glyoxylamide compounds

INVENTOR(S): Yagami, Tatsuro; Takasu, Nobuo

PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan

SOURCE: PCT Int. Appl., 104 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9924033	A1	19990520	WO 1997-JP4104	19971112
W: JP, US				
CA 2308269	A1	19990520	CA 1998-2308269	19981110
WO 9924026	A2	19990520	WO 1998-JP5042	19981110
WO 9924026	A3	19990715		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9897630	A	19990531	AU 1998-97630	19981110
EP 1037630	A2	20000927	EP 1998-951749	19981110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2003522720	T	20030729	JP 2000-520118	19981110
US 20030149000	A1	20030807	US 2002-219931	20020816
PRIORITY APPLN. INFO.:			WO 1997-JP4104	A 19971112
			WO 1998-JP5042	W 19981110
			US 2000-530781	A1 20000505

OTHER SOURCE(S): MARPAT 130:338017

GI




I



II

AB A method is disclosed for the treatment of disorders associated with apoptosis using N-heterocyclic glyoxylamide compds. I [E, F = C, N; the dotted line indicates the presence or absence of a double bond; R11 = alkyl, etc.; R12 = H, halo, etc.; R14 = H, etc.; R15 = H, etc.; R16 = H, carboxyl or ester thereof; R17 = H, alkyl, etc.; X = O, S]. Indole derivative II (preparation given) in vitro suppressed neuronal death depending on its concentration

IT 177558-67-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (method for treatment of disorders associated with apoptosis using
 N-heterocyclic glyoxylamide compds.)
 RN 177558-67-7 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-([1,1'-biphenyl]-2-ylcarbonyl)-2-ethyl-8-
 (phenylmethoxy)-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 66 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:281626 CAPLUS

DOCUMENT NUMBER: 130:337991

TITLE: Facile one-step synthesis of 1-acylindolizines by the reaction of pyridinium salts with Mannich bases in the presence of TPCD

AUTHOR(S): Wang, Bing-Xiang; Hu, Jia-Xin; Hu, Yue-Fei; Hu, Hong-Wen

CORPORATE SOURCE: Dep. Chem., Nanjing Univ., Nanjing, 210093, Peop. Rep. China

SOURCE: Gaodeng Xuexiao Huaxue Xuebao (1999), 20(3), 418-420
CODEN: KTHPDM; ISSN: 0251-0790

PUBLISHER: Gaodeng Jiaoyu Chubanshe

DOCUMENT TYPE: Journal

LANGUAGE: Chinese


AB A facile one-step method is presented for the synthesis of 1-acylindolizines in moderate yield by the reaction of pyridinium salts with Mannich bases in the presence of NaHCO₃ and a mild oxidizing agent, tetrakispyridine cobalt dichromate (TPCD). For example, 1-acetyl-3-benzoylindolizine was prepared in 36% yield from phenacylpyridinium bromide and 4-dimethylamino-2-butanone hydrochloride.

IT 17281-91-3P 51386-41-5P 51386-42-6P
189024-15-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of 1-acylindolizines by reaction of pyridinium salts with Mannich bases in presence of TPCD)


RN 17281-91-3 CAPLUS

CN Methanone, 1,3-indolizinediylbis[phenyl- (9CI) (CA INDEX NAME)




RN 51386-41-5 CAPLUS

CN Ethanone, 1-(3-benzoyl-1-indoliziny)- (CA INDEX NAME)




RN 51386-42-6 CAPLUS

CN Ethanone, 1-(3-benzoyl-7-methyl-1-indolizinyl)- (CA INDEX NAME)



RN 189024-15-5 CAPLUS

CN Methanone, (7-methyl-1,3-indolizinediyl)bis[phenyl- (9CI) (CA INDEX NAME)



L3 ANSWER 67 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:205852 CAPLUS

DOCUMENT NUMBER: 130:338006

TITLE: Synthesis of quaternary salts, anhydrobases, and 9-(1,2-dimethoxycarbonyl-3-benzoyl-7-indolizinylmethylene)-4-azafluorene based on 9-(γ -pyridylmethylene)azafluorenes

AUTHOR(S): Kolyadina, N. M.; Soldatenkov, A. T.; Baktibaev, O. M.; Prostakov, N. S.

CORPORATE SOURCE: Russian University of Peoples' Friendship, Moscow, 117923, Russia

SOURCE: Chemistry of Heterocyclic Compounds (New York) (Translation of Khimiya Geterotsiklicheskikh Soedinenii) (1999), Volume Date 1998, 34(8), 937-940
CODEN: CHCCAL; ISSN: 0009-3122


PUBLISHER: Consultants Bureau

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 130:338006

GI



AB The ratios of E- to Z-isomers of the quaternary salts prepared by mono- and di-quaternization of 9-(γ -pyridylmethylene)-1-(4)-azafluorenes, e.g., I, with iodomethane or bromoacetophenone have been determined. Conversion of the diphenacyl 9-(γ -pyridyl)-4-azafluorenium bromide II into the corresponding anhydrobase (diylide), and also its condensation with acetylenedicarboxylate diester to give 9-(1,2-dimethoxycarbonyl-3-benzoyl-7-indolizinylmethylene)-4-azafluorene III have been carried out.


IT 224428-65-3P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of (indolizinylmethylene)azafluorene and quaternary salts and anhydrobases of (pyridylmethylene)azafluorenes)

RN 224428-65-3 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-7-(5H-indeno[1,2-b]pyridin-5-ylidenemethyl)-, dimethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 68 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:177056 CAPLUS

DOCUMENT NUMBER: 130:337984

TITLE: Synthesis of 5-(2-phenylethenyl)indolizines by selective intermolecular 1,3-dipolar cycloaddition of 2-(2-phenylethenyl)pyridinium N-ylide with alkenes promoted by tetrakis-pyridine cobalt(ii) dichromate

AUTHOR(S): Zhou, Jian; Hu, Yuefei; Hu, Hongwen

CORPORATE SOURCE: Department of Chemistry, Nanjing University, Nanjing, 210093, Peop. Rep. China

SOURCE: Journal of Chemical Research, Synopses (1999), (2), 136-137

CODEN: JRPSDC; ISSN: 0308-2342


PUBLISHER: Royal Society of Chemistry

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 130:337984

GI



AB Intermol. 1,3-dipolar cycloaddns. of 2-(2-phenylethenyl)pyridinium N-ylides, e.g. I, with electron-deficient alkenes, e.g. di-Me maleate, were carried out selectively in the presence of tetrakis-pyridine cobalt(II) dichromate to yield 5-(2-phenylethenyl)indolizines, e.g. II, in moderate yields (48-63%).

IT 224425-03-0P 224425-06-3P 224425-09-6P
224425-10-9P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of indolizines by intermol. dipolar pyridine cobalt dichromate promoted cycloaddn. of (phenylethenyl)pyridinium N-ylides with electron deficient alkenes.)

RN 224425-03-0 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-5-[(1E)-2-phenylethenyl]-, dimethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 224425-06-3 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-5-[(1E)-2-phenylethenyl]-, diethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 224425-09-6 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-5-[(1E)-2-phenylethenyl]-, methyl ester (CA INDEX NAME)


Double bond geometry as shown.



RN 224425-10-9 CAPLUS

CN 1-Indolizinecarbonitrile, 3-benzoyl-5-[(1E)-2-phenylethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT:

20

THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 69 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:43858 CAPLUS

DOCUMENT NUMBER: 130:139271

TITLE: A one-step approach to 1-(fluoroalkyl)indolizine derivatives

AUTHOR(S): Zhang, Xue-chun; Huang, Wei-yuan

CORPORATE SOURCE: Laboratory Organofluorine Chemistry, Shanghai Institute Organic Chemistry, Chinese Academy Sciences, Shanghai, 200032, Peop. Rep. China

SOURCE: Synthesis (1999), (1), 51-54
CODEN: SYNTBF; ISSN: 0039-7881

PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 130:139271


AB A facile 1-step method is presented for the synthesis of 1-(fluoroalkyl)-substituted indolizines in moderate to good yields by reactions of pyridinium, 4-methylpyridinium isoquinolinium, and pyridazinium ylides with $\text{CF}_3\text{CBr:CH}_2$ and $\text{Cl}(\text{CF}_2)_n\text{CH:CHI}$ ($n = 2, 4, 6$), resp., in the presence of base.

IT 135339-04-7P 220042-71-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of (fluoroalkyl)indolizines)


RN 135339-04-7 CAPLUS

CN Methanone, phenyl[1-(trifluoromethyl)-3-indolizinyll]- (CA INDEX NAME)



RN 220042-71-7 CAPLUS

CN Methanone, [7-methyl-1-(trifluoromethyl)-3-indolizinyll]phenyl- (CA INDEX NAME)



REFERENCE COUNT:

17

THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 70 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:708940 CAPLUS
DOCUMENT NUMBER: 129:326101
TITLE: Method for the treatment of stroke using
N-heterocyclic glyoxylamide compounds
INVENTOR(S): Genba, Takefumi; Hori, Yozo
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9847507	A1	19981029	WO 1997-JP1421	19970424
W: JP				
CA 2285094	A1	19981029	CA 1998-2285094	19980423
WO 9847508	A1	19981029	WO 1998-JP1880	19980423
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9870807	A	19981113	AU 1998-70807	19980423
EP 977566	A1	20000209	EP 1998-917656	19980423
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002504893	T	20020212	JP 1998-545475	19980423
US 6214855	B1	20010410	US 1999-402084	19990929
PRIORITY APPLN. INFO.:			JP 1998-545402	A 19970424
			WO 1997-JP1421	A 19970424
			WO 1998-JP1880	W 19980423

OTHER SOURCE(S): MARPAT 129:326101

AB A method or composition is disclosed for the treatment and/or prevention of stroke using N-heterocyclic glyoxylamide compds.


IT 177558-67-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction; heterocyclic glyoxylamide compds. for stroke treatment, preparation, and pharmaceutical compns.)

RN 177558-67-7 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-([1,1'-biphenyl]-2-ylcarbonyl)-2-ethyl-8-(phenylmethoxy)-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 71 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:565671 CAPLUS

DOCUMENT NUMBER: 129:260304

TITLE: A convenient synthesis of 3-benzoylindolizine-5-carbaldehydes

AUTHOR(S): Zhou, Jian; Hu, Yuefei; Hu, Hongwen

CORPORATE SOURCE: Department of Chemistry, Nanjing University, Nanjing, 210093, Peop. Rep. China

SOURCE: Synthetic Communications (1998), 28(18), 3397-3402

CODEN: SYNCAV; ISSN: 0039-7911

PUBLISHER: Marcel Dekker, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 129:260304

AB 3-Benzoylindolizine-5-carbaldehydes, which could be used as derivatization reagents for amino compds. in HPCE were synthesized based on the 1,3-dipolar cycloaddn. of 1-phenacyl-2-(1,3-dioxolan-2-yl)pyridinium ylide with alkenes in the presence of TPCD.

IT 135489-61-1P 135489-62-2P 213549-46-3P


213549-47-4P 213549-48-5P 213549-49-6P

RL: SPN (Synthetic preparation); PREP (Preparation)

(convenient synthesis of 3-benzoylindolizine-5-carbaldehydes)


RN 135489-61-1 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-5-formyl-, dimethyl ester (9CI)
(CA INDEX NAME)




RN 135489-62-2 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-5-formyl-, methyl ester (CA INDEX NAME)




RN 213549-46-3 CAPLUS


CN 1-Indolizinecarbonitrile, 3-benzoyl-5-formyl- (CA INDEX NAME)




RN 213549-47-4 CAPLUS
 CN 5-Indolizinecarboxaldehyde, 1-acetyl-3-benzoyl- (CA INDEX NAME)



RN 213549-48-5 CAPLUS
 CN 5-Indolizinecarboxaldehyde, 1,3-dibenzoyl- (CA INDEX NAME)



RN 213549-49-6 CAPLUS
 CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-5-formyl-, diethyl ester (9CI)
 (CA INDEX NAME)




IT 135489-60-0P 135583-56-1P 213549-50-9P
 213549-51-0P 213549-52-1P 213549-53-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(for convenient synthesis of 3-benzoylindolizine-5-carbaldehydes)


RN 135489-60-0 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-5-(1,3-dioxolan-2-yl)-, methyl ester (CA INDEX NAME)




RN 135583-56-1 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-5-(1,3-dioxolan-2-yl)-, dimethyl ester (9CI) (CA INDEX NAME)




RN 213549-50-9 CAPLUS

CN 1-Indolizinecarbonitrile, 3-benzoyl-5-(1,3-dioxolan-2-yl)- (CA INDEX NAME)




RN 213549-51-0 CAPLUS

CN Ethanone, 1-[3-benzoyl-5-(1,3-dioxolan-2-yl)-1-indoliziny]- (CA INDEX NAME)




RN 213549-52-1 CAPLUS

CN Methanone, [5-(1,3-dioxolan-2-yl)-1,3-indolizinediyl]bis[phenyl- (9CI)
(CA INDEX NAME)



RN 213549-53-2 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-5-(1,3-dioxolan-2-yl)-, diethyl
ester (9CI) (CA INDEX NAME)




REFERENCE COUNT:

24


THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1998:565087 CAPLUS
 DOCUMENT NUMBER: 129:275806
 TITLE: Synthesis of 7,7'-bisindolizines by the reaction of
 4,4'-bipyridinium-ylides with activated alkynes
 AUTHOR(S): Druta, Ioan I.; Dinica, Rodica M.; Bacu, Elena;
 Humelnicu, I.
 CORPORATE SOURCE: Organic Chem. Dep., Al. I. Cuza Univ., Romania, 6600,
 Italy
 SOURCE: Tetrahedron (1998), 54(36), 10811-10818
 CODEN: TETRAB; ISSN: 0040-4020
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English


AB Eight new bis-indolizine heterocycles were prepared A theor. and exptl.
 study looking at the regiochem. of [3+2] dipolar cycloaddns. of
 4,4'-bipyridinium ylides (6-10)1,2 to Et propiolate and di-Me
 acetylenedicarboxylate.
 IT 213988-89-7P 213988-93-3P 213988-94-4P
 213988-95-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation bisindolizines by reaction of bipyridinium ylides with alkynes)
 RN 213988-89-7 CAPLUS
 CN [7,7'-Biindolizine]-1,1'-dicarboxylic acid, 3,3'-dibenzoyl-, diethyl ester
 (9CI) (CA INDEX NAME)



RN 213988-93-3 CAPLUS
 CN [7,7'-Biindolizine]-1,1',2,2'-tetracarboxylic acid, 3,3'-dibenzoyl-,
 tetramethyl ester (9CI) (CA INDEX NAME)




RN 213988-94-4 CAPLUS
 CN [7,7'-Biindolizine]-1,1',2,2'-tetracarboxylic acid, 3,3'-bis(4-
 nitrobenzoyl)-, tetramethyl ester (9CI) (CA INDEX NAME)



RN 213988-95-5 CAPLUS

CN [7,7'-Biindolizine]-1,1',2,2'-tetracarboxylic acid, 3,3'-bis(4-methoxybenzoyl)-, tetramethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT:

13

THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 73 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:547782 CAPLUS

DOCUMENT NUMBER: 129:290034

TITLE: Preparation of indolizine by intramolecular
1,5-dipolar cycloaddition of pyridinium N-allylides

AUTHOR(S): Zhou, Jian; Hu, Yue-Fei; Hu, Hong-Wen

CORPORATE SOURCE: Department of Chemistry, Nanjing University, Nanjing,
210093, Peop. Rep. China

SOURCE: Chemical Research in Chinese Universities (1998),
14(2), 213-214

CODEN: CRCUED; ISSN: 1000-9213

PUBLISHER: Higher Education Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Pyridinium or isoquinolinium allylides, prepared by treatment of
1-chloro-1-buten-3-one and the corresponding pyridinium or isoquinolinium
salts with Et₃N at room temperature, were heated in toluene 3-5 h to give
34-55%

indolizines and benzo[g]indolizines.


IT 51386-41-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of indolizine by intramol. 1,5-dipolar cycloaddn. of pyridinium
N-allylides)

RN 51386-41-5 CAPLUS

CN Ethanone, 1-(3-benzoyl-1-indoliziny)- (CA INDEX NAME)



REFERENCE COUNT:

8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 74 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:122775 CAPLUS

DOCUMENT NUMBER: 128:192513

TITLE: Synthesis of 5-(2'-pyridyl)-indolizines by the reaction of 2-(2'-pyridyl)-pyridinium-ylides with activated alkynes

AUTHOR(S): Druta, Ioan I.; Andrei, Mioara A.; Aburel, Pompiliu S.

CORPORATE SOURCE: Organic Chemistry Department, "Al. I. Cuza" University, Iasi, 6600, Rom.

SOURCE: Tetrahedron (1998), 54(10), 2107-2112

CODEN: TETRAB; ISSN: 0040-4020


PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 128:192513

GI



AB New heterocyclic compds., indolizine derivs. I (X = H, OMe, NO₂, Br, R = R₁ = CO₂Me; X = H, NO₂, Br, R = H, R₁ = CO₂Et), were prepared by 3+2 dipolar cycloaddn. reactions. These compds. were synthesized by the reaction of 2-(2'-pyridyl)-pyridinium-ylides II with di-Me acetylenedicarboxylate or Et propiolate. The structures of the new compds. were established by elemental anal. (C,H,N) and IR and ¹H NMR spectral methods.


IT 203588-19-6P 203588-20-9P 203588-21-0P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of pyridylindolizines by cyclization of alkynes with pyridylpyridinium ylides)


RN 203588-19-6 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-5-(2-pyridinyl)-, dimethyl ester (9CI) (CA INDEX NAME)




RN 203588-20-9 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-(4-nitrobenzoyl)-5-(2-pyridinyl)-,
dimethyl ester (9CI) (CA INDEX NAME)



RN 203588-21-0 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-(4-methoxybenzoyl)-5-(2-pyridinyl)-,
dimethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT:

14

THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 75 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:121449 CAPLUS

DOCUMENT NUMBER: 128:217319

TITLE: A convenient synthesis of polyfluoroalkyl-substituted pyrazolo[1,5-a]pyridine, pyrrolo[1,2-b]pyridazine and indolizine derivatives

AUTHOR(S): Zhang, Xue-chun; Huang, Wei-yuan

CORPORATE SOURCE: 354 Fenglin Lu, Shanghai Institute of Organic Chemistry, Laboratory of Organofluorine Chemistry, Chinese Academy of Sciences, Shanghai, 200032, Peop. Rep. China

SOURCE: Journal of Fluorine Chemistry (1998), 87(1), 57-64


CODEN: JFLCAR; ISSN: 0022-1139

PUBLISHER: Elsevier Science S.A.

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB In the presence of base, Et 2,2-dihdropoly(per)fluoroalkanoates reacted with N-aminopyridinium iodide, N-amino-γ-picolinium iodide or N-aminoisoquinolinium iodide, N-phenacylpyridazinium, N-phenacylpyridinium, and N-phenacylisoquinolinium bromides in DMF to give poly(per)fluoroalkyl-substituted pyrazolo[1,5-a] pyridine, e.g., I, pyrrolo[1,2-a]pyridazine, and indolizine derivs.

IT 204136-68-5P 204136-69-6P 204136-70-9P

204136-71-0P 204136-77-6P 204136-78-7P


204136-79-8P 204136-81-2P 204136-82-3P

204136-83-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 204136-68-5 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-2-(difluoromethyl)-, ethyl ester
(CA INDEX NAME)




RN 204136-69-6 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-2-(3-chloro-1,1,2,2,3,3-hexafluoropropyl)-, ethyl ester (CA INDEX NAME)




RN 204136-70-9 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-2-(5-chloro-1,1,2,2,3,3,4,4,5,5-decafluoropentyl)-, ethyl ester (CA INDEX NAME)




RN 204136-71-0 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-2-(pentadecafluoroheptyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 204136-77-6 CAPLUS


CN 1-Indolizinecarboxylic acid, 3-benzoyl-7-methyl-2-(trifluoromethyl)-, ethyl ester (CA INDEX NAME)




RN 204136-78-7 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-benzoyl-2-(5-chloro-1,1,2,2,3,3,4,4,5,5-decafluoropentyl)-7-methyl-, ethyl ester (CA INDEX NAME)




RN 204136-79-8 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-benzoyl-2-(1,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-hepta-decafluoro-1-nonenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 204136-81-2 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-benzoyl-2-(7-chloro-1,2,3,3,4,4,5,5,6,6,7,7-dodecafluoro-1-heptenyl)-7-cyano-, ethyl ester (9CI) (CA INDEX NAME)




RN 204136-82-3 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-benzoyl-7-cyano-2-(1,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-hepta-decafluoro-1-nonenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 204136-83-4 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-2-(7-chloro-1,2,3,3,4,4,5,5,6,6,7,7-dodecafluoro-1-heptenyl)-7-methyl-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT:

19

THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 76 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:760433 CAPLUS

DOCUMENT NUMBER: 128:61407

TITLE: Synthesis of mesomeric betaines, quinoliziniumides, via back-donated 1,6-cyclization

AUTHOR(S): Matsuda, Yoshiro; Katou, Keisuke; Nishiyori, Takanobu; Uemura, Takashi; Urakami, Maki

CORPORATE SOURCE: Faculty Environmental Studies, Nagasaki University, Nagasaki, 852, Japan

SOURCE: Heterocycles (1997), 45(11), 2197-2208

CODEN: HTCYAM; ISSN: 0385-5414

PUBLISHER: Japan Institute of Heterocyclic Chemistry

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The reaction of 3-aminopyridinium salts with polarized olefins in the presence of triethylamine yielded the corresponding 3-aminopyridinium N-allylides. Thermolysis of 3-aminopyridinium N-allylides in refluxing xylene afforded the 1,5-dipolar cyclization products, 8-aminoindolizines together with the back-donated 1,6-cyclization products, quinoliziniumides. In addition, thermolysis of N-allylides in refluxing AcOH gave quinoliziniumides.


IT 200216-28-0P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of quinoliziniumide mesomeric betaines via back-donated cyclization)

RN 200216-28-0 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-8-(methyamino)-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT:

30

THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 77 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:748900 CAPLUS

DOCUMENT NUMBER: 128:61394

TITLE: Hetarenes with a bridge nitrogen atom. 5. Synthesis of the indolizine ring by transformation of the oxazolo[3,2-a]pyridinium cation when treated with acetylacetone

AUTHOR(S): Babaev, E. V.; Bozhenko, S. V.

CORPORATE SOURCE: M. V. Lomonosov Moscow State University, Moscow, 119899, Russia

SOURCE: Chemistry of Heterocyclic Compounds (New York) (Translation of Khimiya Geterotsiklicheskikh Soedinenii) (1997), 33(1), 125-126


CODEN: CHCCAL; ISSN: 0009-3122

PUBLISHER: Consultants Bureau


DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I



II

AB Indolizines I (Ar = Ph, 4-O₂NC₆H₄) were prepared by the reaction of Na⁺-CH(COMe)₂ with oxazolopyridinium perchlorates II.


IT 200355-81-3P 200355-82-4P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of indolizines by cyclocondensation of acetylacetone with oxazolopyridinium perchlorates)


RN 200355-81-3 CAPLUS

CN Ethanone, 1-(3-benzoyl-2-methyl-1-indoliziny)- (9CI) (CA INDEX NAME)



RN 200355-82-4 CAPLUS

CN Ethanone, 1-[2-methyl-3-(4-nitrobenzoyl)-1-indoliziny]- (CA INDEX NAME)



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 78 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:246472 CAPLUS

DOCUMENT NUMBER: 126:293244

TITLE: A convenient synthesis of 1-acylindolizines by 1,3-dipolar cycloaddition reactions of pyridinium ylides and α,β -unsaturated aldehydes or ketones in the presence of tetrapyridinecobalt dichromate

AUTHOR(S): Zhang, Xuechun; Cao, Weili; Wei, Xudong; Hu, Hongwen
CORPORATE SOURCE: Department of Chemistry, Nanjing University, Nanjing, 210093, Peop. Rep. China

SOURCE: Synthetic Communications (1997), 27(8), 1395-1403
CODEN: SYNCAV; ISSN: 0039-7911

PUBLISHER: Dekker

DOCUMENT TYPE: Journal

LANGUAGE: English


AB In the presence of tetrapyridinecobalt dichromate ($\text{CoPy}_4(\text{HCrO}_4)_2$), pyridinium ylides and α,β -unsatd. aldehydes or ketones undergo 1,3-dipolar cycloaddn. reactions followed by in situ aromatization to give 1-acyl substituted indolizines in moderate to good yields.

IT 17281-91-3P 51386-41-5P 51386-42-6P
189024-15-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 17281-91-3 CAPLUS

CN Methanone, 1,3-indolizinediylbis[phenyl- (9CI) (CA INDEX NAME)




RN 51386-41-5 CAPLUS

CN Ethanone, 1-(3-benzoyl-1-indoliziny)- (CA INDEX NAME)




RN 51386-42-6 CAPLUS

CN Ethanone, 1-(3-benzoyl-7-methyl-1-indoliziny)- (CA INDEX NAME)



RN 189024-15-5 CAPLUS

CN Methanone, (7-methyl-1,3-indolizinediyl)bis[phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

25

THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 79 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:239019 CAPLUS

DOCUMENT NUMBER: 126:330534

TITLE: Indolizines. 4. The synthesis of new
3-vinylindolizines

AUTHOR(S): De Bue, G.; Nasielski, J.

CORPORATE SOURCE: Service de Chimie Organique CP 160/06, Universite
Libre de Bruxelles, Brussels, 1050, Belg.

SOURCE: Bulletin des Societes Chimiques Belges (1997), 106(2),
97-108

CODEN: BSCBAG; ISSN: 0037-9646

PUBLISHER: Bulletin des Societes Chimiques Belges

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 126:330534

AB New 3-vinylindolizines have been synthesized by two methods. The first strategy calls for the Wittig olefination of 3-acylindolizines with methylenetriphenylphosphorane or methoxymethylenetriphenylphosphorane. The best yields are obtained when the ylide is formed at room temperature and the condensation in refluxing THF. The required 3-acylindolizines were obtained by direct acylation of indolizines or by 1,3-dipolar cycloaddns. to acylmethylpyridinium ylides. The following 3-isopropenylindolizines were made with good yields: unsubstituted (85%), 2-Me (98%), 2-C₆H₅ (95%), 1-COOMe (98%), 1-COOMe-2-C₆H₅ (91%), 1,2-di-COOMe (58%). Also synthesized are the following 3- α -styrylindolizines: 2-C₆H₅ (99%), 1-COOMe (93%), 1-COOMe-2-C₆H₅ (87%), 1,2-di-COOMe (66%). 3-(α -Methyl- β -methoxyvinyl)indolizines E (40%) and Z (40%) were also obtained. The second strategy involves the 1,3-dipolar cycloaddn. of dipolarophiles to allylpyridinium ylides. The following new 3-vinylindolizines have been synthesized: 1-carbomethoxy-3-vinylindolizine (21%), 1,2-dicarbomethoxy-3-vinylindolizine (16%), 1-carbomethoxy-3- β -styrylindolizine (43%), 3- β -styrylindolizine (17%), and 1-carbomethoxy-3-(β -carbomethoxy)vinylindolizine (31%).


IT 17281-78-6P 17281-79-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of vinylindolizines)


RN 17281-78-6 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-, dimethyl ester (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 17281-79-7 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-, methyl ester (CA INDEX NAME)



REFERENCE COUNT:

27

THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1997:136196 CAPLUS

DOCUMENT NUMBER: 126:251363

TITLE: A novel approach to the synthesis of
3-acyl-substituted indolizines. The synthesis of
3-(indolizin-2yl)alanine-, and 4-(indolizin-
3yl)homoalanine derivativesAUTHOR(S): Jukic, Lucija; Bratusek, Urska; Skof, Marko; Svete,
Jurij; Stanovnik, BrankoCORPORATE SOURCE: Fac. Chem. Chem. Technol., Univ. Ljubljana, Ljubljana,
SloveniaSOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1996),
(11/12), 1510-1514


CODEN: KGSSAQ; ISSN: 0132-6244

PUBLISHER: Latviiskii Institut Organicheskogo Sinteza

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB A novel approach to the synthesis of 3-acylindolizines and the transformation of some heterocycloacetic acids into tryptophan analogs are described. Reaction of Et 2-pyridinylacetate and Me 2-quinolinylacetate with N-trifluoroacetyl-5-bromo-4-oxonorvaline Me ester led to esters I and II, resp. Treatment of Et 2-pyridinylacetate and 2-pyridinylacetonitrile, first with N,N-dimethylformamide di-Me acetal (DMFDMA) followed by reaction with phenacyl bromide, gave the corresponding 3-benzoylindolizines, while the reaction of Et 2-pyridinylacetate and 2-pyridinylacetonitrile with DMFDMA, followed by treatment with (S)-N-trifluoroacetyl-5-bromo-4-oxonorvaline Me ester, gave III (R = CN, CO₂Et).


IT 25627-81-0P 40624-43-9P

RL: SPN (Synthetic preparation); PREP (Preparation)

(synthesis of acyl-substituted indolizines and indolizine-containing
alanines)


RN 25627-81-0 CAPLUS

CN 1-Indolizinecarbonitrile, 3-benzoyl- (CA INDEX NAME)



RN 40624-43-9 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 81 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:513751 CAPLUS

DOCUMENT NUMBER: 125:247550

TITLE: Potent Inhibitors of Secretory Phospholipase A2:
Synthesis and Inhibitory Activities of Indolizine and
Indene Derivatives

AUTHOR(S): Hagishita, Sanji; Yamada, Masaaki; Shirahase,
Kazuhiro; Okada, Toshihiko; Murakami, Yasushi; Ito,
Yuji; Matsuura, Takaharu; Wada, Masaaki; Kato,
Toshiyuki; et al.

CORPORATE SOURCE: Shionogi Research Laboratories, Shionogi Co. Ltd.,
Osaka, 553, Japan

SOURCE: Journal of Medicinal Chemistry (1996), 39(19),
3636-3658

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Phospholipase A2 is an enzyme which hydrolyzes the sn-2 position of
certain cellular phospholipids. The liberated lysophospholipid and
arachidonic acid are precursors in the biosynthesis of various biol.
active products. As human nonpancreatic secretory phospholipase A2
(sPLA2) is present in high levels in the blood of patients in several
pathol. conditions, the potent sPLA2 inhibitors have been suggested to be
useful drugs. Here the authors describe the synthesis, structure-activity
relationship, and inhibitory activities of indolizine and indene derivs.
1-(Carbamoylmethyl)indolizine derivs. and 1-oxamoylindolizine derivs.
exhibited very potent inhibitory activity. The former was unstable to air
oxidation, but the latter exhibited an improvement both in stability and in
potency. Some compds. approached the stoichiometric limit of the
chromogenic assay.

IT 177558-52-0P 177558-53-1P 177558-54-2P

177558-55-3P 177558-66-6P 177558-67-7P


177558-68-8P 177558-69-9P 177558-70-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation and phospholipase A inhibitory activity of indolizine and
indene derivs.)


RN 177558-52-0 CAPLUS

CN 1-Indolizineacetic acid, 3-([1,1'-biphenyl]-2-ylcarbonyl)-2-ethyl-8-
(phenylmethoxy)-, ethyl ester (CA INDEX NAME)




RN 177558-53-1 CAPLUS


CN 1-Indolizineacetamide, 3-([1,1'-biphenyl]-2-ylcarbonyl)-2-ethyl-8-
(phenylmethoxy)- (CA INDEX NAME)




RN 177558-54-2 CAPLUS
 CN 1-Indolizineacetamide, 3-(3-chlorobenzoyl)-2-ethyl-8-(phenylmethoxy)- (CA INDEX NAME)



RN 177558-55-3 CAPLUS
 CN 1-Indolizineacetamide, 3-(3-chlorobenzoyl)-2-ethyl-8-(2-oxobutoxy)- (CA INDEX NAME)




RN 177558-66-6 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-benzoyl-2-ethyl-8-(phenylmethoxy)-, ethyl ester (CA INDEX NAME)




RN 177558-67-7 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-([1,1'-biphenyl]-2-ylcarbonyl)-2-ethyl-8-(phenylmethoxy)-, ethyl ester (CA INDEX NAME)




RN 177558-68-8 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-(3-chlorobenzoyl)-2-ethyl-8-(phenylmethoxy)-, ethyl ester (CA INDEX NAME)




RN 177558-69-9 CAPLUS

CN 1-Indolizinecarboxylic acid, 2-ethyl-8-(phenylmethoxy)-3-[3-(trifluoromethyl)benzoyl]-, ethyl ester (CA INDEX NAME)




RN 177558-70-2 CAPLUS

CN 1-Indolizinecarboxylic acid, 2-ethyl-3-(1-naphthalenylcarbonyl)-8-(phenylmethoxy)-, ethyl ester (CA INDEX NAME)



L3 ANSWER 82 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1996:386641 CAPLUS
 DOCUMENT NUMBER: 125:195514
 TITLE: Preparation of new nitrogen-bridged heterocycles. 42.
 Synthesis and the reaction of pyridinium N-ylides
 using bifunctional ethyl thiocyanatoacetates
 AUTHOR(S): Kakehi, Akikazu; Ito, Suketaka; Hashimoto, Yasunobu
 CORPORATE SOURCE: Fac. Eng., Shinshu Univ., Nagano, 380, Japan
 SOURCE: Bulletin of the Chemical Society of Japan (1996),
 69(6), 1769-1776
 CODEN: BCSJA8; ISSN: 0009-2673
 PUBLISHER: Nippon Kagakkai
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 125:195514
 GI




AB Various pyridinium (monosubstituted methylide)s I ($R_2, R_3, R_4 = H, Me$; $R_5 = \text{cyano}, \text{CO}_2\text{Et}, \text{COMe}, \text{COPh}$) were smoothly attached to the cyano group in Et thiocyanatoacetate or Et 2-thiocyanatopropionate to afford the corresponding pyridinium (substituted cyanomethylide)s II in low-to-moderate yields, while pyridinium (unsubstituted amidate)s III ($R_1, R_2, R_3 = H, Me$) reacted with the ester carbonyl group in the same reagents to give pyridinium (thiocyanatoacetato)- or (2-thiocyanatopropiono)amidates IV in considerable yields. The 1,3-dipolar cycloaddns. of some pyridinium (unsym. substituted cyanomethylide)s with di-Me acetylenedicarboxylate (DMAD) in various solvents afforded only di-Me 3-cyanoindolizine-1,2-dicarboxylate, except for a few examples. On the other hand, the treatment of pyridinium (thiocyanatoaceto)- or (2-thiocyanatopropiono)amidates with a strong base, such as potassium tert-butoxide, gave new bicyclic mesoionic compds., N-[2-(1,3,4-thiadiazolo[3,2-a]pyridinio)]acetamidate derivs. V, in moderate yields. The intermediacy of N-[1-(2-thiocyanatopyridinio)]acetamidates in the formation reactions of the latter compds. was also proven by independent syntheses.

IT 17281-78-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and reactions of pyridinium N-ylides using bifunctional thiocyanatoacetates)

RN 17281-78-6 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-, dimethyl ester (6CI, 8CI, 9CI) (CA INDEX NAME)



L3 ANSWER 83 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:353213 CAPLUS

DOCUMENT NUMBER: 125:33475

TITLE: preparation of indolizine derivatives as secretory phospholipase A2 (sPLA2) inhibitors

INVENTOR(S): Dillard, Robert D.; Hagishita, Sanji; Ohtani, Mitsuaki

PATENT ASSIGNEE(S): Eli Lilly and Co., USA; Shionogi and Co., Ltd.

SOURCE: PCT Int. Appl., 238 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9603383	A1	19960208	WO 1995-US9381	19950720
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2195570	A1	19960208	CA 1995-2195570	19950720
AU 9531459	A	19960222	AU 1995-31459	19950720
EP 772596	A1	19970514	EP 1995-927422	19950720
EP 772596	B1	20031001		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1158121	A	19970827	CN 1995-195129	19950720
JP 10505584	T	19980602	JP 1995-505935	19950720
HU 77867	A2	19980928	HU 1997-179	19950720
BR 9508298	A	19981103	BR 1995-8298	19950720
AT 251158	T	20031015	AT 1995-927422	19950720
ES 2208685	T3	20040616	ES 1995-927422	19950720
US 6645976	B1	20031111	US 1997-765566	19970428
PRIORITY APPLN. INFO.:			US 1994-278445	A 19940721
			WO 1995-US9381	W 19950720

OTHER SOURCE(S): MARPAT 125:33475


GI



I



II




III

AB Indolizine derivs. [I; R = H, NH₂; R₁ = H, C1-3 alkyl, halo, R₁R₁ = O, S; R₂ = H, C1-3 alkyl, halo, C3-4 cycloalkyl, etc.; R₃ = C7-20 alkyl, alkenyl, alkynyl, carbocyclyl, etc.; R₄, R₅ = H, (un)substituted carbocyclyl, heterocyclyl, etc.; R₆, R₇ = H, an acid group residue linked through a C1-10 divalent chain, etc.; X = O, S], useful in treating septic shock, adult respiratory distress, etc., are prepared and formulated. NaH (60%) was added to a mixture of alc. II and Br(CH₂)₃CO₂Et in DMF with stirring under cooling and N to give 56.2% ester III (R₈ = Et), which was saponified in MeOH to give 49.9% acid III (R₈ = H), which showed IC₅₀ of 1.1 μ M against sPLA₂ in a chromogenic assay. Capsule, tablet, etc. formulations were given.

IT 177558-52-0P 177558-53-1P 177558-54-2P
 177558-55-3P 177558-66-6P 177558-67-7P
 177558-68-8P 177558-69-9P 177558-70-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of indolizine derivs. as secretory phospholipase A₂ (sPLA₂) inhibitors)


RN 177558-52-0 CAPLUS

CN 1-Indolizineacetic acid, 3-([1,1'-biphenyl]-2-ylcarbonyl)-2-ethyl-8-(phenylmethoxy)-, ethyl ester (CA INDEX NAME)




RN 177558-53-1 CAPLUS

CN 1-Indolizineacetamide, 3-([1,1'-biphenyl]-2-ylcarbonyl)-2-ethyl-8-(phenylmethoxy)- (CA INDEX NAME)




RN 177558-54-2 CAPLUS


CN 1-Indolizineacetamide, 3-(3-chlorobenzoyl)-2-ethyl-8-(phenylmethoxy)- (CA INDEX NAME)




RN 177558-55-3 CAPLUS
 CN 1-Indolizineacetamide, 3-(3-chlorobenzoyl)-2-ethyl-8-(2-oxobutoxy)- (CA INDEX NAME)



RN 177558-66-6 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-benzoyl-2-ethyl-8-(phenylmethoxy)-, ethyl ester (CA INDEX NAME)




RN 177558-67-7 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-([1,1'-biphenyl]-2-ylcarbonyl)-2-ethyl-8-(phenylmethoxy)-, ethyl ester (CA INDEX NAME)




RN 177558-68-8 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-(3-chlorobenzoyl)-2-ethyl-8-(phenylmethoxy)-
, ethyl ester (CA INDEX NAME)




RN 177558-69-9 CAPLUS

CN 1-Indolizinecarboxylic acid, 2-ethyl-8-(phenylmethoxy)-3-[3-(trifluoromethyl)benzoyl]-, ethyl ester (CA INDEX NAME)



RN 177558-70-2 CAPLUS


CN 1-Indolizinecarboxylic acid, 2-ethyl-3-(1-naphthalenylcarbonyl)-8-(phenylmethoxy)-, ethyl ester (CA INDEX NAME)




L3 ANSWER 84 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1996:120326 CAPLUS
 DOCUMENT NUMBER: 124:260793
 TITLE: Benzopyrans: Part 34. Reactions of 3-substituted
 1-benzopyran-4-ones with N-phenacylpyridinium bromide
 AUTHOR(S): Ghosh, Chandra Kanta; Sahana, Sirin
 CORPORATE SOURCE: Dep. Biochem., Calcutta Univ., Calcutta, 700 019,
 India
 SOURCE: Indian Journal of Chemistry, Section B: Organic
 Chemistry Including Medicinal Chemistry (1996),
 35B(3), 203-6
 CODEN: IJSBDB; ISSN: 0376-4699
 PUBLISHER: Publications & Information Directorate, CSIR
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 124:260793
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB N-Phenacylpyridinium bromide reacted with benzopyranones I (R = H, Me, Cl, Br; X = CHO, CO₂H) in Me₂CO containing KCO₃ to give mixts. of the indolizines II and pyridinium salts III. Similar treatment of N-phenacylpyridinium bromide with I (R = H, Me; X = CN) gave the azirines IV, and reaction of N-phenacylpyridinium bromide with I (R = H, Me; X = CO₂Me) gave the zwitterions V. The pyridinium bromides III were converted into I by refluxing in pyridine.
 IT 100421-20-3P 175353-64-7P 175353-65-8P
 175353-66-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (formation of benzoylindolizines and pyridinium salts by reaction of benzopyranones with phenacylpyridinium bromides)
 RN 100421-20-3 CAPLUS
 CN Methanone, (3-benzoyl-1-indoliziny1)(2-hydroxyphenyl)- (CA INDEX NAME)




RN 175353-64-7 CAPLUS
 CN Methanone, (3-benzoyl-1-indoliziny1)(2-hydroxy-5-methylphenyl)- (CA INDEX NAME)




RN 175353-65-8 CAPLUS
 CN Methanone, (3-benzoyl-1-indolizinyl) (5-chloro-2-hydroxyphenyl)- (CA INDEX NAME)



RN 175353-66-9 CAPLUS
 CN Methanone, (3-benzoyl-1-indolizinyl) (5-bromo-2-hydroxyphenyl)- (CA INDEX NAME)



IT 176181-69-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 176181-69-4 CAPLUS
 CN Methanone, [1-[2-(acetyloxy)-5-methylbenzoyl]-3-indolizinyl]phenyl- (CA INDEX NAME)



L3 ANSWER 85 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:482938 CAPLUS

DOCUMENT NUMBER: 121:82938

ORIGINAL REFERENCE NO.: 121:14897a,14900a

TITLE: Crystal and molecular structure of
1,2,3-tribenzoylindolizine

AUTHOR(S): Wei, Xudong; Hu, Hongwen; Yu, Kaibei

CORPORATE SOURCE: Dep. Chem., Nanjing Univ., Nanjing, 210008, Peop. Rep.
China

SOURCE: Jiegou Huaxue (1993), 12(1), 26-8


CODEN: JHUADF; ISSN: 0254-5861

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 121:82938

GI




AB Crystal and mol. structure of the title compound I was determined by single
crystal X-ray diffraction anal. The indolizine ring is conjugated only
with the 1-benzoyl group.

IT 17281-90-2P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and crystal and mol. structure of)

RN 17281-90-2 CAPLUS

CN Methanone, 1,2,3-indolizinetriyltris[phenyl- (9CI) (CA INDEX NAME)



L3 ANSWER 86 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:270005 CAPLUS

DOCUMENT NUMBER: 120:270005

ORIGINAL REFERENCE NO.: 120:47823a,47826a

TITLE: A facile one-step synthesis of aromatic indolizines by 1,3-dipolar cycloaddition of pyridinium and related heteroaromatic ylides with alkenes in the presence of TPCD [Copy4(HCrO4)2]

AUTHOR(S): Wei, Xudong; Hu, Yuefei; Li, Tingsheng; Hu, Hongwen

CORPORATE SOURCE: Dep. Chem., Nanjing Univ., Nanjing, 210008, Peop. Rep. China

SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1993), (20), 2487-9


CODEN: JCPRB4; ISSN: 0300-922X

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 120:270005

GI



AB A facile and general one-step method is presented for the preparation of aromatic

indolizine compds. I (R-R2 = alkyl, etc.) in moderate to high yields (53-99%) by reaction of the pyridinium N-ylides II (R = alkyl), quinolinium ylide or isoquinolinium ylide with various olefinic dipolarophiles, such as acrylonitrile, Me acrylate, acrylamide, di-Et maleate and Me crotonate, resp., in the presence of a new oxidant TPCD [Copy4(HCrO4)2, tetrapyridinecobalt(II) dichromate] at 90 °C for 2 h in DMF.

IT 17281-79-7P, Methyl 3-benzoylindolizine-1-carboxylate

25627-81-0P, 3-Benzoyl-1-cyanoindolizine 25627-86-5P

154224-58-5P 154224-59-6P 154224-60-9P


154224-61-0P 154224-62-1P 154224-63-2P

154224-64-3P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation from pyridinium ylide and alkene)

RN 17281-79-7 CAPLUS


CN 1-Indolizinecarboxylic acid, 3-benzoyl-, methyl ester (CA INDEX NAME)




RN 25627-81-0 CAPLUS
CN 1-Indolizinecarbonitrile, 3-benzoyl- (CA INDEX NAME)




RN 25627-86-5 CAPLUS
CN 1-Indolizinecarboxamide, 3-benzoyl- (CA INDEX NAME)




RN 154224-58-5 CAPLUS
CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-, diethyl ester (9CI) (CA INDEX NAME)




RN 154224-59-6 CAPLUS
CN 1-Indolizinecarboxylic acid, 3-benzoyl-2-methyl-, methyl ester (CA INDEX NAME)




RN 154224-60-9 CAPLUS
 CN 1-Indolizinecarboxitrile, 3-benzoyl-5-methyl- (CA INDEX NAME)




RN 154224-61-0 CAPLUS
 CN 1-Indolizinecarboxitrile, 3-benzoyl-7-methyl- (CA INDEX NAME)



RN 154224-62-1 CAPLUS
 CN 6-Indolizinecarboxylic acid, 3-benzoyl-1-cyano-, methyl ester (CA INDEX NAME)




RN 154224-63-2 CAPLUS
 CN 8-Indolizinecarboxylic acid, 3-benzoyl-1-cyano-, methyl ester (CA INDEX NAME)



RN 154224-64-3 CAPLUS


CN 7-Indolizinecarboxylic acid, 3-benzoyl-1-cyano-, methyl ester (CA INDEX NAME)




L3 ANSWER 87 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1993:212886 CAPLUS
DOCUMENT NUMBER: 118:212886
ORIGINAL REFERENCE NO.: 118:36691a,36694a
TITLE: Preparation of indolizine derivatives as testosterone
5 α -reductase inhibitors
INVENTOR(S): Okada, Satoshi; Sawada, Kozo; Kuroda, Akio; Watanabe,
Shinya; Tanaka, Hirokazu
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 64 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
EP 519353	A2	19921223	EP 1992-109968	19920613
EP 519353	A3	19930414		
EP 519353	B1	20000816		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, PT, SE				
ZA 9203958	A	19930224	ZA 1992-3958	19920529
US 5334716	A	19940802	US 1992-892453	19920602
AT 195521	T	20000915	AT 1992-109968	19920613
ES 2149160	T3	20001101	ES 1992-109968	19920613
PT 519353	T	20001229	PT 1992-109968	19920613
HU 61544	A2	19930128	HU 1992-1993	19920615
CA 2071375	A1	19921218	CA 1992-2071375	19920616
CA 2071375	C	20030211		
AU 9218270	A	19921224	AU 1992-18270	19920616
AU 656197	B2	19950127		
CN 1067893	A	19930113	CN 1992-104790	19920616
CN 1042226	B	19990224		
JP 05178856	A	19930720	JP 1992-157074	19920616
RU 2120942	C1	19981027	RU 1992-5011971	19920616
HU 9500394	A3	19950928	HU 1995-394	19950622
GR 3034429	T3	20001229	GR 2000-402118	20000918
PRIORITY APPLN. INFO.:				
			GB 1991-13027	A 19910617
			GB 1991-20764	A 19910930
			GB 1991-24345	A 19911115
			GB 1992-3809	A 19920221
OTHER SOURCE(S):	MARPAT 118:212886			
GI				



I



II

AB Title compds. I [R1 = HO2C, protected-HO2C; R2 = H, alkyl, halo; R3 = (substituted) aryl, aralkyl, -carbamoylalkyl, N-heterocyclyl, etc.; R11 = H, alkyl, A = (substituted) alkylene, alkenylene; Q = CO, alkylene; X = (substituted) Ph, furandiyl; Y = bond, alkylene; Z = alkylene, alkenylene, O, R6N wherein R6 = H, (substituted) alkyl, -aralkyl, protecting group] and their salts are prepared To Et 4-[1-(4-aminobenzoyl)indolizin-3-yl]butyrate (preparation given) in CH2Cl2 were added diisopropylethylamine and bis(4-isobutylphenyl)chlormethane in CH2Cl2 to give Et 4-[1-[4-[bis(4-isobutylphenyl)methylamino]benzoyl]indolizin-3-yl]butyrate to which was added 4N NaOH to give title compound II. II showed IC50 of 4.4 + 10-10 M against testosterone 5 α -reductase.


IT 146922-53-4P 146922-54-5P 146922-57-8P
146922-58-9P 146922-61-4P 146922-62-5P
146922-65-8P 146922-66-9P 146922-75-0P
146922-76-1P 146922-79-4P 146922-80-7P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as intermediate for testosterone reductase inhibitors)


RN 146922-53-4 CAPLUS

CN 1-Indolizinebutanoic acid, 3-(3-nitrobenzoyl)-, ethyl ester (CA INDEX NAME)




RN 146922-54-5 CAPLUS


CN 1-Indolizinebutanoic acid, 3-(4-nitrobenzoyl)-, ethyl ester (CA INDEX NAME)




RN 146922-57-8 CAPLUS
 CN 1-Indolizinebutanoic acid, 3-(4-methoxybenzoyl)-, ethyl ester (CA INDEX NAME)




RN 146922-58-9 CAPLUS
 CN 1-Indolizinebutanoic acid, 3-(3-methoxybenzoyl)-, ethyl ester (CA INDEX NAME)




RN 146922-61-4 CAPLUS
 CN 1-Indolizinebutanoic acid, 3-(3-aminobenzoyl)-, ethyl ester (CA INDEX NAME)




RN 146922-62-5 CAPLUS
 CN 1-Indolizinebutanoic acid, 3-(4-aminobenzoyl)-, ethyl ester (CA INDEX NAME)




RN 146922-65-8 CAPLUS
 CN 1-Indolizinebutanoic acid, 3-(4-hydroxybenzoyl)-, ethyl ester (CA INDEX NAME)



RN 146922-66-9 CAPLUS
 CN 1-Indolizinebutanoic acid, 3-(3-hydroxybenzoyl)-, ethyl ester (CA INDEX NAME)




RN 146922-75-0 CAPLUS
 CN 1-Indolizinebutanoic acid, 2-methyl-3-(4-nitrobenzoyl)-, ethyl ester (CA INDEX NAME)




RN 146922-76-1 CAPLUS

CN 1-Indolizinebutanoic acid, 2-methyl-3-(3-nitrobenzoyl)-, ethyl ester (CA INDEX NAME)




RN 146922-79-4 CAPLUS

CN 1-Indolizinebutanoic acid, 3-(4-aminobenzoyl)-2-methyl-, ethyl ester (CA INDEX NAME)



RN 146922-80-7 CAPLUS

CN 1-Indolizinebutanoic acid, 3-(3-aminobenzoyl)-2-methyl-, ethyl ester (CA INDEX NAME)




IT 146923-35-5P 146923-40-2P 146923-41-3P
146939-30-2P 146939-35-7P 146939-36-8P
146939-37-9P 146939-38-0P 146939-42-6P
146939-48-2P 146939-50-6P 146939-56-2P
146939-59-5P 146939-60-8P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as testosterone reductase inhibitor)

RN 146923-35-5 CAPLUS


CN 1-Indolizinebutanoic acid, 3-[3-[[bis[4-(2-methylpropyl)phenyl]methyl]amino]benzoyl]-, ethyl ester (CA INDEX NAME)



RN 146923-40-2 CAPLUS
 CN 1-Indolizinebutanoic acid, 3-[4-[bis[4-(2-methylpropyl)phenyl]methoxy]benzoyl]-, ethyl ester (CA INDEX NAME)




RN 146923-41-3 CAPLUS
 CN 1-Indolizinebutanoic acid, 3-[3-[bis[4-(2-methylpropyl)phenyl]methoxy]benzoyl]-, ethyl ester (CA INDEX NAME)




RN 146939-30-2 CAPLUS
 CN 1-Indolizinebutanoic acid, 3-[4-[[bis[4-(2-methylpropyl)phenyl]methyl]aminobenzoyl]-, ethyl ester (CA INDEX NAME)

o]benzoyl]- (CA INDEX NAME)




RN 146939-35-7 CAPLUS

CN 1-Indolizinebutanoic acid, 3-[4-[bis[4-(2-methylpropyl)phenyl]methoxy]benzoyl]- (CA INDEX NAME)




RN 146939-36-8 CAPLUS

CN 1-Indolizinebutanoic acid, 3-[3-[bis[4-(2-methylpropyl)phenyl]methoxy]benzoyl]- (CA INDEX NAME)




RN 146939-37-9 CAPLUS

CN 1-Indolizinebutanoic acid, 3-[4-[[bis[4-(2-methylpropyl)phenyl]methyl]amino]benzoyl]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 146939-38-0 CAPLUS

CN 1-Indolizinebutanoic acid, 3-[3-[[bis[4-(2-methylpropyl)phenyl]methyl]amino]benzoyl]-2-methyl-, ethyl ester (CA INDEX NAME)




RN 146939-42-6 CAPLUS

CN 1-Indolizinebutanoic acid, 3-[4-[[1-[4-(2-methylpropyl)phenyl]hexyl]oxy]benzoyl]-, ethyl ester (CA INDEX NAME)




RN 146939-48-2 CAPLUS

CN 1-Indolizinebutanoic acid, 3-[3-[[1-[4-(2-methylpropyl)phenyl]hexyl]amino]benzoyl]-, ethyl ester (CA INDEX NAME)




RN 146939-50-6 CAPLUS

CN 1-Indolizinebutanoic acid, 3-[4-[[1-[4-(2-methylpropyl)phenyl]hexyl]oxy]benzoyl]- (CA INDEX NAME)




RN 146939-56-2 CAPLUS

CN 1-Indolizinebutanoic acid, 3-[3-[1-[4-(2-methylpropyl)phenyl]hexyl]amino]
benzoyl]- (CA INDEX NAME)




RN 146939-59-5 CAPLUS

CN 1-Indolizinebutanoic acid, 3-[4-[[bis[4-(2-methylpropyl)phenyl]methyl]amino]benzoyl]-2-methyl- (CA INDEX NAME)




RN 146939-60-8 CAPLUS

CN 1-Indolizinebutanoic acid, 3-[3-[[bis[4-(2-methylpropyl)phenyl]methyl]amino]benzoyl]-2-methyl- (CA INDEX NAME)



L3 ANSWER 88 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1992:591622 CAPLUS
DOCUMENT NUMBER: 117:191622
ORIGINAL REFERENCE NO.: 117:33087a,33090a
TITLE: A facile preparation of 1,2,3-triaroylindolizines
AUTHOR(S): Wei, Xudong; Hu, Yuefei; Li, Tingsheng; Hu, Hongwen
CORPORATE SOURCE: Dep. Chem., Nanjing Univ., Nanjing, 210008, Peop. Rep. China
SOURCE: Synthetic Communications (1992), 22(14), 2103-9
CODEN: SYNCAV; ISSN: 0039-7911
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 117:191622
GI




AB Fourteen 1,2,3-triaroylindolizines were prepared conveniently by oxidation of corresponding N-phenacyl pyridinium or substituted pyridinium bromides with a versatile oxidant TPCD [tetrakis-pyridino-cobalt (II) dichromate] in 12-42% yields. Thus, oxidation of pyridinium salts I (R = Ph, substituted Ph, 2-naphthyl) gave indolizines II.

IT 17281-90-2P 143718-60-9P 143718-61-0P
143718-62-1P 143718-66-5P 143718-67-6P
143718-68-7P 143718-70-1P 143718-71-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 17281-90-2 CAPLUS

CN Methanone, 1,2,3-indolizinetriyltris[phenyl]- (9CI) (CA INDEX NAME)




RN 143718-60-9 CAPLUS



CN Methanone, 1,2,3-indolizinetriyltris[(4-methylphenyl)]- (9CI) (CA INDEX NAME)




RN 143718-61-0 CAPLUS
 CN Methanone, 1,2,3-indolizinetriyltris[(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 143718-62-1 CAPLUS
 CN Methanone, 1,2,3-indolizinetriyltris[(3,4-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 143718-66-5 CAPLUS
 CN Methanone, 1,2,3-indolizinetriyltris[(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 143718-67-6 CAPLUS
 CN Methanone, 1,2,3-indolizinetriyltris[(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 143718-68-7 CAPLUS
 CN 7-Indolizinecarboxylic acid, 1,2,3-tribenzoyl-, methyl ester (CA INDEX NAME)



RN 143718-70-1 CAPLUS
 CN 8-Indolizinecarboxylic acid, 1,2,3-tribenzoyl-, methyl ester (CA INDEX NAME)



RN 143718-71-2 CAPLUS
 CN 6-Indolizinecarboxylic acid, 1,2,3-tribenzoyl-, methyl ester (CA INDEX NAME)




L3 ANSWER 89 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 1991:492222 CAPLUS
DOCUMENT NUMBER: 115:92222
ORIGINAL REFERENCE NO.: 115:15871a,15874a
TITLE: A new entry to [2.3.4]cyclazines
AUTHOR(S): Miki, Yasuyoshi; Hachiken, Hiroko; Yoshikawa, Masami;
Takemura, Shoji; Ikeda, Masazumi
CORPORATE SOURCE: Fac. Pharm. Sci., Kinki Univ., Higashi-Osaka, 577,
Japan
SOURCE: Heterocycles (1991), 32(4), 655-8
CODEN: HTCYAM; ISSN: 0385-5414
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 115:92222
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Treatment of 2,3-dihydro-2-methyl-3-phenyl-1H-pyrazino[3,4,5-cd]indolizine
2-oxides I (R = H, CO₂Me) with trifluoroacetic anhydride gave new
heterocyclic six-membered betaines II, which underwent 1,3-dipolar
cycloaddn. with di-Me acetylenedicarboxylate and maleimides in hot toluene
to yield the corresponding cycloadducts III and IV (R₁ = Me, Ph) resp.
Treatment of the maleimide adducts IV with p-toluenesulfonic acid in
boiling acetic acid gave the [2.3.4]cyclazines V.
IT 135489-60-0P 135583-56-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and acidic hydrolysis of)
RN 135489-60-0 CAPLUS
CN 1-Indolizinecarboxylic acid, 3-benzoyl-5-(1,3-dioxolan-2-yl)-, methyl
ester (CA INDEX NAME)




RN 135583-56-1 CAPLUS
CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-5-(1,3-dioxolan-2-yl)-,
dimethyl ester (9CI) (CA INDEX NAME)



IT 135489-61-1P 135489-62-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and sequential reductive amination and intramol. cyclization
 of)
 RN 135489-61-1 CAPLUS
 CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-5-formyl-, dimethyl ester (9CI)
 (CA INDEX NAME)



RN 135489-62-2 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-benzoyl-5-formyl-, methyl ester (CA INDEX
 NAME)



L3 ANSWER 90 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1991:491996 CAPLUS

DOCUMENT NUMBER: 115:91996

ORIGINAL REFERENCE NO.: 115:15819a,15822a

TITLE: Fluorocarbon derivatives of nitrogen. Part 18.
Synthesis of fluorinated indolizines through reactions
of pyridinium ethoxycarbonylmethylide or pyridinium
phenacylide with perfluoropropene, perfluorobut-2-yne
and 3,3,3-trifluoropropyne

AUTHOR(S): Banks, Ronald Eric; Khaffaff, Suad Najmaldin

CORPORATE SOURCE: Inst. Sci. Technol., Univ. Manchester, Manchester, M60
1QD, UK

SOURCE: Journal of Fluorine Chemistry (1991), 51(3), 407-18


CODEN: JFLCAR; ISSN: 0022-1139

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 115:91996

GI




AB Fluorinated indolizines I (R = CO₂Et, CPh; R¹ = F, CF₃, H) were prepared by
reaction of pyridinium methylides II, generated from N-
[(ethoxycarbonyl)methyl]pyridinium bromide or N-phenacylpyridinium iodide
and NaH, with CF₂:CFCH₃, CF₃C.tplbond.CCF₂CF₃ and HC.tplbond.CCF₃.

IT 135339-04-7P 135339-07-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 135339-04-7 CAPLUS

CN Methanone, phenyl[1-(trifluoromethyl)-3-indoliziny]- (CA INDEX NAME)




RN 135339-07-0 CAPLUS

CN Methanone, [1,2-bis(trifluoromethyl)-3-indoliziny]phenyl- (CA INDEX
NAME)



L3 ANSWER 91 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 1991:206937 CAPLUS
DOCUMENT NUMBER: 114:206937
ORIGINAL REFERENCE NO.: 114:34894h,34895a
TITLE: Acid-catalyzed reactions of 1- and
3-(α -hydroxybenzyl)indolizines
AUTHOR(S): Miki, Yasuyoshi; Hiroishi, Yuji; Hachiken, Hiroko;
Takemura, Shoji
CORPORATE SOURCE: Fac. Pharm. Sci., Kinki Univ., Higashi-Osaka, 577,
Japan
SOURCE: Journal of Heterocyclic Chemistry (1991), 28(1), 45-8
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 114:206937
GI



AB Treatment of 1- and 3-(α -hydroxybenzyl)indolizines I [R = H, R¹ = CH(OH)Ph, R² = H, Ph, R³ = CO₂Et; R = H, Me, R¹ = CO₂Me, R² = H, Ph, R³ = CH(OH)Ph] with trifluoroacetic acid in dichloromethane gave phenylbis(α -indoliziny)methanes, bis[α -(indoliziny)benzyl] ethers and indolizines, depending upon the presence or absence of the substituent at the 2- or 5-position and the reaction conditions used. Thus, treating I [R = H, R¹ = CH(OH)Ph, R² = Ph, R³ = CO₂Et] with CF₃CO₂H gave phenylbis(indoliziny)methane II and the bis[lindoliziny]benzyl ether III. I [R = R² = H, R¹ = CH(OH)Ph, R³ = CO₂Et] gave only II (R² = H).


IT 17281-79-7P 133619-68-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)

RN 17281-79-7 CAPLUS
CN 1-Indolizinecarboxylic acid, 3-benzoyl-, methyl ester (CA INDEX NAME)




RN 133619-68-8 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-5-methyl-, methyl ester (CA INDEX NAME)



L3 ANSWER 92 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 1991:143047 CAPLUS
DOCUMENT NUMBER: 114:143047
ORIGINAL REFERENCE NO.: 114:24261a,24264a
TITLE: Indolizine derivatives with biological activity. VI.
1-(2-Aminoethyl)-3-benzyl-7-methoxy-2-
methylinolizine, benanserine structural analog
AUTHOR(S): Cingolani, G. M.; Claudi, F.; Massi, M.; Venturi, F.
CORPORATE SOURCE: Dip. Sci. Chim., Univ. Camerino, Camerino, 62032,
Italy
SOURCE: European Journal of Medicinal Chemistry (1990), 25(8),
709-12
CODEN: EJMCA5; ISSN: 0223-5234
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 114:143047
GI



AB The title compound (I) was prepared from 3-(4-methoxy-2-pyridyl)propionate. In comparison with benanserine I showed greatly reduced antihistaminic activity and somewhat reduced antiserotonin activity whereas the anticholinergic activity remained unaffected.


IT 132868-09-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)

RN 132868-09-8 CAPLUS
CN 1-Indolizineacetamide, 3-benzoyl-7-methoxy-2-methyl- (CA INDEX NAME)




L3 ANSWER 93 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1987:213744 CAPLUS
DOCUMENT NUMBER: 106:213744
ORIGINAL REFERENCE NO.: 106:34677a,34680a
TITLE: A novel synthesis of pyrrolo[2,1,5-de]quinolizinones
(cycl[3.3.2]azinones)
AUTHOR(S): Miki, Yasuyoshi; Kinoshita, Hisashi; Yoshimaru,
Toshihiko; Takemura, Shoji; Ikeda, Masazumi
CORPORATE SOURCE: Fac. Pharm. Sci., Kinki Univ., Higashi-Osaka, 577,
Japan
SOURCE: Heterocycles (1987), 26(1), 199-204
CODEN: HTCYAM; ISSN: 0385-5414
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 106:213744
GI



AB 3,5-Diacylbindolizines I (R = H, Me, Ph; R1 = Me, Ph) were prepared by [3 +
2] dipolar cycloaddn. of pyridinium salts II (R2 = Ph, Me, 1,3-dioxolanyl)
and MeO2CC:CCO2Me. I were then cyclized with Al2O3 or K2CO3 to give the
title compds. III in 38-64% overall yields. The NMR of III with CF3CO2D
showed evidence for cyclazinylium ions IV (R3 = OH, H, Ph; R4 = Ph, OH).
IT 108325-76-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and intramol. cyclization of, with alumina and with potassium
carbonate)
RN 108325-76-4 CAPLUS
CN 1,2-Indolizinedicarboxylic acid, 5-acetyl-3-benzoyl-, dimethyl ester (9CI)
(CA INDEX NAME)



L3 ANSWER 94 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1987:213700 CAPLUS

DOCUMENT NUMBER: 106:213700

ORIGINAL REFERENCE NO.: 106:34669a,34672a

TITLE: The synthesis of indolizines: the reaction of α -halo pyridinium salts with β -dicarbonyl species

AUTHOR(S): Nugent, Richard A.; Murphy, Megan

CORPORATE SOURCE: Upjohn Co., Kalamazoo, MI, 49001, USA

SOURCE: Journal of Organic Chemistry (1987), 52(11), 2206-8
CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 106:213700


AB The reaction of β -keto esters and β -diketones with readily accessible 2-halopyridinium salts in the presence of DBU serves as a rapid and convenient method for the synthesis of substituted indolizines. The use of di-Et malonate as the dicarbonyl component of the reaction enables the preparation of previously undescribed 2-hydroxyindolizines.

IT 107846-98-0P 107847-02-9P 107847-06-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 107846-98-0 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-2-methyl-, ethyl ester (CA INDEX NAME)




RN 107847-02-9 CAPLUS

CN Methanone, (2-methyl-1,3-indolizinediyl)bis[phenyl- (9CI) (CA INDEX NAME)



RN 107847-06-3 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-2-hydroxy-, ethyl ester (CA INDEX NAME)



L3 ANSWER 95 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1987:138207 CAPLUS

DOCUMENT NUMBER: 106:138207

ORIGINAL REFERENCE NO.: 106:22545a,22548a

TITLE: The reaction of indolizines with esters of orthoformic acid: synthesis of tris-indolizine molecular propellers

AUTHOR(S): Ceder, Olof; Sharif, Mohammed Rashid

CORPORATE SOURCE: Dep. Org. Chem., Univ. Gothenburg, Goeteborg, S-412 96, Swed.


SOURCE: Chemische Berichte (1987), 120(2), 239-42
CODEN: CHBEAM; ISSN: 0009-2940

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 106:138207

GI




AB The tris(indolizinyl)methanes I ($R = H, Me, CO_2Et, cyano, R_1 = Me; R = Me, R_1 = Ph$) and II ($R_1 = Ph, R_2 = Me; R_1 = Me, R_2 = CO_2Me, COC_6H_4Me-o$) were prepared from $HC(OEt)_3$ and indolizines. I are three-bladed mol. propellers in which the three blades are structurally identical lacking local C_2 -axes. Compds. of this type are chiral and eight stereoisomeric conformations are possible.

IT 105944-61-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 105944-61-4 CAPLUS

CN Methanone, [methyldynetris(2-methyl-1,3-indolizinediyl)]tris[(2-methylphenyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 96 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1986:424147 CAPLUS

DOCUMENT NUMBER: 105:24147

ORIGINAL REFERENCE NO.: 105:4057a,4060a

TITLE: Phase-transfer catalysis of dipolar species.
1,3-Dipolar cycloadditions of pyridinium ylides in a liquid-liquid biphasic system

AUTHOR(S): Gandasegui, M. Teresa; Alvarez-Builla, Julio

CORPORATE SOURCE: Dep. Quim. Org., Univ. Alcala Henares, Madrid, Spain

SOURCE: Journal of Chemical Research, Synopses (1986), (2), 74-5


CODEN: JRPSDC; ISSN: 0308-2342

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 105:24147

GI




AB Pyridinium salts underwent cycloaddn. reactions with alkynoate esters under liquid-liquid phase-transfer-catalyzed conditions to give the corresponding indolizines. E.g., N-phenacylpyridinium bromide and (MeO2CC.tplbond.)₂ were stirred for 8 h at room temperature with CH₂Cl₂ and 50% aqueous K₂CO₃ in the presence of Bu₄NBr to give 76% indolizine I: the yield increased to 82% with ultrasound irradiation

IT 102767-47-5P 102767-53-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 102767-47-5 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-(4-methoxybenzoyl)-, dimethyl ester (9CI) (CA INDEX NAME)



RN 102767-53-3 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-(4-nitrobenzoyl)-, dimethyl ester (9CI) (CA INDEX NAME)




IT 17281-78-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, by phase transfer-catalyzed reaction)


RN 17281-78-6 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-, dimethyl ester (6CI, 8CI, 9CI) (CA INDEX NAME)



L3 ANSWER 97 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1986:224845 CAPLUS
DOCUMENT NUMBER: 104:224845
ORIGINAL REFERENCE NO.: 104:35667a,35670a
TITLE: Stereoselective synthesis of hexa- and tetrahydroindolizin-7-ones through cycloaddition of pyridinium methylides
AUTHOR(S): Tsuge, Otohiko; Kanemasa, Shuji; Takenaka, Shigeori
CORPORATE SOURCE: Interdiscip. Grad. Sch. Eng. Sci., Kyushu Univ., Kasuga, 916, Japan
SOURCE: Journal of Organic Chemistry (1986), 51(10), 1853-5
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 104:224845
GI




AB The 1,3-dipolar cycloaddn. reaction of 4-[(tert-butyltrimethylsilyl)oxy]pyridinium methylides to electron-deficient olefins and acetylenes provides a convenient route to stereochem. defined 1,2,3-trisubstituted or 1,3-disubstituted derivs. of hexahydro- or tetrahydroindolizin-7-ones. Thus, treating ylides I with N-Me maleimide in acrylonitrile 2 h for alkylation and 4 h for the addition step gave 56% pyrroloindolizine II.

IT 101517-36-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 101517-36-6 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-7-hydroxy-, dimethyl ester
(9CI) (CA INDEX NAME)



L3 ANSWER 98 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1986:88475 CAPLUS

DOCUMENT NUMBER: 104:88475

ORIGINAL REFERENCE NO.: 104:14039a,14042a

TITLE: 1,3-Dipolar cycloaddition reaction of chromones and coumarin with pyridinium ylides

AUTHOR(S): Yokoe, Ichiro; Matsumoto, Shunsuke; Shirataki, Yoshiaki; Komatsu, Manki

CORPORATE SOURCE: Fac. Pharm. Sci., Josai Univ., Sakado, 350-02, Japan

SOURCE: Heterocycles (1985), 23(6), 1395-8


CODEN: HTCYAM; ISSN: 0385-5414

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 104:88475


GI




I




II



III



IV



V


AB Cyclocondensation of N-aminopyridinium iodide with chromones I (R = H, Me, Ph; R1 = H, Cl, Me) in DMF containing K2CO3 at room temperature for 4 days gave 18.1-51.4% pyrazolopyridones II. Similar reaction of coumarin gave benzopyranopyrazolopyridine III, and cyclization of the phenacylide IV with I (R = R1 = H) gave indolizine V.

IT 100421-20-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 100421-20-3 CAPLUS

CN Methanone, (3-benzoyl-1-indoliziny1)(2-hydroxyphenyl)- (CA INDEX NAME)



L3 ANSWER 99 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1985:55576 CAPLUS

DOCUMENT NUMBER: 102:55576

ORIGINAL REFERENCE NO.: 102:8585a,8588a

TITLE: Strategies for drug metabolic profiling in human bile after administration of non-radioactive butoprozine

AUTHOR(S): Overzet, F.; De Zeeuw, R. A.

CORPORATE SOURCE: Dep. Toxicol., State Univ., Groningen, 9713 AW, Neth.

SOURCE: Journal of Pharmaceutical and Biomedical Analysis (1984), 2(1), 3-17

CODEN: JPBADA; ISSN: 0731-7085

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A systematic approach to the recognition, isolation and identification of metabolites of butoprozine [62228-20-0] in human bile is described as an example of the general approach in this area. Human profiles are compared with those obtained after administration of ¹⁴C-labeled drug to the dog. The screening method is based on gradient-elution HPLC. Isolation is by isocratic reversed-phase HPLC and the identification procedure is performed using UV, mass, and NMR spectroscopy. The main metabolite excreted in human bile was tentatively identified as 1-hydroxybutoprozine [94419-24-6].


IT 94419-24-6

RL: BIOL (Biological study)


(as butoprozine biliary metabolite, nonradioactive spectroscopic methods in study of, in humans)

RN 94419-24-6 CAPLUS


CN Methanone, [4-[3-(dibutylamino)propoxy]phenyl](2-ethyl-1-hydroxy-3-indoliziny)- (CA INDEX NAME)



L3 ANSWER 100 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1984:591612 CAPLUS
 DOCUMENT NUMBER: 101:191612
 ORIGINAL REFERENCE NO.: 101:29027a,29030a
 TITLE: Use of dipolar species under phase-transfer catalysis.
 Part 1. 1,3-Dipolar cycloaddition in a two-phase
 system
 AUTHOR(S): Alvarez-Builla, Julio; Quintanilla, M. Gloria; Abril,
 Catalina; Gandasegui, M. Teresa
 CORPORATE SOURCE: Dep. Quim. Org., Univ. Alcala de Henares, Madrid,
 Spain
 SOURCE: Journal of Chemical Research, Synopses (1984), (6),
 202-3
 CODEN: JRPSDC; ISSN: 0308-2342
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB Eleven indolizines were prepared in 18-82% yield by 1,3-dipolar cycloaddn.
 of pyridinium ylides with RC.tplbond.CC(=O)OMe (R = MeO2C, Ph) in a 2-phase
 system. Addition of MeO2CC.tplbond.CC(=O)OMe to N-(methoxycarbonylmethyl)pyridi
 nium chloride and KOH, supported on alumina (1:1) suspended in MeCN, at
 room temperature for >18 h, followed by dehydrogenation with 5% Pd-C at reflux
 for 4 h gave 44% indolizine I. Phase-transfer catalysts did not
 significantly improve the yields.
 IT 17281-78-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, by cycloaddn. reaction of pyridinium ylide with acetylenic
 ester, in two-phase system)
 RN 17281-78-6 CAPLUS
 CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-, dimethyl ester (6CI, 8CI,
 9CI) (CA INDEX NAME)



L3 ANSWER 101 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1984:34365 CAPLUS

DOCUMENT NUMBER: 100:34365

ORIGINAL REFERENCE NO.: 100:5327a,5330a

TITLE: Study in the indolizines series. V. Effect of indolizine substitution in position 1 in the butoprozine series

AUTHOR(S): Rosseels, Gilbert; Peiren, Maurits; Cornil, Robert; Inion, Henri; Prost, Maurice; Descamps, Marcel; Bauthier, Jacques; Tornay, Chantal; Collette, Jean Francois; et al.

CORPORATE SOURCE: Cent. Rech. Bruxelles, SANOFI, Brussels, B-1120, Belg.
SOURCE: European Journal of Medicinal Chemistry (1983), 18(4), 339-46



CODEN: EJMCA5; ISSN: 0009-4374

DOCUMENT TYPE: Journal

LANGUAGE: French

OTHER SOURCE(S): CASREACT 100:34365

GI



AB Benzoylindolizines I (R = Bu, Pr, Me, Et; R1 = Br, Cl, OMe, Me; R2 = C1-4 alkyl, Ph, tolyl, halophenyl, anisyl; R3 = Br, Cl, OMe, H; R4 = H, Br, Cl), which were prepared, exhibited vasodilator activity.

(Hydroxybenzoyl)indolizine derivative II was treated with Cl(CH2)3NBu2 and K2CO3 in Me2CO to give I (R = Bu, R1 = R3 = Br, R2 = Me, R4 = H).

IT 88274-09-3P 88274-10-6P 88274-11-7P


88274-12-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation and etherification of, by aminopropyl chloride derivative)

RN 88274-09-3 CAPLUS


CN Methanone, (3-bromo-4-hydroxyphenyl)(1,2-dimethyl-3-indoliziny)- (CA INDEX NAME)




RN 88274-10-6 CAPLUS
 CN Methanone, (3-bromo-4-hydroxyphenyl) (2-ethyl-1-methyl-3-indoliziny)- (CA INDEX NAME)




RN 88274-11-7 CAPLUS
 CN Methanone, (3-bromo-4-hydroxyphenyl) (1-methyl-2-propyl-3-indoliziny)- (CA INDEX NAME)



RN 88274-12-8 CAPLUS
 CN Methanone, (3-bromo-4-hydroxyphenyl) (2-butyl-1-methyl-3-indoliziny)- (CA INDEX NAME)




IT 79283-97-9P 79283-98-0P 86114-00-3P
 86114-01-4P 86114-02-5P 86114-03-6P
 86114-04-7P 86114-05-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and vasodilator activity of)
 RN 79283-97-9 CAPLUS
 CN Methanone, [3-bromo-4-[3-(dibutylamino)propoxy]phenyl] (1,2-dimethyl-3-indoliziny)- (CA INDEX NAME)



RN 79283-98-0 CAPLUS
 CN Methanone, [3-bromo-4-[3-(dibutylamino)propoxy]phenyl] (1,2-dimethyl-3-indoliziny)-, ethanedioate (1:1) (CA INDEX NAME)


CM 1

CRN 79283-97-9
 CMF C28 H37 Br N2 O2




CM 2

CRN 144-62-7
 CMF C2 H2 O4




RN 86114-00-3 CAPLUS
 CN Methanone, [3-bromo-4-[3-(dibutylamino)propoxy]phenyl] (1-methyl-2-propyl-3-indoliziny)- (CA INDEX NAME)



RN 86114-01-4 CAPLUS
 CN Methanone, [3-bromo-4-[3-(dibutylamino)propoxy]phenyl] (1-methyl-2-propyl-3-indoliziny)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1


CRN 86114-00-3
 CMF C30 H41 Br N2 O2



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 86114-02-5 CAPLUS

CN Methanone, [3-bromo-4-[3-(dibutylamino)propoxy]phenyl] (2-butyl-1-methyl-3-indoliziny)- (CA INDEX NAME)




RN 86114-03-6 CAPLUS

CN Methanone, [3-bromo-4-[3-(dibutylamino)propoxy]phenyl] (2-butyl-1-methyl-3-indoliziny)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 86114-02-5


CMF C31 H43 Br N2 O2



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 86114-04-7 CAPLUS

CN Methanone, [3-bromo-4-[3-(dibutylamino)propoxy]phenyl] (2-ethyl-1-methyl-3-indoliziny)- (CA INDEX NAME)




RN 86114-05-8 CAPLUS

CN Methanone, [3-bromo-4-[3-(dibutylamino)propoxy]phenyl] (2-ethyl-1-methyl-3-indoliziny)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 86114-04-7


CMF C29 H39 Br N2 O2



CM 2


CRN 144-62-7

CMF C2 H2 O4



L3 ANSWER 102 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1983:422316 CAPLUS
 DOCUMENT NUMBER: 99:22316
 ORIGINAL REFERENCE NO.: 99:3605a,3608a
 TITLE: Indolizine derivatives
 INVENTOR(S): Rosseels, Gilbert; Inion, Henri
 PATENT ASSIGNEE(S): Labaz N. V., Belg.
 SOURCE: U.S., 19 pp. Cont.-in-part of U.S. Ser. No. 207,270.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4378362	A	19830329	US 1981-232138	19810206
US 4520026	A	19850528	US 1982-393411	19820629
AT 8303334	A	19840515	AT 1983-3334	19830919
AT 376676	B	19841227		
AT 8303335	A	19840515	AT 1983-3335	19830919
AT 376677	B	19841227		
PRIORITY APPLN. INFO.:			US 1980-207270	A2 19801117
			GB 1979-42146	19791206
			AT 1980-5967	A 19801205
			US 1981-232138	A2 19810206
OTHER SOURCE(S):		CASREACT 99:22316; MARPAT 99:22316		
GI				



AB Aminoalkoxybenzoylindolizines I [R, R3 = H, Br, Cl, iodo, MeO; R1 = alkyl, (un)substituted Ph; R2 = H, Cl; R4 = H, Br, Cl, iodo; R5 = (CH2)nNR62; R6 = Me, Et, Pr, Bu; n = 2-6] were prepared Thus, 7.7 g I (R = R3 = Br, R1 = Et, R2 = R4 = R5 = H) was treated with 14.4 g Br(CH2)3Br to give 8 g I [R5 = (CH2)3Br], which (2.2 g) was condensed with 1.2 g Pr2NH to give 2.4 g I [R = R3 = Br, R1 = Et, R2 = R4 = H, R5 = (CH2)3NPr2]. I [R = R3 = Br, R1 = 3-BrC6H4, R2 = R4 = H, R5 = (CH2)3NBu2], at 10 mg/kg i.v. in dogs, increased myocardial blood flow 150% with half-life 100 min.


IT 86114-01-4P 86114-03-6P 86114-05-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 86114-01-4 CAPLUS

CN Methanone, [3-bromo-4-[3-(dibutylamino)propoxy]phenyl](1-methyl-2-propyl-3-indoliziny)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1


CRN 86114-00-3
 CMF C30 H41 Br N2 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 86114-03-6 CAPLUS

CN Methanone, [3-bromo-4-[3-(dibutylamino)propoxy]phenyl] (2-butyl-1-methyl-3-indoliziny)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 86114-02-5


CMF C31 H43 Br N2 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 86114-05-8 CAPLUS

CN Methanone, [3-bromo-4-[3-(dibutylamino)propoxy]phenyl] (2-ethyl-1-methyl-3-indoliziny)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 86114-04-7


CMF C29 H39 Br N2 O2




CM 2

CRN 144-62-7

CMF C2 H2 O4



L3 ANSWER 103 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1983:197976 CAPLUS
 DOCUMENT NUMBER: 98:197976
 ORIGINAL REFERENCE NO.: 98:30083a,30086a
 TITLE: Reaction of 2,2,6-trimethyl-1,3-dioxin-4-one with
 isoquinolinium and pyridinium ylides
 AUTHOR(S): Sato, Masayuki; Kanuma, Norio; Kato, Tetsuzo
 CORPORATE SOURCE: Pharm. Inst., Tohoku Univ., Aobayama, 980, Japan
 SOURCE: Chemical & Pharmaceutical Bulletin (1982), 30(12),
 4359-64
 CODEN: CPBTAL; ISSN: 0009-2363
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 98:197976
 GI




AB The reactions of diketene-acetone adduct [2,2,6-trimethyl-1,3-dioxin-4-one (I)] with heterocyclic ylides were studied. Heating I with isoquinolinium bis(ethoxycarbonyl)methylide gave pyrroloisoquinoline II (R = CO₂Et). Similarly, isoquinolinium cyano(ethoxycarbonyl)methylide and phenacylide gave pyrroloisoquinolinecarbonitrile III and II (R = Bz), resp. Isoquinolinium dicyanomethylide reacted with I to give bis(methyloxooxazinyl)methylide IV. Pyridinium ylides similarly reacted with I to give indolizines and oxazinylmethylides.


IT 85574-80-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 85574-80-7 CAPLUS


CN Ethanone, 1-(3-benzoyl-2-hydroxy-1-indoliziny)- (CA INDEX NAME)



L3 ANSWER 104 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1982:406382 CAPLUS
 DOCUMENT NUMBER: 97:6382
 ORIGINAL REFERENCE NO.: 97:1235a,1238a
 TITLE: Mass spectra of silylindolizines,
 dihydrosilanaphthoindolizine and
 dihydrosilaazaaceanthrenes
 AUTHOR(S): Prostakov, N. S.; Saxena, Navin; Zakharov, P. I.;
 Varlamov, A. V.; Fesenko, D. A.
 CORPORATE SOURCE: Patrice Lumumba Peoples Friendship Univ., Moscow,
 117923, USSR
 SOURCE: Journal of Organometallic Chemistry (1982), 228(1),
 37-51
 CODEN: JORCAI; ISSN: 0022-328X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB The electron-impact fragmentation of silylindolizines,
 dihydrosilanaphthoindolizines, and dihydrosilaazaaceanthrenes, e.g., I,
 II, and III, has been studied. For indolizines having an exocyclic Si
 atom and carbomethoxy and benzoyl groups attached to the five membered
 ring, the loss of OMe from the carbomethoxy groups and the hydrocarbon
 radical from the Si atom takes place with almost equal intensity. In the
 case of dihydrosilanaphthoindolizines the expulsion of the OMe group from
 the carbomethoxy substituents is the most pronounced fragmentation route;
 moreover, a sharp fall in the intensity of their mol.-ion peak (about 5
 times) is registered. The main fragmentation route during dissociative
 ionization of silaazaaceanthrenes, in contrast to silylindolizines and
 silanaphthoindolizines, is the loss of the hydrocarbon radical attached to
 N.
 IT 67433-81-2 75746-59-7
 RL: PRP (Properties)
 (mass spectrum of)
 RN 67433-81-2 CAPLUS
 CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-6-methyl-7-(triphenylsilyl)-,
 dimethyl ester (9CI) (CA INDEX NAME)



RN 75746-59-7 CAPLUS


CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-7-(trimethylsilyl)-, dimethyl ester (9CI) (CA INDEX NAME)



L3 ANSWER 105 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1981:568993 CAPLUS
 DOCUMENT NUMBER: 95:168993
 ORIGINAL REFERENCE NO.: 95:28245a,28248a
 TITLE: Indolizine derivatives, their salts, their
 pharmaceutical or veterinary compositions and method
 for treating pathological syndromes
 INVENTOR(S): Inion, Henri; Rosseels, Gilbert
 PATENT ASSIGNEE(S): Labaz S. A., Belg.
 SOURCE: Braz. Pedido PI, 58 pp.
 CODEN: BPXXDX
 DOCUMENT TYPE: Patent
 LANGUAGE: Portuguese
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
BR 8007691	A	19810609	BR 1980-7691	19801125
IL 61385	A	19841130	IL 1980-61385	19801031
ZA 8006831	A	19811028	ZA 1980-6831	19801105
CH 651041	A5	19850830	CH 1980-8289	19801107
AU 8064292	A	19810611	AU 1980-64292	19801112
AU 536320	B2	19840503		
NL 8006310	A	19810701	NL 1980-6310	19801119
NL 184683	B	19890501		
NL 184683	C	19891002		
GB 2064536	A	19810617	GB 1980-38499	19801201
GB 2064536	B	19830629		
CA 1152077	A1	19830816	CA 1980-365859	19801201
SE 8008444	A	19810607	SE 1980-8444	19801202
SE 441926	B	19851118		
SE 441926	C	19860515		
IN 151241	A1	19830312	IN 1980-CA1344	19801204
CS 222692	B2	19830729	CS 1980-8517	19801204
CS 222698	B2	19830729	CS 1981-4016	19801204
PL 127999	B1	19831231	PL 1980-228265	19801204
PL 127865	B1	19831231	PL 1980-231829	19801204
PL 129365	B1	19840531	PL 1980-231828	19801204
BE 886511	A1	19810605	BE 1980-203053	19801205
DK 8005219	A	19810607	DK 1980-5219	19801205
DK 146977	B	19840305		
DK 146977	C	19840813		
FI 8003792	A	19810607	FI 1980-3792	19801205
FI 67846	B	19850228		
FI 67846	C	19850610		
NO 8003681	A	19810609	NO 1980-3681	19801205
NO 157019	B	19870928		
NO 157019	C	19880106		
JP 56103181	A	19810818	JP 1980-172521	19801205
JP 63025591	B	19880526		
DE 3046017	A1	19810903	DE 1980-3046017	19801205
DE 3046017	C2	19860925		
ES 497504	A1	19820616	ES 1980-497504	19801205
RO 81452	A1	19830429	RO 1980-102781	19801205
SU 1058505	A3	19831130	SU 1980-3213301	19801205
HU 28783	A2	19831228	HU 1980-2915	19801205
HU 185019	B	19841128		
AT 8005967	A	19840415	AT 1980-5967	19801205
AT 376438	B	19841126		
RO 84707	A1	19840717	RO 1980-108948	19801205
RO 85271	A1	19840929	RO 1980-108949	19801205

DD 155069	A5	19820512	DD 1980-225817	19801206
FR 2495616	A1	19820611	FR 1980-26104	19801209
FR 2495616	B1	19830826		
CS 222697	B1	19830729	CS 1981-4015	19810529
ES 508051	A1	19821001	ES 1981-508051	19811216
ES 508052	A1	19821001	ES 1981-508052	19811216
ES 508053	A1	19821001	ES 1981-508053	19811216
SU 1109051	A3	19840815	SU 1981-3367150	19811222
SU 1297726	A3	19870315	SU 1981-3367149	19811222
AT 8303334	A	19840515	AT 1983-3334	19830919
AT 376676	B	19841227		
AT 8303335	A	19840515	AT 1983-3335	19830919
AT 376677	B	19841227		
SU 1287751	A3	19870130	SU 1984-3801012	19841012
PRIORITY APPLN. INFO.:			GB 1979-42146	A 19791206
			AT 1980-5967	A 19801205
OTHER SOURCE(S):		CASREACT 95:168993; MARPAT 95:168993		
GI				



AB Indolizines I (R = alkyl, optionally substituted Ph; R1 = Me, Et, Pr, Bu; R2, R5 = H, Cl, Br, iodo, Me, OMe; R3 = H, Cl, Br, iodo, Me; R4 = H, Cl; n = 2-6) (178 compds.) were prepared. Thus I (R = Me, R1 = Bu, R2 = R5 = Br, R3 = R4 = H, n = 3) (II) was prepared by alkylating the hydroxybenzoylindolizine. At 10 mg/kg i.v. in dogs II gave 125% increase in myocardial blood flow. II also has sympatholytic and antiarrhythmic activity.

IT 79283-98-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 79283-98-0 CAPLUS

CN Methanone, [3-bromo-4-[3-(dibutylamino)propoxy]phenyl] (1,2-dimethyl-3-indoliziny)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 79283-97-9


CMF C28 H37 Br N2 O2




CM 2

CRN 144-62-7

CMF C2 H2 O4




L3 ANSWER 106 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1980:639513 CAPLUS
 DOCUMENT NUMBER: 93:239513
 ORIGINAL REFERENCE NO.: 93:38379a,38382a
 TITLE: γ -Trimethylsilyl(triphenylsilyl)pyridines in the
 synthesis of silicon-containing pyridinium ylides and
 indolizines
 AUTHOR(S): Prostakov, N. S.; Varlamov, A. V.; Saksena, N.;
 Savina, A. A.; Raj, G. Datta; Maslova, L. V.
 CORPORATE SOURCE: Univ. Druzhby Nar. im. Lumumby, Moscow, USSR
 SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1980), (7),
 965-8
 CODEN: KGSSAQ; ISSN: 0453-8234
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 OTHER SOURCE(S): CASREACT 93:239513
 GI




AB Pyridinium ylides and indolizines I, II (R = Me, Ph; R1, R2 = H, Me; R3 = Ph, OEt), III (R4 = R5 = CO2Me, R6 = CO2Ph, CO2Et; R4 = R6 = H, R5 = Ph) were prepared in 14-90% yields from IV. Thus, refluxing IV (R = Me, R1 = R2 = H) with PhCOCH2Br in benzene gave 40% I (R = Me, R1 = R2 = H, R3 = Ph) which on treatment with 40% aqueous KOH gave 90% corresponding II.


IT 67433-81-2P 67433-82-3P 75746-59-7P
 75746-60-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 67433-81-2 CAPLUS
 CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-6-methyl-7-(triphenylsilyl)-, dimethyl ester (9CI) (CA INDEX NAME)




RN 67433-82-3 CAPLUS
 CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-8-methyl-7-(triphenylsilyl)-, dimethyl ester (9CI) (CA INDEX NAME)



RN 75746-59-7 CAPLUS
 CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-7-(trimethylsilyl)-, dimethyl ester (9CI) (CA INDEX NAME)




RN 75746-60-0 CAPLUS
 CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-7-(triphenylsilyl)-, dimethyl ester (9CI) (CA INDEX NAME)




L3 ANSWER 107 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1980:620542 CAPLUS
 DOCUMENT NUMBER: 93:220542
 ORIGINAL REFERENCE NO.: 93:35207a,35210a
 TITLE: Reaction of 2- and 4-vinylpyridines with
 phenacylpyridinium ylides
 AUTHOR(S): Terent'ev, P. B.; Vinogradova, S. M.; Kost, A. N.
 CORPORATE SOURCE: Mosk. Gos. Univ., Moscow, USSR
 SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1980), (5),
 651-6
 CODEN: KGSSAQ; ISSN: 0453-8234
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 OTHER SOURCE(S): CASREACT 93:220542
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Treatment of ylides I ($R_1 = R_2 = H$; $R_1 = NO_2$, $R_2 = H$, CO_2Et ; $R_1 = H$, $R_2 = CO_2Et$, Br, Me) with 2- or 4-vinylpyridine gave 5-29% indolizines II ($R = 2-$ or 4- pyridyl). I and $MeO_2CC:CCO_2Me$ gave a mixture of III and IV. An anomalous reaction occurred between 2-bromo-1-phenacylpyridinium ylide and $MeO_2CC:CCO_2Me$; in addition to 5-bromo-1,2-dicarbomethoxy-3-benzoylindolizine (V), VI was obtained. V was converted to VI by treatment with Al_2O_3 .
 IT 17281-78-6P 75566-81-3P 75566-82-4P
 75566-83-5P 75566-84-6P 75579-46-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 17281-78-6 CAPLUS
 CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-, dimethyl ester (6CI, 8CI, 9CI) (CA INDEX NAME)




RN 75566-81-3 CAPLUS
 CN 1,2,6-Indolizinetricarboxylic acid, 3-benzoyl-, 6-ethyl 1,2-dimethyl ester
 (CA INDEX NAME)




RN 75566-82-4 CAPLUS

CN 1,2,8-Indolizinetricarboxylic acid, 3-benzoyl-, 8-ethyl 1,2-dimethyl ester
(CA INDEX NAME)




RN 75566-83-5 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-6-bromo-, dimethyl ester (9CI)
(CA INDEX NAME)




RN 75566-84-6 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-5-bromo-, dimethyl ester (9CI)
(CA INDEX NAME)



RN 75579-46-3 CAPLUS

CN 1,2,6-Indolizinetricarboxylic acid, 3-(4-nitrobenzoyl)-, 6-ethyl
1,2-dimethyl ester (CA INDEX NAME)



L3 ANSWER 108 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1980:446350 CAPLUS

DOCUMENT NUMBER: 93:46350

ORIGINAL REFERENCE NO.: 93:7651a,7654a

TITLE: Addition reactions of heterocyclic compounds. Part 70. Formation of quinolizines and indolizines from nicotine derivatives and acetylenic esters

AUTHOR(S): Acheson, R. Morrin; Ferris, Michael J.; Sinclair, Neil M.

CORPORATE SOURCE: Dep. Biochem., Univ. Oxford, Oxford, OX1 3QU, UK

SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1980), (1), 78-80


CODEN: JCPRB4; ISSN: 0300-922X

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 93:46350


GI




III




IV



V



VI



VII


AB Cotinine (I), nicotyrine and 3-butylpyridine reacted with MeO2CC.tplbond.CCO2Me (II) to give 1.7-6.3% 9aH-quinolizines III (R = 1-methyl-2-pyrrolidon-5-yl, R1 = H; R = H, R1 = 1-methylpyrrol-2-yl, Bu), which isomerized on heating to give the corresponding 4H isomers IV. Similar treatment of the oxazine V with II gave 8.1% 4H-quinolizone VI directly. I was also converted in 3 steps to the indolizine VII.

IT 74212-61-6P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)

RN 74212-61-6 CAPLUS


CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-6-(1-methyl-5-oxo-2-pyrrolidinyl)-, dimethyl ester (9CI) (CA INDEX NAME)




L3 ANSWER 109 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1980:76245 CAPLUS
 DOCUMENT NUMBER: 92:76245
 ORIGINAL REFERENCE NO.: 92:12555a,12558a
 TITLE: Use of 2,5-dimethyl-4-phenyl(benzyl)pyridines in
 syntheses of substituted indolizines
 AUTHOR(S): Prostakov, N. S.; Gaivoronskaya, L. A.; Anastasi, R.
 I.
 CORPORATE SOURCE: Univ. Druzhby Nar. im. Lumumby, Moscow, USSR
 SOURCE: Izvestiya Vysshikh Uchebnykh Zavedenii, Khimiya i
 Khimicheskaya Tekhnologiya (1979), 22(10), 1197-201
 CODEN: IVUKAR; ISSN: 0579-2991
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 OTHER SOURCE(S): CASREACT 92:76245
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Reaction of pyridines I (R = Ph, benzyl) with R1C6H4COCH2Br (R1 = m-O2N,
 p-Br) gave 85-99% II, which were cyclized to give 24-70% phenylindolizines
 III. II and di-Me acetylenedicarboxylate gave 14.3-23% IV. V were prepared
 in 28.5-72% yield by reaction of II with p-O2NC6H4COCl.
 IT 72768-17-3P 72768-18-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 72768-17-3 CAPLUS
 CN 1,2-Indolizinedicarboxylic acid, 5,8-dimethyl-3-(3-nitrobenzoyl)-7-phenyl-
 , dimethyl ester (9CI) (CA INDEX NAME)




RN 72768-18-4 CAPLUS
 CN 1,2-Indolizinedicarboxylic acid, 5,8-dimethyl-3-(3-nitrobenzoyl)-7-
 (phenylmethyl)-, dimethyl ester (9CI) (CA INDEX NAME)



L3 ANSWER 110 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1979:523620 CAPLUS
 DOCUMENT NUMBER: 91:123620
 ORIGINAL REFERENCE NO.: 91:19947a,19950a
 TITLE: Substituted indolizines and indenoindolizines
 AUTHOR(S): Prostakov, N. S.; Gaivoronskaya, L. A.; Anastassi, Rogiros; Sarata Mohomon, Kamara Maiga; Savina, A. A.
 CORPORATE SOURCE: Univ. Druzhb. Nar. im. Lumumby, Moscow, USSR
 SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1979), (6), 794-8
 CODEN: KGSSAQ; ISSN: 0453-8234
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 OTHER SOURCE(S): CASREACT 91:123620
 GI




AB Reaction of pyridinium salts I (R = Ph, benzyl) with MeO2CC.tplbond.CCO2Me in the presence of Et3N gave 11-2% II. Indenoindolizines III and IV were prepared similarly in 17.5 and 70% yield, resp. Treatment of 9-oxo-3-methyl-2-phenacyl-2-azafluorenium bromide with K2CO3 gave 67% 5-oxo-2-phenylindeno[2,3-f]indolizine, which was converted to V by treatment with Bz2O.
 IT 71348-79-3P 71348-80-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 71348-79-3 CAPLUS
 CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-5,8-dimethyl-7-phenyl-, dimethyl ester (9CI) (CA INDEX NAME)



RN 71348-80-6 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-5,8-dimethyl-7-(phenylmethyl)-, dimethyl ester (9CI) (CA INDEX NAME)



L3 ANSWER 111 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1978:509696 CAPLUS

DOCUMENT NUMBER: 89:109696

ORIGINAL REFERENCE NO.: 89:16921a,16924a

TITLE: Silyl-substituted pyridine bases, silyl-substituted indolizines, and dihydrosilaazaanthracenes

AUTHOR(S): Varlamov, A. V.; Prostakov, N. S.; Vichkanova, S. A.; Adgina, V. V.; Izosimova, S. B.

CORPORATE SOURCE: Univ. Druzhby Nar. im. Lumumby, Moscow, USSR


SOURCE: Biol. Akt. Soedin. Elem. IV B Gruppy (1977), 47-53.
Akad. Nauk SSSR, Sib. Otd., Irkutsk. Inst. Org. Khim.:
Irkutsk, USSR.

CODEN: 380BA2

DOCUMENT TYPE: Conference

LANGUAGE: Russian

GI




AB The title compds. e.g. I-III were prepared Thus, catalytic dehydrocyclization of IV at 520° gave III. Some silylpiperidinols (e.g. V) were tested for their bactericidal, and protozoacidal activity against e.g. staphylococcus aureus, candida albicans and trichomonas vaginalis.

IT 67433-81-2P 67433-82-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 67433-81-2 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-6-methyl-7-(triphenylsilyl)-, dimethyl ester (9CI) (CA INDEX NAME)





RN 67433-82-3 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-8-methyl-7-(triphenylsilyl)-,
dimethyl ester (9CI) (CA INDEX NAME)




L3 ANSWER 112 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1977:422994 CAPLUS
 DOCUMENT NUMBER: 87:22994
 ORIGINAL REFERENCE NO.: 87:3629a,3632a
 TITLE: Investigations on 2-chloropyridinium salts, III.
 Reactions with CH-acidic compounds and cyclization to
 indolizines
 AUTHOR(S): Pauls, Hartmut; Kroehnke, Fritz
 CORPORATE SOURCE: Inst. Org. Chem., Univ. Giessen, Giessen, Fed. Rep.
 Ger.
 SOURCE: Chemische Berichte (1977), 110(4), 1294-303
 CODEN: CHBEAM; ISSN: 0009-2940
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 OTHER SOURCE(S): CASREACT 87:22994
 GI




AB Pyridinium salts I (R₁ = H, R₂ = 4-MeC₆H₄CO, 4-BrC₆H₄CO, Bz, H, Ac; R₁ = Me, R₂ = Bz, Ac) reacted with nitriles R₃CH₂CN (R₃ = cyano, CO₂Et) in PrOH containing (Me₂CH)₂NEt in 2 h at 80° or 6 h at room temperature to give 35-95% resp. pyridines II which cyclized to 40-92% resp. indolizines III. Heating II (R₁ = H, R₂ = Ac, Bz, 4-MeC₆H₄CO, R₁ = Me, R₂ = Bz, R₃ = cyano) with concentrated HCl or II (R₁ = H, R₂ = Bz, 4-MeC₆H₄CO, 4-BrC₆H₄CO, R₁ = Me, R₂ = Ac, R₃ = CO₂Et) with 2NHCl at 100° cleaved CO₂ to give pyridines IV (R₁ = R₂ = H, R₃ = cyano, R₅ = 4-MeC₆H₄, Me; R₁ = Me, R₂ = H, R₃ = cyano, R₅ = Ph).

IT 63014-86-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 63014-86-8 CAPLUS
 CN 1-Indolizinecarbonitrile, 3-benzoyl-2-ethoxy- (CA INDEX NAME)




L3 ANSWER 113 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1977:89516 CAPLUS
 DOCUMENT NUMBER: 86:89516
 ORIGINAL REFERENCE NO.: 86:14125a,14128a
 TITLE: Addition reactions of heterocyclic compounds. Part
 LXIV. Indolizines from reactions of
 hex-3-yne-2,5-dione, but-3-yn-2-one, and
 allenecarboxylic esters with some nitrogen-containing
 heterocyclic ylides
 AUTHOR(S): Acheson, R. Morrin; Bite, Maris G.; Cooper, Martin W.
 CORPORATE SOURCE: Dep. Biochem., Univ. Oxford, Oxford, UK
 SOURCE: Journal of the Chemical Society, Perkin Transactions
 1: Organic and Bio-Organic Chemistry (1972-1999)
 (1976), (18), 1908-11
 CODEN: JCPRB4; ISSN: 0300-922X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB Pyridinium methylides with MeCOC.tplbond.CCOMe, HC.tplbond.CCO2Me,
 HC.tplbond.CCOMe, PhC.tplbond.CCO2Me, MeO2CCH:C:CHCO2Me, CH2:C:CMeCO2Et,
 and MeCH:C:CMeCO2Et gave indolizines. E.g., I with HC.tplbond.CCO2Me in
 refluxing PhMe for 1 hr gave 18% indolizine II.
 IT 17281-79-7P 51386-41-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 17281-79-7 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-benzoyl-, methyl ester (CA INDEX NAME)



RN 51386-41-5 CAPLUS
 CN Ethanone, 1-(3-benzoyl-1-indolizinyloxy)- (CA INDEX NAME)



L3 ANSWER 114 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1975:540719 CAPLUS
DOCUMENT NUMBER: 83:140719
ORIGINAL REFERENCE NO.: 83:22043a,22046a
TITLE: Mass-spectral study of indolizine derivatives
AUTHOR(S): Terent'ev, P. B.; Vinogradova, S. M.; Kost, A. N.
CORPORATE SOURCE: Mosk. Gos. Univ. im. Lomonosova, Moscow, USSR
SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1975), (4),
509-13
CODEN: KGSSAQ; ISSN: 0132-6244
DOCUMENT TYPE: Journal
LANGUAGE: Russian


AB Dissociative ionization of substituted 3-aryllindolizine takes place with
a subsequent loss of the aryl fragment, and then CO. Simultaneously there
is fragmentation of OH and CHO groups. A comparison of the stability of
these compds. with indole analogs was made.

IT 17281-78-6 25627-81-0

RL: PRP (Properties)
(mass spectrum of)


RN 17281-78-6 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-, dimethyl ester (6CI, 8CI,
9CI) (CA INDEX NAME)



RN 25627-81-0 CAPLUS

CN 1-Indolizinecarbonitrile, 3-benzoyl- (CA INDEX NAME)



L3 ANSWER 115 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1974:36969 CAPLUS
DOCUMENT NUMBER: 80:36969
ORIGINAL REFERENCE NO.: 80:6067a,6070a
TITLE: Synthesis and thermal reaction of pyridinium
3,3-diacyl-1-benzoylallylides[3,3-diacyl-1-benzoyl-1-
(1-pyridinio)prop-2-enides]. Formation of indolizine
derivatives

AUTHOR(S): Tamura, Yasumitsu; Sumida, Yoshio; Ikeda, Masazumi
CORPORATE SOURCE: Fac. Pharm. Sci., Osaka Univ., Osaka, Japan
SOURCE: Journal of the Chemical Society, Perkin Transactions
1: Organic and Bio-Organic Chemistry (1972-1999)
(1973), (19), 2091-5
CODEN: JCPRB4; ISSN: 0300-922X

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.


AB Pyridinium phenacylides with 2,2-diacyl-1-ethoxyethylenes gave pyridinium
3,3-diacyl-1-benzoyl-allylides. E.g. pyridinium phenacylide with
EtOCH:C(COMe)₂ gave 75% allylide (I, R = H). I (R = H) in refluxing
Me₂C₆H₄ gave 6% indolizine (II; R = H, R₁ = Bz). 2-Methyl derivs. of I in
refluxing Me₂C₆H₄ gave mainly 1-acetyl-2-phenylindolizines. E.g. I (R =
Me) gave 30% II (R = Ph, R₁ = CH:CHCOMe) and 2% II (R = H, R₁ = Bz).

IT 51386-41-5P 51386-42-6P 51386-46-0P
51386-49-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 51386-41-5 CAPLUS

CN Ethanone, 1-(3-benzoyl-1-indoliziny)- (CA INDEX NAME)




RN 51386-42-6 CAPLUS

CN Ethanone, 1-(3-benzoyl-7-methyl-1-indoliziny)- (CA INDEX NAME)




RN 51386-46-0 CAPLUS

CN Ethanone, 1-(3-benzoyl-6-methyl-1-indoliziny)- (CA INDEX NAME)



RN 51386-49-3 CAPLUS

CN Ethanone, 1-(3-benzoyl-8-methyl-1-indoliziny1)- (CA INDEX NAME)



L3 ANSWER 116 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1973:71825 CAPLUS

DOCUMENT NUMBER: 78:71825

ORIGINAL REFERENCE NO.: 78:11413a,11416a

TITLE: Red dihydroindolizines from N-phenacylpyridinium salts

AUTHOR(S): Schuetze, Detlef Ingo; Kroehnke, Fritz

CORPORATE SOURCE: Inst. Org. Chem., Univ. Giessen, Giessen, Fed. Rep. Ger.

SOURCE: Justus Liebigs Annalen der Chemie (1972), 765, 20-8
CODEN: JLACBF; ISSN: 0075-4617

DOCUMENT TYPE: Journal

LANGUAGE: German

GI For diagram(s), see printed CA Issue.

AB Reaction of p-RC₆H₄COCH₂Z⁺ Br⁻ (Z⁺ = pyridinium; R = H, MeO, Me, Br, Ph, or O₂N) with p-R₁C₆H₄COCHO (R₁ = H or MeO) in alkaline alc. solution in 2:1 molar


ratio gave 30-61% indolizines (I). From the mother liquors, 10-30% p-RC₆H₄COCH₂CH(OH)COC₆H₄R₁-p were isolated. I were converted by acids to give p-RC₆H₄COCH(Z⁺)C-(COC₆H₄R₁-p):CHCOC₆H₄R-p X⁻ (II). I were characterized by dehydrogenation and the NMR spectra of II (X = CF₃CO₂).

IT 17281-90-2P 40240-69-5P 40240-70-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 17281-90-2 CAPLUS

CN Methanone, 1,2,3-indolizinetriyltris[phenyl- (9CI) (CA INDEX NAME)



RN 40240-69-5 CAPLUS


CN Methanone, (2-benzoyl-1,3-indolizinediyl)bis[(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 40240-70-8 CAPLUS

CN Methanone, (2-benzoyl-1,3-indolizinediyl)bis[(4-methylphenyl)- (9CI) (CA

INDEX NAME)



L3 ANSWER 117 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1973:29578 CAPLUS

DOCUMENT NUMBER: 78:29578

ORIGINAL REFERENCE NO.: 78:4663a,4666a

TITLE: Heteroaromaticity. LXIV. Characterization of pyridinium N-allylides

AUTHOR(S): Sasaki, T.; Kanematsu, K.; Kakehi, A.; Ito, G.

CORPORATE SOURCE: Inst. Appl. Org. Chem., Nagoya Univ., Nagoya, Japan

SOURCE: Tetrahedron (1972), 28(19), 4947-58

CODEN: TETRAB; ISSN: 0040-4020

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 78:29578

GI For diagram(s), see printed CA Issue.

AB Pyridine derivs. reacted with γ -bromocrotonates to give pyridinium N-allylides [e.g. I (R = H)] which reacted together or with acetylenic compds. to give 3-ethenylindolizines; e.g. I (R = H) with K₂CO₃ in CHCl₃ at room temperature with or without HC.tplbond.CCO₂Et gave II. I (R = H) with pyridinium N-phenacylide gave the 3-benzoylindolizine (III) indicating the N-allylide to be a 1,3-dipolarophile; I (R = Me) with diphenylcyclopropanone gave Et 3,4-diphenylsalicylate. N-Allylides derived from γ -bromo- β -methylcrotonates cyclized intramol. to give 3-unsubstituted indolizine derivs.; e.g. IV with K₂CO₃-CHCl₃ gave V.


IT 17281-79-7P 40624-43-9P 40624-44-0P

40624-45-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 17281-79-7 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-, methyl ester (CA INDEX NAME)




RN 40624-43-9 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-, ethyl ester (CA INDEX NAME)




RN 40624-44-0 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-7-methyl-, methyl ester (CA INDEX NAME)



RN 40624-45-1 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-7-methyl-, ethyl ester (CA INDEX NAME)



L3 ANSWER 118 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1972:434269 CAPLUS

DOCUMENT NUMBER: 77:34269

ORIGINAL REFERENCE NO.: 77:5703a,5706a

TITLE: Indolizines. I. Direct synthesis of acylindolizines from substituted pyridinium salts

AUTHOR(S): Dainis, I.

CORPORATE SOURCE: Chem. Sch., Univ. New South Wales, Kensington, Australia

SOURCE: Australian Journal of Chemistry (1972), 25(5), 1003-24
CODEN: AJCHAS; ISSN: 0004-9425

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.


AB Several routes to 1-(formylmethyl)-2-methylpyridinium bromide (I) were examined Chichibabin cyclization of I to indolizine failed; an intermol. aldol condensation occurred. Preparation of acyl- and diacylindolizines, e.g., II (R1, R2, R3 = H, Me, Ph) and III (R1, R2 = H, Me, Ph), from 1-(β -oxoalkyl)-2-alkyl- and 1-(β -oxoalkyl)-2-benzylpyridinium salts was described. Using NaOAc-HOAc this reaction gave isomeric products. 1-Acyl-2,3-disubstituted and 3-acyl-1,2-disubstituted indolizines were formed from salts by Chichibabin cyclization and subsequent in situ acylation. 1-Acetyl-2-methylpyridinium bromide gave good yields of 3-acyl- and 1,3-diacylindolizines by this path and also via 1-acetyl-2-acetylmethylene-1,2-dihydropyridine. Thermal cyclization of 2-phenylpyridinium diphenacetylmethylide gave 3-benzoyl-1,2-diphenylindolizine.

IT 37050-11-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 37050-11-6 CAPLUS


CN Methanone, (1,2-dimethyl-3-indoliziny)phenyl- (CA INDEX NAME)



L3 ANSWER 119 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1971:448933 CAPLUS
 DOCUMENT NUMBER: 75:48933
 ORIGINAL REFERENCE NO.: 75:7721a,7724a
 TITLE: Analgesic and antiinflammatory indolizineacetic acids
 INVENTOR(S): Brown, Allan Guilford; Nayler, John H. C.
 PATENT ASSIGNEE(S): Beecham Group Ltd.
 SOURCE: Ger. Offen., 15 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
DE 2046904	A	19710422	DE 1970-2046904	19700923
GB 1268424	A	19720329	GB 1969-48856	19691004
NL 7013584	A	19710406	NL 1970-13584	19700914
ZA 7006287	A	19710630	ZA 1970-6287	19700914
ES 383992	A1	19730901	ES 1970-383992	19700925
AT 295513	B	19720110	AT 1970-8771	19700929
FR 2070109	A1	19710910	FR 1970-35477	19701001
FR 2070109	A5	19710910		
JP 49010517	B	19740311	JP 1970-87040	19701003
US 3806513	A	19740423	US 1972-311466	19721204
PRIORITY APPLN. INFO.:			GB 1969-48856	A 19691004
			US 1970-74916	A2 19700923

GI For diagram(s), see printed CA Issue.
 AB Title compds. are prepared Thus, Ph₃P and Et 2-bromopropionate gives [Ph₃P+CHMeCO₂Et]Br-, which is condensed with 2-formylpyridine in the presence of Na in EtOH to give Et α -methyl- β -(2-pyridyl)acrylate, which is hydrogenated over Pd/C in AcOH to give Et α -methyl- β -(2-pyridyl)propionate. This with bromoacetone in acetone gives α -(2-methylindolizin-1-yl)propionic acid the Et ester of which is acylated with Ac₂O or BzCl and the product hydrolyzed to give I (R = Me or Ph).
 IT 32999-53-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 32999-53-4 CAPLUS
 CN 1-Indolizineacetic acid, 3-benzoyl- α ,2-dimethyl- (CA INDEX NAME)



L3 ANSWER 120 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1971:435631 CAPLUS

DOCUMENT NUMBER: 75:35631

ORIGINAL REFERENCE NO.: 75:5625a,5628a

TITLE: Indolizines from phenacylcyclimonium salts

AUTHOR(S): Froehlich, Juerg; Kroehnke, Fritz

CORPORATE SOURCE: Inst. Org. Chem., Univ. Giessen, Giessen, Fed. Rep. Ger.

SOURCE: Chemische Berichte (1971), 104(5), 1621-8

CODEN: CHBEAM; ISSN: 0009-2940

DOCUMENT TYPE: Journal

LANGUAGE: German

GI For diagram(s), see printed CA Issue.


AB Dipolar 1,3-addition of $\text{H}_2\text{C}:\text{CHCN}$ to N-ylides, generated in situ by bases from N-phenacylcyclimonium salts (I), e.g. N-phenacylpyridinium bromide gave tetrahydroindolizines (II), e.g. 3-benzoyl-1-cyano-1,2,3,8a-tetrahydroindolizine. II were dehydrogenated to dihydroindolizines (III), e.g. 3-benzoyl-1-cyano-2,3-dihydroindolizine and indolizines (IV), e.g. 3-benzoyl-1-cyanoindolizine.

IT 25627-81-0P 32897-05-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 25627-81-0 CAPLUS

CN 1-Indolizinecarbonitrile, 3-benzoyl- (CA INDEX NAME)



RN 32897-05-5 CAPLUS

CN 3,8-Indolizinedicarbonitrile, 3-benzoyl- (8CI) (CA INDEX NAME)



L3 ANSWER 121 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 1971:99969 CAPLUS
DOCUMENT NUMBER: 74:99969
ORIGINAL REFERENCE NO.: 74:16277a,16280a
TITLE: Heteroaromaticity. XLIII. Orientation in the
1,3-dipolar cycloaddition reactions of heteroaromatic
nitrogen methylides with dipolarophiles
AUTHOR(S): Sasaki, Tadashi; Kanematsu, Ken; Yukimoto, Yusuke;
Ochiai, Shigeo
CORPORATE SOURCE: Fac. Eng., Nagoya Univ., Nagoya, Japan
SOURCE: Journal of Organic Chemistry (1971), 36(6), 813-18
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The orientation in the 1,3-dipolar cycloaddn. reactions of several
ring-substituted N methylides with dipolarophiles was investigated. The
cycloaddn. reactions of 3-substituted pyridazinium methylides with
dimethyl acetylenedicarboxylate (DAC) and cyanoacetylene afforded the
corresponding cycloadducts. In reactions of 3,6-dialkoxypyridazinium
methylides with DAC, one of two alkoxyl groups was expelled in the
formation of the adducts. A mixture of isomeric adducts was obtained in the
reactions of 3-substituted pyrazinium methylides and 3-substituted
pyridinium methylides, in which the major product was produced by
cyclization at the C-2 position. An isomeric mixture of the adducts was
also obtained by the reaction of 3,4-dimethylpyridinium methylide;
however, the major product was afforded by cyclization at C-6 position.
Although the thermal addition of 4-methoxycarbonylpyridinium methylide to DAC
afforded the cycloadduct, the methylide was photochem. too stable to
undergo the photocycloaddn.

IT 27415-65-2P 27415-67-4P 27415-70-9P
27415-71-0P 27415-72-1P 27415-73-2P
27425-50-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 27415-65-2 CAPLUS

CN 1,2,7-Indolizinetricarboxylic acid, 3-benzoyl-, trimethyl ester (8CI, 9CI)
(CA INDEX NAME)




RN 27415-67-4 CAPLUS


CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-8-methyl-, dimethyl ester (8CI)
(CA INDEX NAME)




RN 27415-70-9 CAPLUS
 CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-8-cyano-, dimethyl ester (8CI)
 (CA INDEX NAME)



RN 27415-71-0 CAPLUS
 CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-6-cyano-, dimethyl ester (8CI)
 (CA INDEX NAME)




RN 27415-72-1 CAPLUS
 CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-6,7-dimethyl-, dimethyl ester
 (8CI) (CA INDEX NAME)




RN 27415-73-2 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-7,8-dimethyl-, dimethyl ester
(8CI) (CA INDEX NAME)




RN 27425-50-9 CAPLUS


CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-6-methyl-, dimethyl ester (8CI)
(CA INDEX NAME)




L3 ANSWER 122 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1970:78938 CAPLUS
 DOCUMENT NUMBER: 72:78938
 ORIGINAL REFERENCE NO.: 72:14373a,14376a
 TITLE: Chemistry of cyanoacetylenes. V. 1,3-Dipolar
 cycloaddition reactions of cyanoacetylenes with
 N-ylides and N-imines
 AUTHOR(S): Sasaki, Tadashi; Kanematsu, Ken; Yukimoto, Yusuke
 CORPORATE SOURCE: Fac. Eng., Nagoya Univ., Nagoya, Japan
 SOURCE: Journal of the Chemical Society [Section] C: Organic
 (1970), (3), 481-5
 CODEN: JSOOAX; ISSN: 0022-4952
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 72:78938
 AB 1,3-Dipolar cycloaddn. reactions of zwitterionic pyridinium, quinolinium,
 and isoquinolinium phenacylides with cyanoacetylene or
 chlorocyanoacetylene gave 1-cyanoindolizine derivs. Similar reactions of
 N-aminopyridinium and isoquinolinium salts gave 3-cyanopyrazol[1,5-
 a]pyridine derivs. A 3-methylpyridinium ylide reacted with the same
 dipolarophiles at the 2-position, in spite of hindrance by the Me group.
 Reactions of cyclopentadiene ylides with cyanoacetylenes gave
 trans-2-(2-cyanovinyl)cyclopentadiene ylides.
 IT 25627-81-0P 25627-86-5P 25627-87-6P
 25627-88-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 25627-81-0 CAPLUS
 CN 1-Indolizinecarbonitrile, 3-benzoyl- (CA INDEX NAME)



RN 25627-86-5 CAPLUS
 CN 1-Indolizinecarboxamide, 3-benzoyl- (CA INDEX NAME)




RN 25627-87-6 CAPLUS
 CN 1-Indolizinecarboxylic acid, 3-benzoyl- (CA INDEX NAME)



RN 25627-88-7 CAPLUS

CN 1-Indolizinecarbonitrile, 3-benzoyl-8-methyl- (CA INDEX NAME)



ACCESSION NUMBER: 1970:55285 CAPLUS
 DOCUMENT NUMBER: 72:55285
 ORIGINAL REFERENCE NO.: 72:10116h,10117a
 TITLE: Analgesic indolizine-1-acetic acids
 INVENTOR(S): Nayler, John H. C.
 PATENT ASSIGNEE(S): Beecham Group Ltd.
 SOURCE: Brit., 10 pp.
 CODEN: BRXXAA
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1174124		19691210	GB 1967-30271	19670630

GI For diagram(s), see printed CA Issue.
 AB The title compds. (I; R = CO₂H) which exhibit analgesic and antiinflammatory activity were prepared 3-p-Chlorobenzoyl-2-methylindolizine (80%), m. 109-10° (light petroleum) was prepared by reacting 2-methylindolizine with p-ClC₆H₄COCl. 5-Ethoxy-2-methylpyridine (38 g) in 150 ml dry Me₂CO refluxed 15 min with 42 g BrCH₂Ac gave 6-ethoxy-2-methylindolizine, b0.4 113-14°. 2,4-Lutidine (21.4 g) added to 40 g BzCH₂Br in 60 ml dry Me₂-CO, the mixture refluxed 30 min and kept overnight at room temperature gave 2,4-dimethyl-1-phenacylpyridinium bromide, m. 228-9°. This (10 g) in 100 ml H₂O treated with 30 g NaHCO₃ and the mixture refluxed 2 hr gave 97% 7-methyl-2-phenylindolizine, m. 207° (decomposition). A mixture of 31.5 g 2,7-dimethylindolizine and 28 g anhydrous AcONa in 200 ml Ac₂O refluxed 7 hr gave 70% 3-acetyl-2,7-dimethylindolizine, b0.15 136-8°, m. 87-8° (light petroleum). Similarly prepared were 83% 3-acetyl-7-methyl-2-phenylindolizine, b0.35 180-2°; 89% 3-acetyl-2-(p-methoxyphenyl)-indolizine, m. 103-5° (EtOH); and 80% 3-acetyl-6-ethoxy-2-methylindolizine, b0.13 138-40°, m. 75° (light petroleum). A mixture of 7.25 ml AcOH and 5 ml H₂O cooled to 0°, 3.3 ml anhydrous Me₂NH added dropwise followed by 4 ml 40% aqueous HCHO and 12.45 g 3-benzoyl-2-methylindolizine, and the mixture agitated 6.5 hr gave 89% I (R = NMe₂, R₁ = Me, R₂ = Ph, R₃ = H) (II), m. 88° (light petroleum). The following I (R = NMe₂) were similarly prepared [R₁, R₂, R₃, % yield, and m.p. and (or) b.p. given]: Me, p-ClC₆H₄, H, 67, 108°, (light petroleum); Me, Me, H, 83, 56° (light petroleum), b1.4 168-9°; Ph, Me, H, 25, 105° (aqueous Me₂CO), b1.0 190-2°; Bu, Me, H, 59, b7.0 170-4°; Me, Me, 7-Me, 28, b0.35 167-73°; Ph, Me, 7-Me, 78, 107-8° (light petroleum); p-MeOC₆H₄, Me, H, 12, b1.0 240-50°; and Me, Me, 6-OEt, 54, 79-80° (light petroleum), b0.3 173-5°. MeI (6 ml) added to 9.75 g II in 100 ml EtOH, followed by 5.5 g KCN in 60 ml H₂O, and the mixture refluxed 2 hr gave 74% I (R = CN, R₁ = Me, R₂ = Ph, R₃ = H) (II), m. 132-3° (EtOH). The following I (R = CN) were prepared similarly (R₁, R₂, R₃, % yield, and m.p. given): Me, p-ClC₆H₄, H, 78, 163-4° (EtOH) Me, Me, H, 45-50, 138-9° (MeOH); Ph, Me, H, 97.5, 139° (MeOH); H, Me, H, 78, 130-1° (aqueous EtOH); Bu, Me, H, -, 81-2° (light petroleum); Me, Me, 7-Me, 75, 123-4° (aqueous MeOH); Ph, Me, 7-Me, 95, 186-7° (aqueous MeOH); p-MeOC₆H₄, Me, H, 40, -, and Me, Me, 6-OEt, 85, 78° (aqueous MeOH). A solution of 4 g III in 100 ml EtOH added to 8 g KOH in 20 ml H₂O and the mixture refluxed 24 hr gave 2.5 g I (R = CO₂H, R₁ = Me, R₂ = Ph, R₃ = H), m. 195-7° (MeOH). The following I (R = CO₂H) were similarly prepared (R₁, R₂, R₃, % yield, and m.p. given): Me, Me, H (IV), 92, 197-8° (decomposition) (MeOH); Ph, Me, H, 72, 225° (MeOH); H, Me, H, 53, 195-7° (MeOH); Bu, Me, H, 74, 190-1° (decomposition) (aqueous MeOH); Me, Me, 7-Me,

40, 204° (decomposition) (MeOH); Ph, Me, 7-Me, 87, 204° (decomposition) (aqueous MeOH); p-MeOC₆H₄, Me, H, 67.5, 189-90° (MeOH); and Me, Me, 6-OEt, 60, 187-8° (monohydrate), (MeOH). Treating the

the


following I (R = CO₂Me) (R₁, R₂, R₃, % yield, and m.p. given): Me, Me, H, 96, 112-13° (light petroleum); H, Me, H, 83, 76-8° (aqueous Me₂CO); and Ph, Me, 7-Me, 63, 107-8° (light petroleum). IV Na salt and 1 equivalent Et₂NCH₂CH₂Cl in iso-PrOH refluxed 5 hr gave 54% I (R = CO₂CH₂CH₂NEt₂, R₁ = R₂ = Me, R₃ = H), b_{0.1} 185-90°. Preparation and phys. data for many of the intermediates were given.

IT 26466-63-7P 26466-64-8P 26466-65-9P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)


RN 26466-63-7 CAPLUS

CN Ketone, 1-[(dimethylamino)methyl]-2-methyl-3-indolizinyll phenyl (8CI) (CA INDEX NAME)




RN 26466-64-8 CAPLUS

CN 1-Indolizineacetonitrile, 3-benzoyl-2-methyl- (CA INDEX NAME)



RN 26466-65-9 CAPLUS

CN 1-Indolizineacetic acid, 3-benzoyl-2-methyl- (CA INDEX NAME)



ACCESSION NUMBER: 1969:77753 CAPLUS
 DOCUMENT NUMBER: 70:77753
 ORIGINAL REFERENCE NO.: 70:14496h,14497a
 TITLE: Indolizines
 AUTHOR(S): Cardellini, Mario; Ottolino, Sabino; Tafaro, Pietro
 CORPORATE SOURCE: Inst. Chim. Farm. Tossicol., Univ. Bari, Bari, Italy
 SOURCE: Annali di Chimica (Rome, Italy) (1968), 58(11),
 1206-13
 CODEN: ANCRAl; ISSN: 0003-4592
 DOCUMENT TYPE: Journal
 LANGUAGE: Italian

GI For diagram(s), see printed CA Issue.

AB Some substituted indolizine derivs. (I) were prepared Indolizine-1-acetic acid is the structural analog of indole-3-acetic acid (heteroauxin) and showed some auxin-like activity in preliminary tests. A solution of 8 g. Et diazoacetate in 100 cc. C₆H₆ was added dropwise to a boiling solution of 4 g. 3-benzoylindolizine (II) in 100 cc. C₆H₆ containing a small amount Cu₂Cl₂. After cooling and filtering the solution was evaporated to leave an oil which

was

taken up in a 4:1 H₂O-EtOH mixture A 25% solution of NaOH was added and the mixture was refluxed 3 hrs. The solution was concentrated and acidified with

2N HCl

to give a precipitate of 2.5 g. I (R = Bz, R' = CH₂CO₂H) (Ia), m. 191.3°. Ia (0.2 g.) was dissolved in 10 cc. of 4N HCl and refluxed 40 min. to give 0.1 g. 1-carboxymethyl-3H-indolizinium chloride, m. 184-6°. A solution of 8 g. II, 3.5 g. Me₂NH.HCl, and 3.5 g. 40% HCHO in 250 cc. EtOH was heated at 95° 8 hrs. The EtOH was removed and the residue was dissolved in boiling H₂O leaving a small amount of insol. bis(3-benzoylindolizin-1-yl)methane, m. 190°. The H₂O solution gave 7 g. 1-(dimethylaminomethyl)-3-benzoylindolizine (III), m. 206-8°. III (24 g.) was added slowly to a 2N solution of NaH to give 20 g. of a yellow oil which crystallized to form I (R = Bz, R' = CH₂NMe₂) (IV), m. 82-3°. IV (30 g.) was treated with 6.5 g. MeI in 250 cc. EtOH and allowed to stand 12 hrs., to give 40 g. I (R = Bz, R' = CH₂N+Me₃I-) (V), m. 197°. Na (1.5 g.) was mixed with 13.5 g. Et acetamidomaleonate in 100 cc. dioxane and stirred at 90° to disperse the Na. V (25 g.) in 350 cc. dioxane was added and the mixture refluxed 30 hrs. to give 15 g. I [R = Bz, R' = CH₂C(CO₂Et)₂NHAc] (VI), m. 196-7°. VI (14 g.) was refluxed with 6 g. NaH in 70 cc. H₂O and neutralized with HCl to give 10 g. I [R = Bz, R' = CH₂C(CO₂H)₂NHAc] (VII), m. 171-3°. VII (1.5 g.) was suspended in 8 cc. H₂O and heated at 110° 2 hrs. under pressure to give 1.2 g. I [R = Bz, R' = CH₂CH(CO₂H)(NHAc)] (VIII), m. 201-2°. VII (7 g.) was refluxed in 60 cc. 5N HCl 2 hrs. to give 2.7 g. α-amino-β-(indolizin-1-yl)propionic acid (IX) m. 234-6°. VIII (2 g.) was refluxed 1 hr. in 50 cc. 4N HCl to give 0.6 g. IX. IX (0.5 g.) was dissolved in 7 cc. N NaOH and 0.3 cc. BzCl was added dropwise over 30 min. A solution of 2N HCl was added to give a pH of 4-5 and 0.3 g. of I [R = H, R' = CH₂CH(CO₂H)(NHBz)], m. 171-4°, was precipitated IX (0.25 g.) was treated with 10 cc. BzCl in 40 cc. C₆H₆ and

allowed

to stand at room temperature for 48 hrs. to give 0.15 g. I [R = Bz, R' = CH₂CH(CO₂H)(NHBz)], m. 256-7°. The derivs. were characterized from ir and uv spectra.

IT 21640-36-8P 21640-38-0P 21640-39-1P


21640-40-4P 21640-41-5P 21640-42-6P

21640-43-7P 21640-46-0P 21728-16-5P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 21640-36-8 CAPLUS

CN 1-Indolizineacetic acid, 3-benzoyl- (CA INDEX NAME)




RN 21640-38-0 CAPLUS
 CN Ketone, 1-[(dimethylamino)methyl]-3-indolizinyll phenyl, monohydrochloride
 (8CI) (CA INDEX NAME)




● HCl


RN 21640-39-1 CAPLUS
 CN Ketone, 1-[(dimethylamino)methyl]-3-indolizinyll phenyl (8CI) (CA INDEX NAME)




RN 21640-40-4 CAPLUS
 CN Ammonium, [(3-benzoyl-1-indolizinyll)methyl]trimethyl-, iodide (8CI) (CA INDEX NAME)




RN 21640-41-5 CAPLUS
 CN Malonic acid, acetamido[(3-benzoyl-1-indoliziny]methyl]-, diethyl ester
 (8CI) (CA INDEX NAME)



RN 21640-42-6 CAPLUS
 CN Malonic acid, acetamido[(3-benzoyl-1-indoliziny]methyl]- (8CI) (CA INDEX NAME)




RN 21640-43-7 CAPLUS
 CN 1-Indolizinepropionic acid, α-acetamido-3-benzyl- (8CI) (CA INDEX NAME)




RN 21640-46-0 CAPLUS

CN 1-Indolizinepropionic acid, α -benzamido-3-benzoyl- (8CI) (CA INDEX NAME)



RN 21728-16-5 CAPLUS

CN Indolizine, 1,1'-methylenebis[3-benzoyl- (8CI) (CA INDEX NAME)



L3 ANSWER 125 OF 126 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1968:49411 CAPLUS

DOCUMENT NUMBER: 68:49411

ORIGINAL REFERENCE NO.: 68:9551a,9554a

TITLE: Pyridinium ylides in synthesis. III. Synthesis of indolizines

AUTHOR(S): Henrick, C. A.; Ritchie, E.; Taylor, Walter Charles

CORPORATE SOURCE: Univ. Sydney, Sydney, Australia

SOURCE: Australian Journal of Chemistry (1967), 20(11), 2467-77

CODEN: AJCHAS; ISSN: 0004-9425

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.

AB Treatment of pyridinium, quinolinium, and isoquinolinium ylides with acetylenes yields indolizine, such as I, derivs. Pyridinium phenacylide with iodine in dimethylacetamide gives 1,2,3-tribenzoylindolizine. Decomposition of pyridinium phenacylide in the presence of copper or copper oxide affords 1,3-dibenzoylindolizine. 20 references.


IT 17281-78-6P 17281-79-7P 17281-90-2P

17281-91-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 17281-78-6 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-, dimethyl ester (6CI, 8CI, 9CI) (CA INDEX NAME)




RN 17281-79-7 CAPLUS

CN 1-Indolizinecarboxylic acid, 3-benzoyl-, methyl ester (CA INDEX NAME)




RN 17281-90-2 CAPLUS

CN Methanone, 1,2,3-indolizinetriyltris[phenyl- (9CI) (CA INDEX NAME)



RN 17281-91-3 CAPLUS

CN Methanone, 1,3-indolizinediylbis[phenyl- (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 1961:54302 CAPLUS

DOCUMENT NUMBER: 55:54302

ORIGINAL REFERENCE NO.: 55:10447f-i,10448a-d

TITLE: The formation of pyrrocolines by the reaction of dimethyl acetylenedicarboxylate with heterocyclic zwitterions

AUTHOR(S): Boekelheide, V.; Fahrenholtz, K.

CORPORATE SOURCE: Univ. of Rochester, Rochester, NY

SOURCE: Journal of the American Chemical Society (1961), 83, 458-62

CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB The heterocyclic zwitterions from 1-phenacylpyridinium bromide (I), 1-phenacyl-2,5-dimethylpyrazinium bromide (II), and 1-phenacylpyrindanium bromide (III) yielded with (.tplbond.CC02Me) (IV) the corresponding pyrrocoline or azapyrrocoline derivs. 2-Phenylpyrrocoline (V) (3.86 g.) and 2.9 g. IV in 100 cc. PhMe refluxed 20 hrs. under N with 3.0 g. 5% Pd-C yielded 0.826 g. unchanged V and 1.99 g. di-Me ester (VI) of 1,2-dicarboxy-3-phenylcycl[3.2.2]azine (VII), pale yellow needles, m. 139-40° (Me2CO) (all m.ps. corrected). VI (814 mg.) heated 10 hrs. at 50° with 50 cc. 5% KOH-MeOH gave 724 mg. VII, m. 202-5°. VII (350 mg.) and 300 mg. Cu chromite in 20 cc. quinoline heated at 220° under N until CO2 evolution ceased, filtered, poured onto ice, acidified with HCl, and extracted with Et2O gave 2-phenylcycl[3.2.2]azine, yellow, m. 94-5° (sublimed). BzCH2Br (25.0 g.) and 16 cc. 2,5-dimethylpyrazine heated 1 hr. at 55° gave 31.7 g. II, m. 208-10° (MeOH); picrate, yellow, m. 129-30° (EtOH). II (2.0 g.) in 50 cc. H2O treated with excess Na2CO3, the mixture extracted with CHCl3, the solution passed through Al2O3, evaporated, the unstable, orange solid residue, m. 110°, dissolved immediately in 100 cc. PhMe, and refluxed 16 hrs. under N with 2.5 g. IV and 1.5 g. 5% Pd-C yielded 120 mg. 3-Bz derivative (VIII) of IX, yellow, m. 128-9° (Me2CO), and 280 mg. IX, m. 171-2° (C6H6); IX.HBr, needles, m. 219-21°. 1,2,5-Trimethylpyrazinium iodide (2.0 g.) in 50 cc. H2O treated with excess Na2CO3 and extracted overnight with 100 cc. CHCl3 containing 0.90 g. IV and 1.0 g. 5% Pd-C yielded 23 mg. IX, m. 168-70°. VIII (300 mg.) and 2 g. BzCH2Br in 30 cc. MeOH kept 7 days at room temperature and evaporated in vacuo yielded 300 mg. 3-Bz derivative of 1,2-dicarbomethoxy-5-methyl-9-phenyldipyrrolo[a,c]pyrazine (X), yellow, m. 201-2° (PhMe). IX (611 mg.) and 465 mg. BzCH2Br in 20 cc. HCONMe2 heated 24 hrs. at 80°, poured into H2O, and extracted with Et2O yielded 350 mg. X, yellow needles, m. 201-2° (EtOH-Me2CO). X (300 mg.) in alc. KOH refluxed 1 hr. and the resulting acid (295 mg.) decarboxylated in the usual manner with 100 mg. Cu chromite and 20 cc. quinoline gave 160 mg. 2-phenyl-6-methyldipyrrolo[a,c]pyrazine, yellow prisms, m. 195.5-6.0° (Me2CO). II (5.0 g.) in 50 cc. H2O treated with solid Na2CO3, the mixture extracted with CHCl3, and the residue from the extract refluxed 20 hrs. under N in 100 cc. PhMe with 2.56 g. IV and 2.0 g. 5% Pd-C yielded 1.10 g. 1,2-dicarbomethoxy-3-benzoylpyrrocoline (XI), m. 165-6° (Me2CO). XI (100 mg.) heated 6 hrs. at 50° with KOH-MeOH gave 59 mg. 3-benzoylpyrrocoline-2-carboxylic acid (XII), pale yellow, m. 164-6° (Me2CO). XII (130 mg.) in concentrated HCl refluxed 1 hr. gave 47 mg. pyrrocoline-2-carboxylic acid, pale yellow, m. 244-6° (decomposition) (sublimed). Pyrindan (10.54 g.) and 17.6 g. BzCH2Br in 200 cc. 1:1 Et2O-CHCl3 kept 16 hrs. at room temperature, heated 6 hrs. at 50°, and evaporated gave 28 g. III, needles, m. 168-9.5° (EtOH-EtOAc). III (2.0 g.) in 20 cc. H2O treated with excess Na2CO3 and the unstable solid


orange residue from the extract refluxed 6 hrs. under N with 0.90 g. IV and 2.0 g. 5% Pd-C in PhMe yielded 165 mg. 1,2-dicarbomethoxy-3-benzoyl-5,6-trimethylenepyrrocoline, yellow prisms, m. 160.5-1.5° (EtOH).

IT 17281-78-6P, 1,2-Indolizinedicarboxylic acid, 3-benzoyl-, dimethyl ester

RL: PREP (Preparation)
(preparation of)

RN 17281-78-6 CAPLUS

CN 1,2-Indolizinedicarboxylic acid, 3-benzoyl-, dimethyl ester (6CI, 8CI, 9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 07:18:20 ON 21 MAY 2008)

FILE 'REGISTRY' ENTERED AT 07:18:28 ON 21 MAY 2008

L1 STRUCTURE UPLOADED

L2 886 S L1 FULL

FILE 'CAPLUS' ENTERED AT 07:18:58 ON 21 MAY 2008

L3 126 S L2 FULL

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

690.54

869.11

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-100.80

-100.80

STN INTERNATIONAL LOGOFF AT 07:23:43 ON 21 MAY 2008